Truth in evidence-based medicine Challenge conventional wisdom Transform your thinking

Final Program October 20-25, 2007 Washington Convention Center · Washington, DC

CARDIOVASCULAR RESEARCH

FOUNDATION® UC200801693EN_TCT07Ad_v5ƒ_live.pdf 9/21/07 12:13:59 PM

I8I%,7ddi](&&.

C[Zjhed_Y9WhZ_eLWiYkbWh ;dgY^hig^Wji^dc^ci]ZJH6dcan#'%%,BZYigdc^X!>cX#6aag ^\]ihgZhZgkZY#J8'%%-%&+.(:C UC200801693EN_TCT07Ad_v5ƒ_live.pdf 9/21/07 12:13:59 PM

I8I%,7ddi](&&.

C[Zjhed_Y9WhZ_eLWiYkbWh ;dgY^hig^Wji^dc^ci]ZJH6dcan#'%%,BZYigdc^X!>cX#6aag ^\]ihgZhZgkZY#J8'%%-%&+.(:C transcatheter cardiovascular therapeutics

Table of Contents

intRo The Difficult Patient: Diagnostic and Management Dilemmas...... 31 Course Directors...... 6 The Drug-Eluting Stent Summit, Part 1...... 32

Special activities Tough Calls in the Cath Lab: Advanced Hemodynamics and Angiography...... 33 30th Anniversary of Angioplasty...... 7 Vascular Access and Intervention: From Femoral Cath Lab of the Future...... 7 Access to Closure Devices to Transradial Interventions...... 34 Challenging Cases...... 7 Vulnerable Plaque: Pathophysiology, Detection, Percutaneous Intervention for the Surgeon...... 7 and Therapeutic Intervention, Part 1...... 35 TCT-Supported Charity...... 7 International Lounge...... 7 sunday Breakfast Meetings...... 36 TCT Live...... 7 Special Breakfast Session...... 36 Appreciation Luncheon...... 7 High-Risk Angioplasty and Cardiogenic Shock: Live Case Review Stations...... 7 Winners of the Intra-Aortic Balloon Pump Case Competition...... 36 Cme INFORMATION Scientific Symposia and Practical Workshops CME Accreditation And Designation...... 8 Percutaneous Intervention for the Surgeon, Part 2...... 36 Learning Objectives...... 8 Board Review Course with Self Assessment for Target Audience...... 8 Interventional Cardiology and Endovascular Therapy, Part 2...... 36 Activity Evaluation...... 8 Cardiovascular Non-Invasive Imaging: CTA, MRI, and Beyond (with Reading Sessions with the Experts), Part 2...... 37 Disclosure Statement...... 8 Interventional Strategies and Adjunct Pharmacology Program Sponsorship and Support...... 8 in ACS and AMI, Part 2...... 38 Faculty Molecular Cardiology Breakthroughs: International...... 9 Cell Therapy and Angiogenesis, Part 2...... 40 United States...... 13 The Drug-Eluting Stent Summit, Part 2...... 41

live case sites Vulnerable Plaque: Pathophysiology, Detection, and Therapeutic Intervention, Part 2...... 43 International...... 24 Bifurcation and Left Main Stenting: United States...... 24 An Advanced Operator’s Workshop...... 44 saturday Chronic Total Occlusions: Basic and Expert Techniques...... 46 Interventional Therapies for Adult Congenital Heart ScientIfic Symposia and Practical Workshops Disease and Structural Defects (Featuring A Mini-Course on Percutaneous Intervention for the Surgeon, Part 1...... 26 Transseptal Catheterization)...... 48 Board Review Course with Self Assessment Innovative Devices and Futuristic Concepts I: Interventional Cardiology and Endovascular Medicine, Part 1...... 27 Novel Bare Metal and Drug-Eluting Stents...... 49 Registered Cardiovascular Invasive Specialists Innovative Devices and Futuristic Concepts II: (RCIS) Review Course...... 27 Non-Stent-Based Technologies...... 51 Cardiovascular Non-Invasive Imaging: CTA, MRI, and Beyond IVUS and Physiologic Lesion Assessment Workshop: (with Reading Sessions with the Experts), Part 1...... 27 Applications in the DES Era...... 53 Interventional Strategies and Adjunct Pharmacology 16th Annual Nurse and Technologist Symposium...... 54 in ACS and AMI, Part 1...... 28 Peripheral Vascular Intervention: Evaluation and Molecular Cardiology Breakthroughs: Therapeutic Options...... 56 Cell Therapy and Angiogenesis, Part 1...... 29 The Valvular Heart Disease Summit...... 57 Septal Ablation for Hypertrophic Obstructive Evening Symposia...... 59 Cardiomyopathy...... 29 The Carotid Workshop: Exploring the Controversies from Diagnosis to Intervention...... 30

4 truth in evidence based medicine · challenge conventional wisdom · Transform your thinking Table of Contents

monday wednesday Breakfast Meetings...... 60 Breakfast Meetings...... 82

Physician Training Center...... 60 Physician Training Center...... 82 in t ro Main Arena...... 60 Main Arena ...... 82 Coronary Theater...... 61 Coronary Theater...... 83 Endovascular Theater...... 62 Endovascular Theater...... 84 tURDAY agenda

Structural Heart Disease Theater...... 62 Structural Heart Disease Theater...... 84 sa Morning Concurrent Sessions...... 63 Board Review Course with Self Assessment for Lunchtime Activities...... 65 Interventional Cardiology and Endovascular Medicine, Part 5 ...... 85 Hot Topics, Hot Lunches...... 65 Morning Concurrent Sessions...... 85 sun DAY agenda Case Reviews with the Experts...... 66 Lunchtime Activities...... 87 Board Review Course with Self Assessment for Hot Topics, Hot Lunches...... 87 Interventional Cardiology and Endovascular Medicine, Part 3 ...... 66 Case Reviews with the Experts...... 88 agenda Afternoon Concurrent Sessions...... 66 Afternoon Concurrent Sessions...... 89 mon DAY Special Evening Sessions...... 69 Evening Symposia...... 90 Evening Symposia...... 69 Moderated Complex Case Review Sessions agenda tuesday Monday, October 22...... 92 t ues DAY Breakfast Meetings...... 70 Tuesday, October 23...... 92 Physician Training Center...... 70 Wednesday, October 24...... 93 Main Arena...... 70 thursday agenda Coronary Theater...... 71 wed NESDAY Breakfast Meetings...... 94 Endovascular Theater...... 72

Special Breakfast Session: High-Risk Angioplasty and Cardiogenic Structural Heart Disease Theater...... 72 Shock: Winners of the Intra-Aortic Balloon Pump Case Competition..... 94 case

Health and Human Services Town Hall Meeting...... 73 reviews Board Review Course with Self Assessment for Interventional Morning Concurrent Sessions...... 74 Cardiology and Endovascular Medicine: The Final Exam...... 94 Lunchtime ActIvities...... 76 TCT Closing Session: Case Reviews, Complications, and Hot Topics, Hot Lunches...... 76 Brain Teasers, Featuring “Interventional Jeopardy”...... 94 agenda Fellows Lunch: Medical Education and Testing in the US...... 77 t hurs DAY Physician Training Center Case Reviews with the Experts...... 77 Hands On Hearts...... 96 Board Review Course with Self Assessment for TeachImage™...... 96 Interventional Cardiology and Endovascular Medicine, Part 4 ...... 78 t raining Specialty Device Training...... 96 physician Afternoon Concurrent Sessions...... 78 Special Evening Session...... 80 satellite symposia Evening Symposia...... 80 Sunday, October 21...... 98 t elli e even t s Monday, October 22...... 99 sa Tuesday, October 23...... 101 Wednesday, October 24...... 104 Thursday, October 25...... 105 ABS T RAC S

general Commercial Support Acknowledgment...... 129 general

www.tct2007.com 5 transcatheter cardiovascular therapeutics

TCT 2007 Course Directors

Cardiovascular Research Foundation presents the 19th Annual Symposium

Course Directors Associate Directors TCT Organizational Committee

Martin B. Leon, MD Alexandre Abizaid, MD, PhD Alexandra J. Lansky, MD Andrea Abizaid, MD, PhD Gregg W. Stone, MD Michel Bertrand, MD Jeffrey W. Moses, MD Michael B. Collins, MD Robert O. Bonow, MD Issam Moussa, MD Ricardo Costa, MD Antonio Colombo, MD Jeffrey J. Popma, MD Juan F. Granada, MD Course Co-Directors Ted Feldman, MD Mark Reisman, MD Shunichi Homma, MD Bernard J. Gersh, MB, ChB, DPhil Warren Sherman, MD Greg L. Kaluza, MD George D. Dangas, MD, PhD William A. Gray, MD Sigmund Silber, MD Susheel Kodali, MD Roxana Mehran, MD Eberhard Grube, MD Robert J. Sommer, MD Edward M. Kreps, MD Gary S. Mintz, MD Alice K. Jacobs, MD Giora Weisz, MD LeRoy E. Rabbani, MD Michael R. Jaff, DO Harvey D. White, MD Allan Schwartz, MD Barry T. Katzen, MD Mathew Williams, MD Robert S. Schwartz, MD Ajay Kirtane, MD Craig R. Smith, MD Paul S. Teirstein, MD Renu Virmani, MD

TCT Scientific Committee Robert J. Applegate, MD Linda D. Gillam, MD Neal S. Kleiman, MD Eric E. Roselli, MD Daniel S. Berman, MD A. Marc Gillinov, MD David F. Kong, MD Martin T. Rothman, MD, MB, ChB Mark W. Burket, MD Cindy L. Grines, MD Thierry Lefevre, MD Ulrich Sigwart, MD Daniel Burkhoff, MD, PhD Paul A. Gurbel, MD Francesco Maisano, MD Sidney Smith, MD Michael J. Davidson, MD Martial Hamon, MD Shamir R. Mehta, MD, MSc William Spencer, MD Keith D. Dawkins, MD Timothy D. Henry, MD Magnus Ohman, MD Steven R. Steinhubl, MD Bernard De Bruyne, MD, PhD Howard C. Herrmann, MD Mehmet C. Oz, MD H. Robert Superko, MD Gregory J. Dehmer, MD John McB. Hodgson, MD Seung-Jung Park, MD, PhD Martyn R. Thomas, MD Simon R. Dixon, MB, ChB W. Craig Hooper, PhD Nico H. J. Pijls, MD, PhD Zoltan G. Turi, MD Stephen E. Epstein, MD Dean J. Kereiakes, MD Ileana L. Pina, MD Steven D. Wolff, MD, PhD Michael E. Farkouh, MD, MSc Morton J. Kern, MD Stuart J. Pocock, PhD Andreas M. Zeiher, MD Michael C. Fishbein, MD Ferdinand Kiemeneij, MD, PhD Michael Poon, MD Thomas Zeller, MD Anthony H. Gershlick, MD Spencer B. King III, MD Richard L. Popp, MD

Associations and Affiliations • American Society of Echocardiography • Pediatric and Adult Interventional Therapies for Congenital • Asian Society for Interventional Cardiology and Valvular Heart Disease • Athens Interventional Cardiovascular Therapeutics • Peripheral Vascular Surgery Society • British Cardiovascular Intervention Society • Preventive Cardiovascular Nurses Association • CardioVascular Research Foundation Asia • Sociedad Latinoamericana de Cardiología Intervencionista • China Interventional Therapeutics • Society for Cardiovascular Angiography and Interventions • Complex Catheter Therapeutics • Society for Vascular Medicine and Biology • EuroPCR • Society of Invasive Cardiovascular Professionals • International Society of Endovascular Specialists • Science Innovation Synergy • Joint Interventional Meeting • VEITHsymposium

6 truth in evidence based medicine · challenge conventional wisdom · Transform your thinking Special Activities

30th Anniversary of Angioplasty This year marks the 30th anniversary of the first coronary angioplasty. TCT 2007 will incorporate special sessions designed to highlight this milestone.

Don’t miss the TCT 2007 opening session in the Main Arena, Monday, October 22 at 7:45 Am, that will feature an appearance by Dolf Bachmann, who in t ro underwent the world’s first coronary angioplasty by Andreas Gruentig on September 16, 1977. In addition a special session “A Tribute to Andreas Gruentig: A Thirty Year Odyssey and His Legacy of PCI,” will be presented Monday, October 22 at 5:15 p m , in the Main Arena by Bernhard Meier, MD. Interviews with the pioneers who worked with Andreas Gruentzig and who helped shape the subspecialty of interventional cardiology will be broadcast in the main theaters and throughout the convention center the entire week. tURDAY agenda sa Cath Lab of the Future Percutaneous INTERVENTION International Lounge This interactive area, designed to showcase for the Surgeon Visit the International Lounge for a cup of sun DAY cutting-edge ideas, futuristic concepts, and coffee or a quiet place to relax. The lounge agenda This course, representing a comprehensive advanced products for the cath lab under will also include newspapers from around the introduction to percutaneous coronary, development, is located in the center of the world so you’ll never feel that far from home. endovascular, and adult congenital and Exhibit Hall and will create a unique valvular therapies specially designed for the exploratory experience for all attendees. surgeon, will provide an in-depth review of agenda mon DAY The Cath Lab of the Future will feature the core knowledge base and skill set of TCT Live demonstrations from the following companies: interventional cardiology. The understanding Available on-site through the complementary and lessons learned from this 2-day course • Boston Scientific Corporation wireless Internet at the Washington represents the first step toward surgical • GE Healthcare Convention Center or using any hard-wire "cross-training," with the ultimate goal of • Hansen Medical agenda connection, this dedicated Web site will be t ues DAY acquisition of skills both in the catheterization • InfraReDx, Inc your main TCT information resource while at laboratory as well as the surgical suite. All • LightLab Imaging the meeting. There will also be TCT Live and aspects of percutaneous coronary, vascular, • MediGuide, Inc Abstract Kiosks located throughout the and valvular introduction will be covered • Paieon, Inc convention center to allow you to view taped

with in-depth review of the equipment, agenda • Philips Medical Systems live cases, selected late breaking trials, terminology, and basic techniques of wed NESDAY • Prescient Medical, Inc downloadable audio narrated slides, and endovascular and cardiac structural • Siemens Medical Solutions USA, Inc CME evaluations. • Simbionix intervention. The course is being held Please visit www.TCTLive.com. • TopSpin Medical Saturday, October 20 and Sunday, October case

• Vital Images, Inc 21 in room 207. reviews • Volcano Corporation See pages 26 and 36 for course schedules. TCT Appreciation Luncheon TCT would not be possible without the Challenging Cases TCT Supported CharitY continued participation of our fellow agenda colleagues who make TCT a part of their t hurs DAY Over 300 physicians submit their most Every day in the United States thousands of annual educational experience. We are challenging coronary intervention, unused and reusable medical supplies are grateful for their continued attendance at the endovascular intervention, and structural discarded and sent to landfills or are meeting. We will honor those attendees who heart disease cases to be presented at incinerated. At the same time in developing have attended the meeting for the past five

TCT each year. The most remarkable cases t raining

countries, thousands of patients are turned physician years with an Appreciation Luncheon, will be presented during the closing sessions away from hospitals and medical centers due Monday, October 22, 12:00 p m -2:00 p m . This on Thursday, October 25. Additional cases to lack of these supplies. Doc to Dock is a luncheon will be by advance invitation only. highlighting complications and non-profit charity whose mission is to correct demonstrating solutions to complex anatomic this imbalance. t elli e even t s

and patient-related challenges will be sa Doc to Dock, in partnership with the presented from 10:00 Am-3:00 p m Monday LIVE CASES REVIEW STATIONS Cardiovascular Research Foundation, is through Wednesday in the exhibit hall. A asking for TCT attendees to help in this vital Sites performing live cases in conjunction detailed listing and schedule of these need by bringing a stethoscope and/or other with TCT will electronically transfer moderated case presentations can be found portable medical supplies to TCT 2007. angiograms and IVUS studies from their sites

on pages 92 and 93. ABS T RAC S For more information, please visit the Doc to to CardioNow Live Case Review pods powered Dock booth on the L Street Bridge at the by Agfa HealthCare located throughout the entrances of the exhibit hall. Washington Convention Center. Within minutes or hours of live case completion, these studies will be available for clinical general review. The pods locations include the Exhibit Hall, the lower level outside the Coronary Theater and on the 2nd floor near room 207.

www.tct2007.com 7 transcatheter cardiovascular therapeutics

CME/CE Information

CME Accreditation and Learning Objectives Disclosure Statement Designation By the end of this symposium, participants It is the policy of the Cardiovascular should be able to: Research Foundation to ensure balance, The Cardiovascular Research independence, objectivity, and scientific Foundation is accredited by • Understand the results from important rigor in all of its sponsored educational the Accreditation Council for clinical trials and evidence-based programs. Commercial support from industry Continuing Medical Education to provide medicine that guide the management of does not influence educational content, continuing medical education for physicians. patients with atherosclerosis and structural heart disease faculty selection, and/or faculty The Cardiovascular Research Foundation presentations, and, therefore, does not • Integrate new interventional technologies designates this educational activity for a compromise the scientific integrity of the and procedures to the care of patients maximum of 57.0 AMA PRA Category 1 educational activity. Discussion of off-label ™ with complex coronary and endovascular Credit(s) . Physicians should only claim product usage, and/or off-label product use disease credit commensurate with the extent of their during live or taped cases, is made at the participation in the activity. • Explain advances in diagnostic evaluation sole discretion of the faculty and is not Sixty minutes of physician participation in and therapeutics for patients with carotid endorsed by the Cardiovascular Research TCT equals one credit. This does NOT and peripheral arterial disease Foundation or the program directors for this include Breakfast Meetings, Evening • Describe appropriate pharmacologic activity. Faculty participating in continuing Symposia, Challenging Cases presented in management in the care of patients medical education activities sponsored by the Exhibit Hall, or other specialty programs, undergoing diagnostic arteriography and the Cardiovascular Research Foundation are such as Hands on Hearts or TeachImage™. interventional therapies before, during, required to disclose to the program audience Documentation of awarded credit is provided and after catheterization any real or apparent conflict of interest related to the content of their presentation(s). for registered attendees in exchange for • Distinguish between new interventional Faculty not complying with this policy are completed activity evaluations. Certificates technologies and propose their not permitted to participate in this activity. of attendance are provided to all registered appropriate applications to patients with attendees. cardiovascular disease Program Sponsorship and CE ACCREDITATION AND Target Audience Support DESIGNATION This symposium is designed for The Cardiovascular Research Foundation This program has been approved by the interventional cardiologists, radiologists, strives to ensure that its programs are as American Association of Critical Care Nurses clinical cardiologists, basic scientists, educational as possible. To support this (AACN) for 57.0 Contact Hours, Category A, vascular medicine specialists, surgeons, and endeavor, TCT directors and co-directors file number 00014106. other health care professionals with a special create organizational and scientific interest in the field of interventional and committees to assist in educational content vascular medicine. development and content oversight for live cases, concurrent sessions, case reviews, abstract sessions, practical workshops, and Activity Evaluation scientific symposia. These sessions are Evaluation by questionnaire will address developed without influence from content, presentation, possible bias, and commercial supporters. future educational needs. This symposium is sponsored by the Cardiovascular Research Foundation and partially funded through educational grants from commercial supporters.

8 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

International Jozef Bartunek, MD, PhD Stephen J. D. Brecker, MD Chia-Yu Chou, MD Cardiovascular Center, St. George’s Hospital Taipei Veterans General Hospital Alexandre Abizaid, MD, PhD OLV Hospital London, United Kingdom Taipei, Taiwan Instituto Dante Pazzanese Aalst, Belgium Carlo Briguori, MD Alfonso Ciccone, MD in t ro de Cardiologia Kevin J. Beatt, PhD, MBBS Clinica Mediterranea Niguarda Ca Granda Hospital São Paulo, Brazil Mayday University Hospital Naples, Italy Milan, Italy Andrea Abizaid, MD, PhD London, United Kingdom Elchanan Bruckheimer, MBBS Antonio Colombo, MD

Instituto Dante Pazzanese Jorge A. Belardi, MD Schneider Childen’s Columbus Hospital tURDAY agenda

de Cardiologia Instituto Cardiovascular de Medical Center San Raffaele Hospital sa São Paulo, Brazil Buenos Aires Petach Tikva, Israel Milan, Italy Stephan Achenbach, MD Buenos Aires, Argentina Werner Budts, MD, PhD Jose A. Condado, MD Friedrich-Alexander Universitat Lee N. Benson, MD University Hospitals Leuven Centro Medico de Caracas sun DAY Erlangen, Germany The Hospital for Sick Children Leuven, Belgium Caracas, Venezuela agenda Piefrancesco Agostoni, MD Toronto, Canada Jacques Busquet, MD Jose Costa, MD Antwerp Cardiovascular Institute Patrice Bergeron, MD Clinique Chirurgicale Val d’Or Instituto Dante Pazzanese Middleheim St. Joseph’s Hospital Paris-Saint Cloud, France de Cardiologia Antwerp, Belgium Marseille, France Pawel E. Buszman, MD São Paulo, Brazil agenda mon DAY Takashi Akasaka, MD, PhD Daniel H. Berrocal, MD Upper Silesian Heart Center Ricardo A. Costa, MD Wakayama Medical University Hospital Italiano de Buenos Aires Katowice, Poland Instituto Dante Pazzanese Wakayama, Japan Buenos Aires, Argentina Edoardo Camenzind, MD de Cardiologia Remo Albiero, MD Michel E. Bertrand, MD University of Geneva São Paulo, Brazil

Clinica San Rocco di Franciacorta agenda Hopital Cardiologique Geneva, Switzerland Costantino R. Costantini, MD, PhD t ues DAY Ome, Italy Lambersart, France Stephane G. Carlier, MD, PhD Hospital Cardiologico Costantini Ottavio Alfieri, MD Olivier F. Bertrand, MD, PhD Cordis Coporation Europe Curitiba, Brazil San Raffaele Hospital Laval Hospital Waterloo, Belgium Alberto Cremonesi, MD Milan, Italy Quebec City, Canada Didier Carrie, MD Villa Maria Cecilia Hospital Cotignola, Italy agenda Fernando Alfonso, MD, PhD Rafael Beyar, MD, DSc Service de Cardiologie B, CHU wed NESDAY Hospital Universitario San Carlos Rambam Medical Center Rangueil Alain G. Cribier, MD

Madrid, Spain Haifa, Israel Toulouse, France Hôpital Charles Nicolle Yaron Almagor, MD Anuj Bhasin, MD Charles Chan, MD Rouen, France case

Shaare Zedek Medical Center Chang Gung Memorial Hospital Gleneagles Medical Centre Nick Curzen, PhD reviews Jerusalem, Israel Koashiung, Taiwan Singapore Southampton University Hospital Franz Wolfgang Amann, MD Giancarlo Biamino, MD YunDai Chen, PhD Southampton, United Kingdom Cardiovascular Center Zurich Villa Maria Cecilia Hospital Beijing An Zhen Hospital Joost Daemen, MD Zurich, Switzerland Cotignola, Italy Beijing, China Erasmus Medical Center agenda Max Amor, MD Daniel James Blackman, MD Chien-Jen Chen, MD Rotterdam, the Netherlands t hurs DAY Clinique Louis Pasteur Leeds General Infirmary Chang Gung Memorial Hospital Jan-Henk E. Dambrink, MD, PhD Essey-les-Nancy, France Leeds, United Kingdom Kaohsiung, Taiwan Hospital De Weezenlanden Henning Rud Andersen, MD Lucy Blows, MD Jiyan Chen, MD Zwolle, the Netherlands

University of Aarhus St. Thomas Hospital Guangdong Provincial Keith D. Dawkins, MD t raining physician Aarhus, Denmark London, United Kingdom People’s Hospital Southampton University Hospital David Antoniucci, MD Raoul Bonan, MD Guangzhou, China Southampton, United Kingdom Careggi Hospital Montreal Heart Institute Bernard R. Chevalier, MD Adam J. de Belder, MD

Florence, Italy Montreal, Canada Centre Cardiologie du Nord Brighton and Sussex t elli e even t s Yasushi Asakura, MD Philipp Bonhoeffer, MD Saint-Denis, France University Hospitals sa Toyohashi Heart Center Great Ormond Street Alaide Chieffo, MD Brighton, United Kingdom Aichi, Japan Hospital for Children San Raffaele Scientific Institute Mark A. de Belder, MD, MA Gerald Barbeau, MD London, United Kingdom Milan, Italy The James Cook Laval Hospital J. J. R. M. (Hans) Bonnier, MD, PhD Kenneth Chin, MBBS University Hospital ABS T RAC S Quebec City, Canada Catharina Hospital Pantai Medical Centre Middlesbrough, United Kingdom Antonio L. Bartorelli, MD Eindhoven, the Netherlands Kuala Lumpur, Malaysia Bernard De Bruyne, MD, PhD Centro Cardiologico Monzino Alessandro S. Bortone, MD, PhD Aun-Yeong Chong, MD, MBBS Cardiovascular Center Aalst University of Milan Institute of Cardiac Surgery University Hospital Aalst, Belgium Milan, Italy University of Bari Piazia Coventry, United Kingdom general Bari, Italy

www.tct2007.com 9 transcatheter cardiovascular therapeutics

faculty

Pim de Feyter, MD, PhD Andrejs Erglis, MD, PhD Junbo Ge, MD Jose-Maria Hernandez, MD, PhD University Hospital Dijkzigt P. Stradins Clinical Zhongshan Hospital Hospital Universitario Virgen Rotterdam, the Netherlands University Hospital Shanghai, China de la Victoria Jose M. de la Torre, MD, PhD Riga, Latvia Ulrich Gerckens, MD Malaga, Spain Hospital Universitario Peter Ewert, MD Heart Center Siegburg David J. Hildick-Smith, MD Marques de Valdecilla German Heart Institute Siegburg, Germany Brighton and Sussex Santander, Spain Berlin, Germany Anthony H. Gershlick, MD University Hospitals Giuseppe De Luca, MD Jean Fajadet, MD University of Leicester Brighton, United Kingdom Eastern Piedmont University Clinique Pasteur Leicester, United Kingdom Jonathan M. Hill, MB, ChB, MA Novara, Italy Toulouse, France Roger M. Greenhalgh, MD King’s College Hospital Ivan De Scheerder, MD, PhD Erling Falk, MD Charing Cross Hospital London, United Kingdom CV Research Institute Leuven Skejby Hospital, Aarhus London, United Kingdom Duncan H. K. Ho, MD Herent, Belgium University Hospital Liliana R. Grinfeld, MD Queen Elizabeth Hospital Robert J. de Winter, MD, PhD Aarhus, Denmark Hospital Italiano de Buenos Aires Kwoloon, Hong Kong Academisch Medisch Centrum Miroslaw Ferenc, MD Buenos Aires, Argentina Rainer Hoffmann, MD Amsterdam, the Netherlands Heart Center Bad Krozingen Roberto R. Grinfeld, MD University Hospital Aachen Carlo Di Mario, MD Bad Krozingen, Germany Hospital Español de La Plata Aachen, Germany Royal Brompton Hospital Fausto Feres, MD Buenos Aires, Argentina Andrew Holden, MD London, United Kingdom Instituto Dante Pazzanese Eberhard Grube, MD Auckland City Hospital Germano Di Sciascio, MD de Cardiologia Heart Center Siegburg Auckland, New Zealand Campus Bio-Medico University São Paulo, Brazil Siegburg, Germany Eric Horlick, MD, CM Rome, Italy Hans R. Figulla, MD Giulio Guagliumi, MD Toronto General Hospital Stefanie Dimmeler, PhD University Jena Germany Ospedali Riuniti Di Bergamo Toronto, Canada University of Frankfurt Jena, Germany Bergamo, Italy Angela Hoye, MD, PhD Frankfurt, Germany Moshe Y. Flugelman, MD Vivek Gupta, MD Castle Hill Hospital Serge Doucet, MD Lady Davis Carmel Indraprastha Apollo Hospitals Kingston-upon-Hull, Montreal Heart Institute Medical Center New Delhi, India United Kingdom Haifa, Israel Montreal, Canada Jaap N. Hamburger, MD, PhD Jeffrey Hubbell, PhD Andrew J. Dowson, MBBS, PhD Shmuel Fuchs, MD Vancouver General Hospital Institute of Bioengineering Kings College Hospital Rabin Medical Center St Paul’s Hospital Morges, Switzerland Hindhead, United Kingdom Petach Tikva, Israel Vancouver, Canada Ioannis Iakovou, MD Helmut Drexler, MD Anders M. Galloe, MD, PhD Martial Hamon, MD Army Hospital of Thessaloniki Medical University of Hanover Copenhagen County University Hospital of Caen and Blue Cross Hospital Hanover, Germany Hospital in Gentofte Caen, France Thessaloniki, Greece Hellerup, Denmark Henricus J. Duckers, MD, PhD Yaling Han, MD Thomas A. Ischinger, MD Thoraxcenter D. S. Gambhir, MD, DM Shenyang Northern Hospital Klinikum Bogenhausen Rotterdam, the Netherlands Kailash Heart Institute Shenyang, China Munich, Germany Noida, India Dariusz Dudek, MD Jan Harnek, MD, PhD Stefan James, MD Jagiellonian University Run-Lin Gao, MD Lund University Hospital Throaxcenter, Academic Hospital Krakow, Poland Fu Wai Hospital Malmo, Sweden Uppsala, Sweden Beijing, China Vladimir Dzavik, MD Michael Haude, MD Lisette Okkels Jensen, MD, PhD Toronto General Hospital, Eulogio Garcia, MD Lukaskrankenhaus Neuss Odense University Hospital University Health Network Hospital General Universitario Neuss, Germany Odense, Denmark Gregorio Marañon Toronto, Canada Paul J. Hauptman, MD Peter Juni, MD Madrid, Spain Adrian A. Ebner, MD BioControl Medical University of Bern French Hospital Jorge Gaspar, MD Yehud, Israel Bern, Switzerland National Institute of Asuncion, Paraguay Ben He, MD Erhard Kaiser, MD Cardiology of Mexico Holger Eggebrecht, MD, PhD Shanghai Renji Hospital CardioSkills, Frankfurt Mexico City, Mexico University of Duisburg-Essen Shanghai, China Simulation Center Efrain Gaxiola, MD Frankfurt, Germany Essen, Germany Robert A. Henderson, MD Instituto Cardiovascular de Raimund A. Erbel, MD Nottingham University Hospitals Anne K. Kaltoft, MD, PhD Guadalajara en Hospital University of Duisburg-Essen Nottingham, United Kingdom Skejby Hospital, Aarhus Jardines de Guadalupe University Hospital Essen, Germany Michel Henry, MD Zapopan, Mexico Aarhus, Denmark Cabinet de Cardiologie Nancy, France

10 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

Pasi Karjalainen, MD Karl H. Kuck, MD Shu-Zheng Lu, MD Maurizio Menichelli, MD Satakunta Central Hospital Hospital AK St. Georg Beijing An Zhen Hospital San Camillo Hospital Pori, Finland Hamburg, Germany Beijing, China Rome, Italy

Adnan Kastrati, MD Sim Kui-Hian, MD Tom A. Mabin, MD Erich Minar, MD in t ro Deutsches Herzzentrum und Sarawak General Hospital Vergelegen Mediclinic General Hospital of Vienna Medizinische Klinik der Sarawak, Malaysia Somerset West, South Africa Vienna, Austria Technischen Universitat München Michael J. B. Kutryk, MD, PhD Lindsay S. Machan, MD Kazuaki Mitsudo, MD Munich, Germany

St. Michael’s Hospital Vancouver Hospital and Health Kurashiki Central Hospital tURDAY agenda Jens Kastrup, MD, DMSc Toronto, Canada Sciences Center Kurashiki, Japan sa University Hospital Rigshospitalet Vincent On-Hing Kwok, MD Vancouver, Canada Rosli Mohd Ali, MD, MRCP Copenhagen, Denmark Hong Kong Sanatorium Francesco Maisano, MD National Heart Institute Osamu Katoh, MD and Hospital San Raffaele Hospital Kuala Lumpur, Malaysia sun DAY Toyohashi Heart Center Happy Valley, Hong Kong Milan, Italy Friedrich W. Mohr, MD agenda Toyohashi, Japan Gerrit J. Laarman, MD, PhD Nico Majunke, MD Herzzentrum Leipzig Upendra Kaul, MD OLVG Cardiologie CardioVascular Center Frankfurt Leipzig, Germany Fortis Hospital Amsterdam, the Netherlands Frankfurt, Germany Gilles Montalescot, MD, PhD New Delhi, India Jean-Claude Laborde, MD Massimo Mancone, MD Hospital Pitie-Salpetriere agenda mon DAY Henning Kelbaek, MD Clinique Louis Pasteur Department Cardiovascular Paris, France Rigshospitalet Toulouse, France Sciences Marie-Claude Morice, MD Kobenhavn, Denmark Azeem Latib, MB, BCh Rome, Italy Institut Cardiovasculaire Ferdinand Kiemeneij, MD, PhD EMO Centro Cuore Columbus Jean Marco, MD Paris SUD agenda

Onze Lieve Vrouwe Gasthuis Milan, Italy Centre Cardio-Thoracique Massy, France t ues DAY Amsterdam, the Netherlands Guy LeClerc, MD De Monaco Morris Mosseri, MD Hyo-Soo Kim, MD, PhD Centre Hospital Universitaire Monaco, France Meir Medical Center Seoul National De Montreal Attilio Maseri, MD Kfar-Saba, Israel University Hospital Montreal, Canada San Raffaele Scientific Institute Michael J. Mullen, MD Seoul, South Korea Milan, Italy agenda Ronald C. H. Lee, MD Royal Brompton Hospital wed NESDAY Takeshi Kimura, MD National University Hospital Samuel K. Mathew, MD London, United Kingdom

Kyoto University Hospital Singapore Apollo Hospitals David W. M. Muller, MD, MBBS Sakyo-ku, Japan Thierry Lefevre, MD Chennai, India St. Vincent’s Hospital case

Tarlochan Singh Kler, MD Institut Hospitalier Jacques Detlef G. Mathey, MD Darlinghurst, Australia reviews Escorts Hearts Institute and Cartier Hamburg University Toshiya Muramatsu, MD Research Centre Massy, France Cardiovascular Center Saiseikai Yokohama New Delhi, India Suhas S. Lele, MD Hamburg, Germany Eastern Hospital Karel T. Koch, MD, PhD Indian Heart Association Klaus D. Mathias, MD Kanagawa, Japan agenda Academic Medical Baroda, India Radiologische Klinik Masato Nakamura, MD t hurs DAY Center Amsterdam Jonathan Leor, MD Dortmund, Germany Toho University Ohashi Amsterdam, the Netherlands Sheba Medical Center Luiz A. Mattos, MD, PhD Medical Center Tian-Hai Koh, MD Tel-Hashomer, Israel Instituto Dante Pazzanese Tokyo, Japan National Heart Center de Cardiologia

Yean-Leng Lim, MD, PhD Sunao Nakamura, MD, PhD t raining physician Singapore Centre for Cardiovascular São Paulo, Brazil New Tokyo Hospital Jacques J. Koolen, MD, PhD Therapeutics, Western Health Julinda Mehilli, MD Ciba, Japan Catharina Hospital Victoria, Australia Deutsches Herzzentrum Patrick Nataf, MD Eindhoven, the Netherlands und Medizinische Klinik der Hugo F. Londero, MD Centre Cardiologie du Nord t elli e even t s

Ran Kornowski, MD Sanatorio Allende-Cordoba Technischen Universitat Munchen Saint-Denis, France sa Munich, Germany Rabin Medical Center Cordoba, Argentina Matti Jaakko Niemela, MD Petach Tikva, Israel Chaim Lotan, MD Shamir R. Mehta, MD, MSc University of Oulu Jan Kovac, MD Hadassah University Hospital Hamilton Health Sciences Oulu, Finland Hamilton, Canada University Hospitals of Leicester Jerusalem, Israel Christoph A. Nienaber, MD, PhD ABS T RAC S Leicester, United Kingdom Yves R. Louvard, MD Bernhard Meier, MD Medizinische Fakultat Hans Krankenberg, MD Institut Hospitalier Swiss Cardiovascular Center Bern Rostock, Germany Bern, Switzerland Center for Cardiology and Jacques Cartier Eugenia Nikolsky, MD, PhD Vascular Intervention Massy, France Oscar A. Mendiz, MD Rambam Medical Center Hamburg, Germany Fundacion Favaloro Haifa, Israel general Buenos Aires, Argentina

www.tct2007.com 11 transcatheter cardiovascular therapeutics

faculty

Jim Nolan, MD Nico H. J. Pijls, MD, PhD Michael Rokoss, MD Ashok Seth, MD, PhD University Hospital Catharina Hospital McMaster University Max Devki Devi Heart and North Staffordshire Eindhoven, the Netherlands Hamilton, Canada Vascular Institute Stoke-on-Trent, United Kingdom Stuart J. Pocock, PhD Uri Rosenschein, MD New Delhi, India Masahiko Ochiai, MD, PhD London School of Hygiene B’nai Zion Medical Center Imad Sheiban, MD Showa University Northern and Tropical Medicine Haifa, Israel San Giovanni Battista Hospital Yokohama Hospital London, United Kingdom Martin T. Rothman, MD, MB, ChB Torino, Italy Kanagawa, Japan Fabio E. B. Posas, MD The London Chest Hospital Hani Shennib, MD Takao Ohki, MD, PhD Saint Luke’s Medical Center London, United Kingdom McGill University Health Center Jikei University School Quezon City, Philippines Manel Sabate, MD, PhD Montreal, Canada of Medicine Ross Prpic, MD Hospital de Sant Pau Horst Sievert, MD, PhD Tokyo, Japan Pacific Clinical Research Group Barcelona, Spain CardioVascular Center Frankfurt Goran K. Olivecrona, MD, PhD Mosman, Australia Francesco Saia, MD, PhD Frankfurt, Germany Lund University Hospital Shakeel A. Qureshi, MD Policlinico S. Orsola-Malpighi Ulrich Sigwart, MD Lund, Sweden Evelina Children’s Hospital Bologna, Italy University Hospital of Geneva Eustaquio Onorato, MD London, United Kingdom Shigeru Saito, MD Geneva, Switzerland Sant’Orsola Hosptial FBF Afzalur Rahman, MD, PhD Shonan Kamakura Sigmund Silber, MD Brescia, Italy National Institute of General Hospital Muller Hospital John A. Ormiston, MD, MB, ChB Cardiovascular Disease Kanagawa, Japan Munich, Germany Green Lane and Mercy Hospital Dhaka, Bangladesh Luigi Salemme, MD Tomasz Siminiak, MD, PhD Auckland, New Zealand Simon Redwood, MD Montevergine Clinic Poznan University / School of Miodrag C. Ostojic, MD, PhD St. Thomas’ Hospital Mercogliano, Italy Medical Sciences Institute for Cardiovascular London, United Kingdom Teguh Santoso, MD, PhD Kowanowko, Poland Disease, Clinical Centre of Serbia Eveline S. Regar, MD, PhD Medistra Hospital Balbir Singh, MD, DM Belgrade, Serbia Erasmus Medical Center Jakarta, Indonesia Fortis Hospital Keyur H. Parikh, MD Rotterdam, the Netherlands Gennaro Sardella, MD New Delhi, India Heart Care Clinic / Care Bernhard Reimers, MD Policlinico Umberto I, Peter C. Smits, MD, PhD Cardiovascular Consultants Ospedale di Mirano La Sapienza University Medisch Centrum Rijnmond Zuid Ahmedabad, India Mirano, Italy Rome, Italy Rotterdam, the Netherlands Seong-Wook Park, MD, PhD Expedito E. Ribeiro, MD, PhD Erick Schampaert, MD Amanda G. M. R. Sousa, MD, PhD Asan Medical Center The Heart Institute / Hopital du Sacre-Coeur Instituto Dante Pazzanese Seoul, South Korea University of São Paulo de Montreal de Cardiologia Seung-Jung Park, MD, PhD São Paulo, Brazil Montreal, Canada São Paulo, Brazil Asan Medical Center Yoram Richter, PhD Dierk Scheinert, MD Christian M. Spaulding, MD, PhD Seoul, South Korea Biorest Herzzentrum Leipzig Cochin Hospital Carlos Pedra, MD, PhD Tel Aviv, Israel Leipzig, Germany Paris, France Instituto Dante Goetz M. Richter, MD, PhD Bruno Scheller, MD Eugenio Stabile, MD, PhD Pazzanese de Cardiologia University Hospital Heidelberg Innere Medizin III, Clinica Montevergine São Paulo, Brazil Heidelberg, Germany Universitat des Saarlandes Mercogliano, Italy Patrick J. Peeters, MD Robert K. Riezebos, MD Hamburg, Germany Christodoulos I. Stefanadis, MD Imelda Hospital Onze Lieve Vrouwe Gasthuis Joachim Schofer, MD University of Athens Bonheiden, Belgium Amsterdam, the Netherlands Hamburg University Athens, Greece S. Divak Perera, MD Gilles Rioufol, MD, PhD Cardiovascular Center Pieter R. Stella, MD St. Thomas Hospital Hospices Civils de Lyon, Hamburg, Germany Heart Lung Center Utrecht London, United Kingdom Cardiovascular Hospital Helmut Schuhlen, MD Utrecht, the Netherlands Patrick Perier, MD Bron, France Auguste Viktoria Klinikum Ulf Stenestrand, MD, PhD Herz und Gefass Klinik Robert Roberts, MD Berlin, Germany Linköping University Hospital Bad Neustadt, Germany University of Ottawa Heart Gerhard C. Schuler, MD Linköping, Sweden Marco A. Perin, MD, PhD Institute Herzzentrum Leipzig Duncan J. Stewart, MD Hospital Albert Einstein Ottawa, Canada Leipzig, Germany St. Michael’s Hospital São Paulo, Brazil Alfredo Rodriguez, MD, PhD Patrick W. Serruys, MD, PhD Toronto, Canada Matthias E. Pfisterer, MD Sanatorio Otamendi Thoraxcenter Bradley H. Strauss, MD, PhD University Hospital Buenos Aires, Argentina Rotterdam, the Netherlands Sunnybrook Health Basel, Switzerland Sciences Center Toronto, Canada

12 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

Satoru Sumitsuji, MD Alec Vahanian, MD Jochen Wohrle, MD United States Nozaki Tokushukai Hospital Hopital Bichat University Hospital Ulm Osaka, Japan Paris, France Ulm, Germany William T. Abraham, MD Gabor I. Sutsch, MD Marco Valgimigli, MD Wojciech Wojakowski, MD The Ohio State University in t ro HerzZentrum Hirslanden University of Ferrara Silesian School of Medicine Columbus, OH Zurich, Switzerland Ferrara, Italy Katowice, Poland David H. Adams, MD Maarten J. Suttorp, MD, PhD Frans Van de Werf, MD Chiung-Jen Wu, MD The Mount Sinai School

St. Antonius Hospital University Hospital Gasthuisberg Chang Gung Memorial Hospital of Medicine tURDAY agenda

Nieuwegein, the Netherlands Leuven, Belgium Kaohsiung, Taiwan New York, NY sa Takahiko Suzuki, MD Antonius F.W. van der Steen, PhD Yue-Jin Yang, MD Fernando Aguel, MS Toyohashi Heart Center Erasmus Medical Center Cardiovascular Institute and US Food and Drug Administration Aichi, Japan Rotterdam, the Netherlands Fu Wai Hoapital Rockville, MD sun DAY Hideo Tamai, MD Glenn Van Langenhove, MD, PhD Beijing, China David E. Allie, MD agenda Kusatsu Heart Center Middelheim Hospital Antwerp Robaayah Zambahari, MBBS Cardiovascular Institute Shiga, Japan Merelbeke, Belgium National Heart Institute of the South Corrado Tamburino, MD, PhD Stefan Verheye, MD, PhD Kuala Lumpur, Malaysia Lafayette, LA Ospedale Ferraotto Antwerp Cardiovascular Institute, Andreas M. Zeiher, MD Steven L. Almany, MD agenda mon DAY Catania, Italy Middleheim Hospital University Hospital William Beaumont Hospital Arthur Teow Hin Tan, MD, MBBS Antwerp, Belgium Medical Center Royal Oak, MI Gleneagles Medical Center Francesco Versaci, MD Frankfurt, Germany José I. Almeida, MD Singapore Tor Vergata University of Rome Thomas Zeller, MD Miami Vein Center

Miami, FL agenda Huay Cheem Tan, MD Rome, Italy Herzzentrum Bad Krozingen t ues DAY The Heart Institute at National Clemens von Birgelen, MD, PhD Bad Kronzingen, Germany John A. Ambrose, MD University Hospital Medisch Spectrum Twente University of California, Singapore Hospital San Francisco Gunnar Tepe, MD Enschede, the Netherlands Fresno, CA agenda

University of Tuebingen John G. Webb, MD Zahid Amin, MBBS wed NESDAY Tuebingen, Germany St. Paul’s Hospital Children’s Hospital of Omaha

Jacques G. Theron, MD Vancouver, Canada Omaha, NE University Hospital Caen Mark W. I. Webster, MB, ChB Mark B. Anderson, MD case

Caen, France Auckland City Hospital Robert Wood Johnson reviews Martyn R. Thomas, MD Auckland, New Zealand University Hospital King’s College Hospital Jolanda J. Wentzel, PhD New Brunswick, NJ London, United Kingdom Erasmus Medical Center H. Vernon Anderson, MD Christopher R. Thompson, MD Rotterdam, the Netherlands University of Texas Health agenda St. Paul’s Hospital Gerald S. Werner, MD Science Center t hurs DAY Vancouver, Canada Klinikum Darmstadt Houston, TX Leif Thuesen, MD Darmstadt, Germany Dominick J. Angiolillo, MD, PhD Skejby Hospital Robert J. Whitbourn, MD, University of Florida-Shands Jacksonville

Aarhus, Denmark MBBS, BSc t raining Jacksonville, FL physician Damras Tresukosol, MD St. Vincent Hospital Melbourne Siriaj Hospital Melbourne, Australia Brian H. Annex, MD Bangkok, Thailand Harvey D. White, MD Duke University Medical Center Durham, NC Auckland City Hospital t elli e

Etsuo Tsuchikane, MD even t s Toyohashi Heart Center Auckland, New Zealand Gary M. Ansel, MD sa Toyohashi, Japan Peter T. Wilmshurst, MB, ChB Mid-Ohio Cardiology and Royal Shrewsbury Hospital Vascular Consultants, Inc Yasunori Ueda, MD, PhD Columbus, OH Osaka Police Hospital Shrewsbury, United Kingdom Osaka, Japan Stephan Windecker, MD Jiro Aoki, MD Columbia University ABS T RAC S Martin Unverdorben, MD Swiss Cardiovascular Center Bern Bern, Switzerland Medical Center Center for Cardiovascular New York, NY Diseases Bernhard Witzenbichler, MD Rotenburg, Germany Charité-Universitätsmedizin Berlin, Germany general

www.tct2007.com 13 transcatheter cardiovascular therapeutics

faculty

Mark A. Apfelbaum, MD Theodore A. Bass, MD Robert O. Bonow, MD Gregory Campbell, PhD Columbia University University of Florida Northwestern University Feinberg US Food and Drug Administration Medical Center Health Science Center School of Medicine Rockville, MD New York, NY Jacksonville, FL Chicago, IL Christopher P. Cannon, MD Robert J. Applegate, MD Mark C. Bates, MD Brett E. Bouma, PhD Brigham and Women’s Hospital Wake Forest University CAMC Vascular Center Massachusetts General Hospital Boston, MA School of Medicine of Excellence Boston, MA Louis A. Cannon, MD Winston-Salem, NC Charleston, WV Robert C. Bourge, MD Northern Michigan Hospital Michael Argenziano, MD Eric R. Bates, MD University of Alabama at Heart and Vascular Institute / Columbia University University of Michigan Birmingham Petoskey Cardiology Medical Center Medical Center Birmingham, AL Petoskey, MI New York, NY Ann Arbor, MI Thomas J. Brady, MD Blasé A. Carabello, MD Euan Ashley, MD, PhD Daniel R. Bensimhon, MD Massachusetts General Hospital Veterans Affairs Medical Center Stanford University School Moses Cone Health System Boston, MA Houston, TX of Medicine Greensboro, NC Russell A. Brandwein, RPA-C James C. Carr, MD Stanford, CA Alex Berenstein, MD NewYork-Presbyterian Hospital Northwestern University Thomas Aversano, MD Roosevelt Hospital New York, NY Feinberg School of Medicine Johns Hopkins Medical New York, NY Jeffrey A. Brinker, MD Chicago, IL Institutions Peter B. Berger, MD Johns Hopkins University John D. Carroll, MD Baltimore, MD Geisinger Center for School of Medicine University of Colorado Joseph D. Babb, MD Health Research Baltimore, MD Health Sciences Center East Carolina University Danville, PA Bruce R. Brodie, MD Aurora, CO School of Medicine Daniel S. Berman, MD Moses Cone Heart and Joseph P. Carrozza, Jr, MD Greenville, NC Cedars-Sinai Medical Center Vascular Center Beth Israel Deaconess J. Michael Bacharach, MD, MPH Los Angeles, CA Greensboro, NC Medical Center North Central Heart Institute Robert M. Bersin, MD John E. Brush, MD Boston, MA Sioux Falls, SD Seattle Cardiology and the Sentara Cardiovascular Andrew J. Carter DO Juan J. Badimon, PhD Cardiovascular Consultants Research Institute St. Peter’s Hospital The Mount Sinai School of Washington Norfolk, VA Helena, MT of Medicine Seattle, WA Maurice Buchbinder, MD S. Ward Casscells, MD New York, NY Mohit Bhasin, MD Foundation for Cardiovascular United States Department Steven R. Bailey, MD Sentara Heart Hospital Medicine of Defense University of Texas Health Chesapeake, VA La Jolla, CA Washington, DC Science Center at San Antonio Deepak L. Bhatt, MD David S. Buckles, PhD Peter J. Casterella, MD San Antonio, TX The Cleveland Clinic Foundation US Food and Drug Administration Utah Heart Clinic Donald S. Baim, MD Cleveland, OH Rockville, MD Salt Lake City, UT Boston Scientific Corporation Kevin Bliden, BS, RCIS Allen P. Burke, MD Christopher U. Cates, MD Natick, MA Sinai Center for Thrombosis CVPath Institute, Inc Emory University School J. Timothy Baldwin, PhD Research Gaithersburg, MD of Medicine National Heart, Lung, and Baltimore, MD Mark W. Burket, MD Atlanta, GA Blood Institute Peter C. Block, MD University of Toledo Kenneth J. Cavanaugh, Jr, PhD Bethesda, MD Emory University Hospital Medical Center US Food and Drug Administration Stephen Balter, PhD Atlanta, GA Toledo, OH Rockville, MD Cardiovascular Research Ashley B. Boam, MSBE Daniel Burkhoff, MD, PhD Elliot L. Chaikof, MD, PhD Foundation US Food and Drug Administration Columbia University Medical Emory University Hospital New York, NY Rockville, MD Center Atlanta, GA David Baran, MD William E. Boden, MD New York, NY Charles E. Chambers, MD Newark Beth Israel Buffalo General Hospital Samuel M. Butman, MD Hershey Medical Center Medical Center Buffalo, NY University of Arizona Hershey, PA Livingston, NJ Steven F. Bolling, MD Cottonwood, AZ Jeff Chambers, MD Bradley A. Bart, MD University of Michigan John G. Byrne, MD Metropolitan Cardiology Hennepin County Medical Center Ann Arbor, MI Vanderbilt Heart and Vascular Minneapolis, MN Minneapolis, MN Institute Medical Center Seemant Chaturvedi, MD John R. Bartholomew, MD East Nashville, TN Wayne State University The Cleveland Clinic Foundation Detroit, MI Cleveland, OH

14 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

Hina W. Chaudhry, MD David A. Cox, MD Gregory J. Dehmer, MD Ramin Ebrahimi, MD Columbia University Lehigh Valley Hospital Scott and White Clinic West Los Angeles VA Medical Center Bethlehem, PA Temple, TX Medical Center

New York, NY Frank J. Criado, MD Kevin DeMarco, MD Los Angeles, CA in t ro James H. Chesebro, MD Union Memorial Hospital / Michigan State University Elazer R. Edelman, MD, PhD University of Massachusetts MedStar Health East Lansing, MI Brigham and Women’s Hospital Memorial Medical Center Baltimore, MD Mario Deng, MD Cambridge, MA Worcester, MA

Roberta Croce Columbia University Mary K. Egan, BSN tURDAY agenda Todd Chitwood, BS, RCIS Stuart, Florida Medical Center Columbia University sa Oregon Cardiology Jeptha P. Curtis, MD New York, NY Medical Center Diagnostic Center, LLC Yale Medical Group Ali E. Denktas, MD New York, NY Eugene, OR New Haven, CT University of Texas at Houston Neal L. Eigler, MD sun DAY Nicolas A. F. Chronos, MD Donald Cutlip, MD Houston, TX Cedars-Sinai Medical Center agenda Saint Joseph’s Research Institute / Beth Israel Deaconess Todd M. Dewey, MD Los Angeles, CA American Cardiovascular Medical Center Medical City Dallas Andrew J. Einstein, MD, PhD Research Institute Boston, MA Dallas, TX Columbia University Atlanta, GA Tillman Cyrus, MD Nabil Dib, MD, MSc Medical Center agenda mon DAY Daniel G. Clair, MD Washington University University of California, New York, NY The Cleveland Clinic Foundation School of Medicine San Diego Stephen G. Ellis, MD Cleveland, OH St. Louis, MO La Jolla, CA The Cleveland Clinic Foundation David J. Cohen, MD Michael D. Dake, MD Simon R. Dixon, MB, ChB Cleveland, OH Mid-America Heart Institute agenda

University of Virginia William Beaumont Hospital Stephen E. Epstein, MD t ues DAY Kansas City, MO School of Medicine Royal Oak, MI Washington Hospital Center Marc Cohen, MD Charlottesville, VA Jose Dizon, MD Washington, DC Newark Beth Israel George D. Dangas, MD, PhD Columbia University Martin Fahy, BSc, MEngSc Medical Center Columbia University Medical Center Cardiovascular Research Newark, NJ Medical Center New York, NY Foundation agenda wed NESDAY Michael B. Collins, MD New York, NY Michael Domanski, MD New York, NY Columbia University

Tony Das, MD National Heart, Lung, and Peter S. Fail, MD Medical Center Presbyterian Heart Blood Institute Cardiovascular Institute

New York, NY Institute-Dallas Bethesda, MD of the South case reviews Tyrone J. Collins, MD Dallas, TX Michele Dondero, RN Houma, LA Ochsner Clinic Foundation Harold L. Dauerman, MD NewYork-Presbyterian Hospital James I. Fann, MD New Orleans, LA Fletcher Allen Healthcare / New York, NY Stanford University Anthony J. Comerota, MD University of Vermont John S. Douglas, Jr, MD Medical Center Jobst Vascular Center Burlington, VT Stanford, CA agenda Emory University t hurs DAY Toledo, OH Rajesh M. Dave, MD School of Medicine Andrew Farb, MD Mark W. Connolly, MD Central Pennsylvania Atlanta, GA US Food and Drug Administration St. Michael’s Medical Center Cardiovascular Research Institute Robert D. Dowling, MD Rockville, MD Newark, NJ Mechanicsburg, PA University Cardiovascular Michael E. Farkouh, MD, MSc t raining Christopher J. Cooper, MD Charles J. Davidson, MD Surgical Associates The Mount Sinai physician University of Toledo Northwestern Memorial Hospital Louisville, KY School of Medicine Toledo, OH Chicago, IL Brendan J. Doyle, MD New York, NY Nicola Corvaja, MD Michael J. Davidson, MD Mayo Clinic David P. Faxon, MD t elli e even t s

Columbia University Brigham and Women’s Hospital Rochester, MN Brigham and Women’s Hospital sa Medical Center Boston, MA Hesha Jani Duggirala, PhD, MPH Boston, MA New York, NY Jeff Davis, RRT, RCIS US Food and Drug Administration Zahi A. Fayad, PhD Marco A. Costa, MD, PhD Bonita Springs, FL Rockville, MD The Mount Sinai University of Florida-Shands Larry S. Dean, MD Mark Dunlap, MD School of Medicine Jacksonville University of Washington Stokes Veterans Affairs New York, NY ABS T RAC S Jacksonville, FL Regional Heart Center Medical Center William F. Fearon, MD Michael J. Cowley, MD Seattle, WA Cleveland, OH Stanford University Medical College of Virginia David H. Deaton, MD Medical Center

Richmond, VA Georgetown University Hospital Stanford, CA general Washington, DC

www.tct2007.com 15 transcatheter cardiovascular therapeutics

faculty

Steven B. Feinstein, MD Glenna Friedman, RN Sheldon Goldberg, MD Paul A. Gurbel, MD Rush University Medical Center Columbia University Hahnemann University Hospital Sinai Hospital of Chicago, IL Medical Center Philadelphia, PA Baltimore System Frederick Feit, MD New York, NY Mark Goldberger, MD Baltimore, MD New York University Valentin Fuster, MD, PhD Columbia University Lee R. Guterman, PhD, MD Medical Center The Mount Sinai Medical Center Medical Center Catholic Health System of Buffalo New York, NY New York, NY New York, NY Williamsville, NY Marc D. Feldman, MD Anthony J. Galeo, MD Steven Goldman, MD Luis A. Guzman, MD University of Texas Health Benefis Heart Institute Southern Arizona VA University of Florida Science Center at San Antonio Great Falls, MT Health Care System Hospital Jacksonville, FL San Antonio, TX Roger Gammon, MD Tucson, AZ Donald Hagler, MD Ted Feldman, MD Austin Heart James A. Goldstein, MD St. Mary’s Hospital Evanston Hospital Austin, TX William Beaumont Hospital Rochester, MN Evanston, IL Hasan Garan, MD Royal Oak, MI Rebecca Tung Hahn, MD James J. Ferguson III, MD Columbia University David J. Gordon, MD Columbia University Texas Heart Institute Medical Center National Heart, Lung, and Medical Center Houston, TX New York, NY Blood Institute New York, NY Valerian Fernandes, MD Lawrence A. Garcia, MD Bethesda, MD Edward Hannan, PhD Medical University of Beth Israel Deaconess Neil K. Goyal, MD University at Albany South Carolina Medical Center Columbia University School of Public Health Charleston, SC Boston, MA Medical Center Albany, NY Aloke V. Finn, MD Richard H. Gemming, MPH, MBA New York, NY Adam Hansgen Emory University Columbia University Juan F. Granada, MD University of Colorado Health Atlanta, GA Medical Center Cardiovascular Research Sciences Center Robert P. Fiorentino, MD, MPH New York, NY Foundation Aurora, CO US Food and Drug Administration Bernard J. Gersh, MB, ChB, DPhil New York, NY George S. Hanzel, MD Rockville, MD Mayo Clinic Bruce H. Gray, DO William Beaumont Hospital Tim A. Fischell, MD Rochester, MN Greenville Hospital System Royal Oak, MI Heart Institute at Borgess Gary Gershony, MD Greenville, SC Joshua M. Hare, MD Medical Center John Muir Medical Center William A. Gray, MD University of Miami Kalamazoo, MI Piedmont, CA Columbia University Miller School of Medicine Michael C. Fishbein, MD Ian C. Gilchrist, MD Medical Center Miami, FL UCLA Center for Health Sciences Pennsylvania State University / New York, NY Kishore Harjai, MD Los Angeles, CA Hershey Medical Center Roy K. Greenberg, MD Guthrie Clinic Peter J. Fitzgerald, MD, PhD Hershey, PA The Cleveland Clinic Foundation Sayre, PA Stanford University Linda D. Gillam, MD Cleveland, OH Howard L. Haronian, MD Medical Center Columbia University Bartley Griffith, MD Yale School of Medicine Stanford, CA Medical Center University of Maryland New Haven, RI Margaret A. Flannery, FNP New York, NY Baltimore, MD Geoffrey O. Hartzler, MD Columbia University A. Marc Gillinov, MD Cindy L. Grines, MD Cardiovascular Consultants Medical Center The Cleveland Clinic Foundation William Beaumont Hospital Leawood, KS New York, NY Cleveland, OH Royal Oak, MI Marian C. Hawkey, RN Phil B. Fontanarosa, MD, MBA Frank J. Giordano, MD Thomas Gross, MD, MPH Columbia University Journal of the American Yale University School US Food and Drug Administration Medical Center Medical Association of Medicine Rockville, MD New York, NY Chicago, IL New Haven, CT Adam Groothais, MD Alan W. Heldman, MD Jessica Forman RPA-C Leonard N. Girardi, MD Brigham and Women's Hospital University of Miami NewYork-Presbyterian Hospital Weill Medical College of Boston, MA Miller School of Medicine New York, NY Cornell University Michael Guiry, RPA-C Miami, FL William J. French, MD New York, NY NewYork-Presbyterian Hospital William E. Hellenbrand, MD Harbor - UCLA Medical Center Ira J. Goldberg, MD New York, NY Children’s Hospital of NewYork- Torrance, CA Columbia University Manish Prakash Gupta, MD Presbyterian Hospital Medical Center Lenox Hill Hospital New York, NY New York, NY New York, NY

16 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

Jeffrey C. Hellinger, MD Mun K. Hong, MD Ik-Kyung Jang, MD, PhD Dean J. Kereiakes, MD Hospital of the University of St. Luke’s-Roosevelt Massachusetts General Hospital The Lindner Center at Pennsylvania Hospital Center Boston, MA The Christ Hospital

Philadelphia, PA New York, NY Julian J. Javier, MD Cincinnati, OH in t ro Timothy D. Henry, MD W. Craig Hooper, PhD Naples Community Hospital Morton J. Kern, MD Minneapolis Heart Centers for Disease Naples, FL University of California, Irvine Institute Foundation Control and Prevention Lisa K. Jennings, PhD Orange, CA Minneapolis, MN Atlanta, GA

University of Tennessee Health Srinivas Kesanakurthy, MD tURDAY agenda Michael R. Henson L. Nelson Hopkins, MD Science Center Columbia University sa MedFocus Funds Millard Fillmore Gates Hospital Memphis, TN Medical Center Irvine, CA Buffalo, NY Thomas K. Jones, MD New York, NY James B. Hermiller, Jr, MD Keith A. Horvath, MD Seattle Children’s Hospital Umesh Khot, MD sun DAY St. Vincent Hospital / National Heart, Lung, Seattle, WA Indiana Heart Physicians / agenda The Heart Center of Indiana and Blood Institute Ulrich P. Jorde, MD St. Francis Heart Center Indianapolis, IN Bethesda, MD Columbia University Indianapolis, IN Howard C. Herrmann, MD Syed Hossainy, PhD Medical Center R. Stefan Kiesz, MD Hospital of the University Abbott Vascular New York, NY San Antonio Endovascular and agenda mon DAY of Pennsylvania Santa Clara, CA Anand Joshi, MD Heart Institute Philadelphia, PA Nancy Houston Miller, BSN, RN Columbia University San Antonio, TX Richard R. Heuser, MD Stanford Cardiac Medical Center Michael S. Kim, MD University of Arizona Rehabilitation Program New York, NY University of Colorado Health Phoenix, AZ Palo Alto, CA Sciences Center agenda

James D. Joye, DO t ues DAY Stuart T. Higano, MD Kenneth C. Huber, MD El Camino Hospital Aurora, CO Town and Country Cardiovascular St Luke’s Hospital Mountain View, CA Spencer B. King III, MD Group PC Kansas City, MO Lowell Kabnick, MD Fuqua Heart Center St. Louis, MO Barrie J. Huberman, PhD Vein Institute of New Jersey Atlanta, GA Ziyad M. Hijazi, MD, MPH Lenox Hill Hospital Morristown, NJ Nicholas N. Kipshidze, MD, PhD agenda wed NESDAY Rush University Medical Center New York, NY Alan H. Kadish, MD Lenox Hill Hospital Chicago, IL New York, NY

Frank F. Ing, MD Northwestern Memorial Hospital Elizabeth J. Hillebrenner, MSE Texas Children’s Hospital Chicago, IL Ajay J. Kirtane, MD, SM

US Food and Drug Administration Houston, TX Columbia University case Greg L. Kaluza, MD, PhD reviews Rockville, MD Ignacio Inglessis-Azuaje, MD Cardiovascular Research Medical Center Matthew G. Hillebrenner, MSE Massachusetts General Hospital Foundation New York, NY US Food and Drug Administration Boston, MA New York, NY Marc Klapholz, MD Rockville, MD Silviu Itescu, MBBS David E. Kandzari, MD The University of Medicine and Dentistry of New Jersey agenda Tomoaki Hinohara, MD Columbia University Cordis Corporation t hurs DAY Sequoia Hospital Medical Center Warren, NJ Newark, NJ Redwood City, CA New York, NY Samir R. Kapadia, MD Neal S. Kleiman, MD John W. Hirshfeld, Jr, MD Sriram S. Iyer, MD The Cleveland Clinic Foundation The Methodist DeBakey University of Pennsylvania Lenox Hill Hospital Cleveland, OH Heart Center t raining Houston, TX physician Medical Center New York, NY Aaron V. Kaplan, MD Philadelphia, PA Alice K. Jacobs, MD Dartmouth-Hitchcock Lloyd W. Klein, MD John McB. Hodgson, MD Boston University Medical Center Medical Center Clinical Cardiology Associates St. Joseph’s Hospital Boston, MA Lebanon, NH Oak Park, IL t elli e even t s

and Medical Center Michael R. Jaff, DO Saibal Kar, MD Charles S. Kleinman, MD sa Phoenix, AZ Massachusetts General Hospital Cedars-Sinai Medical Center Columbia University Howard M. Holstein, JD Boston, MA Los Angeles, CA Medical Center New York, NY Washington, DC Farouc A. Jaffer, MD, PhD Barry T. Katzen, MD Shunichi Homma, MD Massachusetts General Hospital Baptist Cardiac and Robert A. Kloner, MD, PhD Columbia University Boston, MA Vascular Institute Good Samaritan Hospital ABS T RAC S Los Angeles, CA Medical Center Dennis Jamiolkowski, MD Miami, FL New York, NY Ethicon Annie F. Kelly, MD Patricia E. Knipper, RN Somerville, NJ University of Wisconsin New York, NY

Hospitals and Clinics general Madison, WI

www.tct2007.com 17 transcatheter cardiovascular therapeutics

faculty

William D. Knopf, MD Roger J. Laham, MD JoAnn Lindenfeld, MD James R. Margolis, MD St. Joseph’s Hospital of Atlanta Beth Israel Deaconess University of Colorado Health Miami International Cardiology Atlanta, GA Medical Center Sciences Center Consultants Susheel Kodali, MD Boston, MA Denver, CO Miami, FL Columbia University John R. Laird, Jr, MD Rebecca S. Lipner, PhD Michael L. Marin, MD Medical Center University of California, Davis American Board of Internal The Mount Sinai Medical Center New York, NY Sacramento, CA Medicine New York, NY Joachim Kohn, MD Alexandra J. Lansky, MD Philadelphia, PA Jonathan D. Marmur, MD New Jersey Center for Biometrics Columbia University John J. Lopez, MD SUNY Downstate Medical Center Piscataway, NJ Medical Center The University of Chicago New York, NY David F. Kong, MD New York, NY Chicago, IL Timothy Martens, MD Duke University Medical Center Gregory M. Lanza, MD, PhD Didier F. Loulmet, MD Columbia University Durham, NC Barnes-Jewish Hospital Lenox Hill Hospital Medical Center Marvin A. Konstam, MD St. Louis, MO New York, NY New York, NY Tufts-New England John M. Lasala, MD, PhD Reginald I. Low, MD Amy Elizabeth Martin, MD Medical Center Washington University University of California, Davis BenefisH ospital Boston, MA School of Medicine Sacramento, CA Great Falls, MT Zvonimir Krajcer, MD St. Louis, MO Alan Lumsden, MD Edward T. Martin, MD St. Luke’s Episcopal Hospital Larry A. Latson, MD Methodist DeBakey Heart Center Oklahoma Heart Institute Houston, TX The Cleveland Clinic Foundation Houston, TX Tulsa, OK Christopher M. Kramer, MD Cleveland, OH Michael J. Mack, MD Jack L. Martin, MD University of Virginia Robert J. Lederman, MD Medical City Dallas Bryn Mawr Hospital Health System National Heart, Lung, and Dallas, TX Bryn Mawr, PA Charlottesville, VA Blood Institute Edward G Mackay, MD Steven O. Marx, MD Paul Kramer, MD Bethesda, MD Palm Harbor Medical Arts Columbia University College of Kramer and Crouse Cardiology, PC David P. Lee, MD Palm Harbor, FL Physicians and Surgeons Shawnee Mission, KS Stanford University Akiko Maehara, MD New York, NY Edward M. Kreps, MD Medical Center Columbia University Frederick A. Masoudi, MD, MSPH Columbia University Stanford, CA Medical Center Denver Health Medical Center Medical Center Massoud A. Leesar, MD New York, NY Denver, CO New York, NY University of Louisville Lisa Mainieri, MPH, MSW Vandana S. Mathur, MD Simon Krivor, RCIS, PA-C Louisville, KY NewYork-Presbyterian Hospital Woodside, CA Lenox Hill Hospital Martin B. Leon, MD New York, NY Jon Matsumura, MD New York, NY Columbia University William H. Maisel, MD, MPH Northwestern University Mitchell W. Krucoff, MD Medical Center Beth Israel Deaconess Medical Feinberg School of Medicine Duke University Medical Center New York, NY Center / Harvard Medical School Chicago, IL Durham, NC Norman E. Lepor, MD Boston, MA Matthew S. Maurer, MD Harlan Krumholz, MD Cedars-Sinai Medical Center Raj Makkar, MD Columbia University Yale-New Haven Hospital Beverly Hills, CA Cedars-Sinai Medical Center Medical Center for Outcomes Research Amir Lerman, MD Los Angeles, CA New York, NY New Haven, CT Mayo Clinic Vinay Malhotra, MD Laura Mauri, MD, MSc Spencer H. Kubo, MD Rochester, MN Cardiac Study Center Brigham and Women’s Hospital Acorn Cardiovascular John R. Lesser, MD Tacoma, WA Boston, MA St. Paul, MN Minneapolis Heart Thomas H. Maloney, MS, RCIS Michael V. McConnell, MD Robert Kutys, MS Institute Foundation Memorial Regional Stanford University CVPath Institute, Inc Minneapolis, MN Medical Center Stanford, CA Gaithersburg, MD William W. Li, MD Mechanicsville, VA Daniel J. McCormick, DO Raymond Y. Kwong, MD, MPH The Angiogenesis Foundation Steven V. Manoukian, MD Hahnemann University Hospital Brigham and Women’s Hospital Cambridge, MA Emory University School Philadelphia, PA Boston, MA Michael J. Lim, MD of Medicine James F. McKinsey, MD Elena Ladich, MD Saint Louis University Hospital Atlanta, GA Columbia University CVPath Institute, Inc St. Louis, MO Keith L. March, MD, PhD Medical Center Gaithersburg, MD Indiana Center for Vascular New York, NY Biology and Medicine Indianapolis, IN

18 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

Thomas O. McNamara, MD Michael Mooney, MD Richard F. Neville, MD Gregory D. N. Pearson, MD, PhD UCLA Medical Center Minneapolis Heart Georgetown University Hospital Columbia University Los Angeles, CA Institute Foundation Washington, DC Medical Center

Dwight Meglan, PhD Minneapolis, MN Christopher Nielsen, MD New York, NY in t ro Heartlander Surgical Pedro R. Moreno, MD Medical University of Wesley R. Pedersen, MD Westwood, MA The Mount Sinai Medical Center South Carolina Minneapolis Heart Roxana Mehran, MD New York, NY Charleston, SC Institute Foundation Minneapolis, MN

Columbia University Nicholas Morrissey, MD Hilary Nierenberg, MS, ANP, MPH tURDAY agenda Medical Center Columbia University Columbia University Marc Penn, MD, PhD sa New York, NY Medical Center Medical Center The Cleveland Clinic Foundation George A. Mensah, MD New York, NY New York, NY Cleveland, OH Centers for Disease Jeffrey W. Moses, MD E. Magnus Ohman, MD Emerson C. Perin, MD, PhD sun DAY Control and Prevention Columbia University Duke University Medical Center Texas Heart Institute agenda Duluth, GA Medical Center Durham, NC Houston, TX Franz H. Messerli, MD New York, NY Jeffrey W. Olin, DO John L. Petersen, MD St. Luke’s-Roosevelt Arthur J. Moss, MD The Mount Sinai Duke University Medical Center Hospital Center University of Rochester School of Medicine Durham, NC agenda mon DAY New York NY Medical Center New York, NY Harry R. Phillips, MD D. Christopher Metzger, MD Rochester, NY Beth A. Oliver, RN Duke University Medical Center Wellmont Holston Valley Amir Motarjeme, MD The Mount Sinai Medical Center Durham, NC Medical Center Midwest Vascular New York, NY Steve Phurrough, MD, MPA Kingsport, TN Institute of Illinois agenda

William W. O’Neill, MD Center for Medicare t ues DAY Philip M. Meyers, MD Downers Grove, IL University of Miami and Medicaid Services Columbia University Issam D. Moussa, MD Miami, FL Baltimore, MD Medical Center Columbia University Charles D. O’Shaughnessy, MD Augusto D. Pichard, MD New York, NY Medical Center North Ohio Heart Center Washington Hospital Center Alan D. Michelson, MD New York, NY Elyria, OH Washington, DC agenda wed NESDAY University of Massachusetts M. Reza Movahed, MD, PhD Mehmet C. Oz, MD Ileana L. Pina, MD Medical School University of Arizona Sarver Heart

Columbia University University Hospitals of Cleveland Worcester, MA Center / Southern Arizona VA Medical Center Cleveland, OH

Robert E. Michler, MD Health Care System New York, NY case Duane S. Pinto, MD reviews Tucson, AZ MontefioreM edical Center Igor F. Palacios, MD Beth Israel Deaconess New York, NY J. Brent Muhlestein, MD Massachusetts General Hospital Medical Center Erin D. Michos, MD, MHS LDS Hospital Boston, MA Boston, MA Salt Lake City, UT Johns Hopkins David Paniagua, MD Vincent J. Pompili, MD Medical Institutions James E. Muller, MD agenda St. Luke’s Episcopal Hospital / University Hospitals t hurs DAY Baltimore, MD InfraReDx Texas Heart Institute Case Medical Center Jennifer H. Mieres, MD Burlington, MA Houston, TX Cleveland, OH New York University Charles E. Mullins, MD Manish A. Parikh, MD Michael Poon, MD Medical Center Texas Children’s Hospital Lenox Hill Hospital Cabrini Medical Center t raining New York, NY Houston, TX New York, NY New York, NY physician Gary S. Mintz, MD Bernardo Nadal-Ginard, MD, PhD Sahil Parikh Jeffrey J. Popma, MD Cardiovascular Research The Mount Sinai Brigham and Womens Hospital St. Elizabeth’s Medical Center Foundation School of Medicine Boston, MA Boston, MA t elli e

New York, NY New York, NY even t s Helen Parise, ScD Richard L. Popp, MD sa Greg Mishkel, MD Morteza Naghavi, MD Cardiovascular Research Stanford University Prairie Cardiovascular Association for Eradication of Foundation School of Medicine Consultants, Ltd. Heart Attack (AEHA) New York, NY Los Altos Hills, CA Springfield, IL Houston, TX Juan C. Parodi, MD Darren Powell, RCIS David J. Moliterno, MD Sherif F. Nagueh, MD University of Miami Spokane Community College ABS T RAC S University of Kentucky Methodist DeBakey Heart Center / Pinecrest, FL Spokane, WA Lexington, KY The Methodist Hospital Amit Patel, MD, MS Wayne Powell, MPS Houston, TX Kathryn M. Momary, MD University of Pittsburgh The Society for Cardiovascular

Mercer University Christopher M. Nelson, RN, RCIS Pittsburgh, PA Angiography and Interventions general Atlanta, GA Sentara Healthcare Washington, DC Chesapeake, VA

www.tct2007.com 19 transcatheter cardiovascular therapeutics

faculty

Matthew J. Price, MD John F. Rhodes, MD Allan M. Ross, MD Peter A. Schneider, MD Scripps Clinic and Duke University Medical Center George Washington University Kaiser Permanente Research Foundation Durham, NC Medical Center Honolulu, HI La Jolla, CA Charanjit S. Rihal, MD St. Petersburg, FL Paul Schoenhagen, MD Ramon Quesada, MD Mayo Clinic Carlos E. Ruiz, MD, PhD The Cleveland Clinic Foundation Baptist Cardiac and Rochester, MN Lenox Hill Hospital Cleveland, OH Vascular Institute Michael J. Rinaldi, MD New York, NY Daniel G. Schultz, MD Miami, FL Carolinas Heart Institute John H. Rundback, MD US Food and Drug Administration Sheehan L. Raab, RT(R), RCIS Charlotte, NC Holy Name Hospital Rockville, MD NewYork-Presbyterian Hospital Marian Rippy, DVM, PhD Teaneck, NJ Allan Schwartz, MD New York, NY Rippy Pathology Solutions Mary E. Russell, MD Columbia University LeRoy E. Rabbani, MD Woodbury, MN Ascent Translational Medical Center Columbia University David G. Rizik, MD Sciences, Inc New York, NY Medical Center Scottsdale Heart Group Carlisle, MA Robert S. Schwartz, MD New York, NY Scottsdale, AZ Stuart D. Russell, MD Minneapolis Heart Albert E. Raizner, MD Gregory C. Robertson, MD John Hopkins Medical Institutions Institute Foundation The Methodist DeBakey Emory University Hospital Baltimore, MD Minneapolis, MN Heart Center Atlanta, GA S. Eric Ryan, MD Matthew R. Selmon, MD Houston, TX Keith A. Robinson, PhD CorNova, Inc Heart Hospital of Austin Stephen R. Ramee, MD Saint Joseph’s Research Institute Burlington, MA Austin, TX Ochsner Heart and Vascular Norcross, GA Robert D. Safian, MD Victor L. Serebruany, MD, PhD Institute Krishna Rocha-Singh, MD William Beaumont Hospital HeartDrug Research Laboratories New Orleans, LA Prairie Cardiovascular Royal Oak, MI Towson, MD Shrirang V. Ranade, PhD Consultants, Ltd. David J. Sahn, MD Prediman K. Shah, MD Cappella, Inc. Springfield, IL Oregon Health and Cedars-Sinai Medical Center Auburndale, MA Campbell Rogers, MD Science University Los Angeles, CA Sunil V. Rao, MD Cordis Corporation Portland, OR Samin Sharma, MD Duke University Medical Center Warren, NJ Arash Salemi, MD The Mount Sinai Medical Center Chapel Hill, NC Jason H. Rogers, MD Weill Medical College of New York, NY Elizabeth V. Ratchford, MD University of California, Davis Cornell University Fayaz Shawl, MD Johns Hopkins Sacramento, CA New York, NY Washington Adventist Hospital Medical Institutions Eric A. Rose, MD Timothy A. Sanborn, MD Takoma Park, MD Lutherville, MD Columbia University Evanston Northwestern Warren Sherman, MD Mahmood K. Razavi, MD Medical Center Healthcare Columbia University St. Joseph Vascular Institute New York, NY Evanston, IL Medical Center Orange, CA Eric E. Roselli, MD John S. Sapirstein, MD New York, NY Bernadette Reilly, RN The Cleveland Clinic Foundation US Food and Drug Administration Thomas M. Shimshak, MD NewYork-Presbyterian Hospital Cleveland, OH Rockville, MD Advanced Cardiovascular Institute New York, NY Marlon Rosenbaum, MD Maurice E. Sarano, MD Milwaukee, WI Mireya Reilly, MSN Columbia University Mayo Clinic Susan B. Shurin, MD Columbia University Medical Center Rochester, MN National Heart, Lung, and Medical Center New York, NY Jorge F. Saucedo, MD Blood Institute New York, NY Clive Rosendorff, MD, PhD Oklahoma University Bethesda, MD Mark Reisman, MD The James J. Peters VA Medical Center Daniel I. Simon, MD Swedish Heart Institute Medical Center Oklahoma City, OK University Hospitals Seattle, WA Bronx, NY Gary L. Schaer, MD Case Medical Center Jon R. Resar, MD Kenneth Rosenfield, MD Rush University Medical Center Cleveland, OH John Hopkins University Massachusetts General Hospital Chicago, IL Michael Simons, MD School of Medicine Boston, MA Robert M. Schainfeld, DO Dartmouth-Hitchcock Baltimore, MD Todd K. Rosengart, MD Massachusetts General Hospital Medical Center Frederic S. Resnic, MD, MSc Stony Brook University Newton, MA Lebanon, NH Brigham and Women’s Hospital Medical Center Richard Schatz, MD Charles A. Simonton, MD Boston, MA Stony Brook, NY Scripps Clinic and Carolinas Heart Institute Research Foundation Charlotte, NC La Jolla, CA

20 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your tHINKING faculty

John B. Simpson, MD, PhD Sudhir Srivastava, MD Guillermo Tearney, MD, PhD Frank J. Veith, MD Sequoia Hospital University of Chicago Massachusetts General Hospital The Cleveland Clinic Redwood City, CA Medical Center Boston, MA Foundation / New York

Varinder Singh, MD Chicago, IL Paul S. Teirstein, MD University Medical Center in t ro Columbia University Frederick G. St. Goar, MD Scripps Clinic and Bronx, NY Medical Center Cardiovascular Institute Research Foundation George W. Vetrovec, MD New York, NY Mountain View, CA La Jolla, CA Virginia Commonwealth Univeristy Medical Center

Marvin J. Slepian, MD Richard S. Stack, MD Douglas Throckmorton, MD tURDAY agenda

The University of Arizona SyneCor, LLC US Food and Drug Administration Richmond, VA sa Health Sciences Center Portola Valley, CA Rockville, MD Renu Virmani, MD Tucson, AZ Niel F. Starksen, MD Donna-Bea Tillman, PhD CVPath Institute, Inc Richard Smalling, MD, PhD Santa Clara, CA US Food and Drug Administration Gaithersburg, MD sun DAY Memorial Hermann Heart and Steven R. Steinhubl, MD Rockville, MD Jiri J. Vitek, MD, PhD agenda Vascular Institute University of Kentucky Henry H. Ting, MD, MBA Lenox Hill Hospital Houston, TX Lexington, KY Mayo Clinic New York, NY Craig R. Smith, MD Allan S. Stewart, MD Rochester, MN Gordana Vunjak-Novakovic, PhD Columbia University Columbia University Jonathan M. Tobis, MD Columbia University agenda mon DAY Medical Center Medical Center UCLA Medical Center Medical Center New York, NY New York, NY Los Angeles, CA New York, NY Sidney Smith, MD Gregg W. Stone, MD Carl L. Tommaso, MD Ron Waksman, MD University of North Carolina Columbia University Rush North Shore Medical Center Washington Hospital Center Chapel Hill, NC Washington, DC agenda

Medical Center Skokie, IL t ues DAY Ronald J. Solar, PhD New York, NY On Topaz, MD Jie Wang, MD, PhD Thermopeutix Peter H. Stone, MD McGuire VA Medical Center Columbia University San Diego, CA Brigham and Women’s Hospital Richmond, VA Medical Center New York, NY David H. Solomon, MD, PhD Boston, MA James A. Tumlin, MD Vital Sensors Sergio Waxman, MD agenda Thomas D. Stuckey, MD Southeast Renal wed NESDAY Brooklyn, NY Moses Cone Heart and Vascular Research Institute Lahey Clinic Burlington, MA

John Somberg, MD Center / Lebauer Cardiovascular Charlotte, NC Rush University Medical Center Research Foundation Mark A. Turco, MD W. Guy Weigold, MD Lake Bluff, IL Greensboro, NC Washington Hospital Center case Washington Adventist Hospital reviews Robert J. Sommer, MD Timothy Sullivan, MD Takoma Park, MD Washington, DC Columbia University North Central Heart Institute Zoltan G. Turi, MD Bonnie H. Weiner, MD Medical Center Sioux Falls, SD Cooper University Hospital Worcester Medical Center New York, NY H. Robert Superko, MD Camden, NJ Wocester, MA agenda Ali F. Sonel, MD Fuqua Heart Center / E. Murat Tuzcu, MD Neil J. Weissman, MD t hurs DAY VA Pittsburgh Healthcare System Piedmont Medical Center The Cleveland Clinic Foundation Washington Hospital Center Pittsburgh, PA Atlanta, GA Cleveland, OH Washington, DC Paul Sorajja, MD Lars G. Svensson, MD, PhD Barry F. Uretsky, MD Giora Weisz, MD Mayo Clinic The Cleveland Clinic Foundation Columbia University

Sparks Health System t raining physician Rochester, MN Cleveland, OH Fort Smith, AR Medical Center New York, NY Thomas A. Sos, MD Julie A. Swain, MD Tudor Vagaonescu, MD Weill Medical College of US Food and Drug Administration Robert Wood Johnson Frederick Welt, MD Cornell University Fallbrook, CA Brigham and Women’s Hospital Medical School t elli e even t s

New York, NY Wilson Y. Szeto, MD Princeton, NJ Boston, MA sa Peter A. Soukas, MD Hospital of the University Mani Vannan, MD Grayson H. Wheatley, MD St. Elizabeth’s Medical Center of Pennsylvania University of California, Arizona Heart Institute Boston, MA Philadelphia, PA Irvine Medical Center Phoenix, AZ William Spencer, MD Vivian Tamara, BSN, RN Orange, CA Brian Whisenant, MD ABS T RAC S Medical University NewYork-Presbyterian Hospital Thomas A. Vassiliades, Jr, MD Utah Heart Clinic of South Carolina New York, NY Emory University Hospital Salt Lake City, UT Charleston, SC Doris A. Taylor, PhD Atlanta, GA Christopher J. White, MD University of Minnesota Ochsner Heart and Vascular

Minneapolis, MN Institute general New Orleans, LA

www.tct2007.com 21 transcatheter cardiovascular therapeutics

faculty

Patrick L. Whitlow, MD Katherine C. Wu, MD The Cleveland Clinic Foundation Johns Hopkins Medical Institutions Cleveland, OH Baltimore, MD Mark H. Wholey, MD Jay S. Yadav, MD University of Pittsburgh Piedmont Hospital Medical Center Atlanta, GA Pittsburgh, PA Steven J. Yakubov, MD Michael H. Wholey, MD Mid-Ohio Cardiology and Vascular Consultants TexSan Heart Hospital Columbus, OH San Antonio, TX Alan C. Yeung, MD Samuel A. Wickline, MD Stanford University Washington University Medical Center School of Medicine Stanford, CA St. Louis, MO John J. Young, MD Susan E. Wiegers, MD Swedish Heart and Vascular Institute Hospital of the University of Pennsylvania Seattle, WA Philadelphia, PA Chun Yuan, PhD Josiah N. Wilcox, PhD University of Washington Medtronic Vascular Seattle, WA Santa Rosa, CA Lilly Q. Yue, PhD Robert L. Wilensky, MD US Food and Drug Administration Hospital of the University of Pennsylvania Rockville, MD Philadelphia, PA Andrew Zalewski, MD David O. Williams, MD Thomas Jefferson University Rhode Island Hospital King of Prussia, PA Providence, RI Christopher K. Zarins, MD Mathew Williams, MD Stanford University Columbia University Medical Center Medical Center New York, NY Stanford, CA B. Hadley Wilson, MD James P. Zidar, MD Sanger Clinic-Carolinas Duke University Medical Center Health Care Raleigh, NC Charlotte, NC Bram Zuckerman, MD Robert Wilson, MD US Food and Drug Administration University of Minnesota Rockville, MD Minneapolis, MN Lynn Zwiers, PhD Abigail Woglom, RN Transoma Medical NewYork-Presbyterian Hospital Arden Hills, MN New York, NY Steven D. Wolff, MD, PhD Advanced Cardiovascular Imaging New York, NY S. Chiu Wong, MD Weill Medical College of Cornell University New York, NY John C. Wood, MD, PhD Children’s Hospital Los Angeles Los Angeles, CA Marvin L. Woodall Cardiovascular Research Foundation New York, NY

22 truth in evidence based medicine · challenge conventional wisdom · Transform your thinking week at a glance

AM AM AM AM PM AM AM AM AM AM AM AM 0 0 0 PM PM PM PM PM PM PM PM PM 0 :0 :0 :30 PM 0 PM 0 PM :0 0:30 :30 00 00 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10 1 11:0 11 12 12 1:00 1:30 PM 2:0 2:30 3:0 3:30 PM 4:00 4:30 PM 5: 5:30 PM 6:00 6:30 PM 7: 7:30 PM 8:00 8:30 PM 9:00 9:30 PM 10

Friday Registration – All Attendees and Exhibitor s

Registration – All Attendees and Exhibitors

Saturday Board Review Course with Self Assessment – Core Curriculu m Percutaneous Intervention for the Surgeon Scientific Symposia and Practical Wo rkshops

Breakfast Registration – All Attendees and Exhibitors M eetings Board Review Course with Self Assessment – Core Curriculum Sunday Percutaneous Intervention for the Surgeon Scientific Symposia and Practical W orkshops Evening Symposia Cardiovascular Nurse and T echnologist Symposium Breakfast M eetings Board Review Course with Self Assessment – Coronar y Main Arena First Report Tr ials Main Arena Coronary Theater Case Review s Coronary Theater Monday Endovascular Theater Hot T opics Endovascular Theate r Structural Heart Disease Auditorium Structural Heart Disease Auditorium Concurrent Sessions Concurrent Session sESpecial Session s vening Symposia

Exhibits Open Breakfast M eetings Board Review Course with Self Assessment – Coronar y Main Arena First Report Tr ials Main Arena Coronary Theater Case Review s Coronary Theater Endovascular Theater Hot T opics Endovascular Theate r Tuesday Structural Heart Disease Auditorium Special DES Session Structural Heart Disease Auditorium Concurrent Sessions Concurrent Session sESpecial Session s vening Symposia Health and Human Services (HHS) To wn Hall Meeting

Breakfast M eetings Board Review Course with Self Assessment – Endovascular Main Arena FirstExhibits Report Open Tr ials Main Arena Coronary Theater Coronary Theater Wednesday Endovascular Theater Case Review s Endovascular Theate r Structural Heart Disease Auditorium Hot T opics Structural Heart Disease Auditorium Concurrent Sessions Concurrent Session sEvening Symposia

Breakfast Board Review Course: Final Exam Thursday M eetings TCT Highlights and Closing Sessions, Featuring Interventional Jeopardy Exhibits Open transcatheter cardiovascular therapeutics

Live CAse Sites

International Instituto Dante Pazzanese United States de Cardiologia São Paulo, Brazil Asan Medical Center Alexandre Abizaid, MD, PhD Baptist Cardiac and Vascular Seoul, South Korea Jose Ribamar Costa, MD Institute Myeong-Ki Hong, MD, PhD Fausto Feres, MD, PhD Miami, FL Galo Maldonado, MD Young-Hak Kim, MD, PhD James Benenati, MD Luiz Alberto Mattos, MD, PhD Cheol Whan Lee, MD, PhD Barry T. Katzen, MD J. Edwards M. R. Sausa, MD Seung-Whan Lee, MD, PhD Constantino Pena, MD Rodolfo Staico, MD Duk-Woo Park, MD, PhD Alex Powell, MD Seung-Jung Park, MD, PhD Shaun Samuels, MD Seong-Wook Park, MD, PhD Institut Hospitalier Jacques Gerald Zemel, MD Cartier Auckland City Hospital Massy, France Carolinas Medical Center Auckland, New Zealand Thierry Lefevre, MD Charlotte, NC John A. Ormiston, MB, ChB Yves Louvard, MD Robert H. Haber, MD Peter N. Ruygrok, MB, ChB Marie-Claude Morice, MD Osamu Katoh, MD Jim T. Stewart, MB, ChB Alice Ohanessian, MD Michael J. Rinaldi, MD Mark W. I. Webster, MB, ChB Charles A. Simonton, MD King’s College Hospital B. Hadley Wilson, MD CardioVascular Center Frankfurt London, United Kingdom Frankfurt, Germany Carlo DiMario, MD Evanston Northwestern Healthcare Horst Sievert, MD, PhD Anthony H. Gershlick, MD Evanston, IL Nina Wunderlid, MD Michael J. Mullen, MD Ted Feldman, MD Philip MacCarthy, MD Michael H. Salinger, MD Clinique Louis Pasteur Martyn R. Thomas, MD Timothy A. Sanborn, MD Essey-lès-Nancy, France Max Amor, MD Max Heart and Vascular Institute Hahnemann University Hospital Patrice Bergeron, MD New Delhi, India Philadelphia, PA Christian Breton, MD Sunil Aggarwal, MD Daniel Dadourian, MD Zukai Chati, MD Praveen Chandra, MD Sheldon Goldberg, MD Gerard Ethevenot, MD Anil Dhall, MD Robert Koenigsbeg, DO Serge Kownator, MD Viveka Kumar, MD William Kussmaul, MD Jean-Philippe Simon, MD Roopa Salwan, MD Daniel McCormick, DO Ashok Seth, MD Ted Parris, MD Fu wai Hospital Dhirendra Singhania, MD Beijing, China THE Jack H. Skirball Center for Jilin Chen, MD Rabin Medical Center Cardiovascular Research Petach Tikva, Israel Run-Lin Gao, MD Orangeburg, NY Haibo Liu, MD Abid Assali, MD Juan F. Granada, MD Jie Qian, MD Elchanan Bruckheimer, MD Greg L. Kaluza, MD, PhD Yongjian Wu, MD Shmuel Fuchs, MD Yue-Jin Yang, MD Rafael Hirsh, MD Pei Zhang, MD Ran Kornowski, MD Millard Fillmore Gates Hospital Eli Lev, MD Buffalo, NY HELIOS Heart Center L. Nelson Hopkins, MD Siegburg, Germany St. Paul’s Hospital Bubak Jahromi, MD Elad I. Levy, MD Harald Beucher, MD Vancouver, Canada J. Mocco, MD Lutz Buellesfeld, MD Eve D. Aymong, MD Rodney Samuelson, MD Ulrich Gerckens, MD Ronald G. Carere, MD Adnan H. Siddiqui, MD, PhD Eberhard Grube, MD Jaap N. Hamburger, MD, PhD Rabih Tawk, MD Ralf Mueller, MD John G. Webb, MD

24 truth in evidence based medicine · challenge conventional wisdom · Transform your thinking Live CAse Sites

Minneapolis Heart Institute - Presbyterian Heart Institute Abbott Northwestern Hospital Dallas, TX Minneapolis, MN Tony Das, MD in t ro M. Nicholas Burke, MD James Park, MD Ivan J. Chavez, MD Ken Saland, MD Timothy D. Henry, MD Daniel L. Lips, MD Rush University Medical Center

Michael Mooney, MD Chicago, IL tURDAY agenda Wesley R. Pedersen, MD sa Ziyad M. Hijazi, MD, MPH Anil Poulose, MD Clifford J. Kavinsky, MD, PhD Robert S. Schwartz, MD Roberto Lang, MD Jay Tradirse, MD Oi-Ling Cao, MD Yale L. Wang, MD sun DAY agenda Saint Luke’s Mid America Columbia University Medical Center New York, NY Heart Institute Kansas City, MO Mark A. Apfelbaum, MD agenda Charles W. Barth, MD mon DAY Michael B. Collins, MD David J. Cohen, MD George D. Dangas, MD J. Aaron Grantham, MD William A. Gray, MD Kenneth C. Huber, MD Ajay J. Kirtane, MD, SM Warren L. Johnson, MD Susheel Kodali, MD agenda

Steven B. Laster, MD t ues DAY Edward M. Kreps, MD Steven P. Marso, MD Martin B. Leon, MD Barry D. Rutherford, MD Roxana Mehran, MD David M. Safley, MD Jeffrey W. Moses, MD Issam D. Moussa, MD agenda

LeRoy E. Rabbani, MD Swedish Heart & Vascular Institute wed NESDAY Warren Sherman, MD Seattle, WA Varinder Singh, MD Amish J. Desai, MD Robert J. Sommer, MD Paul P. Huang, MD Gregg W. Stone, MD Thomas K. Jones, MD case reviews Paul S. Teirstein, MD Mark Reisman, MD Giora Weisz, MD R. Jeffrey Westcott, MD John J. Young, MD Alton Ochsner Medical Center

New Orleans, LA agenda

Riverside Methodist Hospital t hurs DAY Tyrone J. Collins, MD Columbus, OH Mark Grise, MD Gary M. Ansel, MD J. Stephen Jenkins, MD Charles F. Botti, Jr, MD Paul McMullen, MD Mitchell J. Silver, DO t raining Stephen R. Ramee, MD physician John Reilly, MD University of Colorado Hospital Christopher J. White, MD Denver, CO John D. Carroll, MD t elli e even t s

Ivan Casserly, MD sa Joel Garcia, MD John Messenger, MD ABS T RAC S general

www.tct2007.com 25 transcatheter cardiovascular therapeutics

Saturday \ october 20, 2007

Scientific Symposia and 9:55 a m - Case Examples and Interactive Q&A 3:00 p m - Valvuloplasty Core Competencies: Moderators: Michael J. Davidson, Transseptal Catheterization and Practical Workshops Mathew Williams Retrograde Aortic Crossing 7:45 a m -7:15 p m Discussants: Michael J. Cowley, Howard C. Herrmann Ajay J. Kirtane, Manish A. Parikh, 3:15 p m - Case Examples and Interactive Q&A Arash Salemi, Zoltan G. Turi Moderators: Susheel Kodali, Percutaneous INTERVENTION 10:10 a m - Break Charles A. Simonton Discussants: Howard C. Herrmann, for the Surgeon, PART 1 10:25 a m - Angioplasty 102: Stent Types and 7:45 a m -7:15 p m Construction, Bare Metal and Drug-Eluting, Issam D. Moussa Room 207AB Mechanism of Action, Acute Success, and 3:30 p m - Practicum II: Simulator Station Director: Mathew Williams Complication Rates and Device Tables: Basic Skills Co-Directors: Michael J. Davidson, John M. Lasala Francesco Maisano, Eric E. Roselli 10:40 a m - Angioplasty 103: Adjunct Hybrid Therapy 7:45 a m - Welcome Introduction Pharmacology Essentials Moderators: John G. Byrne, and Course Objectives Steven V. Manoukian Thomas A. Vassiliades, Jr Mathew Williams 10:55 a m - Angioplasty 104: Interventional 4:45 p m - The Hybrid Suite and Routine 7:50 a m - A New Paradigm: Cardiac Complications and Management Angiographic Assessment After CABG Surgeons as Interventionalists Susheel Kodali John G. Byrne Michael J. Davidson 11:10 a m - Angioplasty 105: Restenosis in 5:00 p m - Hybrid Therapy for Disease of 8:00 a m - Obtaining Training: Different Vascular Beds: Incidence with the Aorta How to Do It and What Is Required Balloon Angioplasty and Stents, Eric E. Roselli Mathew Williams Implications, Mechanisms, and Terminology 5:15 p m - Combined PCI and CABG: Alexandra J. Lansky Techniques, Timing, Pharmacology, A Primer of Percutaneous 11:30 a m - Case Examples and and Clinical Results Angiography and Intervention Interactive Q&A Thomas A. Vassiliades, Jr Moderators: Michael J. Davidson, Moderators: Michael J. Davidson, 5:30 p m - When Surgery Fails: Mathew Williams Mathew Williams Incidence and Results of Percutaneous Discussants: Susheel Kodali, 8:10 a m - The Cath Lab Environment: Intervention of Graft Disease Alexandra J. Lansky, John M. Lasala, Room Setup and Differences from Sheldon Goldberg Steven V. Manoukian the Surgical Suite 5:45 p m - Moderated Discussion and Q&A Arash Salemi 11:45 a m - Lunch and Practicum I: Simulator Panel Moderators: John G. Byrne, Station and Device Tables: Basic Skills 8:25 a m - Introduction to Imaging and Thomas A. Vassiliades Jr Radiation Safety Discussants: Sheldon Goldberg, Stephen Balter Beyond the Basics Eric E. Roselli Moderators: Susheel Kodali, 8:40 a m - Vascular Access and Closure: Charles A. Simonton Alternatives and Complications Evening Session: The Society of Zoltan G. Turi 1:45 p m - Right and Left Heart Surgery and Cardiovascular Hemodynamics: Setup, Information, 8:55 a m - Angiographic Catheters: Shapes, Intervention (SSCI) Indications Sizes, and Selective Vessel Engagement: Moderators: Michael J. Davidson, Larry S. Dean Coronary and Non-Coronary Eric E. Roselli, Arash Salemi, Mathew Williams Ajay J. Kirtane 2:00 p m - Intravascular Ultrasound: Devices, 6:00 p m - SSCI Introduction, Mission, Image Generation, Basic Measures, and 9:10 a m - Basics of Angiography: Manifold Activities, and Call for Membership Utility and Injectors, Anatomy, Angles, Contrast Mathew Williams John McB. Hodgson Agents, and Artifacts 6:15 p m - Keynote Presentation: 2:15 p m - Primary Coronary Angioplasty for Michael J. Davidson The Changing Face of Cardiac Surgery Acute Myocardial Infarction and the 9:25 a m - Introduction to the Coronary Michael J. Mack Thrombus Containing Lesion Angioplasty Procedure: Edited Case Video Mark A. Turco 6:45 p m - Reception Manish A. Parikh 2:30 p m - Understanding and Interpreting 9:40 a m - Angioplasty 101: Guidewires Stent Studies: Drug-Eluting vs. Bare (Including Exchanges), Guide Catheters, Metal, On- vs. Off-Label Balloons (Materials, Compliance, OTW vs. Charles A. Simonton Exchange), Basic Technique, and Mechanism of Action 2:45 p m - PCI vs. CABG: What Most Michael J. Cowley Interventionalists Think (And Rationalize) Issam D. Moussa

26 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Saturday \ october 20, 2007

Board Review Course with 3:55 p m - Coronary Angiography and 12:00 p m - CT Scanners, Acquisition Ventriculography: Anatomy and Anomalies Protocols, and Radiation Exposure Self Assessment for Michael J. Lim (Today and Tomorrow)

Stephan Achenbach in t ro Interventional Cardiology 4:20 p m - Q&A 12:20 p m - Coronary CTA in the and Endovascular Medicine, 4:30 p m - Valvular Heart Disease: Hemodynamic Assessment and Assessment of Acute Chest Pain pART 1: cORE cURRICULUM Interventional Approaches James A. Goldstein 8:00 a m -6:00 p m

Zoltan G. Turi 12:40 p m - Coronary CTA vs. Coronary tURDAY

Room 146ABC agenda Calcium Scoring in Assessment of Stable sa 5:00 p m - Q&A Chest Pain and Asymptomatic Patients 5:15 p m - Congenital Heart Disease Fundamental Knowledge Daniel S. Berman Moderator: George D. Dangas in the Adult: Diagnosis and Interventional Approaches 1:00 p m - Evaluation of Stents and 8:00 a m - Pathology of Atherosclerosis sun DAY Robert J. Sommer Vein Grafts with CTA agenda and Restenosis John R. Lesser Renu Virmani 5:45 p m - Q&A 1:20 p m - Adult Congenital Heart Disease: 6:00 p m - Adjourn 8:40 a m - Q&A When is CT the Test of Choice?

8:55 a m - Medical Statistics and Trial Design Jeffrey C. Hellinger agenda Stuart J. Pocock mon DAY Registered Cardiovascular 1:40 p m - Guidelines and Economics of 9:40 a m - Q&A Coronary CTA Invasive Specialists (RCIS) Michael Poon 10:00 a m - Break 2:00 p m - Q&A 10:15 a m - Radiation Principles and Safety Review Course agenda Stephen Balter 12:00 p m -4:00 p m t ues DAY Room 209ABC CT Workstation Demos: 10:45 a m - Q&A Moderator: Thomas H. Maloney How to Interpret . . . Moderators: Stephan Achenbach, Interventional Pharmacology 12:00 p m - Introduction and the Role of Michael Poon Moderator: George D. Dangas the SICP in Exam Preparation agenda Todd Chitwood 2:15 p m - Coronary CTA (Including wed NESDAY 11:00 a m - Antiplatelet Medications: Anomalies) Classification and Indications in 12:15 p m - Patient Care and Assessment Michael Poon PCI, CABG, ACS, and AMI Darren Powell 2:35 p m - Cardiac Function and George D. Dangas case 1:05 p m - Cardiovascular Disease Process Valvular Heart Disease reviews 12:00 p m - Q&A Jeff Davis John R. Lesser 12:15 p m - Break 1:55 p m - Break 2:55 p m - Bypass Grafts and Stents 1:00 p m - Antithrombin and Thrombolytic 2:05 p m - Hemodynamics with Calculations Stephan Achenbach Medications: Classification and Indications Jeff Davis

3:15 p m - Vascular CTA agenda in PCI, CABG, ACS, and AMI t hurs DAY 2:55 p m - 12 Lead EKG Interpretation W. Guy Weigold Steven V. Manoukian Todd Chitwood 2:00 p m - Q&A 3:45 p m - Sample RCIS Test Q&A The Latest Advances in 2:15 p m - Pre- and Post-PCI Patient Thomas H. Maloney Cardiovascular CT t raining

Management physician 4:00 p m - Adjourn Moderators: John R. Lesser, Vinay Malhotra Alexandra J. Lansky 3:35 p m - Risk Stratification by Coronary CTA 2:40 p m - Q&A Pim de Feyter Cardiovascular Non-Invasive 3:50 p m - Evaluation of In-Stent Restenosis t elli e

Cardiac Catheterization even t s Imaging: CTA, MRI, and and Chronic Total Occlusions with CTA sa Angiography and Structural Beyond (With Reading Vinay Malhotra Heart Disease 4:05 p m - SPECT-CT and PET-CT: Moderators: Michael J. Cowley, Michael J. Lim Sessions with the Experts), Simultaneous or Sequential? 2:50 p m - Vascular Access and Closure: part 1 Daniel S. Berman ABS T RAC S Alternatives and Complications 12:00 p m -6:30 p m 4:20 p m - Evaluation of Patients with Zoltan G. Turi Room 151A Atrial Fibrillation 3:10 p m - Q&A Michael Poon

3:20 p m - Contrast Agents and Cardiac CT Didactic Sessions 4:35 p m - Characterization of

Radiocontrast Nephropathy Moderators: Daniel S. Berman, Pim de Feyter Atherosclerotic Plaque general Roxana Mehran Pim de Feyter

3:45 p m - Q&A 4:50 p m - Q&A

www.tct2007.com 27 transcatheter cardiovascular therapeutics

Saturday \ october 20, 2007

Clinical Case Examples: Read CT 1:02 p m - The Role of Adjunctive Medical ACS III: Antiplatelet Decisions With the Experts Therapies in ACS and NSTEMI (Statins, in NSTEMI Moderators: Daniel S. Berman, Michael Poon Beta Blockers, ACE Inhibitors, and More): Moderators: Alan D. Michelson, Timing and Impact Victor L. Serebruany 5:10 p m - Three Patients with Acute James H. Chesebro Chest Pain 3:05 p m - The Case for Routine Stephan Achenbach 1:14 p m - TCT-2: Biochemical Assessment of Upfront Thienopyridine Loading the Atherosclerotic Plaque Necrotic Core Prior to Angiography in ACS 5:30 p m - Three Patients with Stents and Content in Patients with Coronary Artery Ramin Ebrahimi Vein Graft Disease Disease Vinay Malhotra Adam Rdzanek et al 3:15 p m - Is Clopidogrel Preloading Beneficial: From CURE and CREDO to 5:50 p m - Three Patients with 1:24 p m - Moderated Discussion and Q&A Cardiomyopathy and Valvular Heart Disease PRAGUE-8 and Beyond Panel Moderators: John A. Ambrose, Germano Di Sciascio John R. Lesser Daniel I. Simon 3:25 p m - Thienopyridine Hyporesponsiveness 6:10 p m - Three Patients with Cardiac Discussants: Thomas J. Brady, Arrhythmias and Implanted Devices James H. Chesebro, Anibal A. Damonte, Considerations in ACS: Rationale for Michael Poon Robert J. de Winter, Adam Rdzanek, and Design of OASIS-7 Michael Rokoss 6:30 p m - Adjourn Helmet Schuhlen 3:35 p m - Thienopyridine Hyporesponsiveness: ACS II: NSTEMI Guidelines and Definitions, Implications, and Monitoring Considerations in ACS and PCI Interventional Strategies Evidence-Based Medicine Alan D. Michelson and Adjunct Pharmacology Moderators: Michel E. Bertrand, Alice K. Jacobs 3:47 p m - Properties and Expectations for Novel P2Y Antagonists, PAR-1 Inhibitors, in ACS and AMI, PART 1 12 1:39 p m - Critical Appraisal of the 12:00 p m -6:10 p m and Other Antiplatelet Agents Under “New” European and “New” American Room 151B Development and in Clinical Testing NSTEMI Guidelines Ali F. Sonel Robert J. deWinter ACS I: Invasive vs. Conservative 4:02 p m - Controversies in Platelet 1:54 p m - Evolving US Practices in ACS Strategies and Risk Stratification Function Assessment: Implications and NSTEMI: Lessons from CRUSADE for the Development of New Agents Moderators: John A. Ambrose, John L. Petersen Daniel I. Simon Victor L. Serebruany 2:06 p m - Evolving Global Practices in 4:12 p m - Arguing for Routine Upstream GP 12:00 p m - Use Recommendations for Old ACS and NSTEMI: Lessons from GRACE llb/llla Inhibitors in ACS and NSTEMI and New Biomarkers in Patients with Chest Michel E. Bertrand Pain David F. Kong 2:18 p m - Cost Drivers in ACS and Daniel I. Simon 4:22 p m - Arguing for GP llb/lIla Inhibitors in PCI and Cost-Effectiveness of ACS and NSTEMI During PCI 12:12 p m - Emergency Room Role Different Anticoagulant Approaches Helmut Schuhlen of CTA Imaging to Risk Stratify David J. Cohen Patients with Chest Pain 4:32 p m - Arguing Against GP llb/lIla 2:30 p m - Minimizing Hemorrhagic Thomas J. Brady Inhibitors in ACS and NSTEMI Complications in ACS and PCI: David A. Cox 12:22 p m - Meta-Analysis of PCI vs. Insights from OASIS-5 and ACUITY Medical Therapy in Patients with Martial Hamon 4:42 p m - Moderated Discussion and Q&A Stable and Unstable Angina Panel Moderators: Alan D. Michelson, 2:40 p m - Is the Prevention of Iatrogenic Adnan Kastrati Victor L. Serebruany Bleeding (or Transfusion) Now More Discussants: David A. Cox, 12:32 p m - Making the Case for a Important Than Ischemia in ACS and PCI? Germano Di Sciascio, Ramin Ebrahimi, Routine Early Invasive Strategy Steven V. Manoukian in Unstable Angina and NSTEMI Michael Rokoss, Helmut Schuhlen, 2:50 p m - Moderated Discussion and Q&A Helmet Schuhlen Victor L. Serebruany, Ali F. Sonel Panel Moderators: Michel E. Bertrand, 12:42 p m - Making the Case for a Alice K. Jacobs ACS IV: Antithrombin DecisionS Delayed Invasive Strategy in Discussants: David J. Cohen, in NSTEMI Unstable Angina and NSTEMI Robert J. de Winter, Martial Hamon, Moderators: Martin T. Rothman, Gary L. Schaer Robert J. de Winter John L. Petersen 12:52 p m - TCT-1: Complete vs. Culprit 4:57 p m - New Insights from SYNERGY and Vessel Percutaneous Revascularization Related Trials: When and How Should Low in Patients with Non-ST Segment Molecular Weight Heparins Be Used in Elevation Acute Coronary Syndromes ACS and NSTEMI? Anibal A. Damonte et al Sunil V. Rao

28 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Saturday \ october 20, 2007

5:09 p m - New Insights From ACUITY: Angiogenesis II: Focus on Angiogenesis IV: Clinical Results When and How Should Bivalirudin Endothelial Progenitor Cells and New Directions 2 Be Used in ACS and NSTEMI? Moderators: Stefanie Dimmeler, Moderators: Joshua M. Hare, Timothy D. Roxana Mehran Frank J. Giordano Henry in t ro 5:21 p m - New Insights From OASIS 5: 1:12 p m - What Constitutes an Endothelial 4:21 p m - Synergistic Angiogenesis with When and How Should Fondaparinux Progenitor Cell? Identifying Characteristics Mesenchymal Stem Cells and Laser Be Used in ACS and NSTEMI? William W. Li Revascularization Michael Rokoss Keith A. Horvath tURDAY p m 1:27 - Engineered Endothelial Progenitor agenda 5:33 p m - Antithrombins and Platelet sa Cells: Disease-Specific Cell Targeting 4:33 p m - Novel Epicardial Patch for Reactivity: From Theory to Practical Duncan J. Stewart Angiogenesis: Initial Clinical Observations Considerations Bartley Griffith Lisa K. Jennings 1:42 p m - Endothelial Progenitor Cells: Potential for Myocardial Protection 4:45 p m - Progress with Adipose-Derived sun DAY 5:43 p m - Should All Health Care Systems Sunil V. Rao Cells: Turning Fat into Vessels agenda Strive For Optimal Therapeutic Pathways to Henricus J. Duckers Maximize Outcomes Using Evidence-Based 1:57 p m - Emerging Clinical Relevance Medicine? of De Novo EPC Levels 5:00 p m - Angiogenesis Agents for Critical John A. Ambrose Jonathan M. Hill Limb Ischemia: Second Generation and Beyond agenda 2:09 p m - Moderated Discussion and Q&A mon DAY 5:53 p m - Moderated Discussion and Q&A Michael Simons Panel Moderators: Martin T. Rothman, Panel Moderators: Stefanie Dimmeler, Gary L. Schaer Frank J. Giordano 5:15 p m - Progenitor Cell Therapy for Discussants: John A. Ambrose, Discussants: Jonathan M. Hill, William W. Li, Pulmonary Hypertension: The PHACeT Trial Franz Wolfgang Amann, Lisa K. Jennings, Sunil V. Rao, Duncan J. Stewart Duncan J. Stewart agenda Roxana Mehran, Sunil V. Rao, Michael Rokoss 5:27 p m - TCT-6: Infarct Size and Myocardial t ues DAY Angiogenesis III: Clinical Results Blood Flow After CD133+ Stem Cells Therapy 6:10 p m - Adjourn and New Directions 1 in Large Myocardial Infarction: A Moderators: Roger J. Laham, Michael Simons Randomized Controlled Trial Alessandro Colombo et al Molecular Cardiology 2:24 p m - Gene Therapy Trials for Coronary agenda Artery Disease: “Deciphering the Signals” 5:37 p m - Moderated Discussion and Q&A wed NESDAY Breakthroughs: Cell Michael Simons Panel Moderators: Joshua M. Hare,

Timothy D. Henry Therapy and Angiogenesis, 2:39 p m - SEACOAST Trial Update: Clinical + Discussants: Alessandro Colombo,

Effects and Future Directions of CD133 Cells case PART 1 Henricus J. Duckers, Bartley Griffith, Vincent J. Pompili reviews 12:00 p m -6:00 p m Michael Simons, Duncan J. Stewart Room 154AB 2:54 p m - Autologous CD34+ Cells for 6:00 p m - Adjourn the Treatment of Chronic Myocardial Angiogenesis I: Mechanisms Ischemia: Preliminary Observations Timothy D. Henry and Novel Molecular Strategies agenda Septal Ablation for t hurs DAY Moderators: Stephen E. Epstein, 3:09 p m - Immunoselected Bone Marrow- Jonathan M. Hill Derived Precursor Cells for Chronic Hypertrophic Obstructive Myocardial Ischemia 12:00 p m - The Evolution of Angiogenesis: Cardiomyopathy Silviu Itescu What We Have Learned and Where 12:00 p m -5:45 p m t raining Are We Going? 3:24 p m - The Copenhagen MSC Study: Room 204ABC physician Stephen E. Epstein First Report Moderators: Ulrich Sigwart, William Spencer Jens Kastrup 12:15 p m - Nitric Oxide Production: A Marker of Cell Viability? 3:36 p m - TCT-5: Cellular Interventional Overview of Hypertrophic t elli e Marco A. Costa Therapy for Non-Revascularizable Obstructive Cardiomyopathy and even t s Coronary Artery Disease: How Many sa 12:27 p m - “Small Molecule-Facilitated” Non-Interventional Therapies Patients Are Eligible? Cardiovascular Repair 12:00 p m - Introduction to Hypertrophic Thomas Kiernan et al Stefanie Dimmeler Cardiomyopathy: Etiology, Presentation, 3:46 p m - Vascular Repair with 12:42 p m - Primary and Secondary Mediators and Natural History Bone Marrow Derived Stem Cells of Angiogenesis: VEGF and Beyond Robert Roberts ABS T RAC S Hyo-Soo Kim Frank J. Giordano 12:20 p m - Pacing and Defibrillator Treatment 4:01 p m - Moderated Discussion and Q&A 12:57 p m - Moderated Discussion and Q&A of Hypertrophic Cardiomyopathy Panel Moderators: Stephen E. Epstein, Panel Moderators: Roger J. Laham, Hasan Garan Michael Simons

Jonathan M. Hill 12:35 p m - Surgical Treatment of general Discussants: Timothy D. Henry, Jens Kastrup, Discussants: Marco A. Costa, Hypertrophic Obstructive Cardiomyopathy Thomas Kiernan, Vincent J. Pompili, Stefanie Dimmeler, Frank J. Giordano Paul Sorajja Hyo-Soo Kim, Silviu Itescu

www.tct2007.com 29 transcatheter cardiovascular therapeutics

Saturday \ october 20, 2007

12:50 p m - Moderated Discussion and Q&A Outcomes of Septal Ablation The First Carotid Debate: Position: Moderators: Ulrich Sigwart, William Spencer Carotid Revascularization (Both by Other Techniques Endarterectomy and Stenting) are Discussants: Hasan Garan, 4:15 p m - Septal Ablation Using Overused in the Asymptomatic Patient Robert Roberts, Paul Sorajja Radiofrequency Energy Moderator: Rajesh M. Dave

Paul Sorajja 12:30 p m - Concur: Medical Therapy and The Alcohol Septal Ablation 4:30 p m - Septal Ablation by Coil Surveillance Should Be Frontline Therapy Procedure Embolization Seemant Chaturvedi 1:05 p m - The Origins of Alcohol Septal Ulrich Sigwart 12:40 p m - Object: The Data Supports Ablation: Historical Perspectives and 4:45 p m - Moderated Discussion and Q&A Early Revascularization Lessons Learned Panel Moderators: Ulrich Sigwart, Sriram S. Iyer Ulrich Sigwart William Spencer 12:50 p m - Challenging Questions to the 1:20 p m - Diagnosis and Patient Selection for Discussant: Paul Sorajja Participants from the Audience Alcohol Septal Ablation William Spencer Complex Case Presentations With Carotid Stenting: Procedural 1:40 p m - The Hemodynamics of Hypertrophic Panel Discussion Cardiomyopathy: Relevance to the Alcohol Considerations Moderators: Ulrich Sigwart, William Spencer Moderators: Issam D. Moussa, Septal Ablation Procedure Discussants: Valerian Fernandes, Peter A. Soukas Morton J. Kern Morton J. Kern, Sherif F. Nagueh, 1:00 p m - Carotid Artery Access Techniques: 1:55 p m - The Basic Technique of Alcohol Christopher Nielsen Standard and Exotic Septal Ablation 4:55 p m - Case 1 Issam D. Moussa Christopher Nielsen John W. Hirshfeld, Jr 1:10 p m - “Top Ten” List for Avoiding 2:10 p m - Intraprocedural Use of 5:10 p m - Case 2 Procedural Complications Echocardiography to Guide Massoud A. Leesar Jiri J. Vitek Alcohol Septal Ablation 5:25 p m - Case 3 Sherif F. Nagueh 1:20 p m - When Complications Occur Anyway: Marc D. Feldman Managing CAS Catastrophies 2:25 p m - Tips and Tricks in Alcohol Septal p m Fayaz Shawl Ablation 5:40 - Final Remarks Moderators: Ulrich Sigwart, William Spencer Igor F. Palacios 1:30 p m - Are Lead-In Phase Outcomes 5:45 p m - Adjourn Predictive of Trial Results? First Presentation 2:45 p m - Frequency, Prevention, and of ACT I Lead-In Data and Discussion of Its Management of Complications Relevance to the Pivotal Trial of Alcohol Septal Ablation Kenneth Rosenfield William Spencer The Carotid Workshop:

3:05 p m - Alcohol Septal Ablation: Exploring the The Second Carotid Debate: Position: 10-Year Results Carotid Stent Design Impacts CAS Controversies From Outcomes Valerian Fernandes Moderator: Robert M. Bersin 3:25 p m - Comparison of Surgical Myectomy Diagnosis to Intervention 1:45 p m - Concur: Acute and Late Results and Alcohol Septal Ablation Using MRI 12:00 p m -6:30 p m Room 202A Are Highly Stent-Specific Paul Sorajja Alberto Cremonesi 3:40 p m - Moderated Discussion and Q&A Assessment of the Symptomatic and 1:55 p m - Object: It’s Dealer’s Choice: Panel Moderators: Ulrich Sigwart, The Results are Largely the Same Asymptomatic Patient William Spencer Joachim Schofer Discussants: Valerian Fernandes, Moderators: Seemant Chaturvedi, 2:05 p m - Challenging Questions to the Morton J. Kern, Sherif F. Nagueh, Jeffrey W. Olin Participants from the Audience Christopher Nielsen, Igor F. Palacios, 12:00 p m - An Algorithm to Differentiate Paul Sorajja Among Diagnostic Tests to Evaluate Carotid 2:15 p m - Carotid Plaque Characterization (IVUS, VH, MSCT): Implications for CAS? 4:00 p m - TCT-9: Assessment of Percutaneous Artery Stenosis Erich Minar Transluminal Septal Myocardial Ablation in Jeffrey W. Olin

Hypertrophic Obstructive Cardiomyopathy: 12:15 p m - Medical Management of Carotid 2:30 p m - Embolic Protection Devices: Evaluation by Contrast Enhanced Magnetic Artery Disease as a Stand Alone Modality Is the Utility Presumed or Established Resonance Imaging and Adjunctive to Revascularization and Are the Devices Sufficiently Kamaldeep Chawla et al Bruce H. Gray Differentiated to Justify Selective Use? Bernhard Reimers

30 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Saturday \ october 20, 2007

The Third Carotid Debate: Position: Most 5:20 p m - US Status of Carotid Stenting: The Patient With Chronic Octogenarians Should Not Undergo CAS Operator Training, Devices, Registry Results Moderator: Frank J. Criado Kidney Disease and Ongoing Trials, and Reimbursement Moderators: Jeffrey A. Brinker, 2:45 p m - Concur: Octogenarians L. Nelson Hopkins Roxana Mehran in t ro Are Best Left Alone 5:40 p m - Cerebrovascular Intervention: Mark H. Wholey 1:02 p m - The Frequently Unrecognized, But State of the Art Update of Profound Impact of Chronic Kidney Disease 2:55 p m - Object: CAS Is Safe in the Elderly Pharmacologic, Ultrasonic, and and Radiocontrast Nephropathy and Better than the Alternatives Percutaneous Stroke Therapies Charles J. Davidson tURDAY agenda

Michel Henry Lee R. Guterman sa 1:17 p m - Strategies to Avoid 3:05 p m - Challenging Questions to the 6:00 p m - The Future of Carotid Stenting: Contrast-Induced Nephropathy Participants from the Audience Half-Empty, Half-Full, or Leaking Glass? Carlo Briguori William A. Gray 1:32 p m - Coronary and Endovascular sun DAY Carotid Abstract Session 6:15 p m - Moderated Discussion and Q&A Revascularization Dilemmas in Patients agenda Moderators: Juan C. Parodi, Panel Moderators: William A. Gray, with Chronic Kidney Disease Christopher K. Zarins Panel: Issam D. Moussa, Charanjit S. Rihal Discussants: Seemant Chaturvedi, Discussants: Alberto Cremonesi, R. Stefan Kiesz, Hugo F. Londero, Lee R. Guterman, L. Nelson Hopkins 1:44 p m - Case Presentation and Discussion: A Complex Patient with Chronic Kidney agenda Peter A. Soukas mon DAY 6:30 p m - Adjourn Disease 3:15 p m - TCT-10: Pooled Analysis of Three Case Presenter: Giora Weisz Carotid Artery Stenting Trials: Major Adverse Discussants: Mark A. de Belder, Events in Patients with Anatomic vs. The Difficult Patient: Norman E. Lepor, James A. Tumlin Physiological Risk Factors agenda Barry T. Katzen et al Diagnostic and 1:54 p m - Roundtable Discussion: Managing t ues DAY the Patient with Chronic Kidney Disease 3:30 p m - TCT-11: The CAPTURE Registry: Management Dilemmas Panel Moderators: Jeffrey A. Brinker, 12:00 p m -5:55 p m Timing, Distribution, Severity, and Type of Roxana Mehran Room 206 Stroke Following Carotid Artery Stenting in Discussants: Carlo Briguori,

Symptomatic and Asymptomatic Patients Charles J. Davidson, Mark A. de Belder, agenda

12:00 p m - Symposium Goals wed NESDAY William A. Gray et al Norman E. Lepor, Charanjit S. Rihal, Ajay J. Kirtane, Roxana Mehran 3:45 p m - TCT-12: New Distal Embolic James A. Tumlin Protection Device Using a 3-D Filter: Fibernet, First Carotid Human Study The Diabetic Patient The Elderly Patient case

Moderators: Spencer B. King III, reviews Michel Henry et al Moderators: James R. Margolis, Ajay J. Kirtane 4:00 p m - TCT-13: Evaluation of Proficiency Ramon Quesada Using a Simulator: Results from the 12:05 p m - Special Lecture: Comprehensive Assessment of Operator Performance Management of the Diabetic Patient with 2:09 p m - Why are the Elderly Special? by the Simbionix Carotid Stenting Coronary Artery Disease: From Medication From Metabolic Differences to agenda Simulator Study (ASSESS) Controversies to Revascularization Decisions Revascularization Outcomes t hurs DAY Giora Weisz et al Michael E. Farkouh Morris Mosseri

12:25 p m - Are DES Safe in Diabetic 2:24 p m - How to Safely Choose and Use The Great Carotid Cases: The Thrill Patients? Antiplatelet and Antithrombin Agents Christian M. Spaulding in the Elderly Patient t raining

Of Victory and the Agony Of . . . physician Moderators: Thomas A. Ischinger, 12:37 p m - Case Presentation and Frederick Feit Mark H. Wholey Discussion: The Difficult Diabetic 2:39 p m - Management Considerations in the Case Presenters: Robert M. Bersin, Case Presenter: Yean-Leng Lim Elderly Patient with Combined Coronary Lawrence A. Garcia, Michael H. Wholey Discussants: Kevin J. Beatt, Donald Cutlip, and Valvular Heart Disease t elli e Thomas D. Stuckey even t s Discussants: William D. Knopf, Juan C. Parodi, James R. Margolis sa Giuseppe Sangiorgi, James P. Zidar 12:47 p m - Roundtable Discussion: Decision 2:51 p m - Case Presentation and Making in the Diabetic Discussion: The Elderly Patient Transitioning into the Future Panel Moderators: Spencer B. King III, Moderators: William A. Gray, Case Presenter: Eugenia Nikolsky Ajay J. Kirtane L. Nelson Hopkins Discussants: Larry S. Dean, Discussants: Kevin J. Beatt, Donald Cutlip, Marco A. Perin, Matthias E. Pfisterer ABS T RAC S 5:00 p m - European Status of Carotid Michael E. Farkouh, Efrain Gaxiola, 3:01 p m - Roundtable Discussion: Stenting: Operator Training, Devices, Christian M. Spaulding, Thomas D. Stuckey Registry Results, Ongoing Trials, and New Choices for Old Patients? Reimbursement Panel Moderators: James R. Margolis, Alberto Cremonesi Ramon Quesada general Discussants: Larry S. Dean, Frederick Feit, Morris Mosseri, Eugenia Nikolsky, Marco A. Perin, Matthias E. Pfisterer

www.tct2007.com 31 transcatheter cardiovascular therapeutics

Saturday \ october 20, 2007

Difficult Patients, Difficult Vignette 4: The Patient with High-Risk 12:55 p m - Con: More DES! Coronary Anatomy Who Refuses Cardiac Antonio Colombo Decisions Surgery Moderators: John McB. Hodgson, 1:05 p m - Rebuttal Discussion 5:16 p m - How Safe Is Angioplasty and Michael E. Bertrand Discussants: Antonio Colombo, Jean Fajadet How Effective Are Stents Really in

Vignette 1: The Patient at Increased Patients with High-Risk Features Have Drug-Eluting Stents Lost Risk for Bleeding and Complex Coronary Anatomy? Favor? Do the Potential Risks Ioannis Iakovou Outweigh the Clear Benefits? 3:16 p m - The Patient at Risk for United States Viewpoints Mini-Debate Bleeding: Identification,P rognosis, 5:31 p m - Case Presentation and Discussion: 1:10 p m - Pro: More BMS! and Management Strategies The Patient Who Refuses Appropriate Ron Waksman Steven V. Manoukian Cardiac Surgery Case Presenter: H. Vernon Anderson 1:20 p m - Con: More DES! 3:31 p m - Case Presentation and Discussion: Jeffrey W. Moses The Bleeding Patient Discussants: Kenneth Chin, Case Presenter: David P. Lee Jacques J. Koolen, Jeffrey W. Moses 1:30 p m - Rebuttal Discussion Discussants: Lisa K. Jennings, David F. Kong, 5:41 p m - Roundtable Discussion: Discussants: Ron Waksman, Jeffrey W. Moses

Sunil V. Rao When to Accept and Turn Down 1:35 p m - Does PCI Reduce Mortality? A a Complex, High-Risk Patient 3:41 p m - Roundtable Discussion: Meta-Analysis of 18 Studies Comparing The Patient at Risk to Bleed Panel Moderators: Michel E. Bertrand, PCI (Bare Metal and Drug-Eluting Panel Moderators: Michel E. Bertrand, John McB. Hodgson Stents) vs. Medical Therapy John McB. Hodgson Discussants: Kenneth Chin, Adnan Kastrati Ioannis Iakovou, Jacques J. Koolen, Discussants: Lisa K. Jennings, David F. Kong, 1:50 p m - FDA Perspectives and Jeffrey W. Moses, Bernhard Witzenbichler David P. Lee, Sunil V. Rao Concerns: DES Panel Consensus 5:55 p m - Adjourn Findings, Guidance Documents, Vignette 2: The Non-Compliant Patient and a Changing Regulatory Milieu 3:56 p m - The Prognostic Impact of Andrew Farb Patient Non-Compliance After Medication The Drug-Eluting 2:05 p m - Reactions from Industry Leaders: Prescription and Interventional Therapy Why the Pendulum Has Swung Too Ajay J. Kirtane Stent Summit, PART 1 12:00 p m -6:00 p m Far Away from DES! 4:11 p m - Case Presentation and Discussion: Ballroom C, Level 3 Donald S. Baim The Non-Compliant Patient 2:13 p m - Reactions from Industry Leaders: Case Presenter: Varinder Singh Why the Pendulum Has Swung Too Discussants: Samuel M. Butman, Introduction and Overview Far Away from DES! Lloyd W. Klein, David G. Rizik Moderators: Martin B. Leon, Gregg W. Stone Campbell Rogers 12:00 p m - The Changing Landscape of DES: 4:21 p m - Roundtable Discussion: When the 2:21 p m - Moderated Discussion and Q&A Patient Is Unlikely to Listen Clinical Use Patterns, Technology Trends, Panel Moderator: Antonio Colombo, Panel Moderators: Michel E. Bertrand, and Regulatory Challenges Jeffrey W. Moses John McB. Hodgson Martin B. Leon Discussants: Donald S. Baim, Jean Fajadet, Discussants: Samuel M. Butman, 12:15 p m - The Updated CRF Evidence-Based Andrew Farb, Adnan Kastrati, Ron Waksman, Lloyd W. Klein, David G. Rizik, Varinder Singh Medicine Guidelines for DES Use Campbell Rogers Gregg W. Stone Vignette 3: The Patient Undergoing Non-Cardiac Surgery DES Controversies II: DES Controversies I: Perspectives 4:36 p m - The Patient Undergoing Non- Incorporating Evidence-Based on the Risks vs. Benefits of Cardiac Surgery: Who Should Be Screened Medicine into Stent Selection for Coronary Artery Disease? Who Does Drug-Eluting Stents Decision-Making Revascularization Benefit? Moderators: Antonio Colombo, George D. Dangas Jeffrey W. Moses Moderators: Mitchell W. Krucoff, Stuart J. Pocock 4:51 p m - Case Presentation and Discussion: 12:30 p m - DES Impact on Practice Patterns and Clinical Outcomes: Results from the The Patient Requiring Non-Cardiac Surgery How Valuable are Different Case Presenter: David G. Rizik Medicare Database Before and After DES DES Datasets? Discussants: William E. Boden, Approval in the US 2:35 p m - Large Continuous “Real World” David J. Cohen J. Brent Muhlestein, Henry H. Ting Registries Are Necessary for Inter-Device 5:01 p m - Roundtable Discussion: Have Drug-Eluting Stents Lost Favor? Do Comparisons Screening for Coronary Artery Disease the Potential Risks Outweigh the Clear Ulf Stenestrand Panel Moderators: Michel E. Bertrand, Benefits? European Viewpoints Mini-Debate 2:43 p m - Meta-Analyses of Published DES John McB. Hodgson 12:45 p m - Pro: More BMS! Clinical Trials Are the Best Available Data Discussants: William E. Boden, Jean Fajadet Peter Juni J. Brent Muhlestein, David G. Rizik, Henry H. Ting

32 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Saturday \ october 20, 2007

2:51 p m - Meta-Analyses of DES 4:49 p m – Three-Year Follow-Up from the 12:51 p m - Optimizing Hemodynamic Studies Are Over-Rated and Misleading: Bern-Rotterdam DES Experience Interpretation: Recognizing and Minimizing Large Scale Randomized Trials are Required Joost Daemen Drift, Bubbles, Artifacts, and More

Sigmund Silber John W. Hirshfeld, Jr in t ro 4:57 p m – Off-Label and Untested DES Use in the Multicenter DEScover Registry 1:06 p m - Q&A Meta Or Pooled ANALYSES of DES David O. Williams Randomized Clinical Trials 1:09 p m - Pericardial Effusions and Cardiac Moderators: Mitchell W. Krucoff, 5:05 p m - Clinical Outcomes After Tamponade: How to Recognize and When

Stuart J. Pocock On- vs. Off-Label DES Use in to Act tURDAY agenda sa 2:59 p m - On-Label Cypher and the Multicenter EVENT Registry James A. Goldstein Neal S. Kleiman Taxus Randomized Trials with 1:24 p m - Q&A 5-Year Follow-Up 5:13 p m - Mortality After PCI with BMS and 1:27 p m - Hemodynamic Assessment of Ajay J. Kirtane DES from the Thoraxcentre Database Aortic Stenosis (and Aortic Valvuloplasty) sun DAY 3:11 p m - A Collaborative Network Patrick W. Serruys and Three Ways to Be Fooled agenda Meta-Analysis of All Published 5:21 p m - The DESIRE Single Center (Case Presentations) DES Randomized Clinical Trials São Paulo DES Registry with Late Wesley R. Pedersen Stephan Windecker (Mean 4-Year) Follow-Up 1:42 p m - Q&A 3:23 p m - Moderated Discussion and Q&A Amanda G. M. R. Sousa agenda 1:45 p m - Hemodynamic Assessment of mon DAY Panel Moderators: Mitchell W. Krucoff, 5:38 p m - Moderated Discussion and Q&A Mitral Stenosis (and Mitral Valvuloplasty) Stuart J. Pocock Panel Moderators: Laura Mauri, and Three Ways to Be Fooled Discussants: Peter Juni, Sigmund Silber, Stephan Windecker (Case Presentations) Ulf Stenestrand, Stephan Windecker Discussants: Robert J. Applegate, Igor F. Palacios Joost Daemen, George D. Dangas, agenda Updates and Late Follow-Up from 2:00 p m - Q&A t ues DAY Jose M. de la Torre, Lisette Okkels Jensen, Real-World DES Registries Takeshi Kimura, Neal S. Kleiman, 2:03 p m - Hemodynamic Assessment of Aortic Moderators: Laura Mauri, Stephan Windecker Greg Mishkel, Francesco Saia, Insufficiency and Three Ways to Be Fooled 3:37 p m - Prairie Heart Institute Real-World Patrick W. Serruys, Amanda G. M. R. Sousa, (Case Presentations) DES Experience: 3-Year Follow-Up Ulf Stenestrand, David O. William Samir R. Kapadia agenda

Greg Mishkel wed NESDAY 6:00 p m - Adjourn 2:18 p m - Q&A 3:45 p m - The Wake Forrest DES vs. BMS 2:21 p m - Hemodynamic Assessment of Mitral

Experience in High-Risk Patients: Regurgitation and Three Ways to Be Fooled 2-Year Follow-Up

(Case Presentations) case Robert J. Applegate Tough Calls in the Cath Lab: Ted Feldman reviews 3:53 p m – MATRIX: CRF “All Comers” Advanced Hemodynamics 2:36 p m - Q&A Cypher Registry: 2-Year Follow-Up and Angiography 2:39 p m - Essentials of Adult Congenital George D. Dangas 12:00 p m -6:00 p m Heart Disease Hemodynamics: 4:01 p m – ESTROFA: Late Follow-Up from a Room 201 Now I’m Really Confused! agenda Large Multicenter National DES Registry t hurs DAY Robert J. Sommer Jose M. de la Torre Tough Calls in Hemodynamic 2:54 p m - Q&A 4:09 p m - Late Clinical Follow-Up from the Interpretation: Case-Based ARTS-II Cypher Registry in Multivessel Reviews 2:57 p m - Three Hemodynamic Conundrums: Disease: Emphasis on Late Stent Thrombosis Stump the Experts (and the Audience) t raining

Moderators: William E. Hellenbrand, physician Panel Moderators: William E. Hellenbrand, Patrick W. Serruys John W. Hirshfeld, Jr John W. Hirshfeld, Jr 4:17 p m - The J-Cypher Multicenter 12:00 p m - Introduction: The Most Common Case Presenter: Charanjit S Rihal Real-World Registry: 2-Year Follow-Up Mistakes in the Cath Lab, Again and Again Discussants: Ted Feldman,

Takeshi Kimura Zoltan G. Turi t elli e James A. Goldstein, Samir R. Kapadia even t s sa 4:25 p m - Updates and Insights 12:15 p m - Hemodynamic and from the SCAAR Multicenter Ventriculographic Assessment of Tough Calls in Angiographic National DES and BMS Registry Hypertrophic Obstructive Cardiomyopathy Interpretation: Case-Based Ulf Stenestrand Charanjit S. Rihal Reviews 4:33 p m - Clinical Outcomes (15 months) p m 12:30 - Q&A Moderators: Alexandra J. Lansky, ABS T RAC S After DES and BMS from the Western 12:33 p m - Differentiating Constriction from Jeffrey J. Popma Denmark Multicenter National Registry Restriction: It’s Easier Than You Think Lisette Okkels Jensen 3:12 p m - Optimizing Angiography Morton J. Kern to Minimize Angiographic Errors 4:41 p m - Results at 2 to 3 Years with

12:48 p m - Q&A Charles E. Chambers general DES vs. BMS in the Multicenter Italian REAL Registry 3:27 p m - Q&A Francesco Saia

www.tct2007.com 33 transcatheter cardiovascular therapeutics

Saturday \ october 20, 2007

3:30 p m - Common Mistakes in Coronary Vascular Access and 2:18 p m - Featured Lecture: Established Angiographic Misinterpretation I: Stenosis Devices: AngioSeal, Vasoseal, Perclose, Severity, Calcification vs. Thrombus, Intervention: From Femoral Duett and Others: Tips, Tricks, Complications, Collaterals, TIMI Flow and Blush, Fistulas, Access to Closure Devices and “New” Evidence-Based Medicine and Aneurysms Robert J. Applegate Alexandra J. Lansky to Transradial Interventions 2:38 p m - TCT-15: Relationship Between 12:00 p m -7:00 p m 3:45 p m - Q&A the Use of Vascular Closure Devices Room 202B and Development of Retroperitoneal 3:48 p m - Common Mistakes in Coronary Hemorrhage Following Percutaneous Angiographic Misinterpretation II: Arterial Access and Complications Left Main and Bifurcation Assessment, Coronary Intervention Moderators: Robert J. Applegate, Frederic S. Resnic et al Diffuse Disease, Intramyocardial Vessels, Ferdinand Kiemeneij Spasm, Vein Grafts, and Bypass Conduits 2:53 p m - Emerging Devices: The Boomerang: Jeffrey J. Popma Kickoff Debate: The Debate Should Be Advantages, Technique, Complications, Over: Radial Artery Access is Safer and and Data 4:03 p m - Q&A Should Be the Preferred Access Route! David E. Allie 4:06 p m - Aberrant and Anomalous Coronary 12:00 p m - I Concur: Radial Is the Only Way 3:05 p m - Emerging Devices: Clips (Starclose Vessels: Classification, Recognition, and to Go and Here’s Why! and Angiolink): Advantages, Technique, Anatomy Ferdinand Kiemeneij Frederick Feit Complications, and Data 12:12 p m - Dream On: Femoral Access James B. Hermiller 4:21 p m - Q&A Will Always Dominate! 3:20 p m - Emerging Devices: The Access 4:24 p m - Normal and Abnormal Angiography Harold L. Dauerman Closure MYNX Device: Advantages, of the Left Ventricle and Aorta 12:24 p m - Radial Artery Access Technique, Complications, and Data Luis Guzman Complications: Prevention and Management Mark A. Turco 4:39 p m – Q&A Ian C. Gilchrist 3:32 p m - Perspectives on Extravascular 4:42 p m - Angiography of Adult Congenital 12:39 p m - TCT-14: Vascular Complications Sealing Devices and First Report of the Heart Disease: Now I’m Really Confused! 1998-2007: Evidence for Better Outcomes Exoseal ECLIPSE Trial Eustaquio Onorato Robert J. Applegate et al S. Chiu Wong

4:57 p m - Q&A 12:54 p m - Femoral Artery Access Site 3:47 p m - TCT-16: Extravascular Closure for Complications I: Prevention and Recognition 5:00 p m - Peripheral Angiography: Patients with High-Risk Femoral Anatomy Common Pitfalls Zoltan G. Turi Mitchell N. Rashid et al Peter S. Fail 1:09 p m - Femoral Artery Access Site 4:02 p m - Moderated Discussion and Q&A Complications II: Endovascular Strategies 5:15 p m - Q&A Panel Moderators: Harold L. Dauerman, for Diagnosis and Salvage Timothy A. Sanborn 5:18 p m - Carotid and Cerebral Angiography: Stephen R. Ramee Discussants: David E. Allie, David J. Cohen, Interpretation Beyond the Stenosis James B. Hermiller, Jr, Alan W. Heldman, Alex Berenstein 1:24 p m - Moderated Discussion and Q&A Panel Moderators: Robert J. Applegate, Mark A. Turco, S. Chiu Wong 5:33 p m - Q&A Ferdinand Kiemeneij 5:36 p m - Three Angiographic Conundrums: Discussants: Harold L. Dauerman, Transradial Angiography and Stump the Experts (and the Audience) Ian C. Gilchrist, Stephen R. Ramee Intervention: Advanced Panel Moderators: Alexandra J. Lansky, Jeffrey J. Popma Considerations Vascular Closure Devices Moderators: Martial Hamon, Case Presenter: Zoltan G. Turi Moderators: Harold L. Dauerman, Ferdinand Kiemeneij Discussants: Alex Berenstein, Timothy A. Sanborn Charles E. Chambers, Peter S. Fail, 4:17 p m - Tricks and Technical Considerations Frederick Feit, Luis Guzman, 1:39 p m - Are Closure Devices Cost-Effective for Complex Coronary Intervention Using Eustaquio Onorato After Diagnostic Angiography and Transradial Access Intervention? Martial Hamon 6:00 p m - Adjourn Frederic S. Resnic 4:32 p m - Anticoagulation Considerations in 1:51 p m - Matching the Right Closure Patients Undergoing Transradial Intervention Device to the Right Patient Giora Weisz Alan W. Heldman 4:44 p m - The Transradial Approach to 2:03 p m - Complications of Closure Devices: Chronic Total Occlusions Frequency, Recognition, and Treatment Shigeru Saito Timothy A. Sanborn 4:56 p m - The Transradial Approach to Acute Myocardial Infarction Gerald Barbeau

34 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Saturday \ october 20, 2007

5:08 p m - The Transradial Approach to 12:30 p m - Vulnerable Plaque as a 3:11 p m - Utility of MRA With and Without Bifurcation Disease Systemic Disease: Role of Inflammation Target-Specific Molecular Imaging to Screen Yves R. Louvard in Atherosclerosis Development, for Vulnerable Plaque: Current Realities

Progression, and Plaque Rupture and Future Promise in t ro 5:20 p m - The Transradial Approach to the High-Risk Patient: Left Main Disease, Attilio Maseri Zahi A. Fayad Diminished Left Ventricular Function, 12:45 p m - Has the Role of Inflammation in 3:26 p m - Featured Lecture: PET-Angiography, and Shock Vulnerable Plaque Been Over-Emphasized? PET-CT, and Novel Radionuclide-Based Jean Fajadet Insights from Pathologic and Clinical Studies Molecular Imaging Techniques for the tURDAY agenda

Erling Falk Detection of Subclinical Atherosclerosis sa 5:32 p m - The Transradial Approach to and Vulnerable Plaque Non-Coronary Vascular Interventions 12:57 p m - Is Vulnerable Plaque a Systemic Christopher J. White or Focal Disease? Observations from Tillman Cyrus Cross-Sectional and Longitudinal 3:46 p m - Special Lecture: Nanoparticles for 5:44 p m - TCT-17: Radial Access PCI Is Coronary Preparations, and Perspectives Molecular Imaging and Targeted sun DAY Associated with Reduced Transfusion and agenda 1-Year Mortality Rates: MORTAL Study on Temporal Stability Therapeutics: Application to Vulnerable (Mortality Benefit of Reduced Transfusion James E. Muller Plaque Detection and Treatment Samuel A. Wickline After Angioplasty Using the Arm or Leg) 1:12 p m - Vulnerable Blood: Hematologic Alex J. Chase et al Risk Factors and Measurable Risk 4:01 p m - Multimodality Noninvasive agenda Juan J. Badimon Imaging and Biomarker Assessment: mon DAY 5:59 p m - Logistic Translation of Transradial The High-Risk Plaque Project Intervention in a High-Volume Center 1:27 p m - Serum Biomarkers of Plaque Ferdinand Kiemeneij Vulnerability, Progression, and Rupture: Pedro R. Moreno Classification, Predictive Value, and 4:16 p m - Screen for Systemic 6:09 p m - Moderated Discussion and Q&A Panel Moderators: Martial Hamon, Practical Recommendations Atherosclerosis, Not Vulnerable Plaque: agenda t ues DAY Ferdinand Kiemeneij Michael E. Farkouh Rationale for the SHAPE Initiative, and Future Clinical Investigations Discussants: Gerald Barbeau, Jean Fajadet, 1:42 p m - LP-PLA2 as a Diagnostic Yves R. Louvard, Shigeru Saito, Giora Weisz, Tool and Therapeutic Target Morteza Naghavi Christopher J. White Andrew Zalewski 4:28 p m - TCT-19: Detection of Lipid-Rich

Coronary Plaques Through Blood in Autopsy agenda 6:24 p m - Simulator Training: Radial 1:54 p m - Featured Lecture: Systemic Artery Access and Intervention Therapeutics: Lessons Learned from Specimens with a Novel Catheter-Based wed NESDAY LDL Lowering and HDL Raising Near-Infrared Spectroscopy System 7:00 p m - Adjourn Prediman K. Shah Craig Gardner et al 4:43 p m - Moderated Discussion and Q&A 2:09 p m - TCT-18: Coronary Plaque Burden case Vulnerable Plaque: Is Related to Serum HDL-C Levels, but Panel Moderators: Pedro R. Moreno, reviews not to Other Lipid Parameters: Volumetric Samuel A. Wickline Pathophysiology, Intravascular Ultrasound Analysis Discussants: Tillman Cyrus, Zahi A. Fayad, Detection, and Eduardo Missel et al Morteza Naghavi, Robert S. Schwartz 5:05 p m - Adjourn

2:24 p m - Moderated Discussion and Q&A agenda

Therapeutic Intervention, t hurs DAY Panel Moderators: Erling Falk, PART 1 Prediman K. Shah 12:00 p m -5:05 p m Discussants: Juan J. Badimon, Amir Lerman, Room 150B Attilio Maseri, James E. Muller, Michael E. Farkouh, Renu Virmani, t raining physician The Vulnerable Plaque and the Andrew Zalewski Vulnerable Patient Moderators: Erling Falk, Prediman K. Shah Noninvasive and Molecular Imaging

12:00 p m - Characterizing the Vulnerable Moderators: Pedro R. Moreno, t elli e even t s Plaque: Structural Observations and Samuel A. Wickline sa Natural History Insights from the 2:44 p m - Vulnerable Plaque Screening Core Pathology Laboratory With CT Angiography: Pattern Recognition, Renu Virmani Frequency, and Predictive Accuracy

12:15 p m - Differentiating Between the Robert S. Schwartz ABS T RAC S Vulnerable Plaque and the Vulnerable 2:59 p m - Quantification of Coronary Patient: Core Concepts and the Role of Atherosclerosis with CT Endothelial Dysfunction Pim de Feyter Amir Lerman general

www.tct2007.com 35 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

Breakfast Meetings 8:35 a m - Adult Congenital Heart Disease: 11:50 a m - Panel Discussion and Case Percutaneous Closure of ASD and PFO Demonstration: My Worst Complication, 7:00 a m -8:00 a m (Indications, Devices, Transseptal Techniques, How to Salvage or Avoid Misadventure Refer to pages 98-99 for complete Guidance, Results, and Complications) Case Presenters: Eric E. Roselli, program schedule. Peter C. Block Wilson Y. Szeto, Grayson H. Wheatley

9:00 a m - Moderated Discussion and Q&A 12:10 p m - Lunch and Practicum III: Panel Moderator: John R. Laird, Jr Simulator Station and Device Tables: Valves Special Breakfast Session Discussants: Robert M. Bersin, Peter C. Block and Endografting

High-Risk angioplasty and Special Session: The New Introduction to Transcatheter Cardiogenic SHOCK: CASE Collaborative Environment: Valve Therapy Moderators: Francesco Maisano, Craig R. Smith REVIEWS FROM THE WINNERS Obtaining Training and the Role of 1:15 p m - Aortic and Mitral Balloon the Surgeon in Emerging Catheter OF THE INTRA-AORTIC BALLOON Valvuloplasty: Indications, Basic PUMP COMPETITION Techniques Technique, and Results 9:15 a m : Moderators: Martin B. Leon, Igor F. Palacios 7:00 a m -8:00 a m Room 143A Mathew Williams 1:35 p m - Percutaneous Aortic Valve Moderator: George D. Dangas Discussants: Michael J. Davidson, Replacement: Devices, Procedures, Discussants: Alan W. Heldman, Fayaz Shawl, Todd M. Dewey, Eric E. Roselli, Arash Salemi, Results, and Complications Carl L. Tommaso Wilson Y. Szeto, Grayson H. Wheatley Mathew Williams 9:45 a m - Break 7:00 a m - Case #1 2:00 p m - Transapical Aortic Valve Replacement Aun-Yeong Chong Todd M. Dewey

7:15 a m - Q&A Aortic Endografting 2:15 p m - Percutaneous Mitral Valve Moderators: Eric E. Roselli,Grayson H. Wheatley Therapies: Systems Overview, Interventional 7:20 a m - Case #2 Skills, and Results Manish Prakash Gupta 9:55 a m - Non-Invasive Imaging with CT and MR for Aortic Endograft Procedural Planning Francesco Maisano 7:35 a m - Q&A and Surveillance 2:40 p m - Which Patients are Appropriate 7:40 a m - Case #3 Eric E. Roselli for Transcatheter Valve Therapy: Present Annie F. Kelly 10:10 a m - Abdominal Aortic Endografting I: and Future? 7:55 a m - Q&A Indications, Devices, Results, Complications, Craig R. Smith

8:00 a m - Adjourn and Comparison with Surgery 2:55 p m - Case Demonstration: Transcatheter Christopher K. Zarins Valve Procedures Step-by-Step 10:25 a m - Abdominal Aortic Endografting II: Case Presenters: Francesco Maisano, Scientific Symposia and Video Case Review of the Basic Procedure Mathew Williams Michael D. Dake Practical Workshops 3:20 p m - Moderated Discussion and Q&A 10:40 a m - Thoracic Aortic Endografting I: Moderators: Francesco Maisano, Craig R. Smith Indications, Devices, Results, Complications, Discussants: Todd M. Dewey, Igor F. Palacios, Percutaneous Intervention and Comparison with Surgery Mathew Williams

for the Surgeon, PART 2 Eric E. Roselli 3:30 p m - Practicum IV: Simulator Station 8:00 a m -4:45 p m 11:00 a m - Thoracic Aortic Endografting II: and Device Table: Valves and Endografting Room 207AB Video Case Review of the Basic Procedure 4:30 p m - Closing Remarks Step-by-Step Mathew Williams Endovascular Intervention Grayson H. Wheatley 4:45 p m - Adjourn Moderator: John R. Laird, Jr 11:20 a m - Large Caliber Sheath Access:

8:00 a m - Carotid Intervention: Indications, Screening, Closure Options, and Technique and Devices (Emphasizing Complications Differences from Coronary Intervention), Grayson H. Wheatley

Complications, and Acute and Late Outcomes 11:30 a m - Managing Endoleaks Robert M. Bersin Wilson Y. Szeto

8:15 a m - Peripheral Vascular Intervention 11:40 a m - Moderated Discussion and Q&A (Aorto-Iliac, SFA, and Renal): Indications, Panel Moderators: Eric E. Roselli, Technique and Devices (Emphasizing Grayson H. Wheatley Differences from Coronary Intervention), Discussants: Wilson Y. Szeto, Complications, and Acute and Late Outcomes Christopher K. Zarins John R. Laird, Jr

36 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Board Review Course with 4:00 p m - Chronic Total Occlusion 10:00 a m - Valvular Disease and Flow Intervention: Techniques and Complications Steven D. Wolff Self Assessment for Reginald I. Low 10:20 a m - Adult Congenital Heart Disease in t ro Interventional cardiology 4:20 p m - Q&A Gregory D. N. Pearson and endovascular therapy, 4:30 p m - Small Vessels, Tortuosity and 10:40 a m - Coronary MRI Diffuse Disease James C. Carr pART 2: core curriculum Issam D. Moussa 8:00 a m -6:00 p m 11:00 a m - Q&A p m tURDAY Room 146ABC 5:00 - Q&A agenda sa 5:15 p m - Interventional Close Encounters: MR Workstation Demos: Interventional Cardiology Devices Bare Metal and Drug-Eluting Stents How to Interpret . . . and Outcomes Paul S. Teirstein Moderators: Raymond Y. Kwong, Moderators: George D. Dangas, John J. Young 6:00 p m - Adjourn John R. Lesser sun DAY agenda

8:00 a m - Percutaneous Coronary 11:15 a m - Myocardial Perfusion Intervention: Basic Techniques Raymond Y. Kwong Manish A. Parikh Cardiovascular Non-Invasive 11:35 a m - Coronary MRI 8:20 a m - Q&A Imaging: CTA, MRI, and Beyond Michael McConnell agenda mon DAY 8:30 a m - Directional Atherectomy, (With Reading Sessions with 11:55 a m - Viability and Scar Imaging Rotational Atherectomy, Laser and Christopher M. Kramer Cutting Balloon Angioplasty the Experts), Part 2 8:00 a m -6:25 p m John J. Young 12:15 p m - Valvular Disease and Flow Room 151A Edward T. Martin agenda

9:00 a m - Q&A t ues DAY 12:35 p m - Break 9:10 a m - Drug-Eluting Stent Design The Best CT and MR Abstracts Alexandre Abizaid Moderators: Daniel S. Berman, Michael Poon The Latest Advances in 9:35 a m - Q&A Discussants: Raymond Y. Kwong, W. Guy Weigold Cardiovascular MRI 9:45 a m - Clinical Studies with Moderators: Christopher M. Kramer, agenda 8:00 a m - TCT-30: Association of Severity of wed NESDAY FDA-Approved Drug-Eluting Stents Steven D. Wolff George D. Dangas Aortic Valve Calcification to Segmental p m Coronary Artery Disease as Depicted by 1:30 - MRI Guided Vascular Intervention 10:30 a m - Q&A Number of Significantly Diseased Vessels Robert J. Lederman

10:45 a m - Break Using 64 Slice Cardiac CT Angiography case

1:42 p m - Coronary Imaging: State of the Art reviews 11:10 a m - Restenosis and Thrombosis Shah Azmoon Michael McConnell

of Bare Metal and Drug-Eluting Stents 8:15 a m - TCT-31: Resonant Balloon 1:57 p m - Quantification of Myocardial Iron Roxana Mehran Expandable Stent Designed for the Improved Overload with MRI 12:00 p m - Q&A Visualization and Implantation in MRI John C. Wood Erwin Immel agenda 12:15 p m - Thrombectomy and Distal 2:09 p m - Predicting Arrhythmias and t hurs DAY Protection During Native Coronary Artery and 8:30 a m - TCT-32: Identification of Culprit Prognosis from Contrast-Enhanced MRI Saphenous Vein Graft Intervention Vessel in Acute Coronary Syndrome by Katherine C. Wu Sheldon Goldberg Cardiac Magnetic Resonance 2:21 p m - Is MRI Safe for Patients with Chiara Lanzillo

12:50 p m - Q&A Defibrillators and Pacemakers? t raining physician 8:45 a m - TCT-33: Performance Evaluation of Edward T. Martin 1:00 p m - Break Flat-Panel and 64 Detector Row CT for 2:33 p m - MRI Characterization of Characterization of Vulnerable Plaque Carotid Plaque High-Risk Patients and L. Maximilian Buja

Kevin DeMarco t elli e Complications even t s sa Moderators: Sheldon Goldberg, Ajay J. Kirtane Cardiac MRI Didactic Sessions 2:48 p m - Q&A 2:00 p m - Patient- and Lesion-Specific Moderator: Steven D. Wolff Controversies in Cardiac PCI Considerations 9:00 a m - Quantification of Ventricular Alexandra J. Lansky Size and Function Noninvasive Imaging

Moderators: Michael Poon, Steven D. Wolff ABS T RAC S 2:30 p m - Q&A Christopher M. Kramer 3:03 p m - Special Lecture: Estimating the 2:45 p m - Left Main and Bifurcations 9:20 a m - Myocardial Perfusion Sheldon Goldberg Raymond Y. Kwong Cancer Risk from MSCT Imaging Andrew J. Einstein 3:20 p m - Q&A 9:40 a m - Myocardial Viability and Scar

Imaging 3:15 p m - Clinical Perspective: How Serious general 3:30 p m - Break Steven D. Wolff Is the Radiation Risk from CT Imaging? Stephen Balter

www.tct2007.com 37 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

How Important Is Radiology Over-Reading Interventional Strategies 9:25 a m - FINESSE 2: First Report of the of Cardiac CTA? Unfractionated vs. Low Molecular Weight 3:25 p m - Not Important at All! and Adjunct Pharmacology Heparin Substudy Robert S. Schwartz in ACS and AMI, part 2 Stephen G. Ellis 3:35 p m - Very Important! 8:00 a m -6:25 p m 9:35 a m - Does Early Glycoprotein IIb/IIa Jeffrey C. Hellinger Room 151B Inhibitor Administration Reduce Mortality After Primary PCI? First Report of the EGYPT Evaluation of Cardiomyopathy: Cooperative Study CTA or CMR? stemI I: Choice of Reperfusion Modality: Is Time the Predominant Giuseppe De Luca 3:45 p m - CTA Rules! 9:45 a m - CARESS: Results of Urgent vs. Michael Poon Variable? Moderators: LeRoy E. Rabbani, Mark A. Turco Elective Transfer for PCI after Thrombolytic 3:55 p m - CMR Dominates! Therapy Steven D. Wolff 8:00 a m - Primary PCI vs. Thrombolysis: Dariusz Dudek Rationale for Evolving Guideline What is the Best Test to Evaluate Acute Recommendations 9:55 a m - Risks and Benefits of Rescue and Coronary Syndromes? Eric R. Bates Immediate Routine PCI in the Stent and Balloon Eras: Insights from Meta-Analysis 4:05 p m - MRI! 8:10 a m - Primary PCI vs. Thrombolysis: The Raymond Y. Kwong and Individual Studies RIKS-HIA Experience (Emphasis on the Anthony H. Gershlick 4:15 p m - CTA! Importance of Time) Michael Poon Ulf Stenestrand 10:07 a m - Transfer Strategies for Primary PCI: Long-Term Results of DANAMI-2 8:20 a m - Impact of Symptom-to-Balloon and What is the Best Test to Complement Henning Rud Andersen Cardiac CTA? Door-to-Balloon Times on Death, Reinfarction, and Stroke After Primary PCI 10:15 a m - Rationale and Results of a 4:25 p m - MRI! Compared to Thrombolytic Therapy: Lessons System-Wide Facilitated Transport PCI Steven D. Wolff from the PCAT Randomized Trials Strategy (In the Setting of Numerous 4:35 p m - Nuclear Imaging! Cindy L. Grines Negative Randomized Trials) Daniel S. Berman Timothy D. Henry 8:30 a m - Does Time to Reperfusion Impact 10:25 a m - The Multicenter GLASTO Registry: What is the Best Test for All Patients Equally? New Insights from Characterizing Plaque? CADILLAC and Moses Cone Improved Outcomes with Facilitation Before Angioplasty 4:45 p m - MRI! Bruce R. Brodie Ali E. Denktas Chun Yuan 8:40 a m - Insights from NRMI on the 10:35 a m - Moderated Discussion and Q&A 4:55 p m - CTA! Importance of Time and Patient-Related Panel Moderators: Alice K. Jacobs, Stephan Achenbach Factors on Selection of Reperfusion Modality Duane S. Pinto William W. O’Neill Discussants: Henning Rud Andersen, Clinical Case Examples: Read MRI 8:50 a m - Moderated Discussion and Q&A Kevin J. Beatt, Giuseppe De Luca, with the Experts Panel Moderators: LeRoy E. Rabbani, Ali E. Denktas, Dariusz Dudek, Mark A. Turco Moderator: Michael McConnell Anthony H. Gershlick, Timothy D. Henry Discussants: Eric R. Bates, Bruce R. Brodie, 5:05 p m - Three Patients with Heart Failure Cindy L. Grines, Duane S. Pinto, John R. Lesser Ulf Stenestrand stemI iii: Special Session: 5:25 p m - Three Patients with Chest Pain The ACC D2B Initiative Raymond Y. Kwong stemI II: Special Session: Moderators: Harlan Krumholz, Henry H. Ting 10:50 a m - D2B Briefing: Rationale, 5:45 p m - Three Patients with TIA/Stroke Facilitation, Rescue, and Transfer Description, and Status of the D2B Project Christopher M. Kramer Issues Harlan Krumholz 6:05 p m - Three Patients with Cardiac Moderators: Alice K. Jacobs, William W. O’Neill Arrhythmia 11:00 a m - Improving Door-to-Balloon Times: 9:05 a m - Risks and Benefits of Facilitated The Mayo Clinic Experience Michael McConnell PCI: Insights from Meta-Analysis and Henry H. Ting 6:25 p m - Adjourn Individual Studies Kevin J. Beatt 11:10 a m - Measuring Door-to-Balloon Time: The CMS Perspective and Implications for 9:15 a m - FINESSE 1: New Insights from a Public Reporting and Pay for Performance Trial Comparing Primary Angioplasty vs. Frederick A. Masoudi GP llb/lla Inhibitor Facilitated Angioplasty With or Without Reduced Dose Thrombolytic 11:20 a m - Delays in the Cath Lab: Where Do Therapy They Occur and How Can They be Reduced? Stephen G. Ellis Jeptha P. Curtis

38 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 11:30 a m - Moderated Discussion and Q&A stemI v: Drug-Eluting Stents in 3:02 p m - New Observations from the Panel Moderators: Harlan Krumholz, Acute Myocardial Infarction DEDICATION Trial I: Infarct Size and Henry H. Ting Moderators: Roxana Mehran, ST-Segment Resolution Discussants: Jeptha P. Curtis, Christian M. Spaulding Anne K. Kaltoft in t ro Frederick A. Masoud 3:11 p m - New Observations from the 1:20 p m - Safety and Efficacy of DES in AMI: Perspectives from the Randomized Trials DEDICATION Trial II: 8-Month Clinical stemI iv: The Systems Approach to and Registries and HORIZONS Update Results and Left Ventricular Function Henning Kelbaek Reducing Door to Balloon Times: Gregg W. Stone tURDAY agenda 3:19 p m - Proximal Protection of the Distal sa New Initiatives and Case Studies 1:30 p m - Long-Term Outcomes of DES in Moderators: William J. French, AMI: STRATEGY (3-year) Microcirculation During Primary Angioplasty: Thomas D. Stuckey Marco Valgimigli Is it the Answer? Karel T. Koch 11:45 a m - Are Door-to-Balloon and 1:40 p m - Long-Term Outcomes of DES in sun DAY Symptom-to-Balloon Times (and Resulting AMI: PASSION (2-Year) 3:29 p m - Systemic Review of Failed and agenda Mortality) Decreasing in Transfer and Maarten J. Suttorp Promising Adjunctive Pharmacologic Non-Transfer Patients? Insights from the Strategies to Reduce Infarct Size 1:50 p m - Long-Term Outcomes of DES in NRMI Registries Robert A. Kloner AMI: SESAMI (2-Year) William J. French Maurizio Menichelli 3:41 p m - Supersaturated Oxygen Infusion: agenda mon DAY 11:55 a m - Strategies to Improve Door-to- From Concept to AMIHOT-2 Pre-Presentation 2:00 p m - Long-Term Outcomes of DES in Balloon Times and Their Impact on Patient Jack L. Martin AMI: RESEARCH and T-SEARCH Outcomes Joost Daemen 3:51 p m - Therapeutic Hypothermia for Umesh Khot Anoxic Encephalopathy Cardiac Arrest 2:10 p m - Should Specialized DES for p m Survivors

12:05 - Triage to Dedicated PCI Hospitals agenda AMI Be Developed? Early Experience t ues DAY Based on Pre-Hospital 12-Lead ECG Michael Mooney with Endothelial Progenitor Cell Diagnosis: The Boston EMS Experience Capture Technology 4:01 p m - TCT-4: Angiographic Findings and Kenneth Rosenfield Jan-Henk Dambrink Outcomes in Unresponsive Patients with 12:15 p m - Prospective Study of ST-Elevation Myocardial Infarction

Standardizing Treatment of STEMI by PCI Flash Debate: Should DES Be Resuscitated from Cardiac Arrest agenda in a Large German City Used Routinely During Primary Vinay R. Hosmane et al wed NESDAY Angioplasty in AMI, Today? Raimund A. Erbel 4:11 p m - Protein Kinase-C Inhibition in AMI:

2:20 p m - Yes, the Rationale Is Strong 12:25 p m - Bypassing the ER to Reduce and the Evidence Is Supportive! Background for the DELTA Trial Door-to-Balloon Time: The Israeli Experience Giulio Guagliumi Neal S. Kleiman case reviews Uri Rosenschein 4:21 p m - Opportunities and Challenges of 2:28 p m - No, Not Yet, Not Ever— 12:35 p m - Update on MISSION: LIFELINE, I Implore You! Stem Cell Therapy in AMI the AHA STEMI Initiative Renu Virmani Bernardo Nadal-Ginard Alice K. Jacobs 4:33 p m - Moderated Discussion and Q&A 2:36 p m - Moderated Discussion and Q&A Panel Moderators: James Goldstein, agenda 12:45 p m - The Reperfusion of Acute Panel Moderators: Roxana Mehran, t hurs DAY Myocardial Infarction in Carolina Emergency Christian M. Spaulding Robert A. Kloner Departments (RACE) Project to Increase the Discussants: Joost Daemen, Discussants: Peter B. Berger, Rate and Speed of Coronary Reperfusion Jan-Henk Dambrink, Giulio Guagliumi, Vinay R. Hosmane, Anne K. Kaltoft, B. Hadley Wilson Maurizio Menichelli, Gregg W. Stone, Henning Kelbaek, Neal S. Kleiman, t raining

Karel T. Koch, Jack L. Martin, physician 12:55 p m - TCT-3: ST-Segment Analysis Maarten J. Suttorp, Marco Valgimigli, Michael Mooney, Bernardo Nadal-Ginard Using Wireless Technology in Acute Renu Virmani Myocardial Infarction (STAT-MI) Trial James Maher et al stemI vi: Novel Strategies to stemI vii: The Open Artery t elli e 1:05 p m - Moderated Discussion and Q&A Hypothesis and Other even t s Reduce Infarct Size and Improve sa Panel Moderators: William J. French, Primary PCI Outcomes Controversies Thomas D. Stuckey Moderators: James Goldstein, Moderators: Frederick Feit, Cindy L. Grines Discussants: Raimund A. Erbel, Robert A. Kloner 4:48 p m - The Open Artery Hypothesis William J. French, Alice K. Jacobs, Revisited I: Insights From the Pivotal Umesh Khot, James Maher, Kenneth 2:51 p m - Routine or Selective Use of Distal

OAT Trial ABS T RAC S Rosenfield, Uri Rosenschein, B. Hadley Wilson Protection, Thrombectomy, and Thromboaspiration Catheters During Primary Pawel E. Buszman PCI: Is There Any Evidence (Beyond 4:58 p m - The Open Artery Hypothesis Common Sense) to Support Their Use? Revisited II: From a Conceptual Framework Peter B. Berger to the Realities of the OAT Trial general Bernard J. Gersh

www.tct2007.com 39 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

5:08 p m - SWISS-II: Implications for Infarct 9:00 a m - Moderated Discussion and Q&A 11:45 a m - 3-D Fibroblast Matrix Artery Recanalization (Routine vs. Selective, Panel Moderators: Joshua M. Hare, Implantation After Acute Myocardial Occluded vs. Patent) Doris A. Taylor Infarction Matthias E. Pfisterer Discussants: Daniel Burkhoff, Steven Goldman Hina W. Chaudhry, Frank J. Giordano, 5:18 p m - Rationale, Published Results, 11:57 a m - TCT-7: Results from the and the SCAI Position on Primary Bernardo Nadal-Ginard Multicenter, Prospective, Randomized PCI with No Surgery On-Site Single-Blind Trial on Intracoronary or Gregory J. Dehmer Cell Therapy II: Novel Cell Combined (Percutaneous Intramyocardial and Intracoronary) Administration of 5:28 p m - Primary PCI with No Surgery Sources for Myocyte Repair On-Site: The Michigan Experience and Replacement Non-Selected Autologous Bone Marrow Cells to Patients After Acute Myocardial Infarction Eric R. Bates Moderators: Bernardo Nadal-Ginard, Mariann Gyongyosi et al 5:38 p m - Lessons from C-PORT: National Marc Penn 12:07 p m - Moderated Discussion and Q&A Outcomes at “No Surgery On-Site” Hospitals 9:15 a m - Endogenous Cardiac Progenitor Panel Moderators: Warren Sherman, Thomas Aversano Cells Gordana Vunjak-Novakovic 5:48 p m - Non-Culprit Angioplasty During Doris A. Taylor Discussants: Steven Goldman, Primary PCI: It’s Time to Treat! 9:27 a m - Cell Based Gene Therapy for Mariann Gyongyosi, Timothy Martens, Amit Morris Mosseri Treating Myocardial Dysfunction Patel, Emerson C. Perin, Tomasz Siminiak 5:58 p m - Non-Culprit Angioplasty During Marc Penn 12:22 p m - Break Primary PCI: Rarely or Never! 9:39 a m - Novel Molecular Properties of David A. Cox Mesenchymal Cells Cell Therapy IV: Breaking News: 6:08 p m - Moderated Discussion and Q&A Silviu Itescu Clinical Trials for Left Panel Moderators: Frederick Feit, 9:51 a m - Bone Marrow-Derived Embryonic- Cindy L. Grines Like Cells Ventricular Dysfunction Discussants: Thomas Aversano, Eric R. Bates, Wojciech Wojakowski Moderators: Jozef Bartunek, David A. Cox, Gregory J. Dehmer, Nicolas A. F. Chronos 10:03 a m - Germ-Cell Derived Cardioblasts Bernard J. Gersh, Morris Mosseri, Amit Patel 1:00 p m - “SEISMIC” Outcomes Matthias E. Pfisterer Henricus J. Duckers 10:15 a m - Moderated Discussion and Q&A 6:25 p m - Adjourn Panel Moderators: Keith L. March, 1:15 p m - Myoblasts for Chronic Heart Bernardo Nadal-Ginard, Marc Penn Failure: US Trial Experience Update Discussants: Silviu Itescu, Amit Patel, Nabil Dib Molecular Cardiology Doris A. Taylor, Wojciech Wojakowski 1:30 p m - Clinical Trials for Ischemic Heart Breakthroughs: Cell Failure: Local and Global Effects Emerson C. Perin Therapy and Angiogenesis, Cell Therapy III: Focus on Delivery Routes and Techniques 1:45 p m - From MYOHEART Results to the PART 2 Moderators: Warren Sherman, MARVEL Trial: Objectives and Trial Design 8:00 a m -6:10 p m Gordana Vunjak-Novakovic Warren Sherman Room 154AB 10:30 a m - Surgical-Based Innovations 2:00 p m - Moderated Discussion and Q&A in Cell Delivery Panel Moderators: Jozef Bartunek, Cell Therapy I: Emerging Insights Amit Patel Nicolas A. F. Chronos into Myocyte Regulation and Repair Discussants: Nabil Dib, Henricus J. Duckers, 10:42 a m - Remote Magnetic Navigation for Moderators: Keith L. March, Joshua M. Hare, Emerson C. Perin, Warren Sherman Automated NOGA Mapping and Stem Cell Doris A. Taylor Delivery 8:00 a m - Affecting Cell Cycle Regulation to Emerson C. Perin Cell Therapy V: Acute Myocardial Prevent Ischemic Heart Failure 10:54 a m - Circumventing the Injury Hina W. Chaudhry Microvasculature: Trans-Coronary-Venous Moderators: Timothy D. Henry, 8:15 a m - Targeting Transcription to Avert Interventions Andreas M. Zeiher and Treat Heart Failure Tomasz Siminiak 2:15 p m - Critical Review of Methods for Frank J. Giordano Assessing Left Ventricular Function After 11:06 a m - Perivascular Delivery: Concept 8:30 a m - Activation of Cell-Cycling in to Practice Myocardial Infarction Local Myocytes Warren Sherman Michael Poon Bernardo Nadal-Ginard 2:30 p m - Enhancing Myocardial Mechanics: 11:18 a m - Lessons from Tissue Engineering 8:45 a m - Calcium Transport: A New Gordana Vunjak-Novakovic Non-Cellular Approaches Therapeutic Target? Jonathan Leor 11:33 a m - Complex Cell Preparations: Daniel Burkhoff Delivery Challenges 2:45 p m - Novel Methods for Promoting Timothy Martens Migration of Angiogenic Cells in Acute Injury Helmut Drexler

40 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 3:00 p m - Injectable Extracellular Matrix STEMI Bone Marrow Cell Therapy: Should 9:14 a m - Causes, Patterns, and Treatment Emulsions for Cardiac Repair Large-Scale Clinical Trials Be Initiated? Options for In-Stent DES Restenosis Keith A. Robinson 5:40 p m - Yes, Why Wait? Roxana Mehran

Andreas M. Zeiher in t ro 3:15 p m - Moderated Discussion and Q&A 9:22 a m - Are There Adverse Effects on the Panel Moderators: Timothy D. Henry, 5:50 p m - Not Until Much More Pilot Data on Distant Coronary Vasculature After DES Andreas M. Zeiher Mechanism, Safety, and Efficacy Implantation? Discussants: Helmut Drexler, Jonathan Leor, Bernardo Nadal-Ginard J. Brent Muhlestein Michael Poon

6:00 p m - Challenging Questions from the 9:30 a m - Moderated Discussion and Q&A tURDAY agenda Moderators Panel Moderators: Marie-Claude Morice, sa Cell Therapy VI: STEMI Clinical Panel Moderators: Helmut Drexler, Renu Virmani Trial Results and New Directions Peter C. Smits Discussants: Edoardo Camenzind, Moderators: Gregg W. Stone, Discussants: Bernardo Nadal-Ginard, Donald Cutlip, Giulio Guagliumi, Andreas M. Zeiher J. Brent Muhlestein, Jeffrey J. Popma,

Andreas M. Zeiher sun DAY agenda Ron Waksman 3:30 p m - SELECT AMI: Study Design and 6:10 p m - Adjourn Initial Observations Jozef Bartunek DES Controversies IV: Clopidogrel

3:45 p m - The Apollo Study: Adipose-Derived The Drug-Eluting Stent Use Conundrums agenda Cells for Myocardial Repair Summit, PART 2 Moderators: Paul A. Gurbel, Lisa K. Jennings mon DAY Henricus J. Duckers 8:00 a m -6:35 p m Is Prolonged Clopidogrel (Beyond 4:00 p m - Selected CXCR4+ Cells for STEMI Ballroom C, Level 3 SIX Months) Really of Specific Benefit Wojciech Wojakowski AFTER DES Use?

9:45 AM - Very Clearly Yes: Lessons from agenda 4:15 p m - Allogeneic Mesenchymal Cells: DES Controversies III: Adverse t ues DAY 1-Year Follow-Up from a Phase 1 Study Drug-Eluting Stent Responses the Duke Databank Joshua M. Hare David F. Kong Moderators: Marie-Claude Morice, 9:53 a m - We Are Unable to Demonstrate 4:30 p m - REPAIR AMI: Early and Sustained Renu Virmani Improvement in Clinical Outcomes and This: Lessons from Milan Pathogenesis of Stent Thrombosis Antonio Colombo agenda LV Function: Why Does This Study Stand wed NESDAY After DES Implantation Out Among Many? 10:01 a m - Rebuttal Discussion Andreas M. Zeiher 8:00 a m - The Pathologist’s Perspective Antonio Colombo, David F. Kong

Renu Virmani 4:45 p m - TCT-8: Repeated Autologous Bone

The Role of Aspirin and Clopidogrel case 8:12 a m - The Clinician’s Perspective Marrow Mononuclear Cell Therapy in Responsiveness in Early- and reviews Patients with Large Myocardial Infarction Edoardo Camenzind Late-Stent Thrombosis Yao Kang, Sr et al Clinical Experiences with New Imaging 10:06 a m - Understanding Point-of-Care 4:55 p m - Moderated Discussion Techniques to Detect Early DES Healing Assays for Assessing Platelet Responsiveness Panel Moderators: Gregg W. Stone, Responses in Patients to Drug Therapy: Are the Data Useful for agenda Andreas M. Zeiher 8:22 a m - Angioscopy Clinical Decision Making? t hurs DAY Discussants: Jozef Bartunek, Yasunori Ueda Paul A. Gurbel Henricus J. Duckers, Joshua M. Hare, 8:30 a m - Optical Coherence Tomography 10:16 a m - Platelet Activation During Yao Kang, Sr, Wojciech Wojakowski Giulio Guagliumi Thienopyridine Therapy and After Withdrawal Antonio L. Bartorelli t raining Cell Therapy VII: The Great Debates 8:38 a m - The Clinical Spectrum of Late DES physician Thrombosis: Frequency, Clinical 10:24 a m - The Impact of Clopidogrel Moderators: Helmut Drexler, Peter C. Smits Presentation, Treatment Outcomes, and Hyporesponsiveness on DES Thrombosis: The RECLOSE Trial Mechanical vs. Biological Therapeutics: Introduction to the DESERT Registry How Important Will Biological David Antoniucci

Ron Waksman t elli e Approaches Really Be in the Future even t s 10:32 a m - Relationship Between Thrombotic sa of Interventional Cardiology? 8:48 a m - Applying Consistent Definitions for Stent Thrombosis: Benefits and Limitations Events and a Point-of-Care Clopidogrel 5:10 p m - The Future Will Be All of the Academic Research Consortium (ARC) Responsiveness Assay from the SCRIPPS About the Biology! Standards Real-World DES Registry Frank J. Giordano Donald Cutlip Matthew J. Price

5:20 p m - A Historical Footnote at Best! ABS T RAC S 8:58 a m - Is Late (or Delayed) Restenosis a 10:40 a m - Management Strategies for the Daniel Burkhoff Clinical Concern After DES Implantation? Patient Requiring Non-Cardiac Surgery 5:30 p m - Challenging Questions from Patrick W. Serruys After DES Implantation the Moderators Harry R. Phillips 9:06 a m - Strut Fractures After DES

Panel Moderators: Helmut Drexler, general Implantation: Frequency, Device Specificity, Peter C. Smits and Clinical Impact Discussants: Daniel Burkhoff, Jeffrey J. Popma Frank J. Giordano

www.tct2007.com 41 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

10:48 a m - Moderated Discussion and Q&A Mini-Debate III: DES Will Prevail as Xience V (Polymer-Based Panel Moderators: Paul A. Gurbel, Equivalent to (Or Better Than) CABG in Everolimus-Eluting DES) the Ongoing Randomized Clinical Trials Lisa K. Jennings in Multivessel and Left Main Disease 1:54 p m - The Xience V DES System: Discussants: David Antoniucci, (SYNTAX, FREEDOM, and CARDIA) Technical Review and Clinical Trial Updates Antonio L. Bartorelli, David F. Kong, (SPIRIT 1–4 and Registries) 12:23 p m - Without a Doubt, and These Trials Harry R. Phillips, Matthew J. Price Gregg W. Stone Will Transform Revascularization Decisions!

Martin T. Rothman Postmortem Analyses of Recent DES Controversies V: Other 12:31 p m - Do I Look Worried? These Unsuccessful DES Systems Topics of Interest Trials Will Prove to Be the Greatest 2:09 p m - The CoStar Bioabsorbable Moderators: Dean J. Kereiakes, Benefit to CABG in Many Years! Polymer-Based Paclitaxel-Eluting DES: Christian M. Spaulding Michael J. Mack CoStar II Results and Critical Postmortem

11:03 a m - Clinical Outcomes of DES 12:39 p m - Questions to the Debators Mitchell W. Krucoff Treatment in Diabetics: Are There Safety or from the Moderators 2:19 p m - The Zomaxx PC Polymer-Based Efficacy Concerns and Are There Device Panel Moderators: Dean J. Kereiakes, Zotarolimus-Eluting DES: Why Did Zomaxx I Preferences? Christian M. Spaulding Fall Short of Expectations? Christian M. Spaulding Alan C. Yeung 11:14 a m - The Importance of Procedural FDA-Approved and “Next Wave” U.S. 2:29 p m - Moderated Discussion and Q&A Technique (Stent Sizing, Balloon Pressure, Drug-Eluting Stents Panel Moderators: Jeffrey J. Popma, Lesion Preparation) to Optimize DES Moderators: Jeffrey J. Popma, Alan C. Yeung Alan C. Yeung Implantation: Insights from STLLR Discussants: Donald S. Baim, Stephen G. Ellis, and Other Experiences CYPHER (Polymer-Based Sirolimus-Eluting DES) David E. Kandzari, Mitchell W. Krucoff, Marco A. Costa John M. Lasala, Campbell Rogers, Giora Weisz 12:43 p m - Pivotal Trial Complete: Lessons 11:24 a m - Can Routine IVUS Assessment After 5-Year Follow-Up from the SIRIUS Trial Pre- and Post-DES (with or Without Giora Weisz Other Important DES Systems in Radiofrequency Plaque Characterization) 12:51 p m - CYPHER in Chronic Total Clinical Use Around the Globe Meaningfully Reduce Stent Thrombosis Occlusions: Results from the ACROSS Moderators: Keith D. Dawkins, and Restenosis? Registry and the PRISON II Randomized Stephen G. Ellis Gary S. Mintz Clinical Trial 11:34 a m - After Long-Term Follow-Up, Are David E. Kandzari The “Family” of Biolimus A9-Eluting DES Still a Cost-Effective Therapy? In Which Bioabsorbable Polymer-Based 1:01 p m - New Stent Platforms (Cypher Elite, DES Systems Patient Populations? In Spite of Late Stent CoStar, and PioNIR), New Carrier Systems, Thrombosis? 2:44 p m - The Biosensors BIOMATRIX and Ongoing or Planned Clinical Trials with David J. Cohen Biolimus-Eluting DES Program: Technical Sirolimus-Eluting Stents (CYPHER) Review and Clinical Trial Updates Mini-Debate I: Is Angiographic Late Campbell Rogers (STEALTH, BEACON, and LEADERS) Lumen Loss a Scientifically and Stephan Windecker Clinically Worthwhile Surrogate TAXUS (Polymer-Based Paclitaxel-Eluting DES) Endpoint in DES Clinical Trials? 2:56 p m - The Terumo NOBURI Biolimus- 1:11 p m - Pivotal Trial Complete: Lessons Eluting DES Program: NOBORI-I Phase I 11:43 a m - Clearly Yes: The Value of Late After 5-Year Follow-Up from the Loss Has Stood the Test of Time! Update and a Preview of the Phase II Trial TAXUS-IV Trial Laura Mauri Bernard R. Chevalier Stephen G. Ellis 3:06 p m - The Devax AXXESS Biolimus- 11:51 a m - Clearly Not: Clinical Outcomes 1:19 p m - Important Late Follow-Up (two Must Take Precedence! Eluting Self-Expanding Stent for Bifurcations Years) and Subgroup Results from the Jean Marco (Including Left Main Disease) TAXUS “Real World” ARRIVE Stefan Verheye 11:59 a m - Questions to the Debators Multicenter Registry 3:16 p m - The Xtent CUSTOM Biolimus- from the Moderators John M. Lasala Panel Moderators: Dean J. Kereiakes, Eluting Modular Stent Program (Focus on 1:29 p m - New Stent Platforms (Liberte, Christian M. Spaulding Multivessel and Diffuse Disease) Perseus, and Petal), New Carrier Systems Pieter R. Stella Mini-Debate II: Have the COURAGE . . . (Labcoat), and Ongoing or Planned Clinical Trials with Paclitaxel-Eluting Stents (TAXUS) Tacrolimus-Eluting DES Systems 12:03 p m - To Leave Diseased Arteries Alone! Donald S. Baim Spencer B. King III 3:26 p m - The Sorin JANUS Tacrolimus- Eluting Stent for Acute Coronary Syndrome 12:11 p m - To Perform PCI in Endeavor (PC Polymer-Based Lesions Intermediate Lesions! Zotarolimus-Eluting DES) Jochen Wohrle William F. Fearon 1:39 p m - The Endeavor DES System: Technical Review and Clinical Trial Updates 12:19 p m - Questions to the Debators (ENDEAVOR 1–5 and PROTECT) from the Moderators Martin B. Leon Panel Moderators: Dean J. Kereiakes, Christian M. Spaulding

42 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Other Sirolimus-Eluting Stent Systems 5:13 p m - Q&A 8:42 a m - Nanobubble Based Harmonic, Subharmonic, and Molecular Imaging 3:36 p m - The Translumina YUKON 5:18 p m - DES in Saphenous Vein Grafts: “Polymerless” Sirolimus-Eluting Stent: Should Concerns from RRISC Late Outcomes of Vasa Vasorum Review of the ISAR and Other Trials Influence Clinical Practice? Antonius F. W. van der Steen in t ro Helmut Schuhlen Glenn Van Langenhove 8:57 a m - Virtual Histology I: Technical Evolution, Strengths and Limitations, 3:46 p m - The EXCEL Bioabsorbable 5:28 p m - Q&A Polymer-Based Sirolimus-Eluting Stent: and Insights from Global Registries 5:33 p m - DES in Bifurcation Disease: A Raimund A. Erbel

Results from the CREATE Registries tURDAY

Practical Approach Including and Beyond agenda

Yaling Han sa Provisional Sidebranch Stenting 9:12 a m - Virtual Histology II: Multimodality 3:56 p m - The Sahajanand (SMT) Angela Hoye Imaging of the Coronary Tree in Patients SUPRALIMUS Bioabsorbable Polymer-Based with Acute Coronary Syndromes: Final 5:43 p m - Q&A Sirolimus-Eluting Stent: Clinical Trials Baseline PROSPECT Results 5:48 p m - DES in Chronic Total Occlusions: Gregg W. Stone sun DAY

(SERIES and MAXIMUS) and Future Plans agenda Support for a Full Metal DES Jacket Ashok Seth 9:27 a m - TCT-20: Detection of Lipid Rich (PRISON II, ACROSS, Taxus Registry, etc)? 4:06 p m - The Microport FIREBIRD Lesions in Human Atherosclerotic Gerald S. Werner Polymer-Based Sirolimus-Eluting Stent: Plaques by Intra-Vascular MRI Catheter FIREBIRD in China (FIC) and Other 5:58 p m - Q&A Assaf Weiss et al agenda Clinical Trials 6:03 p m - DES in Multivessel Disease: 9:42 a m - Moderated Discussion and Q&A mon DAY Junbo Ge Practical Clinical Strategies and Panel Moderators: Raimund A. Erbel, Early Insights from SYNTAX Antonius F. W. van der Steen Other Paclitaxel-Eluting Stent Systems Bernard De Bruyne Discussants: Steven B. Feinstein, 4:16 p m - The Sahajanand (SMT) INFINNIUM 6:13 p m - Q&A Morteza Naghavi, Gilles Rioufol, Gregg W. Stone agenda

Bioabsorbable Polymer-Based Paclitaxel- t ues DAY Eluting Stent: Results from the “Real World” 6:18 p m - DES in Unprotected Left Main SIMPLE III Registry Disease: A Bridge Too Far or a Viable Invasive Detection Modalities II: D.S. Gambhir Clinical Option Today? Technology and Clinical Updates Paul S. Teirstein Moderators: Guillermo Tearney, 4:26 p m - The Biosensors AXXION Glycocalix

Robert L. Wilensky agenda “Polymerless” Paclitaxel-Eluting Stent: 6:28 p m - Q&A wed NESDAY

Results from the “Real World” EAGLE Registry 6:35 p m - Adjourn Light-Based Imaging, Spectroscopy, MRI, Thomas A. Ischinger and Molecular Imaging

The Pro-Healing GENOUS Stent System 9:57 a m - Angioscopic Plaque Appearance to Predict Patient and Lesion Risk case 4:36 p m - The Orbus-Neich GENOUS Vulnerable Plaque: reviews Endothelial Progenitor Cell Capture Stent: Pathophysiology, Detection, Yasunori Ueda Clinical Updates from the HEALING Studies, 10:12 a m - OCT Update: Clinical Studies, the AMC “Real World” Registry, and the and Therapeutic Polarization-Sensitive Enhancement, TRIAS Trials Intervention, PART 2 and the Promise of Fourier-Domain OCT agenda

Robert J. de Winter 8:00 a m -5:50 p m Eveline S. Regar t hurs DAY

4:48 p m - Moderated Discussion and Q&A Room 150B 10:27 a m - Fluorescence Imaging in Panel Moderators: Keith D. Dawkins, Cardiovascular Disease: Conceptual Stephen G. Ellis Invasive Detection Modalities I: Framework and a Novel Near-Infrared Discussants: Bernard R. Chevalier, Fluorescence Probe for Macrophage

Technology and Clinical Updates t raining physician Robert J. de Winter, Junbo Ge, Yaling Han, Moderators: Raimund A. Erbel, Imaging of Cathepsin K Activity Thomas A. Ischinger, Helmut Schuhlen, Antonius F. W. van der Steen Farouc A. Jaffer Stefan Verheye, Stephan Windecker, 10:42 a m - Optical Frequency Domain Jochen Wohrle Intravascular Ultrasound, Virtual Imaging, Laser Speckle, and Newer

Histology, and Vasa Vasorum Imaging t elli e Light-Based Plaque Characterization even t s sa The DES Clinical Corner: 8:00 a m - IVUS Imaging of Atherosclerotic Technologies Guidelines for DES Use in Lesion- Plaque: Utility and Limitations in Brett E. Bouma Predicting Vulnerability 10:57 a m - Macrophage Detection, Specific Scenarios Gilles Rioufol Moderators: Sigmund Silber, Stefan Verheye Quantification, and Prognostic Utility by OCT 8:15 a m - Vasa Vasorum and Angiogenesis Discussants: Susheel Kodali, Maurizio Ik-Kyung Jang ABS T RAC S Imaging in Human Atherosclerotic Plaque Menichelli, Albert E. Raizner, Bonnie H. Weiner 11:09 a m - Catheter Based Detection and with 2-D and 3-D Contrast Ultrasound 5:03 p m - DES in Acute Myocardial Photothermolysis of Iron Oxide Loaded Steven B. Feinstein Infarctions (STRATEGY, PASSION, Macrophages 8:30 a m - Ultimate IVUS Update Marc D. Feldman

TYPHOON, SESAME, PREMIER, etc): Use, general Misuse, or Abuse? Morteza Naghavi H. Vernon Anderson

www.tct2007.com 43 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

11:24 a m - Near Infrared Spectroscopy Interventional Therapies for 5:18 p m - An Implantable Device for Detection of Lipid Rich Plaque: Preclinical Vulnerable Plaque Real-Time Detection of Plaque Progression Validation and Human Experiences Moderators: James H. Chesebro, or Rupture (SPECTACL) James E. Muller Tim A. Fischell Sergio Waxman 5:30 p m - Moderated Discussion and Q&A 2:59 p m - The Spectrum of Vulnerable Plaque 11:39 a m - Intravascular MRI: First Report Animal Models: Do Any of Them Represent Panel Moderators: James H. Chesebro, from the Multicenter TopImage Study the Human Condition? James E. Muller Martin B. Leon Juan F. Granada Discussants: Stephen E. Epstein, Tim A. Fischell, Juan F. Granada, 11:54 a m - Raman Spectroscopy for Plaque 3:12 p m - Update on Systemic Therapies Amir Lerman, Pedro R. Moreno, Characterization: Advantages, Drawbacks, for Atherosclerosis and Vulnerable and Development of an Endovascular Christodoulos I. Stefanadis, Renu Virmani, Plaque Passivation: Efficacy of Current Ron Waksman Catheter Pharmaceuticals and Innovative Agents Guillermo Tearney Under Development to Stabilize and/or 5:50 p m - Adjourn 12:06 p m - Moderated Discussion and Q&A Regress Atheroma Panel Moderators: Guillermo Tearney, James H. Chesebro Robert L. Wilensky Bifurcation and Left Main Discussants: Brett E. Bouma, The Great Debate: Does Stent-Based Therapy (DES or BMS) for Vulnerable Stenting: An Advanced Marc D. Feldman, Farouc A. Jaffer, Ik-Kyung Plaque Stand a Chance? Jang, Eveline S. Regar, Yasunori Ueda, Operator’s Workshop Sergio Waxman 3:27 p m - Yes: The Preclinical Data Are 8:00 a m -6:45 p m Strong, the Rationale Is Solid, and Room 150A 12:26 p m - Break the Risks Are Justified! Pedro R. Moreno Invasive Detection Modalities III: Bifurcation Stenting Overview, 3:39 p m - No: The Justification Is Weak and Treatment Perspectives, and Technology and Clinical Updates the Pathology Promises Disaster! Moderators: Peter H. Stone, Renu Virmani Imaging Modalities Antonius F. W. van der Steen Moderators: Antonio Colombo, Thierry Lefevre 3:51 p m - Impact on Macrophages and 8:00 a m - Coronary Bifurcation Treatment Plaque Architecture with an Everolimus- Evaluating the Mechanical Properties of Considerations: Consensus Recommendations Atherosclerotic Plaque Eluting Stent in the Hypercholesterolemic from the European Bifurcation Club Rabbit 1:30 p m - Elastography, Palpography, and Thierry Lefevre Beyond: Core Concepts, 3-D Applications, Stefan Verheye 8:12 a m - Angiographic Assessment Modulography, Thermal Strain Imaging, 4:00 p m - Description and Human Results Subtleties of Bifurcation Lesions: Beyond and More with a VEGF-Inhibiting Bevacizumab-Eluting the Medina Classification (Vessel Size, Antonius F. W. van der Steen Stent Takeoff Angles, and Plaque Characteristics) Christodoulos I. Stefanadis 1:45 p m - Endothelial Shear Stress Imaging I: Alexandra J. Lansky Science, Technique, and Validation 4:15 p m - The Regional Approach to 8:22 a m - The Importance of Sidebranch Flow Jolanda J. Wentzel Vulnerable Plaque Stabilization: Rationale and Patency: Angiographic and Clinical and Reality of Photodynamic Therapy 1:57 p m - Endothelial Shear Stress Imaging Outcomes After Crossing Non-Diseased and Ron Waksman II: In Vivo Identification of High-Risk Plaque Diseased Sidebranches with Bare Metal and from Endothelial Shear Stress Imaging and 4:30 p m - Update on Cryotherapy for Drug-Eluting Stents Expansive Plaque Remodeling Regional Coronary Passivation Jeffrey J. Popma Peter H. Stone Glenn Van Langenhove 8:30 a m - OCT Assessment of Bifurcation 2:12 p m - Integrated VH and Bio-Mechanical 4:42 p m - Can Endothelial Progenitor Cells Lesions May Help to Profile Treatment Imaging of Atherosclerotic Coronary Plaques: Be Used to Stabilize the Progression of Strategies Basic Concepts and Preliminary Clinical Atherosclerotic Plaque? Carlo Di Mario Results Amir Lerman 8:38 a m - Do Dynamic 3-D Anatomic Changes Ran Kornowski 4:54 p m - A Novel Molecular Method for in Coronary Bifurcations Affect Treatment 2:27 p m - TCT-21: High Coronary Compliance Noninvasive Vulnerable Plaque Targeting for Outcomes? Differential Between Stenotic and Distal Imaging and Therapeutic Homing Marco A. Costa Arterial Segments Is Associated with Stephen E. Epstein 8:46 a m - IVUS Imaging of the Main Vessel Coronary Artery Disease Instability 5:06 p m - Development of a Novel Self- and the Sidebranch with Different Anthony J. White et al Expanding Bare Metal Stent for Vulnerable Bifurcation Treatment Approaches (INSIDE I 2:42 p m - Moderated Discussion and Q&A Plaque: Properties, Vascular Responses, and II Trials) Panel Moderators: Peter H. Stone, and Future Directions Ricardo A. Costa Antonius F. W. van der Steen Juan F. Granada 8:54 a m - Kissing Balloons and Plaque Shift: Discussants: Ran Kornowski, IVUS Insights from the INSIGHT Trial Jolanda J. Wentzel Marco A. Costa

44 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 9:02 a m - Moderated Discussion and Q&A 10:32 a m - TCT-26: DES Use for Bifurcation Bifurcation Case Tutorials (Complexities, Panel Moderators: Antonio Colombo, Lesions Treatment: Is There Any Difference Curiosities, and Complications) Thierry Lefevre in Clinical Outcomes Between the One- vs. Moderators: Marco A. Costa, Issam D. Moussa

Discussants: Marco A. Costa, Two-Stent Strategies? in t ro 12:31 p m - Case #1 Ricardo A. Costa, Alexandra J. Lansky Daniela Trabattoni et al James B. Hermiller, Jr 10:42 a m - TCT-27: Comparison of Simple vs. 12:36 p m - Case #2 Complex Stenting Strategy for Coronary Bifurcation Techniques (Step-by- David A. Cox Artery Bifurcation Lesions in Daily Practice

Step Tutorials with Case Examples) tURDAY

12:41 p m – Case #3 agenda Moderators: Maurice Buchbinder, Zhan Gao et al sa Issam D. Moussa Eulogio Garcia 10:52 a m - A Randomized Trial of Crush vs. 12:46 p m - Case #4 9:12 a m - The Provisional Single Stent Provisional T-Stenting: First Report of the Michael B. Collins Approach (And When and How to 30-Day Results from the CACTUS Trial Antonio Colombo 12:51 p m - Case #5 sun DAY

Protect the Sidebranch) agenda Leif Thuesen Yves R. Louvard 11:00 a m - Moderated Discussion and Q&A

9:20 a m - T-Stenting (and Its Variations): Panel Moderators: Carlo Di Mario, 12:56 p m - Case #6 Technique and Preferred Situations Marie-Claude Morice David G. Rizik Pieter R. Stella Discussants: Antonio Colombo, Andrejs Erglis, agenda Zhan Gao, Thierry Lefevre, Daniela Trabattoni mon DAY 9:28 a m - Crush Stenting (and Its Variations): Left Main Stenting Overview, Technique and Preferred Situations Treatment Perspectives, and Eulogio Garcia Sidebranch Considerations Imaging Guidance Moderators: Jeffrey W. Moses, 9:36 a m - V-Stenting for Non-Left Moderators: Raj Makkar, Seung-Jung Park Jeffrey J. Popma

Main Bifurcations: Technique agenda 1:01 p m - Left Main Coronary Interventional t ues DAY 11:10 a m - Focus on the Sidebranch I: and Preferred Situations Treatment Considerations: Consensus The Importance of Predilation and Samin Sharma Recommendations from the First Left Main Take-Off Angles 9:44 a m - Is Coulotte Stenting Underutilized Summit (Jeju, South Korea) Angela Hoye for Bifurcations? Technique and Preferred Martin B. Leon, Seung-Jung Park Situations 11:20 a m - Focus on the Sidebranch II: agenda

1:13 p m - Updated Results from the First wed NESDAY Potential Value of Dedicated Sidebranch Howard C. Herrmann Randomized Trial of Bare Metal and Stents and Bare Metal vs. DES for the a m Drug-Eluting Stents for Unprotected

9:52 - Moderated Discussion and Q&A Sidebranch Panel Moderators: Maurice Buchbinder, Left Main Lesions Liliana R. Grinfeld Eulogio Garcia Andrejs Erglis case reviews Discussants: Howard C. Herrmann, 11:30 a m - Focus on the “Third” Branch: Yves R. Louvard, Samin Sharma, Pieter R. Stella Treatment Approaches for Trifurcation The Main Event #2: PCI vs. CABG for Left Lesions Main Disease Corrado Tamburino 1:23 p m - Point: Until Proven Otherwise (and The Central Issue: Provisional vs. That Means Well Conducted Randomized

11:40 a m - When Is Atherectomy (Rotational agenda Dual Stent Strategies Trials), CABG Remains the “Gold Standard” t hurs DAY or Directional) Plaque ModificationH elpful for Moderators: Carlo Di Mario, Treatment for Unprotected Left Main Bifurcation Lesions? The DESPARADO Trial Marie-Claude Morice Disease! D. Christopher Metzger 10:02 a m - Perspective: Keep It Simple! Michael J. Mack 11:48 a m - When Is Atherotomy (Cutting or Updated Lessons from the Nordic 1:33 p m - Counterpoint: CABG is History! t raining

Scoring Balloon) Plaque Modification physician Bifurcation Trial Left Main PCI with DES Is the Preferred Helpful for Bifurcation Lesions Andrejs Erglis Treatment in Most Patients! Jeffrey W. Moses Antonio Colombo The Main Event #1: Provisional vs. 11:56 a m - Use of Physiology to Guide Two Stents for Bifurcations 1:43 p m - Contrapoint: A Vote for “Balance” Bifurcation Treatment Decisions t elli e even t s

(CABG vs. PCI) in the Treatment of sa 10:12 a m - Point: Provisional Bifurcation Michael J. Lim Stenting Is Now the “Gold Standard” and Unprotected Left Main Disease: What I 12:04 p m - Moderated Discussion Should Be Applied in ALL Patients Tell My Patients and Referring Physicians Panel Moderators: Jeffrey W. Moses, Thierry Lefevre Matthew J. Price Jeffrey J. Popma 1:55 p m - TCT-28: Impact of Diabetes on 10:22 a m - Counterpoint: Provisional Stenting Discussants: Liliana R. Grinfeld, Angela Hoye, Repeat Revascularization After Unprotected ABS T RAC S Is Fine, BUT Most True Bifurcation Lesions Michael J. Lim, D. Christopher Metzger, Left Main Stenting in the Drug-Eluting Stent Require a Sidebranch Stent Strategy from Corrado Tamburino the Outset Era: A Report from the French Left Main Antonio Colombo Dedicated Stents for Bifurcation Lesions TAXUS Registry Beatriz Vaquerizo et al

Moderator: Martin B. Leon general

12:19 p m - An Overview of the Spectrum of Dedicated Bifurcation Stent Designs Martin B. Leon

www.tct2007.com 45 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

2:03 p m - Is Intravascular Ultrasound 3:48 p m - The Asan Medical Center Left Main 5:58 p m - Moderated Discussion and Q&A Guidance a Necessity for the Optimal Experience with BMS and DES Panel Moderators: Jean Fajadet, Diagnosis and PCI Treatment of Left Main Seung-Jung Park Roxana Mehran Lesions? Discussants: Didier Carrie, Alaide Chieffo, 3:57 p m - The Polish National Registry of Left Stuart T. Higano Main Disease and Late Follow-Up from the Takeshi Kimura, Thierry Lefevre, Raj Makkar, Julinda Mehilli, Seung-Jung Park, 2:13 p m - Physiologic Lesion Assessment LEMANS Randomized Trial Using FFR to Guide Left Main Treatment Pawel E. Buszman Matthew J. Price, Patrick W. Serruys, Strategies Marco Valgimigli 4:06 p m - The Cedars-Sinai Left Main PCI vs. William F. Fearon CABG Experience 2:23 p m - Can CT Angiography Be Used to Raj Makkar Left Main Case Tutorials Reliably Diagnose and Follow (After PCI (Complexities, Curiosities, and 4:15 p m - Multicenter DES Registry of Left Treatment) Patients with Left Main Disease? Main Ostial and Body Lesions Complications) Pim de Feyter Alaide Chieffo Moderators: Bernhard Reimers, 2:33 p m - Moderated Discussion and Q&A Gerhard C. Schuler 4:24 p m - The Rotterdam DES Left Panel Moderators: Raj Makkar, Main Experience 6:13 p m - Case #1 Seung-Jung Park Marco Valgimigli John M. Lasala Discussants: Antonio Colombo, Pim de Feyter, 4:33 p m - The Columbia DES Left 6:18 p m - Case #2 Andrejs Erglis, William F. Fearon, Main Experience Costantino R. Costantini Stuart T. Higano, Martin B. Leon, Roxana Mehran Matthew J. Price, Beatriz Vaquerizo 6:23 p m - Case #3 4:42 p m - The Scripps DES Left Yaling Han Left Main Interventional Main Experience 6:28 p m - Case #4 Matthew J. Price Techniques (Step-by-Step Tutorials Toshiya Muramatsu with Case Examples) 4:51 p m - The Gregario Maranon Taxus 6:33 p m - Case #5 Left Main Experience Bernhard Reimers Moderators: Yves R. Louvard; Paul S. Teirstein Eulogio Garcia 6:38 p m - Case #6 2:48 p m - Case Open: Bifurcation Left Main 5:00 p m - The TRUE Taxus Left Main Gerald Barbeau PCI Treatment I: A Simplified, Single-Stent Registry (Late Follow-Up) Approach for “ALL” Patients 6:45 p m - Adjourn Thierry Lefevre Marie-Claude Morice 5:09 p m - A Multicenter Registry of the 2:58 p m - Case Open: Bifurcation Left Main Taxus Stent in Unprotected Left Main PCI Treatment II: A Lesion-Specific 1- and Chronic Total Occlusions: Disease: First Report of the 9-Month Results 2-Stent Treatment Algorithm from the FRIEND Registry Basic and Expert Techniques Seung-Jung Park Didier Carrie 8:00 a m -6:00 p m 3:08 p m - TCT-29: Long-Term Results Room 145AB 5:18 p m - The European Cypher Left Main Comparing Simple vs. Complex Stenting Registry (Late Follow-Up) Techniques in the Treatment of Bifurcational Jean Fajadet CTO Case Selection Unprotected Left Main Disease Moderators: Osamu Katoh, David O. Williams Primiano Lombardi et al 5:26 p m - The Japanese Cypher Left Main Registry (2-Year Follow-Up) 8:00 a m - CTO Indications and Clinical 3:18 p m - The Role of Plaque Modification Takeshi Kimura Outcomes: Symptoms, Ischemia, or Survival? and Debulking Modalities for Left Main PCI Angela Hoye (the PERFECT Registry) 5:34 p m - A Large Randomized Trial of 8:12 a m - Do The Results of OAT Impact the Etsuo Tsuchikane CYPHER vs. Taxus Stents in Unprotected Left Main Disease: First Report of the Indications for CTO Angioplasty? 3:28 p m - Interventional Strategies for Left 30-Day Results from the ISAR-Left Jeffrey W. Moses Main Trifurcation Disease Main Trial 8:22 a m - Importance of Viability Assessment Teguh Santoso Julinda Mehilli Prior to CTO Angioplasty 3:38 p m - Moderated Discussion and Q&A 5:42 p m - Pre-Combat: Preliminary Findings Gerald Barbeau Panel Moderators: Yves R. Louvard, from the Multicenter Korean Left Main 8:32 a m - CTO Case Presentations: The Paul S. Teirstein DES vs. CABG Randomized Trial Consequences of CTO Angioplasty Discussants: Primiano Lombardi, Seung-Jung Park Decision Making (with Baseline Marie-Claude Morice, Seung-Jung Park, Imaging and Long-Term Follow-Up) Teguh Santoso, Etsuo Tsuchikane 5:50 p m - SYNTAX: Preliminary Observations from the Left Main Cohort of the Multicenter Gerald S. Werner Left Main Intervention Registries Taxus vs. CABG Randomized Trial 8:42 a m - Moderated Discussion and Q&A and Trials Patrick W. Serruys Panel Moderators: Osamu Katoh, Moderators: Jean Fajadet, Roxana Mehran David O. Williams Discussants: Gerald Barbeau, Kenneth Chin, Angela Hoye, Jeffrey W. Moses, Gerald S. Werner

46 truth in evidence based medicine · challenge conventional wisdom · transform your thinking CTO Procedural Success and 10:58 a m - Enhanced Outcomes with 2:45 p m - Retrograde Technique III: Avoiding Failure Technique Evolution Over a Decade of CTO and Managing Complications Moderators: Geoffrey O. Hartzler, Angioplasty: Toyahashi Heart Experience Shigeru Saito

Takahiko Suzuki in t ro Jeffrey W. Moses 2:55 p m - Retrograde Case Presentations: 11:08 a m - The “Live Case” Approach Selection of Collaterals 8:57 a m - Western Perspectives: What Are the Current Success Rates and to CTO Angioplasty: Lessons from Kazuaki Mitsudo Four Years of the CTO Summit Predictors of CTO Failure? 3:05 p m - Retrograde Case Presentations: Gregg W. Stone Carlo Di Mario Difficult Lesion Crossing tURDAY agenda 11:20 a m - IVUS Guidance Techniques to Junbo Ge sa 9:07 a m - Eastern Perspectives: What Ensure Intraluminal Wire Position Are the Current Success Rates and 3:15 p m - Retrograde Case Presentations: Predictors of CTO Failure? Yasushi Asakura Externalization of Retrograde CTO Wiring Masato Nakamura 11:32 a m - Antegrade Case Presentation: Yaron Almagor sun DAY IVUS Guided Wiring agenda 9:17 a m - Special Lecture: Just How Safe Is 3:25 p m - TCT-35: The Efficacy of Bilateral CTO Angioplasty? Frequency and Range Satoru Sumitsuji Approach for the Lesions with Chronic Total of CTO Complications (Data and Hair- 11:42 a m - Subintimal Tracking and Reentry: Occlusion in Acute Results: The CART Raising Case Examples) Indications, Technique, Complications, Registry Joachim Schofer and Acute/Late Success Masashi Kimura et al agenda Antonio Colombo mon DAY 9:32 a m - CTO Case Presentation: 3:35 p m - TCT-36: Retrograde Recanalisation More Complications 11:54 a m - Roundtable Discussion of Chronically Occluded Coronary Arteries: Steven J. Yakubov Panel Moderators: J. J. R. M. (Hans) Bonnier, Initial Multicenter Experience Takahiko Suzuki Georgios Sianos 9:42 a m - Factoring in Radiation Exposure, Discussants: Yasushi Asakura, agenda

Contrast Utilization, and Resource 3:45 p m - Moderated Discussion and Q&A t ues DAY Consumption in the Decision to Perform CTO Reginald I. Low, Gregg W. Stone, Panel Moderators: Tomoaki Hinohara, Angioplasty Satoru Sumitsuji, Etsuo Tsuchikane Osamu Katoh Roxana Mehran 12:09 p m - Break Discussants: Yaron Almagor, Masashi Kimura, Kazuaki Mitsudo, Masahiko Ochiai, 9:54 a m - Are Drug-Eluting Stents Imperative for CTO Angioplasty? Literature Review, Shigeru Saito, Georgios Sianos agenda

Crossing the Resistant Lesion wed NESDAY 3-Year Results of PRISON-II, and Moderators: Reginald I. Low, Hideo Tamai Rational for PRISON-III CTO Imaging and Novel Device

1:30 p m - When the Wire Crosses But the Maarten J. Suttorp Balloon Won’t: From Anchor and Guide Approaches 10:06 a m - TCT-34: Drug-Eluting Stents for Techniques to Tornus, Rotablator, and Laser Moderators: Maurice Buchbinder, case reviews the Treatment of Chronic Total Occlusion: Patrick L. Whitlow Charles A. Simonton

A Comparison with Sirolimus, Paclitaxel, 1:45 p m - Antegrade Case Presentations: 4:00 p m - Incorporating CT Angiography into Zotarolimus, Tacrolimus-Eluting, and EPC Strategies to Cross Resistant Lesions CTO Angioplasty: Predictors of Success Capture Stent: Multicenter Registry in Asia After Successful Wiring (Non Tornus) and Role in Procedural Guidance

Sunao Nakamura et al Kenneth C. Huber Manel Sabate agenda t hurs DAY a m 10:16 - Moderated Discussion and Q&A 1:55 p m - Antegrade Case Presentations: 4:12 p m - Blunt Microdissection Revisited: Panel Moderators: Geoffrey O. Hartzler, Multifunctional Use of the Tornus The Ovalum CiTop Guidewire System Jeffrey W. Moses Masahiko Ochiai Keyur H. Parikh Discussants: Roxana Mehran, 2:05 p m - Moderated Discussion and Q&A 4:22 p m - Progress with a Novel High t raining

Sunao Nakamura, Masato Nakamura, physician Panel Moderators: Reginald I. Low, Frequency Oscillating Guidewire System Joachim Schofer, Maarten J. Suttorp, Hideo Tamai Alexandre Abizaid Steven J. Yakubov Discussants: Kenneth C. Huber, 4:32 p m - Device Maturation and Practical Masahiko Ochiai, Patrick L. Whitlow Recommendations for Use of the t elli e

Antegrade Technique Forum even t s

Safe Cross OCR/RF Ablation System sa Moderators: J. J. R. M. (Hans) Bonnier, Charles A. Simonton Takahiko Suzuki Retrograde Technique Forum Moderators: Tomoaki Hinohara, Osamu Katoh 4:44 p m - Final FACTOR Results of 10:31 a m - Guidewire Options and Selection 2:15 p m - Retrograde Fundamentals I: Initial High Frequency Mechanical Ultrasound Criteria: Hydrophilic, Tapered, or Strong or Secondary Approach; Collateral CTO Angioplasty with the Crosser and as Steel? Examination; Guide, Guidewire, and Future Directions ABS T RAC S Martin B. Leon Microcatheter Selection; Lesion Wiring Louis A. Cannon 10:43 a m - Antegrade Guidewire Basics: Masahiko Ochiai 4:56 p m - TCT-37: Recanalization of Guidewire Tip Shaping, Escalation 2:30 p m - Retrograde Fundamentals II: Lesion Chronic Total Coronary Occlusions Strategies, Drilling vs. Penetration, and

Crossing “Antegrade, Retrograde, CART, Using the CROSSER System as a general When to Use (and Not Use) Parallel Wire Reverse CART” Tips and Tricks First Attempt: The CRAFT Study Etsuo Tsuchikane Osamu Katoh Antonio Colombo et al

www.tct2007.com 47 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

5:06 p m - Magnetic Guidance of CTO 8:52 a m - Differentiating Among PFO Closure 10:50 a m - Variables Related to Successful Angioplasty (with and Without Options: What I Like (and Don’t Like) About Acute and Sustained Post Myocardial Integrated CT Angiography) Each Device and How to Choose Infarction VSD Closure Jeffrey W. Moses Stephen J.D. Brecker Eric Horlick

5:16 p m - Progress with a Forward-Looking 9:04 a m - Advanced Techniques for PFO 11:00 a m - Technical Aspects and Advanced IVUS-RF Ablation System Closure and Recognition of Unusual Techniques of Post-MI VSD Closure David O. Williams Situations Ziyad M. Hijazi Paul Kramer 5:26 p m - A New Guidewire Sheath for 11:10 a m - TCT-24: Transcatheter Closure of Resistant Lesion Crossing, and Colleganase 9:16 a m - TCT-22: A Prospective, Multicenter High-Risk Muscular Ventricular Septal Update Clinical Trial to Evaluate the BioSTAR Defects with the CardioSEAL Occluder: Bradley H. Strauss Bioabsorbable Septal Repair Implant for the Midterm Follow-Up from the CardioSEAL Closure of Atrial Level Shunts: VSD Registry 5:41 p m - Moderated Discussion and Q&A Panel Moderators: Maurice Buchbinder, The BEST Study Scott Lim et al Michael J. Mullen et al Charles A. Simonton 11:20 a m - Are Most PDA Repairs Discussants: Antonio Colombo, 9:26 a m - Moderated Discussion and Q&A Unnecessary? Indications for PDA Closure Jeffrey W. Moses, Manel Sabate, Panel Moderators: Paul Kramer, Frank F. Ing Bradley H. Strauss, David O. Williams Jonathan M. Tobis 11:30 a m - Devices and Advanced Discussants: Stephen J. D. Brecker, 6:00 p m - Adjourn Approaches to PDA Closure Ted Feldman, Michael J. Mullen, Carlos E. Ruiz Mark Reisman, David J. Sahn, 11:40 a m - TCT-25: Percutaneous PDA Peter T. Wilmshurst Interventional Therapies Closure Using the Chinese “Blockaid” Duct for Adult Congenital Heart Occluder: Initial Experience ASD Closure: Simple or Not? Sunil Thanvi et al Disease and Structural Moderators: John F. Rhodes, 11:50 a m - Moderated Discussion and Q&A Robert J. Sommer Defects (Featuring a Mini- Panel Moderators: William E. Hellenbrand, 9:41 a m - When to Close and When Course on Transseptal Ziyad M. Hijazi NOT to Close an ASD Discussants: Eric Horlick, Frank F. Ing, Catheterization) Robert J. Sommer Scott Lim, Carlos E. Ruiz, Sunil Thanvi 8:00 a m -6:05 p m 9:51 a m - When Is Surgical ASD Repair Room 149AB Preferred? Mini-Course on Transseptal Ziyad M. Hijazi Catheterization PFO Closure: Alternatives and 10:01 a m - Advanced Techniques for ASD Moderators: Ziyad M. Hijazi, Open Issues Closure: Patient Assessment, Imaging, Robert J. Sommer Moderators: Paul Kramer, Jonathan M. Tobis and Device Selection 12:15 p m - Septal Anatomy and Anatomic Zahid Amin 8:00 a m - Evidence-Based vs. Contemporary Relationships Patient Selection Criteria for Interventional 10:13 a m - The Spectrum of Device James A. Goldstein PFO Closure: Should the Threshold Be Complications After Percutaneous ASD 12:25 p m - Standard Transseptal Equipment, Raised or Lowered? and PFO Closure: Are They Less Technique, and Modifications Ted Feldman Common Than Previously Thought? Howard C. Herrmann William E. Hellenbrand 8:10 a m - PFO Closure for Stroke Prevention: 12:35 p m - Imaging Guidance of Transseptal Clinical Trial Landscape and Early Insights 10:25 a m - TCT-23: Transcatheter Device Puncture I: TTE, TEE, and ICE Jonathan M. Tobis Occlusion of Atrial Septal Defects with David J. Sahn Pulmonary Hypertension: Initial Results 8:20 a m - PFO Closure for Migraine from the MAGIC Registry 12:45 p m - Complications of Transseptal Prevention: Clinical Trial Landscape and Scott Lim et al Catheterization Early Insights Zoltan G. Turi Peter T. Wilmshurst 10:35 a m - Moderated Discussion and Q&A Panel Moderators: John F. Rhodes, 12:55 p m - Training Requirements for 8:30 a m - A Critical Assessment of PFO Robert J. Sommer Transseptal Catheterization Closure for Stroke and Migraine: Why It Discussants: Zahid Amin, Samir R. Kapadia Might or Might Not Work William E. Hellenbrand, Ziyad M. Hijazi, Mark Reisman 1:05 p m - Moderated Discussion and Q&A Scott Lim Panel Moderators: Ziyad M. Hijazi, 8:42 a m - Variability of PFO Anatomy: Robert J. Sommer Insights from Imaging, and Implications for Discussants: James A. Goldstein, Transcatheter Therapy VSD and PDA Closure Moderators: William E. Hellenbrand, Samir R. Kapadia, David J. Sahn, David J. Sahn Ziyad M. Hijazi Zoltan G. Turi

48 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Devices to Close Septal Defects: 4:06 p m - Transcatheter Treatment of 8:00 a m - The Future of Bare Metal Coronary Designs, Clinical Experience, and Paravalvular Leaks Stents in PCI: A Return to the Past or an Shakeel A. Qureshi Exciting New Future? Future Directions Chaim Lotan in t ro Moderators: Mark Reisman, John F. Rhodes 4:16 p m - Left Atrial Appendage Closure I: Long-Term Outcomes After PLAATO 8:10 a m - Optimizing Stent Design by Infinite 1:15 p m - NMT Cardioseal, Starflex, Biostar, Implantation Analysis of Flow Velocity and Wall Shear and Biotrek Devices Peter C. Block Stress Mark Reisman Goetz M. Richter

4:26 p m - Left Atrial Appendage Closure II: tURDAY

1:25 p m - AGA PFO, ASD, VSD, Cribiform, agenda WATCHMAN Device, Registry Results, 8:18 a m - The ICON Molybdenum Thin Strut sa and Duct Occluders and Randomized Trial Status Metallic Stent Eulogio Garcia Kenneth C. Huber Alexandre Abizaid 1:35 p m - Gore Helex Occluder 4:38 p m - Percutaneous Approaches to 8:26 a m - The PROTEX Cobalt Alloy John F. Rhodes sun DAY Left Ventricular Pseudoaneurysms Prohealing Balloon-Expandable Stent agenda 1:44 p m - St. Jude Premere Zoltan G. Turi Mark C. Bates Robert J. Sommer 4:48 p m - After the Defect Is Closed: 8:34 a m - The Invatec SKYLOR Ultra-Thin 1:53 p m - Cardia Intrasept and Atriasept Medications and Long-Term Strut Cobalt Alloy Stent: Follow-Up Clinical Werner Budts Management Issues Outcomes from a Large Registry agenda mon DAY 2:02 p m - Solysafe Device Eric Horlick Pieter R. Stella

Peter Ewert 4:58 p m - Moderated Discussion and Q&A 8:42 a m - The Titanium Nitrate-Coated Cobalt

2:11 p m - The Occlutech Device Panel Moderators: Lee N. Benson, Eric Horlick Alloy IBS NUMEN “Less Mismatch” Horst Sievert Discussants: Zahid Amin, Peter C. Block, Coronary Stent: Early Clinical Experiences Philipp Bonhoeffer, William E. Hellenbrand, Alessandro S. Bortone agenda 2:20 p m - The Johnson and Johnson SeptRx t ues DAY Kenneth C. Huber, Larry A. Latson, Nico Majunke 8:50 a m - The Boston Scientific Platinum- Shakeel A. Qureshi, Zoltan G. Turi Enriched Stainless Steel ELEMENT Stent 2:29 p m - Coherex Louis A. Cannon Brian Whisenant Case Reviews: Complications of 8:58 a m - Platinum-Implanted Cobalt p m 2:38 - VSD NitOcclud agenda Interventional Therapies for Chromium Stent Biocompatibility Carlos Pedra wed NESDAY Congenital Heart Disease S. Eric Ryan 2:47 p m - RF Ablative Devices I: Cierra Moderators: Charles E. Mullins, 9:06 a m - The Sorin Carbofilm-Coated Cobalt PFX System Eustaquio Onorato Alloy Coronary Stent: Results from the Ted Feldman Discussants: Zahid Amin, Frank F. Ing, STELLAR First-in-Man Study case reviews 2:55 p m - RF Ablative Devices II: Coaptus Saibal Kar, Paul Kramer Antonio L. Bartorelli Thomas K. Jones 5:15 p m - Case #1 9:14 a m - The Medinol NIRflex andT hin Strut Jon R. Resar Cobalt Alloy PIONIR Coronary Stent “Advanced” Interventions for 5:25 p m - Case #2 Ran Kornowski agenda

Adult Congenital Heart Disease t hurs DAY Jochen Wohrle 9:22 a m - The Biotronik Prokinetic Bare Moderators: Lee N. Benson, Eric Horlick 5:35 p m - Case #3 Metal Stent: Results from an “All Comers” 3:03 p m - Stent Angioplasty for Congenital Ramon Quesada Clinical Trial Heart Disease I: Coarctation Ran Kornowski 5:45 p m - Case #4 William E. Hellenbrand Shakeel A. Qureshi 9:30 a m - Moderated Discussion and Q&A t raining physician 3:15 p m - Stent Angioplasty for Congenital Panel Moderators: Antonio L. Bartorelli, 5:55 p m - Case #5 Heart Disease II: Branch Pulmonary Stenosis Tim A. Fischell Allen P. Burke and Obstructed Conduits Discussants: Mark C. Bates, Zahid Amin 6:05 p m - Adjourn Alessandro S. Bortone, Louis A. Cannon, t elli e

Ran Kornowski, Chaim Lotan, even t s

3:27 p m - Coronary and Pulmonary Artery sa Fistulae and AV Malformations: Presentation, Goetz M. Richter, S. Eric Ryan Evaluation, and Indications for Treatment Innovative Devices and Larry A. Latson Futuristic Concepts I: Ostial Stent Designs Moderators: Kenneth Chin, Liliana R. Grinfeld 3:39 p m - Devices and Techniques to Treat Novel Bare Metal and Coronary and Pulmonary Artery Fistulae and 9:40 a m - The OSTIAL PRO: A New Tool for ABS T RAC S AV Malformations Drug-Eluting Stents Precise Ostial Stent Placement Lee N. Benson 8:00 a m -7:00 p m Tim A. Fischell Room 152A 3:51 p m - Valvuloplasty for Congenital Aortic 9:48 a m - The OSTIUM Stent: Design

and Pulmonary Stenosis Concept and Early Clinical Experiences general Philipp Bonhoeffer New Bare Metal Coronary Stents Roberto R. Grinfeld Moderators: Antonio L. Bartorelli, Tim A. Fischell

www.tct2007.com 49 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

9:56 a m - The SQUARE ONE Stent-Based Dedicated Sidebranch Stents 1:43 p m - Lessons Learned from Preclinical

Positioning System for Coronary and 11:51 a m - Tryton Evaluation of Bioabsorbable Stents with Peripheral Ostial Lesions Aaron V. Kaplan Serial Angiographic, IVUS, and OCT Imaging James B. Hermiller, Jr Greg L. Kaluza 12:01 p m - Cappella Sideguard 10:04 a m - Moderated Discussion and Q&A Eberhard Grube 1:55 p m - The ABSORB First-in-Man Clinical Panel Moderators: Kenneth Chin, Trial: Early and Late Clinical Outcomes and Liliana R. Grinfeld Carina Expansion Stents IVUS Mechanistic Insights

Discussants: Tim A. Fischell, 12:11 p m - Devax (AXXESS Plus and Patrick W. Serruys Roberto R. Grinfeld, James B. Hermiller, Jr DIVERGE) 2:10 p m - The Biotronik Absorbable Stefan Verheye Magnesium Alloy Stent: Late Clinical

Vulnerable Plaque Stent Designs 12:21 p m - Moderated Discussion and Q&A Follow-Up from the Coronary PROGRESS Moderators: S. Ward Casscells, Panel Moderators: Samin Sharma, Trial and Future Technology Advances Juan F. Granada Stefan Verheye Jacques J. Koolen 10:14 a m - Stent Design Concepts for the Discussants: Alexandre Abizaid, Remo Albiero, 2:20 p m - The BTI Salicylate-Based Treatment (or Stabilization) of Vulnerable Raoul Bonan, Eberhard Grube, Giulio Polyanhydride Ester Absorbable Sirolimus- Plaque: Lessons from the Experimental Guagliumi, Aaron V. Kaplan, Thierry Lefevre Eluting Sent: Design Concept and Laboratory (Abbott and Others) Experimental Findings Pedro R. Moreno Coronary Stent Grafts and Keith A. Robinson 10:24 a m - Self-Expanding Stent Designs Micro-Stent Designs 2:28 p m - The Reva Tyrosine-Derived for Vulnerable Plaque and Acute Coronary Moderators: Steven R. Bailey, S. Chiu Wong Polycarbonate Absorbable Stent: Design Syndrome Lesions: Design Imperatives 12:35 p m - The SESAME Mesh-Covered Characteristics and First-in-Man Experiences and Experimental Findings (Prescient Nanostent System: Design Concepts and from the RESORB Trial and Others) Early Experiences in Saphenous Vein Grafts Eberhard Grube Juan F. Granada Steven R. Bailey 10:34 a m - The Bevacizumab Eluting 12:43 p m - The Inspire MD Woven Polymer 2:36 p m - Moderated Discussion and Q&A Coronary Stent for the Treatment of MGuard Stent Graft: Clinical Experiences in Panel Moderators: Robert S. Schwartz, Vulnerable Plaque: Early Clinical Experiences Native Coronary and Saphenous Vein Graft Ron Waksman Christodoulos I. Stefanadis Lesions Discussants: Eberhard Grube, Greg L. Kaluza, 10:40 a m - Moderated Discussion and Q&A Eberhard Grube Jacques J. Koolen, Patrick W. Serruys Panel Moderators: S. Ward Casscells, 12:51 p m - The Design and Performance Juan F. Granada Bovine Pericardial Covered (Over-Under) First-in-Man Experiences with Discussants: Pedro R. Moreno, Stent Graft: Clinical Status Update Drug-Eluting Stents I and Passive Christodoulos I. Stefanadis Jorge Gaspar and Active Stent Coatings 12:59 p m - The Cardiomind Stent-on-a-Wire Moderators: Andrew J. Carter, Bifurcation Stent Designs Concept: Results from the First-in-Man Nicolas A. F. Chronos Moderators: Samin Sharma, Stefan Verheye CARE 1 Study 2:50 p m - Preclinical Experience with a Complete Bifurcation “Y” Stents Alexandre Abizaid Novolimus-Eluting Stent 1:09 p m - A New Concept for a “Micro” Guy LeClerc 10:45 a m - Medtronic Raoul Bonan Stent-on-a-Wire 2:55 p m - The Elixir Novolimus-Eluting Tim A. Fischell Durable Polymer Stent: Results from the Sidebranch Access Stents 1:17 p m - Moderated Discussion and Q&A EXELLA First-in-Man Study 10:53 a m - StentYs Panel Moderators: Steven R. Bailey, Alexandre Abizaid

Maurice Buchbinder S. Chiu Wong 3:03 p m - The MIV Polymer-Free Discussants: Alexandre Abizaid, 11:01 a m - Abbott Frontier Hydroxyapatite-Coated Sirolimus-Eluting Giulio Guagliumi Tim A. Fischell, Jorge Gaspar, Eberhard Grube Stent: First-in-Man Angiographic and IVUS Follow-Up Results 11:09 a m - BSC Taxus Petal Alexandre Abizaid Maurice Buchbinder Bioabsorbable Stent Designs: The Next Frontier? 3:11 p m - Understanding Vascular Healing 11:17 a m - Invatec Twin-Rail Moderators: Robert S. Schwartz, Ron Waksman Responses After Stent Implantation: Impact Remo Albiero on Delayed Stent Thrombosis, and Effects 1:30 p m - Weighing the Theoretical 11:25 a m - Ymed Side-Kick Advantages and Limitations of Bioabsorbable of Surface Coatings Yaron Almagor Stents: Predictions for Their Future Niche Aloke Finn 11:33 a m - TriReme Medical Application or Widespread Acceptance 3:21 p m - Oxygen Ion Bombarded Metal Alexandre Abizaid Ron Waksman Stents (Bionert): Results from the BIOSAS 11:41 a m - Minvasys Nile Clinical Study Thierry Lefevre Eulogio Garcia

50 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 3:29 p m - The GENOUS Stent Coating with 5:09 p m - Optimized Stabilized Oil-Based Innovative Devices and CD34 Antibodies to Actively Capture Stent Coatings for Drug Delivery Circulating Endothelial Progenitor Cells: Ivan De Scheerder Futuristic Concepts II:

Design Parameters and Effects on Healing in t ro 5:17 p m - SAMs (Self-Assembly Monolayers) Non-Stent-Based and Thrombogenicity to Attach Drugs to Stents Without Polymers Technologies Michael J. B. Kutryk Marc D. Feldman 8:00 a m -6:40 p m 3:37 p m - Elastin Protein Polymers: Potential 5:25 p m - Moderated Discussion and Q&A Room 152B for a More Thromboresistant Stent

Panel Moderators: Elazer R. Edelman, tURDAY agenda

Eilliot L. Chaikof sa Keith A. Robinson Invention and Innovation: The 3:45 p m - Moderated Discussion and Q&A Discussants: Nicolas A. F. Chronos, Panel Moderators: Andrew J. Carter, Ivan De Scheerder, Marc D. Feldman, Foundation of Cardiovascular Nicolas A. F. Chronos Goetz M. Richter, Yoram Richter, Device Development Discussants: Eilliot L. Chaikof, Aloke Finn, Shrirang Ranade, Josiah N. Wilcox Moderators: Richard Schatz, sun DAY agenda Eulogio Garcia, Michael J. B. Kutryk Marvin L. Woodall First-in-Man Experiences with New 8:00 a m - Understanding the Device New Drug Carrier Systems Drug-Eluting Stents II Development Cycle: Generating Intellectual Property, Screening, and Prototyping New Moderators: Elazer R. Edelman, Moderators: Jacques J. Koolen, Guy LeClerc Ideas, Financing Pathways and Pitfalls, and agenda Keith A. Robinson mon DAY 5:35 p m - The Conor GENESIS Study: A Culminating in a Successful “Start-Up” 3:53 p m - New DES Carrier Systems: First-in-Man Clinical Trial Comparing Peter J. Fitzgerald Advantages and Disadvantages of Durable Pimecrolimus + Paclitaxel vs. Single 8:10 a m - So You Have an Idea? Interacting Polymers, Bioabsorbable Polymers, and Drug Therapies with “Big” Industry (Pros And Cons Polymer-Free Systems Keith D. Dawkins agenda Nicolas A. F. Chronos Compared to Start-Ups and VC Financing; t ues DAY 5:45 p m - A Polymer-Based Simvastatin- Protecting Yourself; What to Ask For and 4:03 p m - Non-Polymeric DES Systems: Eluting Stent: Results from the IRIST Trial What to Expect) Technology, Pharmacokinetics, and Eulogio Garcia Roberta Croce Vascular Healing 5:55 p m - The Endeavor RESOLUTE Juan F. Granada 8:20 a m - Reflections from the Consummate First-in-Man Clinical Trial: Late agenda

Clinician-Inventor-Entrepreneur (From wed NESDAY 4:11 p m - Advanced Pharmacodynamics of Angiographic, IVUS, and Clinical Follow-Up ACS to DVI to Perclose and FoxHollow): Drug Release from DES Systems: Issues Robert J. Whitbourn What a Ride! Associated with Bioabsorbable Polymers 6:05 p m - MELISSA: A First-in-Man Study John B. Simpson and Polymer-Free Surface Carriers of a Melatonin-Eluting Stent case Elazer R. Edelman 8:30 a m - Moderated Discussion and Q&A reviews Jacques J. Koolen Panel Moderators: Richard Schatz, 4:21 p m - The Medinol Carrier-Free 6:15 p m - The SMT Synchronium (Heparin + Marvin L. Woodall Drug Elution System Sirolimus) Absorbable Polymer Stent: Discussants: Robert Croce, Peter J. Fitzgerald, Yoram Richter First-in-Man Results from the John B. Simpson

4:29 p m - Prodrug Macromolecules: HARMONY Trial agenda t hurs DAY A New Non-Polymer DES Solution Suhas S Lele Novel Intravascular Imaging and Shrirang Ranade 6:25 p m - First-in-Man Results from a Novel Diagnostic Modalities 4:37 p m - An Ultrathin Juxta-Abluminal Paclitaxel Absorbable Polymer Stent Moderators: John D. Carroll, Coating for DES: Design Concepts and (LUC-Chopin2) Robert L. Wilensky t raining Update from the JACTAX Clinical Trial Pawel E. Buszman physician Keith Robinson 8:35 a m - 3-D Angiography and Image 6:35 p m - The Avastin-Eluting Coronary Stent: Co-Registration Will Be Fundamental to the 4:45 p m - Biocompatibility of Stent Polymer First-in-Man Experiences with Late Cath Lab of the Future! Coatings: Importance of Biochemistry Angiographic and Clinical Follow-Up John D. Carroll and Polymer Thickness t elli e Christodoulos I. Stefanadis even t s Goetz M. Richter 8:45 a m - Integrating 3-D Coronary Imaging sa 6:45 p m - Moderated Discussion and Q&A Using the Paieon Cardoio-Op System into 4:53 p m - The BioFREEDOM Polymer-Free Panel Moderators: Jacques J. Koolen, the Cath Lab of Today Biolimus A9-Eluting Stent: Design Features, Guy LeClerc Ran Kornowski Animal Studies, and Preliminary Clinical Discussants: Pawel E. Buszman, 8:53 a m - Why Is IVUS Underutilized? Experiences Keith D. Dawkins, Eulogio Garcia, Will Cath Lab Integration, Automated ABS T RAC S Eberhard Grube Suhas S Lele, Christodoulos I. Stefanadis, Image Processing, and Virtual Histology 5:01 p m - All Durable Biopolymers Are Not Robert J. Whitbourn Make a Difference? Created Equal: Design Requirements to 7:00 p m - Adjourn Gary S. Mintz Optimize Safety and Effectiveness of Durable Polymers in DES Systems 9:01 a m - Intra-Cardiac Optical Imaging general Josiah N Wilcox for the Structural Interventionalist: Potential and Challenges Mark Reisman

www.tct2007.com 51 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

9:09 a m - Improved Intravascular Optical Access Closure 12:08 p m - The IDev Supera Woven

Imaging Techniques (OCT and OFDI) Will 10:26 a m - The Therus Ultrasound Thermal Interlocking Nitinol Peripheral Stent: Become the Future Diagnostic Standard in Sealing Solution to Access Closure: New Strength, Flexibility, and Fracture Resistance the Cath Lab Design Concepts and Early Clinical Outcomes (Early Clinical Observations) Marc D. Feldman Eberhard Grube Roger Gammon

9:17 a m - An IVUS Surrogate: The 10:34 a m - Arstasis: A Unique Concept for 12:16 p m - A New Flexible Stent for Lumenrecon Catheter to Measure Lumen Arterial Access and Sealing: First-in-Man Peripheral Vascular Disease Cross-Sectional Area and Diameter Using Clinical Experiences Gary M. Ansel Impedance Techniques Adrian A. Ebner 12:24 p m - Bioerodable and Fracture- M. Reza Movahed Resistant Peripheral Vascular Stents Embolic Protection and Thrombectomy 9:25 a m - Moderated Discussion and Q&A Robert M. Bersin Panel Moderators: John D. Carroll, 10:42 a m - The PROTECTOR Device: A Robert L. Wilensky Simple System for Embolic Protection Aortic Endografts Discussants: Marc D. Feldman, in Carotid and SVG Intervention 12:32 p m - The Bolton RELAY Thoracic M. Reza Movahed Richard R. Heuser Endograft: A More Anatomically Adaptive

10:50 a m – TwinOne: A New Cerebral Design (Clinical Trial Updates) Navigation, Telemanipulation, Protection Device: Experience in 200 Cases Frank J. Criado Robotics, and Sensor-Based Jacques G. Theron 12:42 p m - A Self-Expanding Aortic Endograft with Partial Membrane Coverage Guidance 10:58 a m - The Gardia Concept: Integrating Holger Eggebrecht Moderators: Rafael Beyar, David O. Williams Everyday Guidewires with a Modular Embolic Protection Device 9:35 a m - Using the Stereotaxis Magnetic Neurovascular Therapies Uri Rosenschein Guidance System to Treat Coronary CTOs: 12:50 p m - A New Stent Concept for 11:06 a m - The Aspiration FUNNEL Catheter: Combining Image Co-Registration and an RF Exclusion of Cerebral Aneurysms A Simplified and More Effective Approach Magnetically Steered Guidewire Lee R. Guterman (Thoraxcenter Clinical Experiences) for Embolectomy and Thrombectomy 12:58 p m - A Catheter System for Selective Patrick W. Serruys James D. Joye Cerebral Hypothermia to Treat Acute 11:14 a m - The Lumen FIBERNET Embolic 9:45 a m – The Mediguide GPS System Using Ischemic Strokes Protection Device: Clinical Experiences a Sensor-Enabled Guided Measuring Ronald J. Solar Catheter (GMC): Advantages and Challenges During Intervention in the Carotid Moshe Y. Flugelman and Other Vascular Beds Other Innovative SFA Therapies Gary M. Ansel 9:55 a m - Clinical Experiences with the 1:06 p m - Percutaneous AV-Fistula Formation Hansen Medical Catheter Telemanipulation Transseptal Puncture to Treat Severe COPD: Concept, Device System Description, and Initial Clinical Experiences 11:22 a m - La-Crosse: New Tools for Marvin J. Slepian Horst Sievert Intervening in the Left Atrium 10:03 a m - The Corindus CORPATH Remote Neal L. Eigler 1:16 p m - A Directional Excimer Laser Control Percutaneous Coronary Intervention Support Catheter to Improve SFA 11:30 a m - A Novel Transseptal Puncture System: Clinical Experiences and Recanalization: Results from the CELLO Trial Device for Precise Localization of Future Plans Rajesh M. Dave Left Atrial Entry Peter J. Fitzgerald Samir R. Kapadia 1:26 p m - The Ultrasound CROSSER Device 10:11 a m - The Heartlander Miniaturized for Lower Extremity Occlusive Disease: 11:38 a m - Moderated Discussion and Q&A Epicardial Robot to Optimize Heart Interim Results from the Patriot Trial Panel Moderators: Franz Wolfgang Amann, Failure Therapies James D. Joye Glenn Van Langenhove Dwight Meglan Discussants: Gary M. Ansel, Adrian A. Ebner, 1:36 p m - Moderated Discussion and Q&A 10:18 a m - Moderated Discussion and Q&A Neal L. Eigler, Richard R. Heuser, Panel Moderators: Lawrence A. Garcia, Panel Moderators: Rafael Beyar, Samir R. Kapadia, Uri Rosenschein Lindsay S. Machan David O. Williams Discussants: Gary M. Ansel, Robert M. Bersin, Discussants: Peter J. Fitzgerald, The Focus is Endovascular: Frank J. Criado, Rajesh M. Dave, Moshe Y. Flugelman, Dwight Meglan, Holger Eggebrecht, Roger Gammon, Patrick W. Serruys, Marvin J. Slepian Innovative Devices and Therapies Lee R. Guterman, Michel Henry, Moderators: Lawrence A. Garcia, Horst Sievert, Ronald J. Solar Lindsay S. Machan Novel Approaches to Standard Device Therapies: Access Closure, Peripheral Stents Drug-Eluting Balloons Moderators: Elazer R. Edelman, Embolic Protection, 12:00 p m - Early Clinical Experiences with a Bruno Scheller Thrombectomy, and Transseptal New Multilayered Peripheral Stent Puncture Michel Henry Moderators: Franz Wolfgang Amann, Glenn Van Langenhove

52 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 1:51 p m - Overview of Paclitaxel-Eluting 3:23 p m - Moderated Discussion and Q&A A Potpourri of Innovative Devices Balloons to Prevent (And Treat) Restenosis: Panel Moderators: Michael C. Fishbein, and Futuristic Therapies Experimental Findings, Device Mary E. Russell Moderators: Aaron V. Kaplan, Characteristics, Clinical Experiences, and Discussants: Raimund A. Erbel, Hyo-Soo Kim, Martin T. Rothman in t ro Preview of the Upcoming Late Breaking Yoram Richter, Bradley H. Strauss, Registry Reports Francesco Versaci 5:31 p m - Rhythm-Independent Percutaneous Bruno Scheller Cardiac Support Martin T. Rothman 2:03 p m - A Genistein-Eluting Balloon to Novel Drug-Eluting Stents and p m tURDAY 5:39 - The LUCAS Chest Compression agenda Prevent Restenosis: Results from Device Abstracts I sa System for Intra-Procedure CPR an Animal Feasibility Study Moderators: Albert E. Raizner, Richard Schatz Goran K. Olivecrona Imad Sheiban Discussants: Duncan H. K. Ho, 5:47 p m - Transcoronary Delivery of 2:11 p m - A Paclitaxel-Eluting Angiosculpt Nicholas N. Kipshidze, Karl H. Kuck, Catheter: Device Characteristics and Tom A. Mabin a Novel Alginate-Based Myocardial sun DAY Implant for Infarct Repair agenda Preliminary Insights on Drug Elution Kinetics 3:31 p m - TCT-46: Analysis of Left Main Jonathan Leor Adam Groothius Coronary Artery Bifurcation Lesions Treated 5:55 p m - EPITEK: Intra-Pericardial 2:19 p m - A Paclitaxel-Eluting Balloon with Biolimus-Eluting DEVAX AXXESS Plus (DIOR) for Coronary Bifurcation Nitinol Self-Expanding Stent: Intravascular Videoscopic Left Atrial Appendage Exclusion Using a Trans-Epicardial Snare agenda Lesions: Early Clinical Observations Ultrasound Results of the AXXENT Trial mon DAY Pieter R. Stella Takao Hasegawa et al Aaron V. Kaplan 6:03 p m - The Neovasc Coronary Sinus 2:27 p m - Moderated Discussion and Q&A 3:46 p m - TCT-47: FIM Results of Cappella Panel Moderators: Elazer R. Edelman, Sideguard™ for Treatment of Coronary REDUCER for Refractory Ischemia: Bruno Scheller Bifurcations Clinical Trial Update and Future Plans agenda Discussants: Adam Groothius, Eberhard Grube et al Keyur H. Parikh t ues DAY p m Imad Sheiban, Pieter R. Stella 4:01 p m - TCT-48: The pH Paradox in 6:13 - Transcatheter Renal Therapy Using Humans: Impact of Rapid Restoration of the Benephit Catheter to Prevent Contrast- Other Anti-Restenosis Therapies Local Acid Loading on Reperfusion Injury in Induced Nephropathy: Update of Moderators: Michael C. Fishbein, Acute Myocardial Infarction Clinical Trials Mary E. Russell Giora Weisz agenda Naoto Kino et al wed NESDAY p m 2:35 p m - Intra-Coronary Infusion of 4:16 p m - TCT-49: Infarct Thickening with 6:23 - Moderated Discussion and Q&A

Nanoparticle Albumin-Bound Paclitaxel Hydroxyapatite Gel Attenuates Left Panel Moderators: Aaron V. Kaplan, to Prevent Restenosis: Update from the Ventricular Remodeling After MI Martin T. Rothman SNAPIST I and II Clinical Trials Discussants: Jonathan Leor, case Liam P. Ryan reviews Alexandre Abizaid Goran K. Olivecrona, Keyur H. Parikh, Horst Sievert, Giora Weisz 2:43 p m - Systemic Infusion of Liposomal Novel Drug-Eluting Stents and Alendronate to Reduce Inflammation and Device Abstracts II 6:40 p m - Adjourn Prevent Restenosis: Lessons Learned from Moderators: Michael J. Cowley, agenda

the BIO-Australasia Study t hurs DAY Robert J. Whitbourn Yoram Richter Discussants: Jiro Aoki, Greg L. Kaluza, IVUS and Physiologic Lesion 2:51 p m - Antisense Therapy in Combination Ross Prpic, Frederick Welt Assessment Workshop: with Bare Metal Stents to Reduce 4:31 p m - TCT-50: Clinical Outcome Restenosis: Angiographic and IVUS Results Applications in the DES Era

Following PCI Using Titanium-Nitride-Oxide t raining from the APPRAISAL First-in-Man Study 8:00 a m -6:05 p m physician Coated Stents in Complex Patients Raimund A. Erbel Room 147AB Stephan Windecker et al 2:59 p m - Tight Glycemic Control After 4:46 p m - TCT-51: Short- and Mid-Term Angioplasty Reduces Restenosis in IVUS Basics

Intravascular Ultrasound Analysis of the New t elli e Diabetes: Results of the STREAM Study Moderators: Gary S. Mintz, Neil J. Weissman even t s ENDEAVOR CR Zotarolimus-Eluting Stent: sa Bradley H. Strauss Insights from the RESOLUTE Trial 8:00 a m - How to Optimize Image Acquisition 3:07 p m - Erythrocyte Mediated Katsuhisa Waseda et al and Minimize Artifacts Dexamethasone Delivery for the Prevention Neil J. Weissman 5:01 p m - TCT-52: Near-to-Complete of Restenosis After Bare Metal Stent Short-Term Re-Endothelialization in 8:12 a m - How to Measure and Report IVUS

Implantation ABS T RAC S Sirolimus-Eluting DES Using Electro-Grafting Results Francesco Versaci Technology (eG™) Akiko Maehara 3:15 p m – Adjunctive COX-2 Inhibitor Therapy Renu Virmani et al 8:24 a m - Recognizing IVUS Artifacts Reduces Angiographic Restenosis: Results of Gary S. Mintz 5:16 p m - TCT-53: Twelve Month Clinical the COREA-TAXUS Randomized Clinical Trial Outcomes Post Absorbable Metal Stent general Hyo-Soo Kim Implantation in Human Coronary Arteries: Results from the PROGRESS Study Ron Waksman et al

www.tct2007.com 53 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

IVUS Pre-Intervention Assessment 11:48 a m - IVUS Assessment of the Causes FFR in Specific Settings Moderators: John McB. Hodgson, of Drug-Eluting Stent Thrombosis Moderators: Morton J. Kern, Nico H. J. Pijls Gary S. Mintz Marco A. Costa 3:45 p m - FFR for Left Main Disease 8:36 a m - Assessing Intermediate Lesions by 12:00 p m - TCT-39: Yellow Plaques Remain William F. Fearon IVUS: How to and How Accurate? After Sirolimus-Eluting Stent Implantation: 3:57 p m - FFR in Acute Coronary Syndromes Angioscopic Comparison with Bare Metal Andrea Abizaid Takashi Akasaka Stents 8:48 a m - The Necessity of Assessing Masaki Awata et al 4:09 p m - FFR in Multivessal Disease and Left Main Lesions by IVUS Bifurcations 12:15 p m - Break Massoud A. Leesar Nick Curzen 9:00 a m - Qualitative Lesion Assessment by 4:21 p m - TCT-41: A Flow-Guided Concept to IVUS Interventional Guidance II IVUS: Aneurysms, Filling Defects, Hazy Treat Side Branches in True Bifurcation Moderators: John McB. Hodgson, Lesions, and Beyond Lesions: A Randomized Clinical Study Gary S. Mintz Akiko Maehara (Thueringer Bifurcation Study, 9:12 a m - Utility (and Safety) of IVUS 1:00 p m - Case Presentations: Stump the THUEBIS-Study) in Acute Coronary Syndromes Panel: IVUS Guided Stenting, and Hubertus von Korn et al Rainer Hoffmann Complications 4:36 p m - FFR Case Reviews: Stump the Panel Case Presenter: Jonathan M. Tobis 9:24 a m - TCT-38: Pioglitazone Induced Case Presenter: Michael J. Lim Discussants: Takashi Akasaka, Regression and Shift in Plaque Composition Dicsussants: Stephane G. Carlier, Costantino R. Costantini, Junbo Ge, in Coronary Atherosclerosis: Insight from an Stuart T. Higano, Simon Redwood, Rainer Hoffmann, Amir Lerman, Gilles Rioufol Intravascular Ultrasounds Analysis Expedito E. Ribeiro, Clemens von Birgelen, Fabrizio Clementi 1:45 p m - Moderated Discussion and Q&A Gerald S. Werner Panel Moderators: John McB. Hodgson, 9:39 a m - Case Presentations: Stump the 5:21 p m - Moderated Discussion and Q&A Gary S. Mintz Panel: Intermediate Lesions, Left Main Panel Moderators: Morton J. Kern, Discussants: Andrea Abizaid, Lesions, and Oddities Nico H. J. Pijls Massoud A. Leesar, Akiko Maehara, Case Presenter: John McB. Hodgson Discussants: Nick Curzen, William F. Fearon Neil J. Weissman Discussants: Ricardo A. Costa, Junbo Ge, Stuart T. Higano, Rainer Hoffmann, Practicalities and Impact of FFR Ioannis Iakovou, Akiko Maehara, The Basics of Physiologic Lesion 5:36 p m - Clinical Outcomes After FFR-Based Augusto D. Pichard Assessment Decision Making 10:24 a m - Assessing Plaque Composition: Moderators: Bernard De Bruyne, Nico H. J. Pijls Virtual Histology, IB-IVUS, and OCT Massoud A. Leesar 5:51 p m - Diagnostic Work-Up of Patients Stephane G. Carlier 2:00 p m - A Primer on Coronary Physiology with Suspected CAD: A Paradigm Shift 10:39 a m - Moderated Discussion and Q&A for the Interventionalist Morton J. Kern Panel Moderators: John McB. Hodgson, Bernard De Bruyne 6:05 p m - Adjourn Gary S. Mintz 2:15 p m - Fractional Flow Reserve: Concept Discussants: Andrea Abizaid, and Practical Setup Stephane G. Carlier, Rainer Hoffmann, Nico H. J. Pijls Massoud A. Leesar, Akiko Maehara 16th Annual Nurse and 2:27 p m - Hyperemic Stimuli: Why and How? Morton J. Kern Technologist Symposium IVUS Interventional Guidance I 8:00 a m -4:05 p m 2:39 p m - FFR and Angiography: Combining Ballroom A, Level 3 Moderators: Peter J. Fitzgerald, Anatomy and Perfusion Jonathan M. Tobis Directors: Marian C. Hawkey, John McB. Hodgson Alexandra J. Lansky, Thomas H. Maloney, 10:54 a m - Use of IVUS to Optimize 2:51 p m - FFR Pitfalls and Artifacts Hilary Nierenberg Bare Metal Stents Nico H. J. Pijls Co-Directors: Russell A. Brandwein, Neil J. Weissman 3:03 p m - TCT-40: First Results of a New Mary K. Egan, Jessica Forman, Michael Guiry, 11:09 a m - Use of IVUS to Optimize Method for Angiographic Calculation of Christopher M. Nelson Drug-Eluting Stents: Different Than Bare Coronary Flow Reserve 8:00 a m - Introduction and Welcome Metal Stents? Harald Rittger et al Marian C. Hawkey Peter J. Fizgerald 3:18 p m - Investigating the Microcirculation: 8:10 a m - Keynote Presentation: Drug-Eluting 11:24 a m - IVUS Assessment of Post- IMR and Absolute Flow Stent Controversies: Evidence Based Intervention Complications (other Than Stent William F. Fearon Medicine or Medicine by Media Thrombosis and Restenosis) Gregg W. Stone Clemens von Birgelen 3:30 p m - Moderated Discussion and Q&A Panel Moderators: Bernard De Bruyne, 11:36 a m - IVUS Assessment of the Causes Massoud A. Leesar of Drug-Eluting Stent Restenosis Discussants: William F. Fearon, Akiko Maehara John McB. Hodgson, Morton J. Kern, Nico H. J. Pijls

54 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Interventional Cardiology 2007: Cardiac Catheterization Laboratory Endovascular Grafting of the Aorta: and Congestive Heart Failure: No Identification of the Endograft Sound Bites and Discussion Longer Just a Right Heart Cath! Candidate Moderator: Marian C. Hawkey Moderator: Marc Klapholz Moderator: Mathew Williams in t ro Discussants: Todd Chitwood, Discussants: Russell A. Brandwein, Discussants: Jessica Forman, William A. Gray, Howard L. Haronian, Hilary Nierenberg, Jose Dizon, Margaret A. Flannery, Sheehan L. Raab, Allan S. Stewart, Beth A. Oliver, Mathew Williams Simon Krivor, Vivian Tamara Abigail Woglom

8:40 a m - The Future of Interventional 10:00 a m - Case Presentation 11:40 a m - Patient Care Perspectives

Vascular Medicine: Big Picture Perspective Marc Klapholz Jessica Forman tURDAY agenda Howard L. Haronian sa 10:02 a m - Overview of Congestive Heart 11:45 a m - Case Presentation 8:43 a m - Top Priorities for Change and Failure Management Mathew Williams Improvement Marc Klapholz 11:48 a m - Open Surgical Repair vs. Beth A. Oliver 10:10 a m - New Device Therapies for Heart Endovascular Repair: General and Patient- sun DAY 8:46 a m - Credentialing of Cardiac Failure (Fiber Optic Balloon Pump, Specific Considerations: Surgical Perspectives agenda Catheterization Laboratory Staff Temporary Ventricular Assist Devices) Allan S. Stewart Todd Chitwood Russell A. Brandwein 11:58 a m - Open Surgical Repair vs. 8:49 a m - Issues Associated with Antiplatelet 10:17 a m - Technologist Considerations Endovascular Repair: General and Patient Therapy Compliance

During Device Implants Specific Considerations: Endovascular agenda mon DAY Hilary Nierenberg Simon Krivor Perspectives William A. Gray 8:52 a m - Cardiac Catheterization Laboratory 10:22 a m - Nursing Care of the Patient Cross-Dressing: The Cardiothoracic Surgeon Post-Device Implant 12:08 p m - Final Case Result and Discussion and Interventional Cardiologist Vivian Tamara 12:16 p m - Cardiac Catheterization Lab agenda

Mathew Williams t ues DAY 10:27 a m - Biventricular Pacing: Intracardiac Considerations for Aortic Endografting 8:55 a m - Discussion and Closing Comments Defibrillator Implantation Sheehan L. Raab Panel Moderator: Marian C. Hawkey Jose Dizon 12:24 p m - Postcare Considerations for Aortic Discussants: Todd Chitwood, 10:33 a m - Left Ventricular Assist Devices/ Endografting Howard L. Haronian, Hilary Nierenberg,

Cardiac Heart Transplant Abigail Woglom agenda Beth A. Oliver, Mathew Williams Margaret A. Flannery wed NESDAY 12:30 p m - Lunch Pick-Up 10:40 a m - Final Case Result and Discussion

Case Presentations and Discussion Moderators: Christopher M. Nelson, Noninvasive Imaging in an Hilary Nierenberg Invasive World Concurrent Lunch Sessions case reviews Moderator: Christopher M. Nelson 12:45 p m -2:30 p m When Are Medical Therapy, Bypass Discussants: Mohit Bhasin, Todd Chitwood, Surgery, and PCI Appropriate for Edward T. Martin, Michael Poon, I: Tools for the Effective Management of Treatment of Coronary Artery Disease? Robert S. Schwartz Cardiovascular Disease Moderator: Charles A. Simonton Organized in Collaboration with the a m agenda

10:50 - Case Presentation and ARS t hurs DAY Discussants: Mark W. Connolly, David A. Cox, Preventive Cardiovascular Nurses Session Thomas H. Maloney, Mireya Reilly Association (PCNA) Christopher M. Nelson 9:15 a m - Case Presentation and Interactive Room 201 Response 10:55 a m - The Case for CTA Moderator: Hilary Nierenberg Charles A. Simonton Michael Poon Discussants: Marian C. Hawkey, t raining physician 9:20 a m - Balancing the Risk/Benefits of 11:02 a m - The Case for MRA Nancy Houston Miller, Barrie J. Huberman, Thrombosis, Restenosis, and Surgery Edward T. Martin Patricia E. Knipper, Lisa Mainieri

Thomas H. Maloney 11:09 a m - The Case for PET 12:45 p m - Welcome and Introduction 9:27 a m - Medical Perspective: When Is Mohit Bhasin Hilary Nierenberg t elli e even t s

Medical Therapy Appropriate? 11:16 a m - The Case for Unique Invasive 12:50 p m - Staging of Heart Failure: sa Mireya Reilly Imaging Modalities (VH, OCT, IVMRI) Implications for Patients with Coronary 9:34 a m - Surgical Perspective: When Is Robert S. Schwartz Artery Disease Marian C. Hawkey Surgery Appropriate? 11:23 a m - Patient Care Considerations for Mark W. Connolly CT/MRA/PET 1:05 p m - Smoking Cessation: Tools for ABS T RAC S 9:41 a m - Angioplasty Perspective: When Are Todd Chitwood Effective Bedside Counseling Barrie J. Huberman Drug-Eluting and Bare Metal Stents 11:30 a m - Final Case Result and Discussion Appropriate? 1:20 p m - Weight Reduction Strategies David A. Cox Patricia E. Knipper

9:48 a m - Final Case Result and Discussion general

www.tct2007.com 55 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

1:35 p m - Cardiovascular Risk Factor 2:25 p m - Sample RCIS Test Questions and Peripheral Vascular Management: Link to Pay for Performance Answers Hilary Nierenberg Thomas H. Maloney Intervention: Evaluation and

1:45 p m - Educating the Cardiovascular Therapeutic Options IV: The Cardiac Service Line: Current Patient 8:00 a m -6:30 p m Lisa Mainieri and Future Trends Room 202A Room 209ABC Chairs: William A. Gray, Issam D. Moussa 2:00 p m - PCNA: Review of Online Resources Moderator: Michael Guiry and Tools for Cardiovascular Risk Factor Discussants: Larry S. Dean, Glenna Friedman, Management Iliac and SFA Intervention I Richard H. Gemming, Anand Joshi, Nancy Houston Miller Moderators: Gary M. Ansel, Giancarlo Biamino Charanjit S. Rihal 2:15 p m - Moderated Discussion and Q&A 12:45 p m - Welcome and Introduction General Considerations Panel Moderator: Hilary Nierenberg Michael Guiry Discussants: Marian C. Hawkey, 8:00 a m - Non-Invasive Diagnosis and Nancy Houston Miller, Barrie J. Huberman, 12:50 p m - Economics: Analysis and Management of the Patient with Lower Patricia E. Knipper, Lisa Mainieri Forecasting the Cardiovascular Market Extremity Peripheral Arterial Disease Larry S. Dean Jeffrey W. Olin

II: Cardiac Catheterization Laboratory 101: 1:05 p m - New Technology: Capital 8:15 a m - Device Selection for SFA Back to the Basics Investments for the 21st Century Cardiac Intervention: Evidence-Based Medicine and Room 204ABC Service Line Development of Objective Performance Moderator: Mary K. Egan Charanjit S. Rihal Criteria Krishna Rocha-Singh 1:20 p m - Solutions for Maximizing 12:45 p m - Essentials of Hemodynamics Productivity and Efficiency Mark A. Apfelbaum Chronic Total Occlusions Anand Joshi a m 1:10 p m - Fundamentals of Cardiac 8:35 - Optimizing SFA CTO Outcomes 1:35 p m - Clinical Documentation and Coding Catheterization Laboratory Nursing Care Using Available Technology: Guidewires, to Maximize Reimbursement Potential Bernadette Reilly Blunt Microdissection, Lasers, and Optical Glenna Friedman Coherence Reflectometry with Microwave 1:20 p m - Cardiac Catheterization Laboratory 1:55 p m - The Cardiac Service Line: Achieving Ablation Crises: Integrated Management Strategies a “Sustainable Competitive Advantage” Tony Das Mary K. Egan, Christopher M. Nelson Richard H. Gemming 8:50 a m - Tricks, Tools, and Complications of 1:45 p m - Cardiac Catheterization Laboratory 2:10 p m - Moderated Discussion and Q&A False to True Lumen Reentry Preparation: Anticipating the Worst Case Panel Moderator: Michael Guiry Issam D. Moussa Scenario Discussants: Larry S. Dean, Glenna Friedman, Michele Dondero Richard H. Gemming, Anand Joshi, Embolic Protection 2:00 p m - Interventional Cardiology Jeopardy Charanjit S. Rihal 9:05 a m - Is There a Role for Embolic Moderator: Russell A. Brandwein Protection Devices in Ilio-Femoral Hot Topics 2007 Intervention? III: Registered Cardiovascular Invasive Moderators: Russell A. Brandwein, Mahmood K. Razavi Specialists (RCIS) Review Course Thomas H. Maloney 9:15 a m - Moderated Discussion and Q&A Highlights Panel Moderators: Gary M. Ansel, 2:45 p m - Point/Counterpoint: Appropriate Organized by the Society of Invasive Giancarlo Biamino Cardiovascular Professionals (SICP) Treatment of Carotid Artery Disease, “He Says, She Says” Discussants: Issam D. Moussa, Jeffrey W. Olin, Room 206 Mahmood K. Razavi, Krishna Rocha-Singh Moderator: Thomas H. Maloney Anthony J. Galeo, Amy Elizabeth Martin 3:05 p m - Antiplatelet Therapy: Who, 12:45 p m - Introduction: SICP Role in Exam How Much, and How Long Iliac and SFA Intervention II Preparation Moderators: Erich Minar, Thomas M. Shimshak Todd Chitwood Deepak L. Bhatt 3:20 p m - Cardiac Catheterization Laboratory 12:55 p m - Cardiovascular Anatomy and Emerging Clinical Trial Data and Registry Physiology Catastrophes Outcomes Jeffrey J. Popma Darren Powell 9:35 a m - A Multicenter Randomized 3:35 p m - Advanced Techniques for 1:20 p m - Hemodynamics with Calculations Prospective Study of Abciximab Use in Jeff Davis Angioplasty TASC D Femeropopliteal Lesions: Jeffrey W. Moses The RIO Trial Results 1:45 p m - Twelve Lead EKG Interpretation Iris Baumgartner Jeff Davis 3:50 p m - Featured Lecture: Perspectives on 30 Years of Coronary Angioplasty 9:50 a m - Head-to-Head Comparison of Two 2:05 p m - Cardiovascular Pharmacology with David O. Williams SFA Stents: Outcomes of the SUPER-SL Calculations Study Darren Powell 4:05 p m - Networking Reception Dierk Scheinert

56 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 10:05 a m - Debulking and Stent-Grafts for 1:10 p m - TCT-45: Chronic Mesenteric 3:55 p m - Endografts for Thoracic Aortic SFA Stent Restenosis: The SALVAGE Trial Ischemia: Experience with PTA/Stenting in Aneurysms: Technical Challenges to Device John R. Laird, Jr Celiac and SMA Disease in 99 Patients Development

David E. Allie et al Takao Ohki in t ro Novel, Adjunctive, and Alternative SFA Therapies 4:10 p m - Is TEVAR for Dissection Justified? Critical Limb Ischemia and Infra- Results from the IRAD Registry and the 10:20 a m - The “Dark-Side” of SFA Stenting: Instead Trial Frequency, Presentation, and Management Popliteal Intervention Michael L. Marin of Restenosis Moderators: Issam D. Moussa, tURDAY agenda Erich Minar Patrick J. Peeters 4:25 p m - Hybrid Surgical and Endograft sa 1:25 p m - Diagnostic Approaches to Critical Approaches to Aortic Arch Disease 10:35 a m - Pros, Cons, and Unknowns of Allan S. Stewart Atherectomy as an Adjunct to SFA Limb Ischemia and Infra-Popliteal Disease Intervention David E. Allie sun DAY Gary M. Ansel 1:40 p m - A Critical Appraisal of Endovascular Renal Artery Intervention agenda and Surgical Approaches in Critical Limb Moderators: Kenneth Rosenfield, 10:50 a m - Design Specifications for the Christopher J. White “Perfect” SFA Stent Ischemia Roger Gammon Anthony J. Comerota 4:40 p m - Current US Outcomes in Renal p m Stenting: the SOCRATES Trial a m 1:55 – Self-Expanding Nitinol Stents for

11:05 - Injectable Adventitial Therapy: agenda Mark C. Bates mon DAY Concept, Enabling Devices, and Preclinical Infra-Popliteal/Critical Limb Disease: Results Mid-Term Results from the XCELL Trial 4:55 p m - A European Non-Randomized William A. Gray James D. Joye Case-Controlled Assessment of Patient 2:10 p m - Drug-Eluting Stents for Infra- Outcomes After Renal Artery Stenting 11:20 a m - PATHWAY Medical: Multicenter Thomas Zeller

Popliteal Disease: Current Data Synthesis, agenda Evaluation of a Novel Atherectomy Device in t ues DAY SFA Lesions Lessons Learned, and Future Directions 5:10 p m - Preprocedural Predictors of Thomas Zeller Lindsay S. Machan Favorable Clinical Responses to Renal 2:25 p m - Orbital Atherectomy for Infra- Stenting: Optimizing Patient Selection 11:35 a m - The Evolution of SFA Drug-Eluting Christopher J. White Stents: From SIROCCO to Zilver Popliteal Disease: Device Concept and agenda Outcomes to Date 5:25 p m - Intra-Procedural Assessment Michael D. Dake wed NESDAY Robert D. Safian Techniques of Renal Stenosis Severity 11:50 a m - SFA Percutaneous Bypass: p m Massoud A. Leesar Description and Early/Late Results 2:40 - Outcomes Using a Scoring Balloon James D. Joye in Infra-Popliteal Disease: Acute and Long 5:40 p m - Randomized Outcome Data in Results from the AngioSculpt Registry Renal Stenting: The RESIST Trial case 12:05 p m - Moderated Discussion and Q&A reviews Gary Gershony Christopher J. Cooper Panel Moderators: Erich Minar, Thomas M. Shimshak 2:55 p m - Case Study: Wound Management in 5:55 p m - Medicare Coverage for Renal Discussants: Iris Baumgartner, Critical Limb Ischemia Stenting: Carotid Stenting Redux? Michael D. Dake, William A. Gray, Michael R. Jaff John H. Rundback agenda

James D. Joye, John R. Laird, Jr, 3:10 p m - Moderated Discussion and Q&A 6:10 p m - Moderated Discussion and Q&A t hurs DAY Dierk Scheinert Panel Moderators: Issam D. Moussa, Panel Moderators: Kenneth Rosenfield, Patrick J. Peeters Christopher J. White Endovascular Abstracts Discussants: David E. Allie, Discussants: Mark C. Bates, Moderators: Mark W. Burket, Anthony J. Comerota, Gary Gershony, Christopher J. Cooper, Massoud A. Leesar, t raining James F. McKinsey Michael R. Jaff, James D. Joye, John H. Rundback, Thomas Zeller physician Lindsay S. Machan, Robert D. Safian Discussants: Tyrone J. Collins, 6:30 p m - Adjourn Hans Krankenberg, Michael J. Rinaddi, Peter A. Soukas Thoracic and Abdominal t elli e p m Endograft Repair even t s 12:25 - TCT-42: The PATRIOT (Peripheral The Valvular Heart Disease sa Approach to Recanalization in Occluded Moderators: Jacques Busquet, Summit Totals) Study Results Christoph A. Nienaber 8:00 a m -7:00 p m James D. Joye et al 3:25 p m - A Triumph of Technology Over Room 202B 12:40 p m - TCT-43: Renal Angioplasty and Surgery? Summary of AAA EVAR and View of

Future Opportunities ABS T RAC S Stenting Under Protection: Limitations, First Mitral Regurgitation: Core Human Study with a 3-D Filter: The Fibernet Juan C. Parodi Concepts Michel Henry et al 3:40 p m - The Case for EVAR Treatment of Moderators: Robert O. Bonow; Allan Schwartz 12:55 p m - TCT-44: Endovascular Repair of Small AAA: Theoretical and Clinical Drivers Roger M. Greenhalgh 8:00 a m - Understanding the Pathology

Thoracic Aortic Aneurysms and Symptomatic general Type B Dissections in High-Risk Nonsurgical of Mitral Regurgitation in Varying Disease Patients: Results of a Single-Center Study States: Heart Failure, Ischemia, and Prolapse Joaquin Solis et al David H. Adams

www.tct2007.com 57 transcatheter cardiovascular therapeutics

Sunday \ October 21, 2007

8:10 a m - A Physiology Primer of Mitral 10:14 a m - Moderated Discussion and Q&A Percutaneous Mitral Valve Repair Regurgitation Panel Moderators: Steven F. Bolling, and Replacement: Direct Allan Schwartz Lars G. Svensson Annuloplasty Discussants: Ottavio Alfieri, Robert O. Bonow, 8:20 a m - Assessment of Mitral Regurgitation Moderators: Ted Feldman, Jan Harnek with Echocardiography: Qualitative vs. Didier F. Loulmet, Francesco Maisano, 12:08 p m - Direct Annuloplasty: Mitralign: Quantitative Methods and Scales, Artifacts, Patrick Perier, Todd K. Rosengart Device Evolution, Technique, and and Prognostic Implications First-in-Man Results Maurice E. Sarano Percutaneous Mitral Valve Repair Ted Feldman 8:32 a m - Assessment of Mitral and Replacement: Overview and the 12:16 p m - Direct Annuloplasty: Guided Regurgitation with Magnetic Coronary Sinus Approach Delivery Systems: Device Evolution, Resonance: A New Gold Standard? Moderators: Ted Feldman, John G. Webb Technique, and First-in-Man Results Steven D. Wolff 10:29 a m - Pivotal Clinical Trial Design Didier F. Loulmet 8:42 a m - Moderated Discussion and Q&A Considerations for Percutaneous Devices for 12:24 p m - Direct Annuloplasty: Quantum Panel Moderators: Robert O. Bonow, (a) Organic Mitral Valve Disease and Cor: Device Evolution, Technique, and Allan Schwartz (b) Functional Mitral Regurgitation First-in-Man Results Discussants: David H. Adams, Julie A. Swain Richard R. Heuser Robert J. Lederman, Maurice E. Sarano, 10:41 a m - Coronary Sinus Anatomy in the Steven D. Wolff 12:32 p m - Dynamic Mitral Valve Ring MR Population: Implications for Annuloplasty: The Micardia Concept Percutaneous Sinoplasty Maurice Buchbinder Surgical Approaches to Mitral Raj Makkar 12:40 p m - Moderated Discussion and Q&A Regurgitation 10:51 a m - Coronary Sinus Annuloplasty Panel Moderators: Ted Feldman, Jan Harnek Moderators: Steven F. Bolling, Lars G. Svensson Procedure, Results, and Complications: Discussants: Maurice Buchbinder, Edwards MONARC 8:52 a m - Indications for Surgery of the Richard R. Heuser, Didier F. Loulmet Regurgitant Mitral Valve: Summary of the Alec Vahanian New Guidelines 11:01 a m - Coronary Sinus Annuloplasty Percutaneous Mitral Valve Repair Robert O. Bonow Procedure, Results, and Complications: and Replacement: Other 9:04 a m - Surgical Techniques I: Annuloplasty Cardiac Dimensions CARILLON (Edited Video Case Review) Joachim Schofer Approaches Moderators: Ted Feldman, Jan Harnek Lars G. Svensson 11:11 a m - Coronary Sinus Annuloplasty p m 9:14 a m - Surgical Techniques II: Leaflet and Procedure, Results, and Complications: Viacor 12:48 - Indirect Annuloplasty, Ample PS3: Chordal Repair (Edited Video Case Review) Stephen G. Ellis Device Evolution, Technique, and First-in- Man Results Didier F. Loulmet 11:21 a m - Moderated Discussion and Q&A Jason H. Rogers 9:24 a m - Surgical Techniques III: Edge-to- Panel Moderators: Ted Feldman, Edge Repair (Edited Video Case Review) John G. Webb 12:58 p m - Transpericardial Chamber and Ottavio Alfieri Discussants: Stephen G. Ellis, Raj Makkar, Annulus Therapy: Myocor iCoapsys Joachim Schofer, Julie A. Swain, Wesley R. Pedersen 9:34 a m - Critical Appraisal of Surgical Alec Vahanian Repair I: Freedom from Death and 1:08 p m - Rationale for and Progress with MR/Reoperation After MR Surgery for Catheter-Based Mitral Valve Prolapse/Degenerative Disease Percutaneous Mitral Valve Repair Replacement: Endovalve Francesco Maisano and Replacement: Edge to Edge Howard C. Herrmann p m 9:44 a m - Critical Appraisal of Surgical Moderators: Ted Feldman, John G. Webb 1:18 - Other Novel Mitral Regurgitation Repair Approaches on the Horizon Repair II: Freedom from Death and MR 11:36 a m - Mitral Leaflet Repair with the Recurrence/Reoperation After MR Surgery in MitraClip: EVEREST Trials Update Peter J. Fitzgerald Heart Failure and Ischemic Heart Disease Ted Feldman 1:28 p m - Moderated Discussion and Q&A Steven F. Bolling Panel Moderators: Ted Feldman, Jan Harnek 11:48 a m - Suture Mediated Edge-to-Edge Discussants: Peter J. Fitzgerald, 9:54 a m - Limitations of Surgical Repair of Repair Postmortem Ischemic Mitral Regurgitation Maurice Buchbinder Wesley R. Pedersen, Jason H. Rogers Patrick Perier 11:58 a m - Moderated Discussion and Q&A Pulmonic Valve Therapies 10:04 a m - Surgical Outcomes with the Panel Moderators: Ted Feldman, Moderators: Eric Horlick, Carlos E. Ruiz Coapsys System John G. Webb 1:38 p m - Percutaneous Pulmonic Valve Todd K. Rosengart Discussant: Maurice Buchbinder Replacement (Medtronic): Device Description and Updated Clinical Results Philipp Bonhoeffer

58 truth in evidence based medicine · challenge conventional wisdom · transform your thinking 1:50 p m - Percutaneous Pulmonic 3:41 p m - The Inspiration for Percutaneous 5:46 p m - Direct Flow: Design and First-in- Valve Replacement (Medtronic): Aortic Valve Replacement Man Experiences with an Inflatable, Early US experiences Henning Rud Andersen Cuff-Supported Percutaneous Aortic Valve

William E. Hellenbrand Peter C. Block in t ro 3:51 p m - Generational Advances of the 1:58 p m - Percutaneous Pulmonic Valve Edwards Balloon Expandable 5:54 p m - Aortx: Final Design and Directions Replacement (Edwards): Device Description Aortic Valve Prosthesis for a Folded, Rolled, Repositionable and Updated Clinical Results Alain G. Cribier Percutaneous Aortic Valve Ziyad M. Hijazi Louis A. Cannon

4:01 p m - Percutaneous Approach with the tURDAY agenda 2:06 p m - Moderated Discussion and Q&A Edwards Balloon Expandable Aortic Valve 6:02 p m - Advanced Bioprosthetic Surfaces: sa Panel Moderators: Eric Horlick, Carlos E. Ruiz Prosthesis: Comprehensive Global Report Nanotechnology Nitinol Aortic Valve Discussants: Philipp Bonhoeffer, of Acute Success, Complications, and Replacement Technology William E. Hellenbrand, Ziyad M. Hijazi Long-Term Results Steven R. Bailey Martin B. Leon sun DAY 6:10 p m - Endoluminal Technology Research: agenda Aortic Stenosis: Core Concepts and 4:16 p m - The PARTNER Pivotal Trial: A Low ProfileA ortic Valve Classic Surgical Results Design and Recruitment Status Replacement System Moderators: Robert O. Bonow, Susheel Kodali David Paniagua Michael J. Mack 4:21 p m - Transapical Approach with the 6:18 p m - The Jena Valve Low Profile agenda 2:12 p m - The Pathology of Calcific and Edwards Balloon Expandable Aortic Valve “Clip-On” Transcatheter Aortic Valve mon DAY Bicuspid Aortic Stenosis: Implications for Prosthesis: Comprehensive Global Report Replacement Concept Implantation of a Percutaneous Prosthesis of Acute Success, Complications, and Hans R. Figulla David H. Adams Long-Term Results 6:26 p m - The HTV Low-ProfileT ranscatheter 2:22 p m - Epidemiology, Natural History, and Todd M. Dewey Aortic Valve Replacement System agenda Surgical Treatment of Aortic Stenosis t ues DAY 4:33 p m - Real-Time MRI Guided Transapical Robert Wilson Lars G. Svensson Aortic Valve Replacement 6:34 p m - Who Needs a Prosthesis? Radiation 2:32 p m - Patient Selection for Intervention in Keith A Horvath Following Balloon Valvuloplasty (And Aortic Stenosis and Insufficiency: 4:43 p m - Generational Advances of the RADAR Pivotal Trial Update)

Guideline Update CoreValve Self-Expanding Aortic Valve Wesley R. Pedersen agenda Robert O. Bonow Prosthesis wed NESDAY 6:42 p m - Moderated Discussion and Q&A 2:42 p m - Comparison and Accuracy of Ulrich Gerckens Panel Moderators: Alain G. Cribier, Jan Kovac Scoring Systems to Assess Surgical Risk: 4:53 p m - Comprehensive Global Report of Discussants: Steven R. Bailey, Peter C. Block, STS vs. Standard and Logistic Euroscore Acute Success, Complications, and Louis A. Cannon, Hans R. Figulla, Eberhard case Michael J. Mack Long-Term Results with the CoreValve Grube, David Paniagua, Wesley R. Pedersen, reviews 2:52 p m - In-Hospital Complications and Self-Expanding Aortic Valve Prosthesis Robert Wilson Long-Term Survival After Surgical Aortic Jean-Claude Laborde 7:00 p m - Adjourn Valve Replacement in Low-, High-, and 5:03 p m - Creative Vascular Access Ultra High-Risk Patients

Solutions for Patients with Severe agenda Allan S. Stewart Peripheral Vascular Disease Evening Symposia t hurs DAY 3:04 p m - Moderated Discussion and Q&A Eric E. Roselli 8:00 p m -10:00 p m Panel Moderators: Robert O. Bonow, 5:18 p m - Moderated Discussion and Q&A Michael J. Mack Panel Moderators: Martin B. Leon, Refer to pages 98-99 for complete Discussants: David H. Adams, program schedule. t raining

Friedrich W. Mohr physician Allan S. Stewart, Lars G. Svensson Discussants: Henning Rud Andersen, Alain G. Cribier, Todd M. Dewey, Transcatheter Aortic Valve Ulrich Gerckens, Keith A Horvath,

Replacement: Overview and Widely Jean-Claude Laborde, Eric E. Roselli, t elli e even t s Studied Devices Paul Schoenhagen, Julie A. Swain sa Moderators: Martin B. Leon, Friedrich W. Mohr Transcatheter Aortic Valve Replacement: 3:19 p m - Pivotal Clinical Trial Design Next Generation Devices Considerations for Percutaneous Devices for Moderators: Alain G. Cribier, Jan Kovac Aortic Stenosis in the (a) Ultra High-Risk 5:38 p m - Sadra: Design and First-in-Man ABS T RAC S Patient and (b) the Less High-Risk Patient Experiences with a Repositionable, Julie A. Swain Self-Expanding Percutaneous Aortic Valve 3:31 p m - Emerging Concepts of Aortic Eberhard Grube Valve and Aortic Root Imaging with Multidetector CT general Paul Schoenhagen

www.tct2007.com 59 transcatheter cardiovascular therapeutics

MONDAY \ OCTOBER 22, 2007

Breakfast Meetings Plenary Session 4: Late Breaking Late Breaking Studies and First 7:00 a m -8:00 a m Clinical Trials I Report Investigations Refer to pages 99-101 for complete Moderator: Martin B. Leon, Gregg W. Stone Moderators: William D. Knopf, Sigmund Silber program schedule. “Blockbuster” Trial of the Day: 12:15 p m - SPIRIT-III: A Prospective, ENDEAVOR 4 Randomized Trial Comparing an Everolimus- Eluting Stent and a Paclitaxel-Eluting Stent 10:30 a m - An Evidence-Based Medicine Physician Training Center Assessment of Drug-Eluting Stents: Safety in Patients With Coronary Artery Disease: 10:00 a m -5:00 p m and Efficacy for “On-Label” and “Off-Label” 1-Year Follow-Up and Subgroup Analysis Lower Level Clinical Indications Gregg W. Stone Gregg W. Stone 12:27 p m - Critical Appraisal of Hands on Hearts, Specialty Device the SPIRIT-III Trial 10:50 a m - ENDEAVOR 4: A Randomized Training, TeachImage™ Comparison of a Zotarolimus-Eluting Stent Stephen G. Ellis Refer to pages 96-97 for details. and a Paclitaxel-Eluting Stent in Patients 12:30 p m - NOBORI I Phase II: A Prospective, with Coronary Artery Disease: 8-Month Randomized Trial Comparing a Biolimus Angiographic and 9- and 12-Month A9-Eluting Stent and a Paclitaxel-Eluting Main Arena Clinical Results Stent in Patients With Coronary Artery 7:45 a m -6:30 p m Martin B. Leon Disease: 9-Month Clinical and Angiographic Results Ballrooms ABC, Level 3 11:05 a m - Critical Appraisal of the ENDEAVOR 4 Trial Bernard R. Chevalier Plenary Session 1: TCT Crossfire Patrick W. Serruys 12:42 p m - Critical Appraisal of the NOBORI I Phase II Trial Moderators: Martin B. Leon, Gregg W. Stone 11:10 a m - Panel Discussion Ron Waksman 7:45 a m - The Journey of Percutaneous Panel Moderator: Gregg W. Stone Cardiovascular Intervention: From Discussants: Bernard R. Chevalier, 12:45 p m - TRIAS HR Pilot: A Prospective, Empiricism to Evidence-Based Medicine, Mitchell W. Krucoff, Alexandra J. Lansky, Randomized Trial Comparing EPC Capture From Balloons to Innovative Biotech Martin B. Leon, Jean Marco, Laura Mauri, Stent Technology and a Paclitaxel-Eluting Devices: The Next Challenges? Stuart J. Pocock, Patrick W. Serruys, Stent in Lesions at High Risk for Ma r t i n B. Leon, Gregg W. Stone Alan C. Yeung Restenosis: 6-Month Clinical and Angiographic Outcomes 11:30 a m - ISAR-TEST-3: A Prospective, Plenary Session 2: TCT SPECIAL Randomized Comparison of Sirolimus- Robert J. de Winter SESSION Eluting Stents Using a Durable Polymer, 12:57 p m - Critical Appraisal of the a Bio-Absorbable Polymer, and No Polymer: TRIAS HR Pilot Trial Moderators: Martin B. Leon, Gregg W. Stone 9-Month Clinical and Angiographic Results Cindy L. Grines 8:15 a m - A Celebration of 30 Years of PCI Julinda Mehilli 1:00 p m - TAXUS Atlas Small and Long: Featuring Dolf Bachmann, Who Underwent 11:42 a m - Critical Appraisal of Multicenter Registry Investigations of a the World’s First Coronary Angioplasty by the ISAR-TEST-3 Trial 2.25 mm and 38 mm Paclitaxel-Eluting Andreas Gruentzig on September 16, 1977 Jeffrey J. Popma Stent: 9-Month Clinical and Angiographic Spencer B. King III, Martin B. Leon, Follow-Up Bernhard Meier, Gregg W. Stone 11:45 a m - ARMYDA-4: A Prospective, Double-Blind, Randomized Trial Evaluating Mark A. Turco Plenary Session 3: Live Case a 600 mg Clopidogrel Loading Dose Prior to 1:18 p m - Critical Appraisal of the TAXUS PCI in Patients on Chronic Clopidogrel Atlas Small and Long Studies Session I Therapy Stefan Verheye Moderator: Martin B. Leon Germano Di Sciascio Co-Moderator: Rafael Beyar 1:21 p m - EUROSTAR II: A Prospective, Live Case Discussants: Gary M. Ansel, 11:57 a m - Critical Appraisal of the Randomized Trial Comparing a J. Michael Bacharach, Tony Das, ARMYDA-4 Trial Bioabsorbable Polymer-Based Stephen G. Ellis, Adnan Kastrati, Dominick J. Angiolillo Paclitaxel-Eluting Stent and an Identical Bare Metal Stent Stuart T. Higano, Eustaquio Onorato, 12:00 p m - AMETHYST: A Prospective, Nico H. J. Pijls, Albert E. Raizner, Randomized Trial of a Novel Distal Sigmund Silber Eric A. Rose, Hani Shennib Protection Device During Saphenous Vein 1:33 p m - Critical Appraisal of Graft Intervention the EUROSTAR II Trial 8:30 a m - Instituto Dante Pazzanese de Cardiologia Dean J. Kereiakes Carlo Di Mario 12:12 p m - Critial Appraisal of 9:00 a m - CardioVascular Center Frankfurt the AMETHYST Trial 9:30 a m - Fu Wai Hospital Gabor I. Sutsch 10:00 a m - Columbia University Medical Center

60 truth in evidence based medicine · challenge conventional wisdom · transform your thinking MONDAY \ OCTOBER 22, 2007

1:36 p m - ABSOLUTE: A Prospective, 5:00 p m - Report From the “Front Lines:” 8:40 a m - Drug-Eluting Stent Adjunct Randomized Trial Comparing a Durable The Interacting Forces of Politics, Medicine, Pharmacology Controversies: Rational Polymer-Based Paclitaxel-Eluting Stent, and the Military: A Cardiovascular Treatment Algorithms Despite a Bioabsorbable Polymer-Based Paclitaxel- in t ro Physician’s Perspectives Incomplete Data Eluting Stent, and Rapamycin Analogue- S. Ward Casscells Steven R. Steinhubl Eluting Stents: 30-Day and 6-Month Clinical Outcomes 5:15 p m - A Tribute to Andreas Gruentzig: 8:55 a m - The Importance of Technique in Alaide Chieffo A 30-Year Odyssey and His Legacy of PCI Optimizing Drug-Eluting Stent Outcomes:

Bernhard Meier Stent Expansion (Balloon Pressure), tURDAY agenda

1:48 p m - Critical Appraisal of the sa Geographic Miss, Incomplete ABSOLUTE Trial Apposition, and More Stephan Windecker Plenary Session 8: PCI Controversies I Marco A. Costa 9:10 a m - The Next Generation of Drug- Plenary Session 5: PCI Indications I: Moderator: Gregg W. Stone sun DAY Eluting Stents: Are There Meaningful agenda 5:30 p m - A National “Door-to-Balloon” Time Treatment for Stable Symptomatic Differences? Initiative is Necessary to Dramatically (and Asymptomatic) CORONARY Eberhard Grube Improve Acute MI Outcomes artery Disease John E. Brush Live Case Session I: Bifurcations Moderator: Gregg W. Stone agenda 5:45 p m - “No Holds Barred” Panel (sPONSORED BY SOCIEDAD mon DAY 2:00 p m - What Is “Optimal” Medical Therapy Discussion and When Is PCI Clearly NOT Indicated? LATINOAMERICANA DE Henning Rud Anderson, John E. Brush, CARDIOLOGIA INTERVENCIONISTA) Bernard J. Gersh David A. Cox, Raimund A. Erbel, Moderator: Eberhard Grube Bernard J. Gersh, Alice K. Jacobs, DEBATE: PCI vs. Optimal Medical Therapy Co-Moderator: Jorge A. Belardi agenda

Ulf Stenestrand t ues DAY 2:15 p m - Medical Therapy as the First Live Case Discussants: Jorge Gaspar, Choice for Most Patients 6:00 p m - Thought Leader’s Critique: Patent Efrain Gaxiola, Luiz A. Mattos, William E. Boden Foramen Ovale Closure Remains Poorly Oscar A. Mendiz, Marie-Claude Morice, Understood, Underutilized, and Paralyzed 2:30 p m - PCI as the First Choice for Marco A. Perin, Expedito E. Ribeiro, by Regulatory and Clinical Trial Issues Alfredo Rodriguez, Samin Sharma,

Most Patients agenda Robert J. Sommer Dean J. Kereiakes Leif Thuesen wed NESDAY 6:15 p m - “No Holds Barred” Panel 2:45 p m - Moderated Discussion and Q&A 9:30 a m - Instituto Dante Pazzanese de

Discussion Discussants: William E. Boden, Cardiologia Stephen J. D. Brecker, Tony Das, David J. Cohen, Dean J. Kereiakes, 10:30 a m - Fu Wai Hospital Paul Kramer, Bernhard Meier, case Stephan Wendecker reviews Michael J. Mullen, Robert J. Sommer, 11:30 a m - Columbia University Medical Peter T. Wilmshurst Center Plenary Session 6: Live Case 6:30 p m - Adjourn 12:00 p m - Break Session II Live Case Moderator: Gregg W. Stone agenda

Complex Patients, Complex Lesions t hurs DAY Co-Moderator: Patrick W. Serruys Moderator: David O. Williams Live Case Discussants: Alex Berenstein, Coronary Theater William E. Boden, Mark W. Connolly, 8:00 a m -6:30 p m 2:00 p m - The Comprehensive Approach to Bernard De Bruyne, Raimund A. Erbel, Lower Level the Patient With Diabetes Mellitus: From Eulogio Garcia, James D. Joye, the Rosiglitazone Controversy to Cath t raining Barry T. Katzen, Gary S. Mintz, Drug-Eluting Stent Update Lab Considerations physician Jay S. Yadav, Steven J. Yakubov Moderator: Eberhard Grube David J. Moliterno

3:00 p m - St. Paul’s Hospital 8:00 a m - Normal and Abnormal Pathologic 2:15 p m - Chronic Kidney Disease and Vascular Responses to Bare Metal and Contrast Nephropathy: Prognostic Impact 3:30 p m - Millard Fillmore Gates Hospital t elli e and the “Hottest” Data on Prevention even t s Drug-Eluting Stents and Their Relation sa 4:00 p m - Auckland City Hospital to Clinical Outcomes Therapies 4:30 p m - The Jack H. Skirball Center for Elazer R. Edelman Roxana Mehran Cardiovascular Research 8:20 a m - Safety of Drug-Eluting Stents for 2:30 p m - Simple and Complex Bifurcation On- and Off-Label Use: Integration of the Lesions: Classification(s), Single and Dual

Plenary Session 7: Featured Latest Clinical Trial and Observational Stent Options, Clinical Outcomes, and a ABS T RAC S Lectures I Registry Data Simple Treatment Algorithm Moderator: Gregg W. Stone David J. Cohen Yves R. Louvard general

www.tct2007.com 61 transcatheter cardiovascular therapeutics

MONDAY \ OCTOBER 22, 2007

2:45 p m - Interventional Approaches to Live Case Session I: Carotid and Structural Heart Disease Angiographic Thrombus and the Diseased Neurointervention Theater Saphenous Vein Graft: What Really Works? Moderator: Klaus D. Mathias 8:00 a m -6:30 p m Simon R. Dixon Co-Moderator: Jay S. Yadav Lower Level 3:00 p m - Chronic Total Occlusions: Live Case Discussants: Alex Berenstein, Novel Technical Approaches and Improving Robert M. Bersin, Lee R. Guterman, Success Rates Sriram S. Iyer, Patrick J. Peeters, Adult Congenital Heart Disease I: Masahiko Ochiai Michael J. Rinaldi, Giuseppe Sangiorgi, General Concepts and PFO Closure Moderator: Robert J. Sommer 3:15 p m - Left Main Intervention: Patient Maarten J. Suttorp, Christopher J. White Selection, Operator Technique, and Clinical 9:30 a m - Millard Fillmore Gates Hospital 8:00 a m - Anatomy, Embryology, and Outcomes Pathophysiology of Congenital Heart Disease: 10:00 a m - CardioVascular Center Frankfurt Paul S. Teirstein A Primer for the Adult Cardiologist 10:30 a m - Millard Filmore Gates Hospital James A. Goldstein 11:00 a m - Columbia University Live Case Session II: Multivessel 8:15 a m - The Use of Cardiac Imaging Medical Center and Diffuse Disease Techniques (TEE, ICE, CT/MR) for Moderator: David O. Williams 11:30 a m - CardioVascular Center Frankfurt Diagnosis and to Assist Therapy in Co-Moderator: Michael J. Cowley 12:00 p m - Break Adult Congenital Heart Disease Live Case Discussants: Theodore A. Bass, John D. Carroll Charles Chan, Costantino R. Costantini, Carotid Intervention II 8:30 a m - Transeptal Puncture: Technique D.S. Gambhir, Samuel K. Mathew, Moderator: John R. Laird, Jr Variations, Guidance Modalities, and Use Seong-Wook Park, Vincent J Pompili, Co-Moderator: Nicola Corvaja During New Transcatheter Procedures Arthur Teow Hin Tan, Clemens von Birgelen Panel Discussants: Zvonimir Krajcer, Howard C. Herrmann 3:30 p m - Columbia University Medical Center Juan C. Parodi, Mark H. Wholey 8:45 a m - Anatomic Variations and Clinical

4:30 p m - Hahnemann University Hospital 2:00 p m - Established Pathways and Syndromes Associated with PFOs (Indications for Transcatheter Closure) 5:30 p m - Auckland City Hospital Future Directions for Carotid Imaging and Stent Evaluation Jonathan M. Tobis 6:30 p m - Adjourn Michael R. Jaff 9:00 a m - Perspectives on PFO Closure:

2:25 p m - Panel Discussion Clinical Trials for Stroke Prevention and Migraines 2:30 p m - Carotid Stents and Embolic Endovascular Theater Mark Reisman 8:00 a m -6:30 p m Protection Systems: Differentiating 9:15 a m - Basic and Advanced Techniques for Lower Level the Devices Joachim Schofer PFO Closure: A Step-By-Step Approach and an Overview of New Device Alternatives 2:55 p m - Panel Discussion Carotid Intervention I Robert J. Sommer Moderator: Klaus D. Mathias 3:00 p m - Clinical Trials in Symptomatic and Co-Moderator: Jay S. Yadav Asymptomatic Patients with Obstructive Live and Taped Cases Session I Panel Discussants: Tyrone J. Collins, Carotid Disease: Summary Data from Moderator: Robert J. Sommer Alberto Cremonesi, Dariusz Dudek Completed Trials and Early Lessons from Co-Moderator: John D. Carroll CREST and ACT One 8:00 a m - Observations from the Innovator: Live Case Discussants: Ottavio Alfieri, Sriram S. Iyer Historical Perspectives and Lessons Ulrich Gerckens, Richard R. Heuser, Learned From Three Decades of Carotid 3:25 p m - Panel Discussion Saibal Kar, Vincent On-Hing Kwok, Angioplasty and Stenting Shakeel A. Qureshi, Jon R. Resar, Klaus D. Mathias Live Case Session II: Carotid and Richard Smalling, Neil J. Weissman 8:25 a m - Panel Discussion Neurointervention 9:30 a m - Evanston Northwestern Healthcare

8:30 a m - European Perspectives on Moderator: John R. Laird, Jr 10:30 a m - Taped Cases Carotid Stenting: Current Standards Co-Moderator: Mark H. Wholey 11:00 a m - St. Paul’s Hospital and Impact of Clinical Trial Data Live Case Discussants: Franz Wolfgang Aman, Bernhard Reimers Christopher U. Cates, Thomas A. Ischinger, 12:00 p m - Break Philip M. Meyers, Greg Mishkel, 8:55 a m - Panel Discussion Jacques G. Theron, Jiri J. Vitek, Valvular Heart Disease I: Aortic 9:00 a m - Insights From Post-Market Approval Robaayah Zambahari, James P. Zidar Data in Carotid Stenting: Trends and Stenosis and Regurgitation Relevance to Contemporary Practice and 3:30 p m - Hahnemann University Hospital Moderator: Howard C. Herrmann Ongoing and Future Investigation 4:30 p m - Columbia University Medical Center 2:00 p m - Aortic Stenosis and Regurgitation: Jay S. Yadav 5:30 p m - Millard Fillmore Gates Hospital Natural History, Pathophysiology, Patient 9:25 a m - Panel Discussion Profiling, Guidelines for Treatment, Valve 6:30 p m - Adjourn Choices and Surgical Results Blasé A. Carabello

62 truth in evidence based medicine · challenge conventional wisdom · transform your thinking MONDAY \ OCTOBER 22, 2007

2:25 p m - Echocardiographic Assessment 8:24 a m - Low Molecular Weight Heparins: 10:36 a m - TCT-55: Clopidogrel Pretreatment of Aortic Stenosis and Regurgitation New Insights into Safety, Efficacy, and vs. Clopidogrel Exposure Prior to PCI in the Linda D. Gillam Appropriate Use in PCI, ACS, and AMI ACUITY Trial: Does it Really Matter?

Marc Cohen Steven R. Steinhubl in t ro 2:35 p m - Hemodynamic Assessment of Aortic Stenosis and Regurgitation 8:36 a m - Fondaparinux: New Insights into 10:51 a m - TCT-56: Impact of Anemia on Morton J. Kern Safety, Efficacy, and Appropriate Use in 1-Year Ischemic Events and Mortality PCI, ACS, and AMI Among Patients with Acute Coronary 2:45 p m - Balloon Aortic Valvuloplasty: Michael Rokoss Syndromes Undergoing Percutaneous Current Indications, Techniques, and tURDAY agenda

Coronary Intervention sa Clinical Outcomes 8:48 a m - Tough Questions to the Speakers Wesley R. Pedersen from the Moderators and Audience Steven V. Manoukian Panel Moderators: James J. Ferguson III, 3:00 p m - Comprehensive Overview of the Case Review Session: Clinical and Edwards Transcatheter AVR Program Neal S. Kleiman Discussants: Marc Cohen, Interventional Cases Involving Difficult sun DAY Alain G. Cribier agenda Steven V. Manoukian, Michael Rokoss Anticoagulant Decisions 3:15 p m - Comprehensive Overview of the 11:06 a m : Moderators: James J. Ferguson III, Corevalve Transcatheter AVR Program Drilling Down Neal S. Kleiman Maurice Buchbinder Moderator: Neal S. Kleiman Case Presenters: Harold L. Dauerman, John J. Lopez, Vincent J. Pompili, agenda 9:03 a m - Bleeding and Transfusion: mon DAY Live and Taped Cases Session II Is This Our New Primary Concern? Discussants: James H. Chesebro, Moderator: Howard C. Herrmann Sunil V. Rao Lisa K. Jennings, David F. Kong Co-Moderator: James R. Margolis 11:45 a m - Adjourn Live Case Discussants: Lee N. Benson, 9:15 a m - Subtle and Not So Subtle Steven F. Bolling, George S. Hanzel, Manifestations of Heparin-Induced agenda t ues DAY Jan Harnek, Frank F. Ing, Michael J. Mack, Thrombocytopenia: Recognition and Robert J. Russo, Lars G. Svensson, Management Confrontational Angioplasty: Brian Whisenant Neal S. Kleiman Fiercely Debating the Issues 9:27 a m - Timing and Transitioning of 3:30 p m - CardioVascular Center Frankfurt (Sponsored by the british ACS Patients to the Cath Lab: cardiovascular intervention agenda 4:00 p m - Evanston Northwestern Healthcare Evidence-Based Recommendations society) wed NESDAY 5:00 p m - CardioVascular Center Frankfurt Marc Cohen 8:00 a m -11:55 a m 5:30 p m - St. Paul’s Hospital 9:39 a m - Clopidogrel Loading Issues and Room 151AB Relationship to Antithrombin and llb/llla 6:30 p m - Adjourn 8:00 a m - Introduction case

Inhibitor Efficacy reviews Martyn R. Thomas Steven R. Steinhubl Morning Concurrent 9:51 a m - Moderated Discussion and Q&A Angiographic Case Reviews: Sessions Panel Moderator: Neal S. Kleiman “What Happens Next?” Discussants: Marc Cohen, Sunil V. Rao, Moderator: Martyn R. Thomas agenda Steven R. Steinhubl Discussants: Keith D. Dawkins, t hurs DAY Anticoagulant Alternatives: Keynote Address Gregory J. Dehmer, Anthony H. Gershlick Low Molecular Weight Heparins, Moderator: Neal S. Kleiman 8:05 a m - Case #1

Direct Anti-Thrombins, Xa 10:06 a m - Future Antithrombin Alternatives Daniel J. Blackman t raining Inhibitors, and More Deepak L. Bhatt 8:20 a m - Case #2 physician 8:00 a m -11:45 a m Martyn R. Thomas Room 145AB Oral Abstracts 8:35 a m - Case #3 Moderator: Peter B. Berger Mark A. de Belder Antithrombin Alternatives Discussants: Lisa K. Jennings, t elli e even t s

Moderator: James J. Ferguson III David J. Moliterno, Jorge F. Saucedo sa A Contentious Debate: On-Site PCI 8:00 a m – Summary Overview: 10:21 a m - TCT-54: Long-Term Outcomes of Back-Up for Failed Coronary Surgery So Many Antithrombins, So Little Time: Patients with Acute Coronary Syndromes Is Now More Relevant than Surgical A Framework for Rational Selection and Chronic Renal Insufficiency Undergoing Back-Up for Failed Coronary Angioplasty James J. Ferguson III Percutaneous Coronary Intervention and Moderator: Anthony H. Gershlick ABS T RAC S 8:12 a m - Bivalirudin: New Insights into Being Treated with Bivalirudin vs. Heparin 8:50 a m - I Concur: When Is Surgery Safety, Efficacy, and Appropriate Plus a Glycoprotein IIb/IIIa Inhibitor: for Failed PCI Ever Needed? Use in PCI, ACS, and AMI Results from the Randomized ACUITY Trial Adam de Belder Steven V. Manoukian Roxana Mehran general

www.tct2007.com 63 transcatheter cardiovascular therapeutics

MONDAY \ OCTOBER 22, 2007

9:00 a m - I Object: Surgical Standby for PCI Distal Protection and Microcirculatory Protection in Is Still Necessary and Improves Outcomes Thrombectomy Devices in the Acute Myocardial Infarction Spencer B. King III Coronary and Endovascular Moderators: Franz Wolfgang Amann, Jeffrey J. Popma 9:10 a m - Moderated Discussion and Rebuttal Circulations Panel Moderator: Anthony H. Gershlick 9:47 a m - Should Thrombectomy and Distal 8:00 a m -11:50 a m Discussants: Adam de Belder, Room 147AB Protection Devices in AMI Be Abandoned? Spencer B. King III An Overview of Randomized Trials Saphenous Vein Graft Intervention Giuseppe De Luca How-To Session State of the Art 9:59 a m - Beyond the Randomized Trials: Moderator: Martin T. Rothman Moderators: Simon R. Dixon, John S. Douglas, Jr Can We (and Should We) Prevent Distal 9:25 a m - How to Best Treat Simple Embolization in AMI? 8:00 a m - The Spectrum of Distal Protection and Complex Bifurcations Devices in Saphenous Vein Graft Raimund A. Erbel David J. Hildick-Smith Intervention: Are There Meaningful 10:09 a m - TCT-78: Coronary Stent 9:40 a m - How to Stent the Distal Left Main Differences (and How to Choose) Prescription with Computed Keith D. Dawkins Joseph P. Carrozza, Jr Tomographic Coronary Angiography Christopher A. Glover et al 9:55 a m - How to Perform PCI when the 8:12 a m - Technical Tips and Tricks for Ejection Fraction is <30% Optimal Utilization of Distal Protection 10:19 a m - Advantages of Proximal Simon Redwood Devices in Saphenous Vein Grafts (Case Protection in AMI: Devices, Results, Review) and Case Experiences Confrontational Abstracts James B. Hermiller, Jr David A. Cox Moderator: Adam de Belder 8:22 a m - Do Balloon Occlusion and 10:29 a m - Moderated Discussion and Q&A Discussants: Keith D. Dawkins, Aspiration Systems Have a Current Role in Panel Moderators: Franz Wolfgang Amann, Anthony H. Gershlick, Martin T. Rothman, Saphenous Vein Graft Intervention? Jeffrey J. Popma Martyn R. Thomas D. Christopher Metzger Discussants: David A. Cox, Giuseppe De Luca, 10:10 a m - TCT-73: Late and Very Late Stent Raimund A. Erbel, Christopher A. Glover, 8:32 a m - Update on Proximal Saphenous Thrombosis Following Elective Drug-Eluting Vein Graft Protection: New Technologies Stent Implantation in Unprotected Left Main and Clinical Experience Protecting the Peripheral Circulation Coronary Artery: A Multicenter Registry Moderators: Mark W. Burket, Michel Henry Gabor I. Sutsch Alaide Chieffo et al 10:44 a m - Distal Protection During 8:42 a m - Do Undersized Stents Reduce 10:25 a m - TCT-74: Dual Antiplatelet Peripheral Intervention With and Without Embolization While Preserving Long-Term Therapy Following Percutaneous Coronary Atherectomy: Rationale and Results Outcomes in Saphenous Vein Grafts? Intervention with Stent Implantation in Michael H. Wholey Augusto D. Pichard Patients on Chronic Oral Anticoagulation 10:54 a m - Complications of Distal Renata Rogacka et al 8:52 a m - Does Adjunct Pharmacology Protection During Carotid Intervention: Make a Difference in Saphenous 10:40 a m - TCT-75: Percutaneous Coronary Frequency, Prevention, and Management Vein Graft Intervention? Interventions in Patients >90 Years of Age: J. Michael Bacharach Michael Haude Are We Pushing the Limits? 11:04 a m - TCT-79: Carotid Angioplasty and Abid Assali et al 9:02 a m - TCT-77: Impact of Distal Stenting Under Protection is Becoming Embolization Occurring During Direct PCI 10:55 a m - TCT-76: Transfer of ST-Elevation the Gold Standard Treatment of a Carotid on Infarct Size and Infarct Transmurality: Myocardial Infarction Patients Stenosis in High- and Low-Risk Patients A Magnetic Resonance Imaging Study with Cardiogenic Shock for Primary Michel Henry et al Massimo Napodano Percutaneous Coronary Intervention 11:14 a m - Proximal Protection During Timothy D. Henry et al Debate: Why Aren’t We Using Distal Carotid Intervention: Devices, Data, and Protection Devices in Every Eligible When to Use Rather Than Distal Protection Angiographic Case Reviews: Managing Saphenous Vein Graft Intervention? Bernhard Reimers Life-Threatening Complications of PCI 9:12 a m - Good Question: We Should Be! Moderator: Keith D. Dawkins Simon R. Dixon 11:24 a m - Protecting the Microcirculation During Renal Angioplasty: Can the Discussants: Carlo Di Mario, Jim Nolan, 9:22 a m - Good Question: Because Benefits Ever Be Demonstrated? Martyn R. Thomas They’re Not Necessary! Michel Henry 11:10 a m - Case #1 Tim A. Fischell 11:34 a m - Moderated Discussion and Q&A Nick Curzen 9:32 a m - Moderated Discussion and Q&A Panel Moderators: Mark W. Burket, 11:25 a m - Case #2 Panel Moderators: Simon R. Dixon, Michel Henry Lucy Blows John S. Douglas, Jr Discussants: J. Michael Bacharach, Discussants: Joseph P. Carrozza, Jr, 11:40 a m - Case #3 Bernhard Reimers, Michael H. Wholey Tim A. Fischell, Michael Haude, Robert A. Henderson James B. Hermiller, Jr, 11:50 a m - Adjourn 11:55 a m - Adjourn D. Christopher Metzger, Massimo Napodano, Augusto D. Pichard, Gabor I. Sutsch

64 truth in evidence based medicine · challenge conventional wisdom · transform your thinking MONDAY \ OCTOBER 22, 2007

Lunchtime Activities 12:45 p m - Moderated Discussion and Q&A 1:20 p m - Moderated Audience Q&A Panel Moderator: Stuart J. Pocock Panel Moderators: Alice K. Jacobs, Special Lunch Session Discussants: Ajay J. Kirtane, David F. Kong, Alexandra J. Lansky

12:00 p m -2:00 p m Roxana Mehran, John L. Petersen, Discussants: Andrea Abizaid, in t ro Bram Zuckerman Liliana R. Grinfeld, Saibal Kar, The Bioabsorbable Revolution: Patricia E. Knipper, Erin Michos, From Drug-Eluting Carriers to Stents Optimizing Care for Women with Jennifer H. Mieres, Eugenia Nikolsky, Room 202B Cardiovascular Disease Elizabeth V. Ratchford tURDAY

Moderators: Syed Hossainy, Jeffrey Hubbell Room 202A agenda sa Chairs: Alice K. Jacobs, Alexandra J. Lansky Interventional Cardiovascular 12:00 p m - History of Bioabsorbable Stent Simulation: Current Uses, Future Technology Development: The First 20 Years 12:15 p m - Introduction and Session Goals Richard S. Stack Alexandra J. Lansky Projections Room 207B 12:15 p m - Q&A 12:20 p m - Cardiovascular Disease in sun DAY Moderators: John D. Carroll, Giora Weisz agenda Women: Why the Emphasis? 12:18 p m - Synthetic Absorbable Polymers: 12:15 p m - Rationale and Evidence for the Design Considerations for Medical Devices Liliana R. Grinfeld Benefits of Cardiovascular Simulation Dennis Jamiolkowski 12:25 p m - Apical Ballooning (Broken Heart Christopher U. Cates Syndrome): Implications for Women 12:33 p m - Q&A 12:25 p m - Q&A agenda Amir Lerman mon DAY 12:36 p m - Challenges in Preclinical 12:27 p m - Education and Training: Evaluation of Bioabsorbable Stents: 12:30 p m - Risk Stratifying Women: from the The European Perspective The Role of Histology and Imaging Framingham to the Reynolds Score Erhard Kaiser Greg L. Kaluza Erin Michos 12:35 p m - The AHA Red Dress Campaign: 12:37 p m - Q&A p m agenda 12:51 - Q&A t ues DAY Purpose and Impact 12:39 p m - Cognitive and Hands-On 12:54 p m - Absorption Mechanisms and Alice K. Jacobs Coronary Skills: The ABIM Experience Predictive Models to Estimate the Rebecca S. Lipner Lifetime of Bioabsorbable Implants 12:40 p m - Noninvasive Diagnosis of Syed Hossainy Coronary Disease in Women: Common 12:49 p m - Q&A

Pitfalls agenda 12:51 p m - First Experience with 1:09 p m - Q&A wed NESDAY Jennifer H. Mieves Endovascular Testing Using Simulators: 1:12 p m - Discovery of a Promising Biomaterial 12:45 p m - Diagnosis and Management of The ABVM Experience for Use in Cardiovascular Stents from a Vascular Disease in Women Bruce H. Gray Combination Materials Design Approach

Elizabeth V. Ratchford case 1:01 p m - Q&A Joachim Kohn reviews 12:50 p m - Special Considerations for 1:27 p m - Q&A 1:03 p m - Assessment of Carotid Stenting Women with Acute Myocardial Infarction Proficiency: The ASSESS Trial 1:30 p m - Absorbable Particle-Based Alexandra J. Lansky Giora Weisz Technology for Cardiovascular Applications 12:55 p m - Implications of Chronic Kidney Jeffrey Hubbell 1:13 p m - Q&A agenda

Disease and Contrast Exposure in Women t hurs DAY 1:15 p m - Procedure Targeted Simulator for 1:45 p m - Q&A Eugenia Nikolsky Radial Access 1:48 p m - Moderated Discussion and Q&A 1:00 p m - Medication Dosing and Errors in Yves R. Louvard Panel Moderators: Syed Hossainy, Women Jeffrey Hubbell Andrea Abizaid 1:25 p m - Q&A t raining Discussants: Dennis Jamiolkowski, 1:27 p m - Patient Based Simulation physician 1:05 p m - The Obesity Epidemic and Greg L. Kaluza, Joachim Kohn, Richard S. Stack Weight Management Strategies: Giora Weisz 2:00 p m - Adjourn Implications for Women 1:37 p m – Q&A

Patricia E. Knipper 1:39 p m - Simulation of Structural Heart t elli e even t s

1:10 p m - Case Presentation: Evaluation and Disease Interventions sa Hot Topics, Hot Lunches Treatment of an Elderly Woman with Pan John D. Carroll 12:15 p m -1:45 p m Vascular Atherosclerosis 1:49 p m - Q&A Case Presenter: Saibal Kar Interpreting Current Trials: Discussants: Andrea Abizaid, Diabetes and Cardiovascular Disease: What’s New and What Makes Sense Liliana R. Grinfeld, Patricia E. Knipper, Attacking the Epidemic ABS T RAC S Room 201 Erin Michos, Jennifer H. Mieres, Room 206 Chair: Stuart J. Pocock Eugenia Nikolsky, Elizabeth V. Ratchford Chair: Michael E. Farkouh 12:15 p m - A Critical Statistical Review 12:15 p m - Introduction and Session Goals of Recent Trials Including COURAGE,

Michael E. Farkouh general DES Safety, ACUITY, Avandia, etc Stuart J. Pocock

www.tct2007.com 65 transcatheter cardiovascular therapeutics

MONDAY \ OCTOBER 22, 2007

12:20 p m - Metabolic Syndrome: Diagnosis Case Reviews with the Structural Heart Disease I: PFO, and Approach to Treatment ASD, and VSD Closure Tips, Tricks, J. Brent Muhlstein Experts and Complications 12:15 p m -1:45 p m 12:25 p m - The Diabetic Platelet Room 144A Dominick J. Angiolillo John M. Lasala, Bernhard Meier, High-Risk Intervention: Richard Smalling, Brian Whisenant 12:30 p m - Does Tight Glycemic Control Shock, Only Remaining Vessel, etc of Diabetes Improve Outcomes? Room 144B James H. Chesebro David Antoniucci, Hans R. Figulla, Board Review Course with 12:35 p m - The Rosiglitazone Controversy: Fayaz Shawl, Carl L. Tommaso Rationale and Recommendations Self Assessment for J. Brent Muhlestein Chronic Total Occlusions: Advanced Treatment Strategies I Interventional Cardiology 12:40 p m - Stents, Surgery, or Medical Room 150A Therapy in Diabetes? Update on BARI-2D and Endovascular Medicine, Yasushi Asakura, YunDai Chen, Frederick Feit PART 3: CORONARY ESSENTIALS Miodrag C. Ostojic, Satoru Sumitsuji 2:00 p m -6:00 p m 12:45 p m - Outcomes of Bypass Graft Room 146ABC Surgery in Diabetes Mellitus: Real-World My Worst Complications: Evaluation Coronary Intervention I PCI Indications and Outcomes Michael J. Mack Room 150B According to Clinical Presentation 12:50 p m - Stent Selection in Diabetes: Joseph D. Babb, Larry S. Dean, Moderators: David P. Faxon, John J. Young DES vs. BMS? Sirolimus vs. Paclitaxel? Fabio E. B. Posas, Uri Rosenschein Donald Cutlip 2:00 p m - PCI in Acute Coronary Syndromes Complex Carotid and Brachiocephalic David P. Faxon 12:55 p m - FREEDOM Trial Update Michael E. Farkouh Interventions I 2:45 p m - Q&A Room 149AB 3:00 p m - PCI in Chronic Coronary 1:00 p m - Implications of Chronic Kidney Deepak L. Bhatt, Tyrone J. Collins, Artery Disease Disease and Contrast Nephropathy in Sriram S. Iyer, Michael J. Rinaldi the Diabetic Patient Bernard J. Gersh Carlo Briguori Limb Salvage Techniques 3:35 p m - Q&A 1:05 p m - Impact of Hyperglycemia in Room 143A 3:45 p m - Break Acute Myocardial Infarction David E. Allie, Gary Gershony, Norman E. Lepor Thomas O. McNamara, Gregory C. Robertson Emergency PCI Moderators: Manish A. Parikh, Jeffrey J. Popma 1:10 p m - Special Considerations for My Worst Complications: Primary Angioplasty in the Diabetic 4:00 p m - PCI in Acute MI: Primary, Rescue, with Acute Myocardial Infarction Endovascular Intervention I Facilitated and Beyond Thomas D. Stuckey Room 143B Cindy L. Grines Jacques Busquet, John H. Rundback, 1:15 p m - Case Presentation: 44-Year-Old 5:00 p m - Q&A Matthew R. Selmon, John J. Young Insulin-Requiring Diabetic Patient with 5:15 p m - Cardiogenic Shock and Unstable Angina and Renal Insufficiency Complex Coronary Intervention Hemodynamic Support Panel Moderator: Michael E. Farkouh Emphasizing Advanced Techniques Jeffrey J. Popma Case Presenter: Aloke Finn and Procedural Strategy I 5:45 p m - Q&A Discussants: Dominick J. Angiolillo, Room 143C Carlo Briguori, James H. Chesebro, 6:00 p m - Adjourn Daniel H. Berrocal, John S. Douglas, Jr, Donald Cutlip, Frederick Feit, Michael J. B. Kutryk, Detlef G. Mathey Norman E. Lepor, Michael J. Mack, J. Brent Muhlestein, Thomas D. Stuckey, Unprotected Left Main Disease: Afternoon Concurrent Douglas E. Vaughan How and When to Treat Sessions 1:25 p m - Moderated Audience Q&A Room 152B Panel Moderator: Michael E. Farkouh Clemens von Birgelen, Kenneth Chin, Platelet Inhibition I: New Insights Discussants: Dominick J. Angiolillo, Ben He, Raj Makkar into Aspirin and Thienopyridine Carlo Briguori, James H. Chesebro, Utilization and Resistance Donald Cutlip, Frederick Feit, Aloke Finn, Bifurcation Disease: Technique 2:00 p m -6:10 p m Norman E. Lepor, Michael J. Mack, Selection and the Step-by-Step Room 145AB J. Brent Muhlestein, Thomas D. Stuckey, Approach I Douglas E. Vaughan Room 152A Platelets, Antiplatelet Agents, and Vladimir Dzavik, Jorge Gaspar, How to Monitor Them Vivek Gupta, Sunao Nakamura Moderators: Dominick J. Angiolillo, Paul A. Gurbel

66 truth in evidence based medicine · challenge conventional wisdom · transform your thinking MONDAY \ OCTOBER 22, 2007

2:00 p m - The Central Role of the Platelet 4:30 p m - Roundtable Discussion 2:22 p m - On-Site Surgery Is Unnecessary in the Genesis of Post-PCI Adverse Events Panel Moderators: Matthew J. Price, for Primary Angioplasty: Is it Time for a Lisa K. Jennings Steven R. Steinhubl National Policy?

Discussants: David Antoniucci, Gregory J. Dehmer in t ro 2:15 p m - Methods of Determining Platelet Peter B. Berger, Paul A. Gurbel, Function: Do They All Measure the 2:32 p m - TCT-99: Regional STEMI Networks Same Parameters? Stefan Hoffmann, Daniel I. Simon in Southern California Reduce Door-to-Balloon Neal S. Kleiman Times: Pooled Data from Four Counties Next Generation Antiplatelet Therapy Ivan C. Rokos et al

2:30 p m - Aspirin in Cardiovascular Disease: tURDAY

Moderators: Paul A. Gurbel, agenda What Is the Right Dose, and Is It Only About Steven R. Steinhubl 2:42 p m - Roundtable Discussion sa COX-1 Inhibition? Insights from the Panel Moderators: Alice K. Jacobs, ASPECT Study 4:45 p m - Impact of Cilostazol on Platelet Spencer B. King III Kevin Bliden Function: First Report from the Placebo- Discussants: Eric R. Bates, Bruce R. Brodie, Controlled Randomized OPTIMUS-2 Trial John E. Brush, Gregory J. Dehmer, sun DAY 2:45 p m - Platelet P2Y12 Inhibition with Dominick J. Angiolillo agenda Clopidogrel: Insights into Acute and Timothy D. Henry, Ivan C. Rokos, Chronic Dosing and Onset of Action 4:57 p m - TCT-83: Impact of Cilostazol Ulf Stenestrand on Performance of Drug-Eluting Stent Dominick J. Angiolillo 2:57 p m - Utilization of Rescue and According to Stent Type: Subgroup Facilitated Angioplasty: Guideline 3:00 p m - TCT-80: High Clopidogrel Analysis of DECLARE Trial agenda Review and Critical Appraisal mon DAY Maintaining Dosage Improves Long-Term Seung-Whan Lee et al Clinical Outcomes in Patients with Acute Spencer B. King III 5:07 p m - Update on the New Antiplatelet Coronary Syndrome Undergoing Drug-Eluting 3:09 p m - Late Recanalization of Occluded Stent Implantation Agents: Novel P2Y12 Inhibitors Infarct Arteries: Guideline Review and Yaling Han et al Alan D. Michelson Critical Appraisal agenda 5:22 p m - Update on the New Vladimir Dzavik t ues DAY 3:10 p m - Roundtable Discussion Antiplatelet Agents: PAR-1 Inhibitors Panel Moderators: Dominick J. Angiolillo, 3:21 p m - TCT-100: The FINESSE Paul A. Gurbel David J. Moliterno (Facilitated Intervention with Enhanced Discussants: Kevin Bliden, Yaling Han, 5:37 p m - Antiplatelet Effects of Reperfusion Speed to Stop Events) Trial: Lisa K. Jennings, Adnan Kastrati, Anticoagulants: Potential of Oral

Results of the Formal Low Molecular agenda

Neal S. Kleiman Factor Xa Inhibitors to Prevent Weight Heparin Substudy wed NESDAY Arterial Thrombosis Gilles Montalescot

Antiplatelet Resistance: Steven R. Steinhubl 3:31 p m - Controversial and Unsettled STEMI What Does It Mean and What 5:52 p m - Moderated Discussion and Q&A Guideline Issues: The European Perspective case

Should We (Or Can We) Do About It? Panel Moderators: Paul A. Gurbel, Sigmund Silber et al reviews Moderators: Matthew J. Price, Steven R. Steinhubl 3:46 p m - Moderated Discussion and Q&A Steven R. Steinhubl Discussants: Dominick J. Angiolillo, Panel Moderators: Alice K. Jacobs, 3:25 p m - Clopidogrel and Aspirin Non- Seung-Whan Lee, Alan D. Michelson, Spencer B. King III Responders: Definitions and Detection David J. Moliterno Discussants: Gregory J. Dehmer, agenda Steven R. Steinhubl 6:10 p m - Adjourn Vladimir Dzavik, Lloyd W. Klein, t hurs DAY 3:40 p m - Relationship between Post-PCI Gerrit J. Laarman, Gilles Montalescot, Platelet Function and Subsequent Adverse Guidelines and Evidence-Based Sigmund Silber Ischemic Events and Stent Thrombosis: Medicine Review I: ACS, AMI, and The New Cardiovascular Risk Factor? NSTEMI Guidelines and Evidence-Based t raining Paul A. Gurbel Adjunct Pharmacology Medicine physician 2:00 p m -6:00 p m Moderators: Sigmund Silber, Sidney Smith 3:55 p m - TCT-81: Variability in P2Y12- Room 151AB Mediated Platelet Reactivity Is Not 4:01 p m - Early Invasive vs. Delayed Invasive Associated with Peri-Procedural Ischemic vs. Conservative Approaches in NSTEMI:

STEMI Guidelines and Evidence-Based t elli e Events in Patients on Maintenance Guideline Review and Critical Appraisal even t s Medicine sa Clopidogrel Therapy Treated with Bivalirudin Moderators: Alice K. Jacobs, Robert J. de Winter Monotherapy Spencer B. King III 4:13 p m - Data-Driven Recommendations Matthew J. Price et al for the Use of Biomarkers and Risk 2:00 p m - Time to Treatment (and Transport) 4:05 p m - Management of Aspirin and Issues and Selection of Reperfusion Stratification Variables in ACS Clopidogrel Hypo-Responders: Pharmacologic Modality, and Primary Angioplasty Michael E. Farkouh ABS T RAC S Options Today and Tomorrow and Will with No On-Site Surgery: Guideline 4:23 p m - TCT-101: Primary PCI Performed Changing Therapy Improve Outcomes? Review and Critical Appraisal with Delay <120 Minutes from Diagnosis Daniel I. Simon Eric R. Bates Seems Acceptable in Terms of Short-Term 4:20 p m - TCT-82: Clopidogrel Resistance Clinical Outcomes: Results from 2:12 p m - Is Door-to-Balloon Time the general and Stent Thrombosis: A Causal Relation? Right Metric? EUROTRANSFER Registry Stefan Hoffmann Timothy D. Henry Zbigniew Siudak

www.tct2007.com 67 transcatheter cardiovascular therapeutics

MONDAY \ OCTOBER 22, 2007

4:33 p m - Moderated Discussion and Q&A Best of Coronary Interventional 3:45 p m - TCT-64: 3-Year Clinical Results Panel Moderators: Sigmund Silber, Abstracts: FOCUS ON DRUG-ELUTING from the TAXUS V De Novo Trial: Long-Term Sidney Smith Safety and Efficacy of the Paclitaxel-Eluting STENTS Discussants: Robert J. de Winter, TAXUS Stent in Complex Lesions 2:00 p m -6:00 p m Michael E. Farkouh, Alice K. Jacobs, Stephen G. Ellis Room 147AB Spencer B. King III, Zbigniew Siudak Drug-Eluting Stents III Drug-Eluting Stents I Adjunct Pharmacology (STEMI and Moderators: Jorge A. Belardi, Moderators: Theodore A. Bass, NSTEMI) Guidelines and Evidence- Ivan De Scheerder Jacques J. Koolen Based Medicine Discussants: Anders M. Galloe, Discussants: Daniel H. Berrocal, Moderators: Sigmund Silber, Sidney Smith Ioannis Iakovou, Vincent On-Hing Kwok, Jose M. de la Torre, Maurizio Menichelli, Frederick Welt 4:43 p m - Antithrombin Agents in David G. Rizik NSTEMI and STEMI: Guideline 4:00 p m - TCT-65: Safety and Durable 2:00 p m - TCT-60: Triple Antiplatelet Therapy Review and Critical Appraisal Efficacy of the Polymer-Based, Improves Long-Term Outcomes After Marc Cohen Paclitaxel-Eluting TAXUS Stent: Final Percutaneous Coronary Intervention in 5-Year Outcomes from the TAXUS IV Trial 4:55 p m - Glycoprotein IIb/IIIa Inhibitor Patients with Acute Coronary Syndromes Stephen G. Ellis Use in NSTEMI and STEMI: ER or Cath Yaling Han Lab Initiation, Routine or Selective Use: 4:15 p m - TCT-66: Stent Thrombosis, 2:15 p m - TCT-58: The Impact of Stent Guideline Review and Critical Appraisal Myocardial Infarction, and Mortality Thrombosis on the Long-Term Efficacy of Sunil V. Rao following Drug-Eluting and Bare Metal Drug-Eluting Stents in Patients with Acute Stent Coronary Interventions in Patients 5:07 p m - Clopidogrel Timing in NSTEMI: Myocardial Infarction: Insights into the with Diabetes Mellitus Pre- and Post-Angiography and What Dose? RESEARCH and T-SEARCH Registries Michael Maeng Guideline Review and Critical Appraisal Joost Daemen Peter B. Berger 4:30 p m - TCT-72: Long-Term (Up to Five 2:30 p m - TCT-59: 4-Year Follow-up Years) Clinical Outcomes of Drug-Eluting 5:19 p m - TCT-102: Safety and Efficacy of of Patients with ST-Segment Elevation Stents for Coronary In-Stent Restenosis in Bivalirudin With and Without Glycoprotein Acute Myocardial Infarction Treated the Real World: Insights from the IIb/IIIa Inhibitors in Patients with Acute with Sirolimus-Eluting Stent and Paclitaxel- DESIRE-ISR Registry Coronary Syndromes Undergoing Eluting Stent: Multicenter Registry Julio P. Maia Percutaneous Coronary Intervention: 1-Year Sunao Nakamura Results from the Randomized ACUITY Trial 4:45 p m - TCT-68: Percutaneous Treatment of 2:45 p m - TCT-57: Time Course of Neointimal Harvey D. White Unprotected Left Main Coronary Stenoses Coverage Following Sirolimus-Eluting Stent with Paclitaxel-Eluting Stents: Mid-Term 5:29 p m - Controversial and Unsettled Implantation: Up to Two Years Serial Results of a French Prospective Multicenter Adjunct Pharmacology Guideline Angioscopic Study Study (FRIEND Registry) Issues: The European Perspective Masaki Awata Didier Carrie Gilles Montalescot Drug-Eluting Stents II 5:44 p m - Moderated Discussion and Q&A Drug-Eluting Stents IV Moderators: Manel Sabate, Ron Waksman Panel Moderators: Sigmund Silber, Moderators: Ajay J. Kirtane, Alan C. Yeung Discussants: Andrea Abizaid, Serge Doucet, Sidney Smith Discussants: Alaide Chieffo, Ronald C. H. Lee, Greg L. Kaluza, Bradley H. Strauss Discussants: Peter B. Berger, LeRoy E. Rabbani, Alfredo Rodriguez Michel E. Bertrand, Marc Cohen, 3:00 p m - TCT-61: Diabetes as a Predictor for 5:00 p m - TCT-69: Impact of Sirolimus- Gregory J. Dehmer, James J. Ferguson III, Stent Thrombosis, Myocardial Infarction, and Eluting Stent and Paclitaxel-Eluting Stent on Spencer B. King III, Gilles Montalescot, Mortality after Coronary Stent Implantation: the Outcome of Patients with Sirolimus- Sunil V. Rao, Harvey D. White A Danish Population-Based Cohort Study Eluting Stent Failure: Multicenter Registry Michael Maeng 6:00 p m - Adjourn Sunao Nakamura 3:15 p m - TCT-62: Predictors of Adverse 5:15 p m - TCT-70: Long-Term Results After Events in Patients with Unprotected Left Sirolimus-Eluting Stent Implantation for Main Disease Treated with Drug-Eluting In-Stent Restenosis: Evidence for a Late Stents: Evidence from a Collaborative Catch-Up Phenomenon? Meta-Regression Imad Sheiban Giuseppe Biondi Zoccai 5:30 p m - TCT-67: ABSORB Trial: 12-Month 3:30 p m - TCT-63: The European Multicenter, Results of Clinical Evaluation of the Randomized, Double-Blind Study of the Bioabsorbable Everolimus-Eluting Coronary Sirolimus-Eluting Stent in the Treatment Stent System in the Treatment of Patients of Patients with De Novo Coronary Artery with De Novo Native Coronary Artery Lesions Lesions: 5-Year Clinical Outcomes of the Patrick W. Serruys E-SIRIUS TRIAL Henning Kelbaek

68 truth in evidence based medicine · challenge conventional wisdom · transform your thinking MONDAY \ OCTOBER 22, 2007

5:45 p m - TCT-71: Prevalence and Clinical 7:45 p m - Moderated Discussion and Q&A Implication of Stent Fracture after Panel Moderators: Linda D. Gillam, Sirolimus-Eluting Stent Implantation: Shunichi Homma

The Impact of Lesion Complexity Discussants: Rebecca Tung Hahn, in t ro Kazushige Kadota Frederick G. St. Goar, Christopher R. Thompson, Mani A. Vannan, 6:00 p m - Adjourn Neil J. Weissman, Susan E. Wiegers

8:00 p m - Adjourn tURDAY agenda Special Evening Sessions sa Endovenous Treatment of Varicose Echocardiography in the Veins: An Emerging Subspecialty Interventional Setting: A Renewed 6:00 p m -8:00 p m sun DAY Partnership (Sponsored by the Room 154AB agenda American Society of Director: Jose I. Almeida Co-Director: Julian J. Javier Echocardiography) 6:00 p m -8:00 p m 6:00 p m - Why Should Cardiologists Be Room 149AB Interested in Venous Disease: agenda Moderators: Linda D. Gillam, Is Extra Training Required? mon DAY Shunichi Homma Julian J. Javier

6:00 p m - Echocardiography in the Cath 6:15 p m - Scope of the Problem: Lab: Choosing Between TTE, TEE, ICE Historical Treatment Modalities Anthony J. Comerota

and 2-D/3-D agenda t ues DAY Linda D. Gillam 6:30 p m - Why Endovenous Ablation Has

6:15 p m - Mitral Valvuloplasty: Update Replaced Traditional Surgery on Patient Selection, Intra-Procedural Jose I. Almeida Monitoring, and Outcomes Assessment 6:45 p m - Clinical and Duplex Ultrasound Rebecca Tung Hahn Evaluation of Varicose Veins agenda wed NESDAY 6:30 p m - Percutaneous Mitral Repair: Lowell Kabnick Echocardiographic Patient Selection p m

7:00 - Endovenous Laser and Criteria, Procedural Guidance, and Outcomes Radiofrequency Ablation of the Saphenous

Susan E. Wiegers Vein: Is One Better than the Other? case reviews 6:45 p m - Percutaneous Aortic Valve Jose I. Almeida Replacement: Echocardiographic 7:15 p m - Ambulatory Phlebectomy: Patient Selection Criteria, Procedural A Necessary Adjunct Guidance, and Outcomes Edward G. Mackay

Neil J. Weissman agenda 7:30 p m - Sclerotherapy: t hurs DAY 7:00 p m - Echocardiographic Guidance of Its Uses and Limitations Septal Defect Closure and Left Atrial Lowell Kabnick Appendage Exclusion 7:45 p m - Moderated Discussion and Q&A Mani A. Vannan Panel Moderators: Jose I. Almeida, t raining 7:15 p m - Reality Check: The Julian J. Javier physician Interventionalist’s Perspective on the Discussants: Anthony J. Comerota, Strengths and Limitations of Lowell Kabnick, Edward G. Mackay Echocardiography 8:00 p m - Adjourn t elli e

Frederick G. St. Goar even t s sa

Interesting Case Presentations 7:25 p m - Case Presentations: EVENING SYMPOSIA Echocardiographic Diagnosis of 8:00 p m -10:00 p m Intra-Procedural Complications Refer to page 99-101 for complete program Christopher R. Thompson schedule. ABS T RAC S 7:35 p m - Case Presentations: ICE vs. TEE Mani A. Vannan general

www.tct2007.com 69 transcatheTEr cardiovascular therapeutics

Tuesday \ october 23, 2007

Breakfast Meetings Plenary Session 11: Late Breaking 12:27 p m - Critical Appraisal of the ARMYDA-5 Trial 7:00 a m -8:00 a m Clinical Trials II Daniel I. Simon Refer to pages 101-104 for complete Moderator: Martin B. Leon program schedule. 12:30 p m - OPTIMA: Prospective, 10:30 a m - AMIHOT II: A Prospective, Randomized Evaluation of Immediate Versus Randomized Evaluation of Supersaturated Deferred Angioplasty in Patients with Physician Training Center Oxygen Therapy After Primary Angioplasty in High-Risk Acute Coronary Syndromes Anterior Myocardial Infarction Robert K. Riezebos 10:00 a m -5:00 p m Gregg W. Stone Lower Level 12:42 p m - Critical Appraisal of the 10:42 a m - Critical Appraisal of the OPTIMA Trial Hands on Hearts, 3-D Imaging, AMIHOT II Trial Adnan Kastrati Specialty Device Training Michael Haude 12:45 p m - EXPORT: A Prospective, Refer to pages 96-97 for details. 10:45 a m - NORTHERN: A Prospective, Randomized Trial of Thromboaspiration Randomized, Double-Blind Placebo- during Primary Angioplasty in Acute Controlled Evaluation of Intramyocardial Myocardial Infarction Main Arena VEGF-165 Plasmid DNA Gene Therapy in Bernard R. Chevalier 8:00 a m -6:30 p m Patients with Refractory Angina 12:57 p m - EXPIRA: A Prospective, Ballrooms ABC, Level 3 Duncan J. Stewart Randomized Trial of Thromboaspiration 10:57 a m - Critical Appraisal of the During Primary Angioplasty in Acute Plenary Session 9: Live Case NORTHERN Trial Myocardial Infarction Session III Roger J. Laham Gennaro Sardella Moderator: Martin B. Leon 1:09 p m - PIHRATE: A Prospective, Co-Moderator: Howard C. Herrmann “Blockbuster” Trial of the Day: RESILIENT Randomized Trial of Thromboaspiration Live Case Discussants: Yaron Almagor, a m 11:00 - A Critical Review of Treatment During Primary Angioplasty in Acute Henning Rud Andersen, Daniel S. Berman, Options for Patients with Superficial Femoral Myocardial Infarction Upendra Kaul, J. J. R M. Bonnier, Artery Disease Dariusz Dudek Edoardo Camenzind, William A. Gray, Michael R. Jaff William D. Knopf, Daniel J. McCormick, 1:21 p m - Critical Appraisal of the EXPORT, 11:20 a m - RESILIENT: A Prospective, James F. McKinsey, Jonathan M. Tobis EXPIRA, and PIHRATE Trials Randomized Trial Comparing a Self- Giuseppe De Luca 8:00 a m - Columbia University Medical Expanding Nitinol Stent and Balloon Center Angioplasty in SFA Lesions: 1-Year Results 1:26 p m - THUNDER: A Prospective, Barry T. Katzen Randomized Trial of a Paclitaxel-Eluting 8:30 a m - Asan Medical Center Balloon, Intra-Arterial Paclitaxel, and Control 11:35 a m - Critical Appraisal of the 9:00 a m - Rabin Medical Center in SFA Lesion: 1-Year Angiographic and RESILIENT Trial 9:30 a m - Clinique Louis Pasteur Clinical Results Dierk Scheinert Gunnar Tepe 11:40 a m - Panel Discussion 1:38 p m - Critical Appraisal of the THUNDER Plenary Session 10: PCI Panel Moderator: Dierk Scheinert Controversies II Trial Discussants: Michael R. Jaff, James D. Joye, Erich Minar Moderator: Martin B. Leon Barry T. Katzen, Hans Krankenberg, 1:41 p m - CAPTURE-2 and EXACT: Carotid 10:00 a m - Technology at the Crossroads: Daniel J. McCormick, Krishna Rocha-Singh, Stent Outcomes and Achievement of AHA Carotid Stenting “Under Siege” (Again): John H. Rundback, Christopher K. Zarins Target Goals in a Large Multicenter Registry Recent Clinical Trial and Reimbursement William A. Gray Perspectives Career Achievement Award William A. Gray Moderator: Martin B. Leon 1:53 p m - Critical Appraisal of the CAPTURE-2 and EXACT Studies 10:15 a m - “No Holds Barred” Panel 12:00 - TCT 2007 Career Achievement John R. Laird, Jr Discussion Award Presentation Discussants: David S. Buckles, Martin B. Leon William A. Gray, Michael R. Jaff, Steve E. Plenary Session 12: PCI Indications Phurrough, Krishna Rocha-Singh, Kenneth Late Breaking Studies and First II: When Revascularization Therapy Rosenfield, Robert D. Safian, Mark H. Wholey Report Investigations is Indicated for Coronary Disease Moderator: Gregg W. Stone Moderators: Antonio Colombo, Patrick L. Whitlow 2:00 p m - The Modern Era of Cardiac Surgery (And Cardiac Surgeons): Advanced 12:15 p m - ARMYDA-5: A Prospective, Technology Breakthroughs, Improved Double-Blind Randomized Trial of Outcomes, and a Changing Paradigm for Clopidogrel Loading Upstream vs. In-Lab Clinical Decision Making Germano Di Sciascio Friedrich W. Mohr

70 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Tuesday \ october 23, 2007

Debate: PCI vs. Surgery 6:00 p m - Opinion Statement: Coronary CT 9:30 a m - Asan Medical Center 2:15 p m - PCI as the First Choice for Angiography is Already a Useful Modality for 10:30 a m - Columbia University Most Patients the Management of Patients with Known or Medical Center

Paul S. Teirstein Suspected Coronary Disease: Techniques, in t ro 11:30 a m - Rabin Medical Center 2:30 p m - Surgery as the First Choice for Clinical Data, and Next Steps Most Patients Daniel S. Berman Special Session: Drug-Eluting vs. Craig R. Smith 6:15 p m - “No Holds Barred” Panel Discussion Bare Metal Stent Selection: Late p m Discussants: Daniel S. Berman, 2:45 - Moderated Discussion and Q&A tURDAY agenda

Discussants: Jean Marco, Gary L. Schaer, Jeffrey A. Brinker, Bernard DeBruyre, Breaking Registries and sa Craig R. Smith, Paul S. Teirstein Andrew J. Einstein, Jeffrey C. Hellinger, Emerging Data John McB. Hodgson, James R. Margolis Moderators: Martin B. Leon, Gregg W. Stone Plenary Session 13: Live Case 6:30 p m - Adjourn 12:10 p m - SCAAR Update: Outcomes of sun DAY Session IV Drug-Eluting Compared to Bare Metal Stents agenda Moderator: Gregg W. Stone in the Country of Sweden Co-Moderator: Antonio Colombo Coronary Theater Stefan K. James Live Case Discussants: Gerald Barbeau, 8:00 a m -6:30 p m Peter C. Block, Mark W. Burket, Junbo Ge, Lower Level 12:20 p m - Late Breaking DES Registry

- Western Denmark: Outcomes of Drug- agenda Sheldon Goldberg, Michel Henry, Eric Horlick, mon DAY Yean-Leng Lim, Tom A. Mabin, Acute Coronary Syndromes and Eluting Compared to Bare Metal Stents in Matthias E. Pfisterer, Gerhard C. Schuler Western Denmark (2-Year Follow-Up) Myocardial Infarction Lisette Okkels Jensen 3:00 p m - Saint Luke’s Mid America Heart Moderator: Paul S. Teirstein Institute 12:30 p m - Late Breaking DES Registry

8:00 a m - Diagnostic Alternatives for agenda - Asan Medical Center DES Registry: t ues DAY 3:30 p m - Riverside Methodist Hospital Vulnerable Plaque Detection: From Outcomes of Drug-Eluting Compared to Bare Biomarkers to Noninvasive and Invasive 4:00 p m - Carolinas Medical Center Metal Stents from Two Academic Hospitals Imaging 4:30 p m - Swedish Heart and Vascular in Korea (1- and 3-Year Follow-Up) Pedro R. Moreno Institute Seung-Jung Park 8:15 a m - Evidence-Based Medicine agenda

12:40 p m - NY State Database: Outcomes of wed NESDAY Therapies in Acute Coronary Syndromes: Plenary Session 14: Featured Drug-Eluting Compared to Bare Metal Stents From Principles to Practice Lectures II in New York E. Magnus Ohman Edward L. Hannan Moderator: Gregg W. Stone 8:35 a m - Primary Angioplasty in AMI case

12:50 p m - Late Breaking Registry - STENT reviews 5:00 p m - Lessons from Autopsy Findings Controversies: Door-to-Balloon Time and Registry: Outcomes of Drug-Eluting and Experimental Models: Can Basic Transport Adjunct Pharmacology, DES, and Compared to Bare Metal Stents from Science be Utilized to More Accurately Multivessel Intervention Multiple US Hospitals (2-Year Follow-Up) Develop Cardiovascular Devices and Predict Giuseppe De Luca Bruce R. Brodie Clinical Outcomes?

8:55 a m - Fibrinolysis Before Angioplasty and agenda Renu Virmani 1:00 p m - Late Breaking Registry - GHOST: t hurs DAY Angioplasty after Fibrinolysis: Strategies and Outcomes of Drug-Eluting Compared to Bare 5:15 p m - Has “Medicine by the Media” Recommendations in 2007 Metal Stents from the Guthrie Health System Gone Too Far? How to Best Serve Physicians Frans Van de Werf (2- to 3-Year Follow-Up) and the Lay Public 9:15 a m - Management Strategies for Kishore Harjai Mehmet C. Oz t raining Advanced Left Ventricular Dysfunction and physician 1:10 p m - First Report Investigation - EVENT: Cardiogenic Shock: Medications, Support Plenary Session 15: PCI Implications of Changing PCI Practice and Devices, and Destination Therapies Stent Use Patterns Between 2004 and 2006 Controversies III Daniel Burkhoff on Clinical Outcomes

Moderator: Gregg W. Stone t elli e

Neal S. Kleiman even t s sa 5:30 p m - The Escalating “Conflict of Live Case Session III: Left Main 1:20 p m - First Report Investigation - TAXUS Interest” Dilemma: Current Status and Disease Landmark Analysis: Impact of Long-Term Roadmap for Physicians (Sponsored by Asian Pacific Society of Clopidogrel Usage on Death, Myocardial Richard L. Popp Interventional Cardiology) Infarction, and Stent Thrombosis 5:45 p m - “No Holds Barred” Panel Discussion Gregg W. Stone Moderator: Paul S. Teirstein ABS T RAC S Discussants: Peter J. Fitzgerald, Co-Moderator: Andrejs Erglis Gregory J. Dehmer, Aaron V. Kaplan, Live Case Discussants: Balram Bhargava, Spencer B. King, III, Richard L. Popp, Kenneth Chin, Chia-Yu Chou, Yaling Han, Sigmund Silber, Bonnie H. Weiner Duncan H. K. Ho, Takeshi Kimura, Manish A. Parikh, Takahiko Suzuki, general Hideo Tamai

www.tct2007.com 71 transcatheTEr cardiovascular therapeutics

Tuesday \ october 23, 2007

1:30 p m - Moderated Discussion and Q&A Endovascular Theater 3:00 p m - Mesenteric Intervention 2007: Panel Moderators: Martin B. Leon, Overview of Indications, Anatomic 8:00 a m -6:30 p m Gregg W. Stone Lower Level Evaluation, Technique, and Outcomes Discussants: Bruce R. Brodie, Donald Cutlip, Greg Mishkel Edward L. Hannan, Kishore Harjai, 3:25 p m - Moderated Panel Discussion Stefan K. James, Lisette Okkels Jensen, SFA and Iliac Intervention Neal S. Kleiman, Roxana Mehran, Moderator: Giancarlo Biamino Seung-Jung Park, Patrick W. Serruys, Co-Moderator: Erich Minar Live Case Session IV: Renals Moderator: Christopher J. Cooper Charles A. Simonton, Bram Zuckerman Panel Discussants: Daniel G. Clair, Anthony J. Galeo, Amir Motarjeme Co-Moderator: Kenneth Rosenfield Live Case Discussants: Rajesh M. Dave, 8:00 a m - Selection Between Interventional Pharmacology Andrew Holden, Massoud A. Leesar, Moderator: Maurice Buchbinder Revascularization Options for Peripheral Vascular Disease: Critical Review of the Oscar A. Mendiz, Charles D. O’Shaughnessy, 2:00 p m - Prognostic Impact of Hemorrhagic 2007 TASC Classifications Robert D. Safian, Peter A. Schneider, Complications and Myocardial Infarction in Patrick J. Peeters Thomas A. Sos, Thomas Zeller ACS and PCI: Establishing Priorities 3:30 p m - Ochsner Medical Center Sunil V. Rao 8:25 a m - Moderated Panel Discussion 5:00 p m - Riverside Methodist Hospital 8:30 a m - A Data-Driven Therapeutic 2:15 p m - Aspirin and Thienopyridine 6:30 p m - Adjourn Optimization in ACS and PCI: Dose Duration Algorithm for Choosing Among Currently and Point-of-Care Testing Available Tools for SFA Intervention Adnan Kastrati Giancarlo Biamino 8:55 a m - Moderated Panel Discussion Structural Heart Disease 2:30 p m - Glycoprotein IIb/IIIa Inhibitors: Evolving Role in Interventional Cardiology 9:00 a m - The Future of SFA Endovascular Theater David F. Kong Intervention: A 5-Year Forecast 8:00 a m -6:30 p m John R. Laird, Jr Lower Level 2:45 p m - Unfractionated and Low-Molecular- Weight Heparins: Recent Trials, and Current 9:25 a m - Moderated Panel Discussion Use Recommendations Adult Congenital Heart Disease II: Neal S. Kleiman Live Case Session III: SFA and Iliacs Shunts and Septal Defects 3:00 p m - Direct Anti-Thrombins: Use in Moderator: Giancarlo Biamino Moderator: Ziyad M. Hijazi Co-Moderator: Erich Minar Stable and Unstable Coronary Syndromes 8:00 a m - Anatomy, Evaluation, and Harvey D. White Live Case Discussants: Mark C. Bates, Procedural Guidance of Atrial and Ventricular Frank J. Criado, Bruce H. Gray, 3:15 p m - Factor Xa Inhibitors: From Oasis to Septal Intervention Using TEE and ICE Jean‑Claude Laborde, Nicholas Morrissey, Integration in an Interventional Environment Charles S. Kleinman Amir Motarjeme, Robert M. Schainfeld, Shamir R. Mehta 8:20 a m - A Comprehensive Tutorial for ASD Matthew R. Selmon, Michael H. Wholey Closure: Indications, Techniques, Clinical Live Case Session IV: Chronic Total 9:30 a m - Ochsner Medical Center Outcomes Occlusions 10:30 a m - Clinique Louis Pasteur John F. Rhodes Moderator: Maurice Buchbinder 12:00 p m - Break 8:40 a m - Muscular VSD Closure in the Co-Moderator: Takahiko Suzuki Adult: Clinical Spectrum and Catheter-Based Live Case Discussants: Louis A. Cannon, Renal and Mesenteric Intervention Closure Charles Chan, Chia-Yu Chou, Angela Hoye, Moderator: Christopher J. Cooper Zahid Amin Roger J. Laham, Kazuaki Mitsudo, Co-Moderator: Kenneth Rosenfield 8:50 a m - Post-Infarct VSD Closure: Masahiko Ochiai, Shigeru Saito, Panel Discussants: John R. Laird, Jr, Indications, Techniques, and Clinical Etsuo Tsuchikane Erich Minar, Robaayah Zambahari Outcomes 3:30 p m - Columbia University Medical Center Eustaquio Onorato 2:00 p m - A Critical Appraisal of Renal 4:30 p m - Saint Luke’s Mid America Intervention: Do the Data Support 9:00 a m - Patent Ductus Arteriosis: Heart Institute Widespread Use? Diagnosis, Treatment Indications, and Christopher J. Cooper Interventional Therapies 5:30 p m - Carolinas Medical Center Ziyad M. Hijazi p m 6:30 p m - Adjourn 2:25 - Moderated Panel Discussion 9:15 a m - Pulmonary Ateriovenous 2:30 p m - Is Embolic Protection in Renal Intervention Ready for Prime Time? Review Malformations and Coronary AV Fistulae: of the Data and Technical Challenges Diagnosis, Treatment Indications, and Andrew Holden Interventional Therapies Lee N. Benson 2:55 p m - Moderated Panel Discussion

72 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Tuesday \ october 23, 2007

Live and Taped Case Session III 4:30 p m - Columbia University Medical Center The Challenges of Clinical Research Moderator: Roxana Mehran Moderator: Ziyad M. Hijazi 5:30 p m - Taped Cases Co-Moderator: Richard Smalling 10:45 a m - FDA Perspectives 6:30 p m - Adjourn Live Case Discussants: Stephen J. D. Brecker, Bram Zuckerman in t ro Jeffrey C. Hellinger, David P. Lee, 10:52 a m - NHLBI Perspectives Chaim Lotan, Reginald I. Low, Michael Domanski Francesco Maisano, Michael Mooney, Health and Human Services Charles E. Mullins, Jason H. Rogers Town Hall Meeting 10:59 a m - US Physician Perspectives Roxana Mehran tURDAY agenda

9:30 a m - Rabin Medical Center 8:00 am-5:00 p m sa Room 207AB 11:06 a m - European Physician Perspectives 10:30 a m - Taped Case Directors: Michael Domanski, Aaron V. Kaplan, Keith D. Dawkins 11:00 a m - Swedish Heart and Mitchell W. Krucoff, Roxana Mehran, 11:13 a m - Industry Perspectives Vascular Institute Steve Phurrough, Gregg W. Stone, Scott Ward sun DAY 12:00 p m - Break Bram Zuckerman agenda 11:20 a m - Moderated Discussion and Q&A Panel Moderator: Roxana Mehran Valvular Heart Disease II: Mitral Perspectives and New Directions Discussants: Donald S. Baim, Stenosis and Regurgitation in 2007/2008 Ashley B. Boam, David A. Cox, Keith D. Dawkins, Michael Domanski, agenda Moderator: Allan Schwartz 8:00 a m - Introduction mon DAY Andrew Farb, Robert P. Fiorentino, 2:00 p m - Balloon Mitral Valvuloplasty for Gregg W. Stone Donald Hagler, Matthew G. Hillebrenner, Mitral Stenosis: Treatment Indications, 8:05 a m - FDA/CDRH David E. Kandzari, William D. Knopf, “Modern Era” Techniques and Clinical Daniel G. Schultz John L. Petersen, Steve E. Phurrough, Outcomes

8:25 a m - NIH/NHLBI Mary E. Russell, Gerrit-Anne van Es, agenda Igor F. Palacios t ues DAY Susan B. Shurin Scott Ward, Bram Zuckerman 2:15 p m - Echocardiographic Assessment of 8:45 a m - CMS 12:00 p m - Break Mitral Regurgitation: Etiologies and Severity Steve E. Phurrough Assessment as a Guide to Therapy Options Avoiding Adverse Device and Drug Maurice E. Sarano 9:05 a m - Moderated Discussion with Q&A Effects: Over Reaction or Not Stringent Enough? agenda

Panel Moderator: Gregg W. Stone wed NESDAY 2:30 p m - Clinical Management Decisions in Discussants: Steve E. Phurrough, Moderator: Aaron V. Kaplan Patients with Degenerative and Functional Daniel G. Schultz, Susan B. Shurin p m 1:00 - CDRH Perspectives Mitral Regurgitation: Pathophysiology, Donna-Bea Tillman Natural History, Medical Therapy, and case

Operative Timing Hot Topics 2007/2008 (General) 1:07 p m - CDER Perspectives reviews Allan Schwartz Barriers to New Device Development Douglas C. Throckmorton and Approval 2:45 p m - Understanding Mitral Valve 1:14 p m - Cardiac Safety Critical Path Moderator: Mitchell W. Krucoff Surgical Repair Options: Video Case Reviews Mitchell W. Krucoff 9:30 a m - CDRH Perspectives and Clinical Outcomes 1:21 p m - Statistical Limitations in Safety agenda

Daniel G. Schultz t hurs DAY A. Marc Gillinov Evaluation

3:00 p m - Transcatheter Therapies for Mitral 9:40 a m - CDER Perspectives Stuart J. Pocock Douglas C. Throckmorton Regurgitation I: The Evalve Edge-to-Edge 1:28 p m - Perspectives from a Journal Editor Program 9:50 a m - CMS Perspectives Phil B. Fontanarosa Ted Feldman Steve E. Phurrough t raining 1:35 p m - Moderated Discussion and Q&A physician 3:15 p m - Transcatheter Therapies for Mitral 10:00 a m - Industry Perspectives Panel Moderator: Aaron V. Kaplan Regurgitation II: Coronary Sinus and Direct Paul LaViolette Discussants: Gregory Campbell, Annuloplasty Devices 10:10 a m - Moderated Discussion and Q&A Phil B. Fontanarosa, David J. Gordon, John G. Webb Panel Moderator: Mitchell W. Krucoff Alice K. Jacobs, Mitchell W. Krucoff, t elli e even t s Discussants: Rick Anderson, Laura Mauri, Steve E. Phurrough, sa Live and Taped Cases Session IV J. Timothy Baldwin, Gregory Campbell, Stuart J. Pocock, John Somberg, Live Case Moderator: John G. Webb Michael R. Henson, Howard M. Holstein, Douglas C. Throckmorton, Donna-Bea Tillman, Co-Moderator: Ted Feldman Dean J. Kereiakes, Paul LaViolette, Scott Ward, Marvin L. Woodall Live Case Discussants: Joseph P. Carrozza, Jr, William H. Maisel, John F. Maroney,

A. Marc Gillinov, James A. Goldstein, Steve E. Phurrough, Daniel G. Schultz, ABS T RAC S Michael J. Mullen, Sherif F. Nagueh, Patrick W. Serruys, Douglas C. Throckmorton, Wesley R. Pedersen, Matthew J. Price, Clyde W. Yancy, Bram Zuckerman Charanjit S. Rihal, Jochen Wohrle

3:30 p m - Swedish Heart and general Vascular Institute

www.tct2007.com 73 transcatheTEr cardiovascular therapeutics

Tuesday \ october 23, 2007

Session III: Hot Topics 2007/2008 4:08 p m - Introductory Remarks II 9:19 a m - Controversial and Unsettled (Specific) William H. Maisel Guideline Issues in Patients with Stable Coronary Artery Disease: The European Regulatory Pathways for Percutaneous 4:16 p m - Introductory Remarks III Aortic Valves Krishna Sudhir Perspective Moderator: Martin B. Leon Jean Marco 4:24 p m - Moderated Discussion and Q&A 2:15 p m - FDA Perspectives Panel Moderator: Roxana Mehran 9:34 a m - Moderated Discussion and Q&A Matthew G. Hillebrenner Discussants: Ashley B. Boam, Donald Cutlip, Panel Moderators: Gregory J. Dehmer, Sidney Smith 2:20 p m - Industry Perspectives Michael Domanski, Hesha Jani Duggirala, Discussants: Eric R. Bates, Bernard J. Gersh, Jodi J. Akin Andrew Farb, Thomas Gross, Elizabeth J. Hillebrenner, Mitchell W. Krucoff, Michael J. Lim, Jean Marco, M. Reza Movahed, 2:25 p m - Moderated Discussion and Q&A William H. Maisel, Steve E. Phurrough, Matthias E. Pfisterer, Jason W. Ryan, Panel Moderator: Martin B. Leon Campbell Rogers, John Somberg, Barry F. Uretsky, Bonnie H. Weiner Discussants: Steven F. Bolling, Ted Feldman, Krishna Sudhir, Lilly Q. Yue, Bram Zuckerman Matthew G. Hillebrenner, Mehmet C. Oz, Drug-Eluting vs. Bare Metal Stent Issues Steve E. Phurrough, Stanton Rowe, 5:00 p m - Adjourn and Adjunct Pharmacology John S. Sapirstein, Julie A. Swain, Moderators: Alice K. Jacobs, Jodi J. Akin, John G. Webb Spencer B. King III Morning Concurrent Regulatory Pathways for Percutaneous 9:54 a m - On- and Off-Label Drug-Eluting Mitral Valve Repair Sessions Stent Use: Guideline Review and Critical Moderator: Stephen G. Ellis Guidelines and Evidence-Based Appraisal 2:45 p m - FDA Perspectives John McB. Hodgson Julie A. Swain Medicine Review II: Percutaneous Coronary Intervention and 10:09 a m - SCAAR Update and the National 2:50 p m - Industry Perspectives Response to “Home-Grown” Registry Data Ferolyn T. Powell Drug-Eluting Stents Stefan James 8:00 a m -11:50 a m p m 2:55 - Moderated Discussion and Q&A 10:21 a m - Perspectives on the Relative Room 151AB Panel Moderator: Stephen G. Ellis Impact of a Severe Low Frequency Event Discussants: Fernando Aguel, Donald S. Baim, Revascularization in Patients with (Stent Thrombosis) vs. a Less Severe, More James I. Fann, Matthew G. Hillebrenner, Stable Coronary Artery Disease Frequent Event (Restenosis): Cost, Quality of Didier F. Loulmet, Mehmet C. Oz, Moderators: Gregory J. Dehmer, Sidney Smith Life, and Survival Steve E. Phurrough, Ferolyn T. Powell, 8:00 a m - Indications for Revascularization John W. Hirshfeld, Jr Stanton Rowe, John S. Sapirstein, in Patients with Stable Angina and Silent 10:33 a m - TCT-106: Outcomes and Lars G. Svensson, Frederick G. St. Goar, Ischemia Complications with Off- vs. On-Label Use of Julie A. Swain Bernard J. Gersh Drug-Eluting Stents: Results from the Endovascular Pathways for Device 8:15 a m - What New Insights Does STENT Registry Approvals, Investigation, and COURAGE Bring to the Approach to Stable Bruce R. Brodie et al Reimbursement Ischemic Heart Disease? 10:43 a m - Adjunct Pharmacology Issues I: Moderator: Michael R. Jaff Eric R. Bates Role of Aspirin and Clopidogrel Compliance 3:15 p m - FDA Perspectives 8:25 a m - Should Clinical Practice Change in Stent Selection David S. Buckles After COURAGE? Sidney Smith p m 3:20 - Industry Perspectives Bonnie H. Weiner 10:55 a m - Adjunct Pharmacology Issues II: Mary Bellack 8:35 a m - Perspectives on PCI in Silent Chronic Management of the Stent Patient 3:25 p m - CMS Perspectives Ischemia: COURAGE, ACIP, and SWISS II Requiring Warfarin Steve E. Phurrough Matthias E. Pfisterer Neal S. Kleiman

3:30 p m - Moderated Discussion and Q&A 8:47 a m - Evaluation and Revascularization 11:07 a m - TCT-105: Comparison of Panel Moderator: Michael R. Jaff of Patients before Non-Cardiac Surgery: Outcomes Between Patients Undergoing Discussants: Mary Bellack, David S. Buckles, Guideline Review and Critical Appraisal Percutaneous Coronary Stent Implantation Kenneth J. Cavanaugh, Jr, Robert P. Fiorentino, Barry F. Uretsky with Eptifibatide and Abciximab: An Analysis William A. Gray, David E. Kandzari, Using Propensity Score Methods 8:59 a m - TCT-103: Nationwide Trends in the Jean-Pierre Dery et al Klaus D. Mathias, Thomas L. Meskan, Utilization of Coronary Artery Bypass Surgery Steve E. Phurrough, Krishna Rocha-Singh (CABG) in the United States 11:17 a m - Controversial and Unsettled M. Reza Movahed et al Guideline Issues in Stent Selection: The Revolutionary Directions in the DES European Perspective Approval Process and Post-Market 9:09 a m - TCT-104: Temporal Trends in Sigmund Silber Surveillance: New Directions Since the Coronary Revascularization Procedures, December 2006 Special Panel Meeting Outcomes, and Costs: Results From the US Moderator: Roxana Mehran Medicare Program 4:00 p m - Introductory Remarks I Jason W. Ryan et al Ashley B. Boam

74 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Tuesday \ october 23, 2007

11:32 a m - Moderated Discussion and Q&A Ischemic Heart Disease 11:35 a m - TCT-110: Noninvasive Imaging of Panel Moderators: Alice K. Jacobs, Moderators: Nicolas A. F. Chronos, the Human Coronary Sinus and Its Spencer B. King III Robert A. Kloner Relationship to Mitral Annulus and Coronary

Discussants: Bruce R. Brodie, Jean-Pierre Dery, Arteries in Normal and Mitral Regurgitation in t ro 9:40 a m - Novel Observations from the John W. Hirshfeld, Jr, John McB. Hodgson, Development and Rupture of Vulnerable Patients Stefan James, Laura Mauri, Sigmund Silber, Plaque: Implications for Detection and Olivier Dubreuil et al Sidney Smith, David O. Williams Intervention 11:45 a m - Moderated Discussion and Q&A 11:50 a m - Adjourn Greg L. Kaluza Panel Moderators: Daniel Burkhoff, tURDAY agenda

Michael C. Fishbein sa 9:50 a m - Plaque Rupture vs. Erosion: Interventional Pathobiology: Histoanatomy, Frequency, and Risk Factors Discussants: Steven L. Almany, Olivier Dubreuil, Insights and Clinical Implications Erling Falk Elena Ladich, Robert S. Schwartz 12:00 p m - Adjourn 8:00 a m -12:00 p m 10:00 a m - Experimental Study of sun DAY Room 147AB Reperfusion Injury in Acute Myocardial agenda Animal Models and Drug-Eluting Stents Infarction: Past Lessons Learned and Future Plaque Modification and Debulking Moderators: Elazer R. Edelman, Renu Virmani Prospects in the Coronary and Peripheral Robert A. Kloner Circulations: Atherectomy, 8:00 a m - The Spectrum of Animal Models to 10:10 a m - Insights From Animal Atherotomy, and Laser agenda Study Atherosclerosis and Pathologic mon DAY Investigation of Angiogenesis and Cell Dedicated to the Memory of Responces to Intravascular Implants: Therapy: Are We Growing New Blood Vessels Gregory A. Braden, MD Rabbits and Pigs and Mice, Oh My! and Myocytes? 8:00 a m -11:45 a m Juan F. Granada Stefanie Dimmeler Room 145AB 8:10 a m - Animal Model Metrics to Predict 10:20 a m - TCT-109: Influence of Metabolic agenda

Plaque Modification andM odulation t ues DAY Stent Safety and Efficacy: How Accurate Syndrome on Coronary Atherosclerosis: During Coronary and Peripheral Are They? Angiographic Evaluation of 500 Patients Intervention Keith A. Robinson with Stable and Unstable Angina Moderators: Gary Gershony, Dierk Scheinert 8:20 a m - In Vitro Assessment of Stefano Galli et al 8:00 a m - Coronary Plaque Modification and Endothelialization: From Structure 10:30 a m - Moderated Discussion and Q&A agenda

Modulation: What Are the Indications? wed NESDAY to Function Panel Moderators: Stefanie Dimmeler, Steven R. Bailey Renu Virmani Robert A. Kloner

8:10 a m - When (and Why) to Use Cutting 8:30 a m - Vascular Responces to Drug- Discussants: Erling Falk, Stefano Galli, Greg L. Kaluza and Scoring Balloons: Intuition or Evidence-

Eluting Stents I: Novel Clues to Stent case

Based Medicine? reviews Thrombosis Jorge F. Saucedo Aloke Finn Structural Heart Disease Moderators: Daniel Burkhoff, 8:20 a m - Plaque Modulation During 8:40 a m - Vascular Responses to Drug- Michael C. Fishbein Peripheral Artery Intervention: Rationale, Eluting Stents II: Which of the New Devices Devices, and Results Look Safer? 10:45 a m - Aortic and Mitral Valve Disease: agenda

Dierk Scheinert t hurs DAY Renu Virmani Relevance of Pathology to Percutaneous Valve Replacement and Repair 8:30 a m - TCT-111: The Effect of Debulking 8:50 a m - Designing a Safer Drug-Eluting Elena Ladich Pre-Drug-Eluting Stent for Bifurcated Stent: Novel Insights from the Animal Coronary Lesions in Unprotected Left Main: Laboratory 10:55 a m - Structure of the Atrial and Ventricular Septum: Implications for Subanalyses of the PERFECT Registry Elazer R. Edelman t raining physician Percutaneous Closure of Septal Defects in Yuji Oikawa et al 9:00 a m - TCT-107: Defective Insulin Congenital Heart Disease and Post-MI 8:40 a m - Moderated Discussion and Q&A Signaling Induces a Relative Resistance to Robert S. Schwartz Panel Moderators: Gary Gershony, Rapamycin via Loss of mTOR Regulation of Kip1 a m Dierk Scheinert p27 Protein Levels 11:05 - Morphology and Geometry of the t elli e Discussants: Steven R. Bailey, Yuji Oikawa, even t s T. Cooper Woods et al Left Atrial Appendage and Its Role in sa Thromboembolic Disease: Implications for Jorge F. Saucedo 9:10 a m - TCT-108: Increased Tissue Factor Exclusion and Stroke Prevention Expression After DES Implants in Porcine Steven L. Almany Directional Atherectomy (Silverhawk) Coronary Arteries May Contribute to Late Moderators: David E. Allie, Rajesh M. Dave Stent Thrombosis 11:15 a m - The Pathology of Heart Failure

8:55 a m - Silverhawk Atherectomy in ABS T RAC S Go Haraguchi et al and Insights from Experimental Models to Device Efficacy (VADs, Resynchronization, Peripheral Occlusive Disease: Technique 9:20 a m - Moderated Discussion and Q&A and Contractility Approaches, etc) Evolution and Long-Term Results Panel Moderators: Elazer R. Edelman, Daniel Burkhoff Lawrence A. Garcia Renu Virmani 9:10 a m - Coronary Experiences with Discussants: Aloke Finn, Juan F. Granada, 11:25 a m - Atrial Arrhythmia Ablation: general Silverhawk Atherectomy: Time to Go Haraguchi, Keith A. Robinson, Expected and Surprising Tissue Reactions Reconsider? T. Cooper Woods Michael C. Fishbein Gregory C. Robertson

www.tct2007.com 75 transcatheTEr cardiovascular therapeutics

Tuesday \ october 23, 2007

9:20 a m - First-in-Man Outcomes with the 11:30 a m - Moderated Discussion and Q&A Panel Moderator: Richard L. Popp OCT-Navigated Nighthawk Atherocath Panel Moderators: Roger Gammon, On Topaz Case Presenter: Louis A. Cannon Pawel E. Buszman Discussants: Rajesh M. Dave, Discussants: Steven R. Bailey, Jacques J. Koolen Donald S. Baim, Tim A. Fischell, 9:30 a m - TCT-112: First-in-Man Experience Peter J. Fitzgerald, Chaim Lotan, with Foxhollow™ Coronary Plaque Excision 11:45 a m - Adjourn Device for Treatment of Complex Coronary Alan C. Yeung Bifurcation Lesions 1:10 p m - Moderated Discussion and Q&A R. Stefan Kiesz et al Lunchtime Activities Panel Moderator: Richard L. Popp Discussants: Steven R. Bailey, 9:40 a m - Moderated Discussion and Q&A 12:15 p m - 1:45 p m Panel Moderators: David E. Allie, Donald S. Baim, Louis A. Cannon, Rajesh M. Dave Tim A. Fischell, Peter J. Fitzgerald, Discussants: Pawel E. Buszman, Hot Topics, Hot Lunches Chaim Lotan, Alan C. Yeung Lawrence A. Garcia, R. Stefan Kiesz, Gregory C. Robertson Conflict of Interest in New Directions in Lipid Coronary and Peripheral Atherectomy Cardiovascular Interventional Management in Patients with Moderators: Eulogio Garcia, Thomas Zeller Investigation and Practice Atherosclerosis, ACS, and PCI 9:55 a m - Selective or Frequent Use of High Room 201 Room 202A Speed Rotational Atherectomy during Chair: Richard L. Popp Chairs: LeRoy E. Rabbani, H. Robert Superko Percutaneous Coronary Intervention? 12:15 p m - Introduction, Session Goals, and 12:15 p m - Pleiotropic Effects of Statins in DESPERADO Results Background Patients with Atherosclerosis D. Christopher Metzger Richard L. Popp Michael Haude 10:05 a m - Tips and Tricks for High Speed 12:20 p m - Where is the Conflict? Physicians 12:20 p m - Statin Therapy in ACS and AMI: Rotational Atherectomy Use Prior to DES as Enrollers of Their Own Patients in Timing and Intensity Implantation Investigational Studies LeRoy E. Rabbani Eulogio Garcia Chaim Lotan 12:25 p m - How Low Should LDL be Driven? 10:15 a m - Orbital Atherectomy: Results of 12:25 p m - Where is the Conflict? The James H. Chesebro the US Registry in Peripheral Arterial Company Paid/Equity Holding Advisor as 12:30 p m - Safety of Long-Term Statins: Disease and Initial Coronary Experiences Cath Lab Purchasing Agent From Myositis to ALS: A Critical Appraisal Jeff Chambers Alan C. Yeung Sidney Smith 10:25 a m - The Pathway Medical Device: 12:30 p m - Where is the Conflict? The 12:35 p m - Can the Statin/Clopidogrel 6-Month Results from the European Gen-1 Company Paid/Equity Holding Advisor as an Interaction Issue Finally Be Put to Rest? Registry and Preliminary Results with the Investigator in a Study of the Company’s Stephen R. Steinhubl Gen-2 Device Product Thomas Zeller Louis A. Canon 12:40 p m - HDL-Based Therapeutics for Atherosclerosis 10:35 a m - TCT-113: Orbital Atherectomy for 12:35 p m - Where is the Conflict? The H. Robert Superko Percutaneous Treatment of Below-the-Knee Independent Clinical Investigator in an Vascular Stenosis: Results of the OASIS Industry Sponsored Study of Its Product 12:45 p m - Re-Examination of the Role of Multicenter Study Steven R. Bailey Statins in the PCI Patient Khusrow Niazi et al Germano Di Sciascio 12:40 p m - Where is the Conflict? The 10:45 a m - Moderated Discussion and Q&A Company Paid/Equity Holding Advisor as a 12:50 p m - Lessons Learned from the Panel Moderators: Eulogio Garcia, Thomas Zeller Speaker at International Meetings Torcetrapib Trials Discussants: Jeff Chambers, Peter J. Fitzgerald E. Murat Tuzcu D. Christopher Metzger, Khusrow Niazi 12:55 p m - Is Hypertriglyceridemia the New 12:45 p m - Where is the Conflict? Device Excimer Laser Photoablation Inventors as Investigator of Their Device Risk Factor? (and How to Treat It) Moderators: Roger Gammon, On Topaz Tim A. Fischell Mark Goldberger 1:00 p m - Special Considerations for Lipid 11:00 a m - When to Consider Lasers in the 12:50 p m - Where is the Conflict? Company Coronary Circulation Employees as Speakers about Their Management in the Diabetic Patient Jacques J. Koolen Company’s Product Mark Goldberger 11:10 a m - Excimer Laser in Coronary Donald S. Baim

Chronic Total Occlusions 12:55 p m - Case Presentation: A New Device On Topaz Recently Used in a First-in-Man Study 11:20 a m - Results of the CELLO Trial (Turbo Reported at an International Medical Booster in SFA Lesions) Meeting Rajesh M. Dave

76 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Tuesday \ october 23, 2007

1:05 p m - Case Presentation: Diagnosing and 1:00 p m - When to Consider Lumen Re-Entry 1:40 p m - Moderated Discussion and Q&A Treating Refractory Hyperlipidemia in a for SFA Occlusions Panel Moderators: Joseph D. Babb, Patient with Premature Atherosclerosis James D. Joye Gloria Weisz

Panel Moderators: LeRoy E. Rabbani, H. Discussants: David P. Faxon, Michael R. Jaff, in t ro 1:05 p m - Distal Protection in SFA Robert Superko Interventions: When, Where, and in Whom Jeffery J. Popma, Kenneth Rosenfield Case Presenter: Peter J. Casterella Mahmood K. Razavi Discussants: James H. Chesebro, 1:10 p m - Case Presentation: Occlusive SFA Germano Di Sciascio, Mark Goldberger, Case Reviews With the Disease with Infra-Popliteal Involvement tURDAY

Michael Haude, Stephen R. Steinhubl, agenda Panel Moderator: James D. Joye sa E. Murat Tuzcu Experts Case Presenter: Bruce H. Gray 1:15 p m - Moderated Discussion and Q&A Discussants: Roger Gammon, Hans Acute Infarct Angioplasty and the Panel Moderators: LeRoy E. Rabbani, Krankenberg, John R. Laird, Jr, Thrombus-Containing Lesion I H. Robert Superko Lindsay S. Machan, D. Christopher Metzger, Room 150A sun DAY agenda Discussants: Peter J. Casterella, Richard F. Neville, Elizabeth V. Ratchford, David A. Cox, Simon R. Dixon, Mark A. Turco, James H. Chesebro, Germano Di Sciascio, Mahmood K. Razavi, Dierk Scheinert, Bernhard Witzenbichler Mark Goldberger, Michael Haude, Thomas M. Shimshak Sidney Smith, Stephen R. Steinhubl, Angioplasty Potpourri: Anatomic and 1:20 p m - Moderated Discussion and Q&A E. Murat Tuzcu Clinical Oddities agenda Panel Moderator: James D. Joye mon DAY Room 144B Discussants: Roger Gammon, Bruce H. Gray, Fernando Alfonso, H. Vernon Anderson, SFA and Infra-popliteal Disease: Hans Krankenberg, Lindsay S. Machan, Jeffrey A. Brinker, Chien-Jen Chen What is the Standard of Care? D. Christopher Metzger, Richard F. Neville, Room 202B Elizabeth V. Ratchford, Mahmood K. Razavi, Bifurcation Disease: Technique agenda Moderator: James D. Joye Dierk Scheinert, Thomas M. Shimshak t ues DAY Selection and the Step-by-Step

12:15 p m - Essentials of Medical Approach II Management: How Far Can Drugs Take You? Fellows Lunch: Medical Room 152A Elizabeth V. Ratchford Education and Testing Jiyan Chen, Frederic S. Resnic, Huay Cheem Tan, Damras Tresukosol 12:20 p m - Variables Favoring Surgery for agenda

in the US wed NESDAY Peripheral Vascular Disease Room 209ABC Complex Carotid and Brachiocephalic Richard F. Neville Moderators: Joseph D. Babb, Giora Weisz Interventions II 12:25 p m - Variables Favoring Percutaneous Room 149AB

12:15 p m - Interventional Cardiology Training case Intervention for Peripheral Vascular Disease Alberto Cremonesi, Robert D. Safian, Programs: Structure, Function and reviews Thomas M. Shimshak Luigi Salemme, Jiri J. Vitek Evaluation 12:30 p m - Is Stenting Now the Gold Joseph D. Babb Standard for Short and Long Lesions in Evolving Strategies for Iliofemoral the SFA? 12:25 p m - Q&A Disease

Hans Krankenberg 12:30 p m - Certification and Recertification Room 143C agenda Rajesh M. Dave, Anthony J. Galeo, t hurs DAY 12:35 p m - Stent Fracture after Bare Metal Issues in Interventional Cardiology Rosli Mohd Ali, Michael H. Wholey and Drug-Eluting Peripheral Stents: David P. Faxon Magnitude of the Problem and 12:40 p m - Q&A My Worst Complications: Endovascular Consequences 12:45 p m - Vascular Medicine and

Intervention II t raining Dierk Scheinert physician Endovascular Therapy Training Room 143B 12:40 p m - Status of Drug-Eluting Stents for Kenneth Rosenfield Robert M. Bersin, Mark W. Burket, the Periphery 12:55 p m - Q&A Thomas A. Ischinger, Jean-Claude Laborde Lindsay S. Machan

1:00 p m - The Vascular Boards t elli e p m My Worst Complications: Coronary even t s 12:45 - The Role of Novel Peripheral Michael R. Jaff sa Arterial Interventions: Laser, Cryoplasty, Intervention II Cutting Balloon, Angiosculpt, and Angioslide 1:10 p m - Q&A Room 150B John R. Laird, Jr 1:15 p m - Integrating Endovascular Training Antonio L. Bartorelli, Joseph P. Carozza, Jr, Within the Interventional Cardiology Program Tarlochan Singh Kler, Michael Mooney 12:50 p m - The Case for Routine Curriculum Atherectomy in SFA Disease ABS T RAC S Structural Heart Disease II: My Worst Roger Gammon Jeffrey J. Popma Complications: ASD, PFO, and VSD 1:25 p m - Q&A 12:55 p m - The Case against Routine Misadventures Atherectomy in SFA Disease 1:30 p m - The Role of High Fidelity Room 144A Simulation in Training and Certification D. Christopher Metzger Peter S. Fail, Ignacio Inglessis-Azuaje, general Giora Weisz Jon R. Resar, Jochen Wohrle

www.tct2007.com 77 transcatheTEr cardiovascular therapeutics

Tuesday \ october 23, 2007

Renal Artery Stenting With and Without 2:30 p m - TCT-96: Cytotoxic T Lymphocyte 5:05 p m - Gene Therapy for Endstage Protection Antigen 4 Gene Polymorphism Associated Ischemic Heart Disease: Current Status and Room 143A with ST-Segment Elevation Acute Myocardial Future Directions Bernard De Bruyne, Michel Henry, Infarction Duncan J. Stewart Hon-Kan Yip et al Robaayah Zambahari, Thomas Zeller 5:20 p m - Gene Therapy for Peripheral 2:40 p m - From Genes and Biomarkers to Vascular Disease: Current Status and Future Clinical Perspectives and Metabolomics: Directions Board Review Course with Emerging Tools for Future Clinicians Brian H. Annex Frank J. Giordano Self Assessment for 5:35 p m - TCT-97: Gene Transfer of Sarco/ 2:55 p m - Moderated Discussion and Q&A Endoplasmic Reticulum Calcium ATPase Interventional Cardiology Panel Moderators: W. Craig Hooper, Inhibits Neointima Formation in Human and Endovascular Medicine, Michael Simons Mammary Arteries While Augmenting Discussants: James H. Chesebro, Endothelial Cell Proliferation PART 3: Coronary essentials Frank J. Giordano, Hon-Kan Yip Roger Hajjar et al 2:00 p m -6:15 p m Room 146ABC Emerging Themes 5:45 p m - Moderated Discussion and Q&A Moderators: James H. Chesebro, Panel Moderators: Hina W. Chaudhry, H. Robert Superko Frank J. Giordano Special Interventional Imaging Discussants: Brian H. Annex, Session 3:10 p m - Genetic Variation, Sex, Age, and Ethnicity: Implications for Cardiovascular Helmy H. El-Ghawaby, Kathryn Momary, Moderators: Gary S. Mintz, Nico H. J. Pijls Disease Duncan J. Stewart, H. Robert Superko 2:00 p m - IVUS and Physiologic Lesion W. Craig Hooper 6:00 p m - Adjourn Assessment in Clinical Practice 3:25 p m - The Role of Genomics in Healthy William F. Fearon Disparities: Implications for Race-Based Top Interventional Trials of the 2:45 p m - Q&A Medicine, and What is Normal? Last Year: Digging Beneath the 3:00 p m - Physiologic Lesion Assessment George A. Mensah Surface Case Presentations with Integrated Q&A 3:40 p m - Genetic Network Analysis of 2:00 p m -6:00 p m Nico H. J. Pijls Restenosis Room 151AB 3:30 p m - Intravascular Ultrasound Case Euan Ashley Trials Investigating the Appropriateness Examples with Integrated Q&A 3:55 p m - TCT-98: Diagnostic and Prognostic of PCI Gary S. Mintz Values of Platelet Glycoprotein IIb/IIIa Gene Moderators: Roxana Mehran, 4:30 p m - Angiographic Imaging Q&A Polymorphism in the Pathogenesis of David O. Williams Morton J. Kern In-Stent Restenosis 2:00 p m - The COURAGE Trial Helmy H. El-Ghawaby et al 5:10 p m - PCI Imaging Q&A Eric R. Bates Michael J. Lim 4:05 p m - Moderated Discussion and Q&A 2:10 p m - The OAT Trial Panel Moderators: James H. Chesebro, 6:15 p m - Adjourn Eric R. Bates H. Robert Superko Discussants: Euan Ashley, Roger Hajjar, 2:20 p m - TCT-134: Treatment of Patients W. Craig Hooper, George A. Mensah with Single Lesion in the Proximal Segment Afternoon Concurrent of Left Anterior Descending Artery Suffering Sessions Emerging Clinical Applications from Chronic Stable Angina: Drug-Eluting Moderators: Hina W. Chaudhry, Stents vs. Surgical Treatment with Left Frank J. Giordano Internal Mammary Artery Grafting Cardiovascular and Interventional Eleftherios Tsiamis et al Genetics, Genomics and Proteomics 4:20 p m - Multi-Biomarker Panels: 2:30 p m - Critical Appraisal: How Should 2:00 p m -6:00 p m Implications for Cardiovascular Disease These Trials Change Practice? Room 145AB Management Using an Integrative Family History, Genomic, and Proteomic Approach Jeffrey J. Popma Core Concepts H. Robert Superko 2:42 p m - Moderated Discussion and Q&A Moderators: W. Craig Hooper, Michael Simons 4:35 p m - Featured Lecture: Genetic Panel Moderators: Roxana Mehran, David O. Williams 2:00 p m - Basic Genetic Science for the Approaches to the Prevention of Ischemic Discussants: Eric R Bates, Larry S. Dean, Cardiologist: From Genomics to Proteomics Heart Disease and the Treatment of Michael J. Lim, Jeffrey J. Popma, Helmut James H. Chesebro Myocardial Infarction Hina W. Chaudhry Schuhlen, Eleftherios Tsiamis 2:15 p m - Featured Lecture: Role of Genetics 4:50 p m - Immunomodulation, HDL, and and Proteomics in Determining the Studies Investigating the Appropriate Vaccines for Atherosclerosis Development and Natural History of Use of Drug-Eluting Stents Kathryn Momary Atherosclerosis Moderators: Howard C. Herrmann, Michael Simons David O. Williams

78 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Tuesday \ october 23, 2007

2:57 p m - On-Label DES Use: Meta-Analyses 5:02 p m - TCT-137: Safety and Efficacy of 2:45 p m - TCT-85: Severe Calcification and of the Prospective, Double-Blind Trials (And Switching from Either Unfractionated Length of Stented Segments Are the ARC Definitions) Heparin or Enoxaparin Plus a Glycoprotein Independent Risk Factors for Stent Fractures

Roxana Mehran IIb/IIIa Inhibitor to Bivalirudin Monotherapy Jacqueline Sax et al in t ro in Patients with Non-ST Elevation Acute 3:07 p m - TCT-135: Comparison of Vascular Endovascular Intervention Response to Zotarolimus-Eluting Stent Coronary Syndromes Managed with an Moderators: Amir Motarjeme, Versus Paclitaxel-Eluting Stent Implantation: Invasive Strategy: Results from the Michael H. Wholey IVUS Results from the Zomaxx I Trial Randomized ACUITY Trial Discussants: R. Stefan Kiesz, tURDAY

Harvey D. White et al agenda

Katsuhisa Waseda et al Mahmood K. Razavi, Luigi Salemme, sa 5:12 p m - FINESSE 3:17 p m - The SCAAR Registry (Updated James P. Zidar Stephen G. Ellis Follow-Up) 3:00 p m - TCT-88: Treating Below-the-Knee Stefan James 5:22 p m - CARESS Critical Limb Ischemia with Drug-Eluting Dariusz Dudek Stents: Early and Late Clinical Outcomes sun DAY 3:27 p m - The Western Denmark Registry agenda (Extended Follow-Up to 24 Months) 5:32 p m - Critical Appraisal: How Should Andrew Feiring Leif Thuesen These Trials Change Practice? 3:15 p m - TCT-89: Long-Term Durability of Steven R. Steinhubl 3:37 p m - The Munich Meta-Analysis of Endoluminal Stenting for Obstructive DES vs. BMS and PES vs. SES 5:44 p m - Moderated Discussion and Q&A Lesions of the Subclavian Artery: Multicenter agenda Adnan Kastrati Panel Moderators: Dean J. Kereiakes, Registry mon DAY Steven R. Steinhubl Sunao Nakamura et al 3:47 p m - A 38-Trial Network Meta-Analysis Peter Juni Discussants: Dariusz Dudek, Stephen G. Ellis, 3:30 p m - TCT-90: The Long-Term Prognosis Frederick Feit, Expedito E. Ribiero, of Patients with Small Abdominal Aortic 3:57 p m - SORT-OUT II (with Follow-Up Allan M. Ross, Ulf Stenestrand, Harvey D. White Aneurysms Following Surgery or Surveillance: agenda

Extended to 18 Months) t ues DAY 12-Year Final Follow-Up of Patients Enrolled Anders M. Galloe 6:00 p m - Adjourn in the UK Small Aneurysm Trial 4:07 p m - TCT-136: Efficacy and Safety at Roger M. Greenhalgh et al Three and Five Years in the Canadian Best of Endovascular 3:45 p m - TCT-91: Increased Incidence of Multicenter, Randomized, Double-Blind Trial Interventional Abstracts

Device-Related Complications with the Use agenda of the Sirolimus-Eluting Stent in the 2:00 p m -5:00 p m of SilverHawk Atherectomy for the Treatment wed NESDAY Treatment of Patients with De Novo Coronary Room 147AB of Infrainguinal Peripheral Arterial Disease Artery Lesions (C-SIRIUS) Luis A. Guzman et al Donald A. Palisaitis et al SFA Intervention

Moderators: Mark C. Bates, case 4:17 p m - Critical Appraisal: How Should Carotid Intervention Hans Krankenberg reviews These Studies Affect Decisions to Select Moderators: Alberto Cremonesi, Peter S. Fail Discussants: Adrian A. Ebner, Drug-Eluting vs. Bare Metal Stents and Discussants: Franz Wolfgang Amann, Nicholas Morrissey, Robert M. Schainfeld, SES vs. PES? Nicola Corvaja, Zvonimir Krajcer, Fayaz Shawl Matthew R. Selmon Sigmund Silber 4:00 p m - TCT-92: Three-Year Follow-Up 2:00 p m - TCT-84: Long-Term Results of p m agenda 4:32 - Moderated Discussion and Q&A After Carotid Artery Stenting in High t hurs DAY Stenting TASC C Lesions in the SIROCCO II Panel Moderators: Howard C. Herrmann, Surgical Risk Patients: The BEACH and Study: Multicenter, Prospective, Double- David O. Williams CABERNET Trials Blinded, Randomized, Two-Arm Feasibility Discussants: Anders M. Galloe, Stefan James, L. Nelson Hopkins et al Clinical Investigation of the Cordis Sirolimus Peter Juni, Adnan Kastrati, Donald A. Palisaitis, Coated SMART™ Nitinol Self-Expandable 4:15 p m - TCT-93: Report of the US t raining

Sigmund Silber, Leif Thuesen, Alec Vahanian, physician Stent for the Treatment of Obstructive Experience in Post-Marketing Trials in Ron Waksman, Katsuhisa Waseda Superficial Femoral Artery Disease Carotid Stenting in Asymptomatic High Dierk Scheinert et al Surgical -Risk Patients: Achievement and Trials Investigating Adjunct Characterization of Targeted Outcomes 2:15 p m - TCT-87: Interim Report on the

Pharmacology in Acute Coronary t elli e

William A. Gray et al even t s

Syndromes and Myocardial Infarction Zilver(R) PTX™ Clinical Trial sa Moderators: Dean J. Kereiakes, Mark W. Burket et al 4:30 p m - TCT-94: Closed- or Open-Cell Stents in Carotid Artery Stenting? Short-Term Steven R. Steinhubl 2:30 p m - TCT-86: Diagnostic Accuracy of Outcome of Patients Undergoing Carotid Renal Pressure Measurements to Assess the 4:52 p m - ACUITY 1-Year and the Impact of Stenting According to Stent Type Significance ofR enal Artery Stenosis: Adverse Events Dimitrios N. Nikas et al Frederick Feit Comparison with Intravascular Ultrasound, ABS T RAC S Quantitative Angiography, and Duplex 4:45 p m - TCT-95: Hyperperfusion Syndrome Ultrasound Following Carotid Artery Stenting: The Massoud A. Leesar et al Largest Single-Operator Series to Date Hutton P. Brantley et at general 5:00 p m - Adjourn

www.tct2007.com 79 transcatheTEr cardiovascular therapeutics

Tuesday \ october 23, 2007

Special Evening Session

Breakthroughs in Cardiac Surgery: What the Interventionalist Needs to Know 6:00 p m -8:00 p m Room 149AB In Memoriam Moderators: Steven F. Bolling, Mehmet C. Oz, Craig R. Smith

6:00 p m - When is Minimally Invasive Robotic Surgery Better than Stents for the LAD? When Should Hybrid Procedures Be Considered? Sudhir Srivastava

6:15 p m - Q&A

6:20 p m - Surgical vs. Endograft Management of Thoracic Aortic Aneurysms Leonard N. Girardi

6:35 p m - Q&A

6:40 p m - Repairing the Aortic Valve: Science Fiction or Reality? Allan S. Stewart

6:55 p m - Q&A

7:00 p m - Transcatheter Aortic Valve Replacement: Advantages and Limitations of Gregory A. Braden, MD Transapical vs. Femoral Access Gregory A. Braden, MD, a pioneer in the treatment Mathew Williams of patients with complex coronary artery disease and 7:15 p m - Q&A emerging interventional devices, died on 7:20 p m - Percutaneous Mitral Valve Repair August 13, 2007, at the age of 50. is the Future for Many Patients Mehmet C. Oz Dr. Braden was a yearly faculty member at the annual 7:35 p m - Q&A TCT Symposium in addition to numerous other courses sponsored 7:40 p m – Why Minimally Invasive Mitral by the Cardiovascular Research Foundation. Valve Repair Will Remain the Gold Standard He was a superb clinician as well as a dedicated Michael Argenziano academic interventional cardiologist. 7:55 p m – Q&A We will greatly miss Greg’s talents and insights, 8:00 p m - Adjourn inspiration, camaraderie, and heartwarming humor.

Evening Symposia the Cardiovascular Research Foundation 8:00 p m -10:00 p m Refer to pages 101-104 for complete program schedule.

80 truth in evidence based medicine · challenge conventional wisdom · transform your thinking What Can the INVESTIGATE

Cardiovascular Research EVALUATE

Foundation Do for You? EDUCATE

Cardiovascular Research Foundation

The Cardiovascular Research ideas into improvements in Foundation (CRF) is dedicated patient care. From academic to improving the quality of life researchers and individual of patients with cardiovascular investigators to medical disease by advancing the device and pharmaceutical development and use of safe, companies, to medical societies effective, and minimally invasive and independent health cardiovascular treatments. We professionals, CRF has the work with partners in diverse experience and expertise to focus fields and at various stages and advance your vision. to translate knowledge and

Preclinical Research: Investigating scientific models to enhance the development of cardiovascular disease therapies.

Clinical Trials Management: Evaluating new therapies in a full spectrum of clinical research trials.

Education and Physician Training: Educating medical professionals and the public to enhance patient outcomes.

Stop by the Cardiovascular Research Foundation Booths on the L Street Bridge

www.crf.org

For more information about our services, call 212-851-9300 or e-mail [email protected] transcatheter cardiovascular therapeutics

wednesday \ october 24, 2007

Breakfast Meetings Plenary Session 18: Late Breaking 12:15 p m - BIFURCATIONS Bad Krozingen: A Prospective, Randomized Trial of Provisional 7:00 a m -8:00 a m Clinical Trials III Moderator: Gregg W. Stone and T-Stent Techniques in Patients with Refer to pages 104-105 for complete Bifurcation Disease: 9-Month Angiographic program schedule. “Blockbuster” Trial of the Day: HORIZONS AMI and 12-Month Clinical Results Miroslaw Ferenc 10:30 a m - Balancing Pharmacologic and Physician Training Center Interventional Strategies in Patients with 12:27 p m - Critical Appraisal of the Acute Coronary Syndromes and Myocardial BIFURCATIONS Bad Krozingen Trial 9:00 a m -5:00 p m Yves R. Louvard Lower Level Infarction Christopher P. Cannon 12:30 p m - CACTUS: A Prospective,

Hands on Hearts, Specialty Device 10:50 a m - HORIZONS AMI: A Prospective, Randomized Comparison of Crush vs. Training, TeachImage™ Randomized Comparison of Bivalirudin vs. Provisional T Stenting in Bifurcated Coronary Lesions: Angiographic and 30-Day Results Refer to pages 96-97 for details. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Antonio Colombo Myocardial Infarction: 30-Day Results 12:42 p m - NORDIC STENT TECHNIQUE: A Main Arena Gregg W. Stone Prospective, Randomized Trial of the Crush 11:05 a m - Critical Appraisal of the and Culotte Techniques in Patients with 8:00 a m -6:15 p m Bifurcation Disease: 6-Month Clinical Results Ballrooms ABC, Level 3 HORIZONS AMI Trial Michel E. Bertrand Matti J. Niemela 12:54 p m - Critical Appraisal of the CACTUS Plenary Session 16: 11:10 a m - Panel Discussion and NORDIC STENT TECHNIQUE Trials Live Case Session V Panel Moderator: Jeffrey J. Popma Discussants: Michel E. Bertrand, Jeffrey W. Moses Moderator: Gregg W. Stone James J. Ferguson III, William D. Knopf, 12:59 p m - CHREDIT: A Prospective, Co-Moderator: Ted Feldman Shamir R. Mehta, LeRoy E. Rabbani, Randomized Trial of Selective vs. Routine Live Case Discussants: Antonio L. Bartorelli, Allan M. Ross, Gregg W. Stone, Paclitaxel-Eluting Stent Use in Patients with Maurice Buchbinder, Christopher J. Cooper, Harvey D. White Multivessel Disease: Cost-Effectiveness Alain G. Cribier, L. Nelson Hopkins, Analysis at 12 through 24 Months Paul Kramer, Gary S. Mintz, 11:30 a m - DEDICATION STENT: A Massimo Mancone Martin T. Rothman, Dierk Scheinert, Prospective, Randomized Comparison of Alec Vahanian, Robert L. Wilensky Drug-Eluting and Bare Metal Stents in Acute 1:11 p m - Critical Appraisal of the Myocardial Infarction: 8-Month Clinical and CHREDIT Trial 8:00 a m - HELIOS Heart Center Angiographic Results David J. Cohen 8:30 a m - Columbia University Medical Center Henning Kelbaek 1:14 p m - PACCOCATH ISR 1 and 2: A 9:00 a m - University of Colorado Hospital 11:42 a m - Critical Appraisal of the Prospective, Randomized Trial of a 9:30 a m – King’s College Hospital DEDICATION STENT Trial Paclitaxel-Eluting Balloon in In-Stent Bruce R. Brodie Restenosis Lesions: 2-Year Results Bruno Scheller Plenary Session 17: 11:45 a m - TITAX AMI: A Prospective, PCI Controversies IV Randomized Trial Comparing a Titanium- 1:26 p m - Critical Appraisal of the Moderator: Gregg W. Stone Nitride-Oxide Coated Stent and a Paclitaxel- PACCOCATH ISR 1 and 2 Trials Eluting Stent in Acute Myocardial Infarction: Keith D. Dawkins 10:00 a m - A “Balanced” Perspective on 1-Year Clinical Results Transcatheter Aortic and Mitral Valve 1:29 p m - PEPCAD I SVD and PEPCAD II: Pasi Karjalainen Therapies: Managing the Conundrum of Investigations of a Paclitaxel-Eluting Balloon Patient Need, Evolving Technology, Physician 11:57 a m - Critical Appraisal of the in Small Vessels and In-Stent Restenosis Training, and Clinical Trials TITAX AMI Trial Lesions: 6-Month Clinical and Angiographic Robert O. Bonow Christian M. Spaulding Results 10:15 a m - “No Holds Barred” Panel Martin Unverdorben Discussion Late Breaking Studies and First 1:41 p m - Critical Appraisal of the PEPCAD I Discussants: Don Bobo, Steven F. Bolling, Report Investigations SVD and PEPCAD II Studies Robert O. Bonow, Ted Feldman, Moderators: John McB. Hodgson, Antonio Colombo Martin B. Leon, Ferolyn T. Powell, Erick Schampaert 1:44 p m - MIST I Final and MIST III: Allan Schwartz, John G. Webb, 12:00 p m - ENDEAVOR SAFETY: Adjudicated Sham-Controlled Randomized Evaluation of Bram Zuckerman Pooled Meta-Analysis of the Early and Late PFO Closure to Prevent Migraine: Long-Term Safety of a Zotarolimus-Eluting Stent and Crossover Results Laura Mauri Andrew J. Dowson

12:12 p m - Critical Appraisal of ENDEAVOR 1:56 p m - Critical Appraisal of the MIST I SAFETY Meta-Analysis Final and MIST III Trials Mitchell W. Krucoff Jonathan M. Tobis

82 truth in evidence based medicine · challenge conventional wisdom · transform your thinking wednesday \ october 24, 2007

Plenary Session 19: PCI Indications 5:45 p m - Will Stem Cell Therapies Become a EuroPCR Special Session III: When PCI Therapy Is Indicated Meaningful Alternative for Refractory Moderators: Jean Marco, Patrick W. Serruys Ischemia and/or Heart Failure in the Future? for Coronary ARTERY Disease Stephen E. Epstein The Drug-Eluting Stent Debate: Have We in t ro Moderator: Martin B. Leon Moved Beyond the Safety Concerns? 6:00 p m - “No Holds Barred” Panel Discussion 2:00 p m - A Critical Appraisal of Drug-Eluting Discussants: Daniel Burkhoff, Nabil Dib, 11:00 a m - Pro: The Benefits Are Real, the Stent Safety: How Should the Current Data Stephen E. Epstein, Moshe Y. Flugelman, Safety Issues Manageable Impact Decision-Making and What Are the Warren Sherman, Doris A. Taylor Stephan Windecker Unanswered Questions? tURDAY 11:15 a m - Contra: Safety Concerns Still agenda Stephan Windecker 6:15 p m - Adjourn sa Dictate Treatment Decisions Debate: Bare Metal Stents vs. Stefan K. James Drug-Eluting Stents Live Case Session VI 2:15 p m - BMS as the First Choice for Coronary Theater 11:30 a m - Institut Hospitalier Jacques Cartier sun DAY Majority of Patients 8:00 a m -6:30 p m agenda Moderator: Patrick W. Serruys Jean Marco Lower Level Co-Moderator: Jean Marco 2:30 p m - DES as the First Choice for Most Live Case Discussants: Kevin J. Beatt, JIM Special Session Patients Giancarlo Biamino, Joost Daemen, Moderator: Antonio Colombo Patrick W. Serruys Bernard De Bruyne, Jose M. de la Torre, agenda mon DAY 2:45 p m - Panel Discussion Percutaneous Aortic Valve Replacement Robert J. de Winter, Gerrit J. Laarman, Discussants: Antonio Colombo, Jean Marco, Alec Vahanian, Stefan Verheye 8:00 a m - Percutaneous Aortic Valve Patrick W. Serruys, David O. Williams, Replacement I: Device Overviews and Percutaneous Aortic Valve Replacement Global Results with the Edwards and Is Here: Are We Ready? agenda Plenary Session 20: CoreValve Prostheses t ues DAY 1:00 p m - Pro: CE Mark is Here, Live Case Session VI Susheel Kodali Reimbursement Is Coming: Patients Benefit Moderator: Martin B. Leon 8:15 a m - Percutaneous Aortic Valve Patrick W. Serruys Co-Moderator: Antonio Colombo Replacement II: A Detailed Review 1:15 p m - Contra: Surgery Is Still the Live Case Discussants: Raoul Bonan, of the Transfemoral Procedure with Benchmark agenda Jeffrey A. Brinker, Bernard R. Chevalier, Essential Tips and Tricks for Success Patrick Nataf wed NESDAY Larry S. Dean, Liliana R. Grinfeld, Jeffrey W. Moses John McB. Hodgson, Karel T. Koch,

EuroPCR Didactic Session: European Hans Krankenberg, Richard Schatz, Live Case Session V Perspectives: Complex Coronary

James F. McKinsey, Peter T. Wilmshurst Intervention case 8:30 a m - HELIOS Heart Center reviews 3:00 p m - Rush University Medical Center Moderator: Antonio Colombo 1:30 p m - Multivessel Disease and Left Main Co-Moderator: Jeffrey W. Moses Revascularization: Lessons Learned from 3:30 p m - Max Heart and Vascular Institute Live Case Discussants: Alexandre Abizaid, Euro Heart Survey 4:00 p m - Minneapolis Heart Institute Andrea Abizaid, David Antoniucci, Sigmund Silber p m 4:30 - University of Colorado Hospital agenda Anders M. Galloe, Ioannis Iakovou, 1:45 p m - Long-Term Follow-Up After t hurs DAY Ross Prpic, Bernhard Reimers, Multivessel Drug-Eluting Stents: Impact of TCT Award Presentation Bruno Scheller, Glenn Van Langenhove Gender Moderator: Martin B. Leon Bernard De Bruyne Complex Coronary Intervention 5:00 p m - TCT 2007 Thomas J. Linnemeier 10:00 a m - Unprotected Left Main Stenting: Interventional Potpourri t raining Spirit of Interventional Cardiology Young physician Current Experience, Case Selection, and Moderator: Jeffrey W. Moses Investigator Award Literature Review Gregg W. Stone 2:00 p m - Optimal Management of Simple Alaide Chieffo and Complex Multivessel Disease: Deciding Between Medical, Surgical, 10:20 a m - The Individualized Approach to t elli e

Plenary Session 21: even t s Bifurcation Lesions: A Case-Based Review and PCI Strategies sa PCI Controversies V Demonstrating Current Recommendations Keith D. Dawkins Moderator: Martin B. Leon Azeem Latib 2:20 p m - Cath Lab Misadventures: When 5:15 p m - Vulnerable Plaque Pathophysiology, 10:40 a m - Three Interesting Teaching Cases: Disaster Strikes (Management of Detection, and Therapy: What Are the What You Don’t See Every Day Perforations, Vessel Closure, and Other

Critical Data Gaps? Does Focal or Regional Antonio Colombo “Rich Emotional Experiences”) ABS T RAC S Interventional Therapy Stand a Chance? John S. Douglas, Jr Valentin Fuster 2:35 p m - The Transradial Approach to 5:30 p m - “No Holds Barred” Panel Discussion Coronary Intervention: Rationale and a Discussants: Valentin Fuster, Juan F. Granada, Step-by-Step Guide general James E. Muller, Harry R. Phillips, Martial Hamon Christodoulos I. Stefanadis, Renu Virmani, Sergio Waxman

www.tct2007.com 83 transcatheter cardiovascular therapeutics

wednesday \ october 24, 2007

2:55 p m - Perspectives on Access Site Live Case Session V: Aortic and Structural Heart Disease Closure Devices: Penetration Patterns, Thoracic Aneurysms Theater Patient Selection, Value-Added Justification, Moderator: Roy K. Greenberg 8:00 a m -6:30 p m and an Assessment of Current and Future Co-Moderator: Christopher K. Zarins Lower Level Devices Live Case Discussants: Jacques Busquet, Robert J. Applegate Eilliot L. Chaikof, David H. Deaton, 3:15 p m - Septal Ablation for Hypertrophic Hugo F. Londero, Takao Ohki, Adult Congenital Heart Disease III: Cardiomyopathy: Patient Selection, Juan C. Parodi, Allan S. Stewart, Obstructive Lesions and More Technique, Clinical Outcomes, and Physician Frank J. Veith, Grayson H. Wheatley Moderator: William E. Hellenbrand Training Requirements William Spencer 9:30 a m - Baptist Cardiac and Vascular 8:00 a m - The Growing Subspecialty of Adult Institute Congenital Heart Disease: An Integrated Approach to Complex Lesion Assessment and Live Case Session VII: Unusual 11:00 a m - Columbia University Medical Center Therapy Alternatives (Surgery or Cases Interventional Repair) Moderator: Jeffrey W. Moses p m 12:00 - Break Marlon Rosenbaum Co-Moderator: Jeffrey J. Popma Live Case Discussants: Jorge A. Belardi, 8:30 a m - Coarctation of the Aorta: Clinical Endovascular Potpourri Presentation, Interventional Treatment, and John S. Douglas, Jr, Run-Lin Gao, Moderator: Krishna Rocha-Singh James B. Hermiller, Jr, Jacques J. Koolen, Clinical Outcomes Co-Moderator: Mahmood K. Razavi William E. Hellenbrand D. Christopher Metzger, Masato Nakamura, Panel Discussants: Lindsay S. Machan, Sigmund Silber, George W. Vetrovec Luigi Salemme, Frederick G. St. Goar 8:45 a m - Closure of Large Vascular Connections with Plugs, Occluders, and 3:30 p m - King’s College Hospital 2:00 p m - Stop The Madness! A Non- Other Appliances 4:30 p m - Max Heart and Vascular Institute Interventional Perspective of Endovascular Eric Horlick 5:30 p m - Minneapolis Heart Institute Therapies Elizabeth V. Ratchford 9:00 a m - Stenosis of the Right Ventricular 6:30 p m - Adjourn Outflow Tract, Pulmonary Valve, and Branch 2:25 p m - Moderated Panel Discussion Pulmonary Arteries: Treatment Indications 2:30 p m - Critical Limb Ischemia: Have and Transcatheter Alternatives (Balloons, Endovascular Theater Emerging Data Established Percutaneous Stents, and Stent-Valves) 8:00 a m -6:30 p m Intervention as the Default Therapy? Philipp Bonhoeffer Lower Level Dierk Scheinert 2:55 p m - Moderated Panel Discussion Live and Taped Case Session V

Abdominal and Thoracic Aortic 3:00 p m - Pharmacologic and Interventional Moderator: William E. Hellenbrand Aneurysms Management Options for Iliofemoral DVT: Co-Moderator: Carlos E. Ruiz Moderator: Roy K. Greenberg When Is an Aggressive Approach Warranted? Live Case Discussants: Peter J. Casterella, Panel Discussants: Vivek Gupta, Mahmood K. Razavi William J. French, John M. Lasala, Didier F. Loulmet, Igor F. Palacios, Lindsay S. Machan, James F. McKinsey 3:25 p m - Moderated Panel Discussion Augusto D. Pichard, Ramon Quesada, 8:00 a m - Management Considerations for Campbell Rogers, Niel F. Starksen Patients with Aortic Aneurysms: Screening, Live Case Session VI: Unusual Cases 9:30 a m - Rush University Medical Center Preprocedural Assessment, Therapeutic Moderator: Krishna Rocha-Singh Options and Follow-Up Testing Co-Moderator: Mahmood K. Razavi 10:30 a m - Taped Case J. Michael Bacharach Live Case Discussants: Roger Gammon, 11:00 a m - HELIOS Heart Center Lawrence A. Garcia, Gary Gershony, 8:25 a m - Moderated Panel Discussion 12:00 p m - Break Lindsay S. Machan, Thomas O. McNamara, 8:30 a m - Abdominal Aortic Endograft Nicholas Morrissey, Frederick G. St. Goar, State-Of-The-Art: Device Innovation and Eugenio Stabile, Jacques G. Theron Structural Heart Disease: A Limitations and Future Solutions 3:30 p m - Baptist Cardiac and Vascular Potpourri of Topics Roy K. Greenberg Institute Moderator: Horst Sievert 8:55 a m - Moderated Panel Discussion 5:00 p m - Presbyterian Hospital of Dallas 2:00 p m - Alcohol Septal Ablation for 9:00 a m - Thoracic Aortic Aneurysm and Obstructive Hypertrophic Cardiomyopathy: 6:30 p m - Adjourn Dissection: Natural History and Results of Pathophysiology, Treatment Indications, Surgical and Device-Based Intervention Technique Variations, and Clinical Outcomes Christoph A. Nienaber William Spencer

9:25 a m - Moderated Panel Discussion 2:30 p m - Left Atrial Appendage Closure for Stroke Prevention: Rationale, Treatment Indications, Clinical Outcomes, and New Device Alternatives Peter C. Block

84 truth in evidence based medicine · challenge conventional wisdom · transform your thinking wednesday \ october 24, 2007

2:45 p m - Transcatheter Treatment of 9:20 a m - Subclavian and Vertebral 6:00 p m - Adjourn Peri-Valvular Leaks: Diagnosis, Treatment Arterial Disease Indications, Techniques, and Clinical Krishna Rocha-Singh

Outcomes in t ro 9:45 a m - Diseases of the Thoracic Aorta and Morning Concurrent Eulogio Garcia Aortic Arch Sessions 3:00 p m - Transcatheter “Exclusion” of Left Frank J. Criado Ventricular Aneurysms: Concept, Devices, 10:10 a m - Q&A and Early Clinical Results Platelet Inhibition II: a m tURDAY

10:35 - Break agenda

Horst Sievert New Insights into Glycoprotein sa IIb/IIIa Inhibitor Use 3:15 p m - The “Cross-Training” of Structural Renal, Mesenteric and Abdominal 8:00 a m -12:10 p m Heart Disease Therapists: Is There a Role for Aortic Disease Room 145AB Cardiac Surgeons? (my Personal Moderators: Michael R. Jaff, Experiences) sun DAY Kenneth Rosenfield agenda Mathew Williams From Bench to Bedside 10:50 a m - Evaluation of Renal Arterial Moderators: Howard C. Herrmann, Disease Dean J. Kereiakes Live and Taped Case Session VI Michael R. Jaff Moderator: Horst Sievert 8:00 a m - Anti-inflammatory Effects of GP 11:10 a m - Renal Arterial Disease: IIb/IIIa Inhibitors: In Vitro Assessment and agenda Co-Moderator: Igor F. Palacios mon DAY Technical Approach Live Case Discussants: Zahid Amin, Relevance to Clinical Outcomes Christopher J. Cooper Steven R. Bailey, Jeff Chambers, Jorge F. Saucedo Adrian A. Ebner, Peter S. Fail, 11:30 a m - Mesenteric Arterial Disease 8:12 a m - Relationship Between Platelet Ignacio Inglessis-Azuaje, Morris Mosseri, Timothy Sullivan Reactivity and Stent Thrombosis: agenda Carlos Pedra, E. Murat Tuzcu 11:50 a m - Abdominal Aortic Disease Implications for GP IIb/IIIa Inhibitors t ues DAY 3:30 p m - Columbia University Medical Center Jon Matsumura Paul A. Gurbel

4:30 p m - Rush University Medical Center 12:15 p m - Q&A 8:27 a m – Moderated Discussion and Q&A Panel Moderators: Howard C. Herrmann, 5:30 p m - Taped Case 12:30 p m - Lunch Break Dean J. Kereiakes agenda 6:30 p m - Adjourn Arterial Disease of the Lower Extremity Discussants: Paul A. Gurbel, Jorge F. Saucedo wed NESDAY Moderators: Issam D. Moussa, Daniel G. Clair Impact of Adjunct Pharmacology on

Board Review Course with 1:45 p m - Approach to the Patient with Results with GP IIb/IIIa Inhibitors

Arterial Disease of the Lower Extremity Moderators: Howard C. Herrmann, case Self Assessment for Michael R. Jaff Dean J. Kereiakes reviews 2:10 p m - Iliac and Femoral Arterial Disease Interventional Cardiology 8:40 a m - Impact of Clopidogrel Preloading and Endovascular Medicine, Issam D. Moussa on GP IIb/IIIa Efficacy in ACS and PCI Part 4: Endovasular 2:50 p m - Endovascular Treatment of Critical David F. Kong Limb Ischemia agenda 8:55 a m - Role of Systematic Overdosing and t hurs DAY essentials John J. Young Renal Insufficiency in Bleeding a m p m 8:00 -6:00 3:15 p m - Surgical Approach to Lower Complications After GP IIb/IIIa Inhibitors Room 146ABC Extremity Disease Frank V. Aguirre Daniel G. Clair 9:10 a m - Moderated Discussion and Q&A

Carotid, Vertebral, Subclavian and t raining 3:45 p m - Q&A Panel Moderators: Howard C. Herrmann, physician Thoracic Aortic Disease Dean J. Kereiakes Moderators: Michael R. Jaff, Nicholas Morrissey 4:00 p m - Break Discussants: Frank V. Aguirre, David F. Kong 8:00 a m - Welcome and Introduction: Venous Disease Oddities and

Description of the Endovascular t elli e Endovascular Complications GP IIb/IIIa Inhibition in ACS and AMI even t s Board Review Day sa Moderator: Michael R. Jaff Moderators: David F. Kong, Harvey D. White Michael R. Jaff 9:25 a m - Are Half-Dose Lytics Plus GP 4:25 p m - Endovascular Treatment of Venous 8:10 a m - Approach to the Patient Disease IIb/IIIa Inhibitors Preferred to Full-Dose with Carotid Artery Disease Robert M. Schainfeld Lytics in the Patient Undergoing Facilitated Michael R. Jaff or Rescue PCI? 4:50 p m - Unusual Vascular Disorders, ABS T RAC S 8:35 a m - Carotid Artery Stenting: Allan M. Ross Clinical Syndromes, and Anatomic Variants Technical Approach John R. Bartholomew 9:40 a m - Contemporary Role of GP IIb/IIIa Daniel J. McCormick Inhibitors in High- and Low-Risk Patients 5:15 p m - Vascular Access and Complications 9:00 a m - Intracranial Intervention and Acute Undergoing PCI (ACUITY PCI, ISAR REACT

of Endovascular Procedures general Stroke Therapies II, REPLACE-2, and Others) Alan Lumsden Philip M. Meyers Helmut Schuhlen 5:45 p m - Q&A

www.tct2007.com 85 transcatheter cardiovascular therapeutics

wednesday \ october 24, 2007

9:55 a m - Upstream Routine vs. Deferred Interventional Heart Failure I: 10:00 a m - Modulation of Cardiac Selective GP IIb/IIIa Inhibitors in ACS: Recent Developments and New Contractility: Impulse Dynamics Insights and Recommendations from Alan H. Kadish Directions EVEREST, ACUITY, and Others 8:00 a m -12:35 p m 10:10 a m - Cardiokinetics: A Percutaneous Harvey D. White Room 151AB Ventricular Partitioning Device for Ischemic 10:10 a m - Moderated Discussion and Q&A Moderators: Daniel Burkhoff, Ileana L. Pina Cardiomyopathy Panel Moderators: David F. Kong, Horst Sievert David Antoniucci Approaches to the Patient with Acute 10:20 a m - Surgical Perspectives on the Discussants: Allan M. Ross, Helmut Schuhlen Decompensated Heart Failure Current and Future Role of LVADs for Acute Moderators: Peter C. Block, Daniel Burkhoff and Chronic Heart Failure: Destination Bolus Only GP IIB/IIIa Inhibition During 8:00 a m - Impella: Safety and Clinical Utility Therapy or Bridge to Transplantation? PCI: Has the Time Come? of a Temporary Transaortic Forward Flow Mario Deng Moderators: David Antoniucci, David F. Kong Hemodynamic Support Device 10:32 a m - Surgical Approaches to Chronic 10:25 a m - Bolus IIb/IIIa Inhibitors I: Simon R. Dixon Heart Failure: Update from the STICH Trial Rationale and Registry Experiences 8:12 a m - The CardiacAssist Tandem Heart Robert E. Michler Jonathan D. Marmur Device: Device Description, Indications, and 10:42 a m - Use of the Bioventrix Blue Egg 10:37 a m - Bolus IIb/IIIa Inhibitors Plus Clinical Studies During Ventricular Reconstruction and Infusion vs. Bolus Only GP IIb/IIIa Inhibition Peter C. Block Implications for a Percutaneous Device During PCI: The EASY Trial 8:24 a m - Orquis: Physiologic and Clinical Gary Gershony Olivier F. Bertrand Impact of Continuous Aortic Flow 10:52 a m - ACORN Update: Results of 10:52 a m - Intercoronary Abciximab During Augmentation Ventricular Restraint in Heart Failure PCI: Rationale and Evidence Marvin A. Konstam Patients with and Without Mitral Jochen Wohrle 8:36 a m - Management of Acute Fluid Regurgitation, and New Regulatory 11:04 a m - Moderated Discussion and Q&A Overload: Diuretics vs. Aquaphoresis Directions Panel Moderators: David F. Kong, Bradley A. Bart Spencer H. Kubo David Antoniucci 8:48 a m - Recovery of Left Ventricular 11:04 a m - A Minimally Invasive Micro-Assist Discussants: Olivier F. Bertrand, Function in Cardiogenic Shock after Technology for Class III and Early Class IV Jonathan D. Marmur, Jochen Wohrle Temporary LVAD Implantation: Experience Congestive Heart Failure: Circulite with IMPELLA 5.0 and Implantable VADs Bartley Griffith Hot Topics and Important Patient Mark B. Anderson Subgroups 11:14 a m - The AbioCor Implantable Replacement Heart: Indications, Moderators: Dean J. Kereiakes, David F. Kong 8:58 a m - Nitric Oxide Scavengers and Hemoglobin Solutions for Cardiogenic Shock Complications, and Clinical Role 11:19 a m - Age Dependent Effects of David Baran Robert D. Dowling Abciximab: Insights from ISAR REACT II 11:24 a m - The Syncardia Temporary Julinda Mehilli 9:08 a m – Panel Discussion with Audience Q&A CardioWest Total Artificial Heart: Indications, 11:31 a m - Do GP IIb/IIIa Inhibitors Improve Moderators: Peter C. Block, Daniel Burkhoff Complications, and Clinical Role Outcomes Following Drug-Eluting Stents in Discussants: Mark B. Anderson, David Baran, Marvin J. Slepian Diabetic Patients? Bradley A. Bart, Simon R. Dixon, 11:34 a m - Featured Lecture: Endpoints for Eugenia Nikolsky Marvin A. Konstam Studies of Devices for Heart Failure: Clinical 11:43 a m - GP IIb/IIIa Inhibitors for Acute and Regulatory Considerations Stroke: A Meta-Analysis Device-Based Management of Worsening Ileana L. Pina Alfonso Ciccone Chronic Heart Failure 11:49 a m - Panel Discussion with Audience Q&A 11:55 a m - Moderated Discussion and Q&A Moderators: William T. Abraham, Moderators: William T. Abraham, Ileana L. Pina Panel Moderators: Dean J. Kereiakes, Ileana L. Pina Discussants: Mario Deng, Robert D. Dowling, David F. Kong 9:23a m - Current Indications and Future Gary Gershony, Barry Greenberg, Discussants: Alfonso Ciccone, Julinda Mehilli, Directions for Cardiac Defibrillators in Bartley Griffith, Paul J. Hauptman, Eugenia Nikolsky Patients with Heart Failure and Left Ventricle Alan H. Kadish, Spencer H. Kubo, 12:10 p m - Adjourn Dysfunction Robert E. Michler, Arthur J. Moss, Arthur J. Moss Horst Sievert, Marvin J. Slepian

9:35 a m - Featured Lecture: Cardiac Resynchronization Therapy: How Efficacious Special Lunchtime Demonstration Is It? Are the Indications Expanding? 12:05 p m - How-To Session: Demonstration of William T. Abraham Cardiopulmonary Stress Testing Moderator: Ileana L. Pina 9:50 a m - Chronic Vagal Stimulation for Heart Failure: Biocontrol Demonstration Leaders: Daniel R. Bensimhon, Paul J. Hauptman Stuart D. Russell 12:35 p m - Adjourn

86 truth in evidence based medicine · challenge conventional wisdom · transform your thinking wednesday \ october 24, 2007

Advanced Medical Therapies for 10:00 a m - Guidelines for Management of 12:15 p m - Aspirin and Thienopyridine the Interventionalist: Treatment Hypertension: Keeping it Simple Resistance: Diagnosis, Implications, and Clive Rosendorff Practical Recommendations of Diabetes, Hyperlipidemia, Matthew J. Price in t ro Hypertension, and Heart Failure 10:15 a m - Role for Renin Inhibitors in the Modern Management of Hypertension 12:20 p m - Myths about Antiplatelet 8:00 a m -12:00 p m Franz H. Messerli Resistance Room 147AB Victor L. Serebruany Moderator: Michael E. Farkouh 10:30 a m - Panel Discussion with Audience Q&A

Moderators: Michael E. Farkouh, 12:25 p m - Clopidogrel Loading, Dosing, and tURDAY agenda Managing Diabetes Vandana S. Mathur Timing in PCI and ACS sa Moderators: Bernard J. Gersh, Discussants: Andrea Abizaid, Dominick J. Angiolillo James H. Chesebro, Franz H. Messerli, H. Robert Superko 12:30 p m - Duration of Antiplatelet Therapy Clive Rosendorff 8:00 a m - Diabetes, Glycemic Control and after Bare Metal and Drug-Eluting Stents sun DAY Cardiovascular Disease: Recommendations Managing Heart Failure LeRoy E. Rabbani agenda

in Light of the TZD Controversy Moderators: JoAnn Lindenfeld, 12:35 p m - Importance of Bleeding Steven B. Feinstein Robert C. Bourge Complications and Evaluation of 8:15 a m - New Advances in the Management 10:45 a m - Heart Failure Refractory to Bleeding Risk of Diabetes: The Pipeline Medical Therapy: Treatment Failure or Eugenia Nikolsky agenda mon DAY Norman E. Lepor Failure to Treat? 12:40 p m - Antiplatelet and Antithrombin Ulrich P. Jorde 8:30 a m - TCT-114: Efficacy ofT riple Agents in the Patient Undergoing Cardiac Antiplatelet Therapy for Diabetic Patients 11:00 a m - Role of BNP Monitoring in the Surgery: Why Surgeons Are Concerned after Percutaneous Coronary Intervention Management of Heart Failure Mark W. Connolly Yaling Han Mario Deng agenda

12:45 p m - IIb/IIIa Inhibitors in ACS and PCI: t ues DAY Discussants: James H. Chesebro, 11:15 a m - Panel Discussion with Audience Q&A Still the Default Therapy for All Diabetics, Steven B. Feinstein, Norman E. Lepor, Moderators: Robert C. Bourge, ACS, and AMI? Alfredo Rodriguez JoAnn Lindenfeld Jorge F. Saucedo

Discussants: Mario Deng, Ulrich P. Jorde, 12:50 p m – Low Molecular Weight Heparin in 8:45 a m - Moderated Discussion and Q&A Marvin A. Konstam ACS and PCI: When to Consider agenda Panel Moderators: Bernard J. Gersh, wed NESDAY Jonathan D. Marmur H. Robert Superko Medical Therapy

12:55 p m - Bivalirudin During ACS and PCI: Discussants: James H. Chesebro, Moderators: Jeffrey A. Brinker, Time to Eliminate Heparin and IIb/IIIa Steven B. Feinstein, Norman E. Lepor, H. Robert Superko Alfredo Rodriguez Inhibitors? case Discussants: Antonio L. Bartorelli, reviews Timothy A. Sanborn Jorge Gaspar Managing Hyperlipidemia 1:00 p m - Critique of High-Profile 11:30 a m - TCT-116: Impact of Transfusion Moderators: Michael E. Farkouh, Pharmacotherapy Trials: What to Look on 1-Year Ischemic Events and Mortality Bernard J. Gersh Out For Among Patients with Acute Coronary a m Helen Parise agenda 9:00 - HDL Therapy: Life after Torcetrapib Syndromes Undergoing Percutaneous t hurs DAY H. Robert Superko Coronary Intervention 1:05 p m - Case Presentation and Discussion: 9:15 a m - Statins and LDL: How Low Do Steven V. Manoukian et al Adjunct Pharmacology in a 62-Year-Old We Go? Patient with Recurrent Stent Thrombosis and 11:45 a m - TCT-117: Is N-acetylcysteine Thienopyridine Resistance Michael Haude Effective for Prevention of Contrast-Induced t raining Moderator: George D. Dangas physician 9:30 a m - TCT-115: Effect of Lipid Lowering Nephropathy? Case Presenter: Nick Curzen Therapy on Progression of Intermediate Cezar S. Staniloae et al Coronary Atherosclerotic Plaque Evaluated Discussants: Dominick J. Angiolillo, 12:00 p m - Adjourn by Virtual Histology Intravascular Ultrasound Mark W. Connolly, Jonathan D. Marmur,

Eugenia Nikolsky, Helen Parise, t elli e Moderator: Kenya Nasu even t s sa Discussants: Michael Haude, Matthew J. Price, LeRoy E. Rabbani, Harry R. Phillips, H. Robert Superko Lunchtime Activities Timothy A. Sanborn, Jorge F. Saucedo, 12:15 p m –1:45 p m Victor L. Serebruany 9:45 a m - Panel Discussion with Audience Q&A Moderators: Michael E. Farkouh, 1:15 p m – Moderated Discussion and Q&A Panel Moderator: George D. Dangas

Bernard J. Gersh ABS T RAC S Discussants: Michael Haude, Hot Topics, Hot Lunches Discussants: Dominick J. Angiolillo, Harry R. Phillips, H. Robert Superko Mark W. Connolly, Nick Curzen, Controversies in Adjunct Jonathan D. Marmur, Eugenia Nikolsky, Managing Hypertension Helen Parise, Matthew J. Price, Moderators: Michael E. Farkouh, Pharmacology LeRoy E. Rabbani, Timothy A. Sanborn, general Room 201 Vandana S. Mathur Jorge F. Saucedo, Victor L. Serebruany Moderator: George D. Dangas

www.tct2007.com 87 transcatheter cardiovascular therapeutics

wednesday \ october 24, 2007

Renal Artery Intervention: Chronic Kidney Disease and Fellows Lunch: Reimbursement Unsettled Issues Contrast Administration: Issues in Interventional Room 202A Implications for the PCI Patient Cardiology Moderator: John R. Laird, Jr Room 202B Sponsored by Society for Cardiovascular 12:15 p m - Clinical Implications of Renal Moderator: Roxana Mehran Angiography and Interventions Room 209ABC Artery Stenosis: Over-Hyped or the Real 12:15 p m - Introduction and Session Goals Silent Killer? Roxana Mehran Moderators: Christopher U. Cates, Elizabeth V. Ratchford Carl L. Tommaso 12:20 p m - Prognostic Implications of Chronic 12:20 p m - Position Statement I: Stenting Kidney Disease 12:15 p m - Basic Primer on the Payment Should be the Default Strategy for Renal Vandana S. Mathur System: From Public Insurance to Private Artery Stenosis Payors, from RVUs to Technical and 12:25 p m - Prognostic Implications of Peter A. Schneider Professional Charges Contrast Nephropathy in the PCI Patient Wayne Powell 12:25 p m - Position Statement II: Renal Norman E. Lepor Artery Stenting Should Be Reserved for 12:40 p m - CPT Codes in Interventional 12:30 p m - Does Choice of Contrast Media Medical Failures Cardiology Affect the Risk of Contrast Nephropathy? Christopher J. Cooper Joseph D. Babb Jeffrey A. Brinker 12:30 p m - Position Statement III: Embolic 1:10 p m - Specific Billing Issues Related to 12:35 p m - Cath Lab Strategies to Reduce Protection Is Beneficial During Renal Artery Coronary and Vascular Procedures: Contrast Load Stenting Diagnostic and Interventional Robert J. Applegate Andrew Holden Carl L. Tommaso 12:40 p m - Nephrogenic Sclerosing Fibrosis: 12:35 p m - Position Statement IV: Embolic 1:30 p m - Moderated Discussion and Q&A Pathogensis, Prevention, and Treatment Protection Is Unnecessary During Renal Panel Moderators: Christopher U. Cates, Carlo Briguori Artery Stenting Carl L. Tommaso Hans Krankenberg 12:45 p m - N-Acetylcysteine: The Data and Discussants: Joseph D. Babb, Wayne Powell How to Use It 12:40 p m - Review of Completed and Ongoing Antonio L. Bartorelli Randomized Trials of Renal Artery Intervention 12:50 p m - Does Bicarbonate Reduce Case Reviews With Mark C. Bates Contrast Nephropathy? the Experts Charles J. Davidson 12:45 p m - Top Five No-Nonsense Tips and Tricks for Successful Renal Artery Stenting 12:55 p m - When Should Venovenous Acute Infarct Angioplasty and the John R. Laird, Jr Hemofiltration be Considered? Thrombus-Containing Lesion II John W. Hirshfeld, Jr Room: 149AB 12:50 p m - Outcomes of Renal Artery Stenting Based on IVUS and Physiologic 1:00 p m - Targeted Renal Therapy to Prevent Dariusz Dudek, Mun K. Hong, Upendra Kaul, Guidance Contrast Nephropathy Thomas D. Stuckey Massoud A. Leesar Giora Weisz Acute Stroke and Intracranial 1:05 p m - Case Presentation: A 49-Year-Old 12:55 p m - In-Stent Renal Artery Stenosis: Intervention Diabetic Man with Acute Anterior Myocardial Frequency, Implications, and Treatment Room 152A Infarction and a Creatinine of 4.0 mg/dl Thomas Zeller Alex Berenstein, Philip M. Meyers, Moderator: Roxana Mehran 1:00 p m - Case Presentation: Treatment of Bernhard Reimers, Jacques G. Theron Case Presenter: George W. Vetrovec Renal Artery Aneurysms Discussants: Robert J. Applegate, Moderator: John R. Laird, Jr Chronic Total Occlusions: Advanced Antonio L. Bartorelli, Carlo Briguori, Case Presenter: Thomas O. McNamara Treatment Strategies II Jeffrey A. Brinker, Charles J. Davidson, Discussants: Mark C. Bates, Room 150A John W. Hirshfeld, Jr, Norman E. Lepor, Christopher J. Cooper, Andrew Holden, Yasushi Asakura, Jaap N. Hamburger, Vandana S. Mathur, Giora Weisz Hans Krankenberg, Massoud A. Leesar, Tomoaki Hinohara, Gerald S. Werner Elizabeth V. Ratchford, Peter A. Schneider, 1:15 p m - Moderated Discussion and Q&A Thomas Zeller Panel Moderator: Roxana Mehran Complex Coronary Intervention Discussants: Robert J. Applegate, Emphasizing Advanced Techniques 1:10 p m - Moderated Discussion and Q&A Antonio L. Bartorelli, Carlo Briguori, Panel Moderator: John R. Laird, Jr and Procedural Strategy II Jeffrey A. Brinker, Charles J. Davidson, Discussants: Mark C. Bates, (Sponsored by China Interventional John W. Hirshfeld, Jr, Norman E. Lepor, Christopher J. Cooper, Andrew Holden, Therapeutics) Vandana S. Mathur, George W. Vetrovec, Hans Krankenberg, Massoud A. Leesar, Room 143A Giora Weisz Thomas O. McNamara, Elizabeth V. Ratchford, Moderator: Run-Lin Gao Peter A. Schneider, Thomas Zeller Case Presenters: Jiyan Chen, Yaling Han, Shu-Zheng Lu, Yue-Jin Yang

88 truth in evidence based medicine · challenge conventional wisdom · transform your thinking wednesday \ october 24, 2007

Intravascular Imaging (IVUS and 2:45 p m - TCT-121: 6-Month Echo Interventional Heart Failure II: Beyond): Shifting Paradigms and Assessment of Prosthetic Aortic Valve Endovascular and Surgical Function Following Transcatheter Aortic Procedural Guidance Approaches Room 143C Valve Replacement: A Report from the in t ro 2:00 p m -5:20 p m Jose Costa, Costantino R. Costantini, REVIVAL-II Trial Room 151AB Efrain Gaxiola, Giulio Guagliumi Mathew Williams et al Moderators: Daniel Burkhoff, Ileana L. Pina My Worst Complications: Endovascular Percutaneous Mitral Valves

Cardiac Monitoring Devices for CHF tURDAY

Intervention III Moderators: Jason H. Rogers, Allan Schwartz agenda Moderators: Robert C. Bourge, sa Discussants: Jose A. Condado, Room 143B JoAnn Lindenfeld Bruce H. Gray, Zvonimir Krajcer, Richard R. Heuser, Niel F. Starksen, James F. McKinsey, Patrick J. Peeters Zoltan G. Turi 2:00 p m - HF-ACTION Daniel R. Bensimhon 3:00 p m - TCT-122: Redilation of Balloon sun DAY My Worst Complications: Coronary Expandable Aortic Valves (BEAV): What Do 2:10 p m - Bioreactance-Based Noninvasive agenda Intervention III We Know? Cardiac Output Monitoring During Stress Test Room 150B Sanjeevan Pasupati et al Matthew S. Mauer J.J.R.M. (Hans) Bonnier, Samuel M. Butman, 3:15 p m - TCT-123: Significant Reverse 2:20 p m - Overview of Chronic Invasive Alan W. Heldman, Aaron V. Kaplan Remodeling of the Left Ventricle 1-Year After Pressure Monitoring agenda mon DAY Percutaneous Mitral Repair with the JoAnn Lindenfeld Structural Heart Disease III: Complex MitraClip™ Device 2:35 p m - CHRONICLE and Optival: Invasive Anatomy and Advanced Techniques Michael J. Rinaldi et al Measures of Pressure vs. Thoracic Fluid Room 144A Volume for Detection of Volume Overload Eric Horlick, Paul Kramer, 3:30 p m - TCT-124: Percutaneous Treatment

Robert C. Bourge agenda Daniel J. McCormick, Eustaquio Onorato of Functional Mitral Regurgitation: Interim t ues DAY Evolution Study Results with the Monarc 2:47 p m - Clinical Studies with a Left Atrial System Pressure Sensor: Savacor Afternoon Concurrent Karl H. Kuck et al Neal L. Eigler 3:45 p m - TCT-125: Percutaneous Trans- 2:57 p m - Clinical Studies with a Pulmonary Sessions Coronary Venous Repair of Mitral Valve Using agenda Artery Pressure Sensor I: Ramon Medical wed NESDAY CARILLON™ Device: Initial Single-Center Keyur H. Parikh Best of Structural Heart Disease Experience 3:07 p m - Clinical Studies with a Pulmonary Tomasz Siminiak et al Abstracts: fOCUS ON Transcatheter Artery Pressure Sensor II: Cardiomems case

Valve THERAPEUTICS William T. Abraham reviews Miscellaneous 2:00 p m -5:00 p m Moderators: Jan Harnek, James R. Margolis 3:17 p m - Chronic Monitoring of Left Room 147AB Discussants: George S. Hanzel, Saibal Kar, Ventricular Pressure: Transoma David W. M. Muller, Steven J. Yakubov Lynn Zwiers Percutaneous Aortic Valves 3:27 p m - Vital Sensors: A Novel Microsensor Moderators: Philipp Bonhoeffer, 4:00 p m - TCT-126: Long-Term Durability and agenda t hurs DAY Maurice Buchbinder Safety of Percutaneous Septal-Sinus for Pressure Measurement Discussants: Louis A. Cannon, Chaim Lotan, Shortening David H. Solomon David Paniagua, Wesley R. Pedersen Jason H. Rogers et al Debate: Role of Invasive Pressure 2:00 p m - TCT-118: Transarterial 4:15 p m - TCT-127: Percutaneous Reduction Monitoring for Management of Chronic

Heart Failure t raining Percutaneous Aortic Valve (PAV) Insertion: of Periprosthetic Leaks: A Promising physician Canadian Single Centre Experience Alternative to Repeat Surgery 3:37 p m - Invasive Pressure Measurements Sanjeevan Pasupati et al Jeannot Potvin et al Will Be Proven Essential for Keeping Heart Failure Patients Out of the Hospital! 2:15 p m - TCT-119: 6-Month to 1-Year 4:30 p m - TCT-128: Indications, Description,

and Results of Percutaneous Transcatheter Robert C. Bourge t elli e Clinical Outcomes Following Retrograde even t s sa Percutaneous Aortic Valve Replacement in Repairs of Mitral Paravalvular Regurgitations 3:49 p m - Nonsense: All I Need is a Good High-Risk Patients: A Report from the Marcelino Cortes et al Scale and a Compliant Patient!

REVIVAL-II Trial 4:45 p m - TCT-129: Long-Term Follow-Up of Mark Dunlap Susheel Kodali et al Percutaneous Closure of Left Atrial 4:01 p m - Rebuttal 2:30 p m - TCT-120: Transapical Aortic Valve Appendage ABS T RAC S Implantation in High-Risk Surgical Patients: GianPaolo Ussia et al

Medium-Term Results 5:00 p m - Adjourn Michael A. Borger et al general

www.tct2007.com 89 transcatheter cardiovascular therapeutics

wednesday \ october 24, 2007

4:09 p m - Moderated Discussion and Q&A Panel Moderators: Daniel Burkhoff, Ileana L. Pina Discussants: William T. Abraham, Daniel R. Bensimhon, Robert C. Bourge, Mark Dunlap, Neal L. Eigler, JoAnn Lindenfeld, Matthew S. Mauer, Keyur H. Parikh, David H. Solomon, Lynn Zwiers

Abstract Session: Therapeutics in Heart Failure Moderators: Daniel Burkhoff, Ileana L. Pina Discussants: Keyur H. Parikh, Richard Smalling, Jie Wang

4:20 p m - TCT-130: PROTECT I: A Prospective Feasibility Trial Investigating the Use of the IMPELLA® RECOVER® LP 2.5 System in High-Risk PCI Patients William O’Neill

4:35 p m - TCT-131: First-in-Man Use of the Reitan Catheter Pump (RCP) for Circulatory Support in Patients Undergoing High-Risk Percutaneous Coronary Intervention (PCI) Martin T. Rothman

4:50 p m - TCT-132: Safety and Feasibility of Percutaneous Autologous Skeletal Myoblast Transplantation for Ischemic Cardiomyopathy: 1-Year Results of the CAUSMIC Trial Nabil Dib

5:05 p m - TCT-133: Heart Failure Improvement After Autologous Bone Marrow Mononuclear Cell (ABMMC) Transplantation Jorge Tuma-Mubarack

5:20 p m - Adjourn

Evening Symposia 8:00 p m -10:00 p m Refer to page 104-105 for complete program schedule.

90 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Save the dates for these important meetings.

Fifth International CHRONIC TOTAL INVESTIGATE OCCLUSION EVALUATE SUMMIT EDUCATE FOURTH INTERNATIONAL CONFERENCE ON February 21-22, 2008 New York Marriott Cell Therapy for Marquis Hotel Cardiovascular Diseases New York, NY COURSE DIRECTORS January 16-18, 2008 Martin B. Leon, MD Columbia University · Alfred Lerner Hall Jeffrey W. Moses, MD New Yo rk, NY Gregg W. Stone, MD Course Director Warren Sherman, MD Course Co-Directors Jozef A. Bartunek, MD, PhD Stefanie Dimmeter, PhD Gordon M. Keller, PhD Joshua M. Hare, MD Marc Penn, MD, PhD Michael R. Rosen, MD Gordana Vunjack-Novakovi, PhD

sponsored by THE CARDIOVASCULAR RESEARCH FOUNDATION

Please visit www.crf.org for more information. transcatheter cardiovascular therapeutics

moderated complex case review sessions

Monday, October 22 Endovascular Cases 10:45 a m - Treatment of AMI in a Patient with Abdominal Aortic Occlusion 10:00 a m -3:00 p m Moderators: Henning Rud Andersen, Exhibit Hall, 2nd Level Hugo F. Londero, Thomas A. Sos Norimasa Taniguchi 1:00 PM - Endovascular Approach to Tadem Endovascular Cases Coronary Cases Subclavian and Carotid Stenosis Moderators: Oscar A. Mendiz, Moderators: Fernando Alfonso, Joanna J. Wykrzykowska Charles D. O’Shaughnessy, Gary L. Schaer Christoph A. Nienaber, Takao Ohki 1:15 PM - Management of Restenosis After 11:00 AM - Interventional Management of 10:00 a m - Ventricular Assist Device Use in a Stenting a Totally Occluded Brachiocephalic Ascending Aorta Pseudoaneurysm Patient with Severe Aortic Stenosis and Left Trunk Rajneesh Kapoor Main Disease Jennifer Franke Alessandro S. Bortone 11:15 AM - Stent Graft for the Treatment of 1:30 PM - Renal Stenting Complicated By Iatrogenic Aortic Endoleak 10:15 a m - Acute Myocardial Infarction Perforation Jindal K. Rajesh Associated with Left Main Occlusion Massoud A. Leesar Song Lin 11:30 AM - Percutaneous Occlusion of Aortic 1:45 PM - Recanalization of Subclavian Vein Pseudoaneurysm 10:30 a m - Stent Thrombosis in a Pregnant Occlusion via AV Fistula Frank Breuckmann Woman Who Refused CABG Jose M. Garcia Lee Sang Rok 11:45 AM - Hybrid Approach to Type B Aorta Dissection 10:45 a m - Stent Lost in the Left Main for Coronary Cases Twelve Years Moderators: Mark A. Apfelbaum, Holger Eggebrecht Douglas Bogart Tian-Hai Koh, David W.M. Muller Coronary Cases 2:00 p m - Multiple Stent Thromboses Moderators: Samuel M. Butman, Structural Heart Disease Cases After AMI Tom A. Mabin, Luiz A. Mattos Moderators: Peter J. Casterella, Marian Bystroń Thomas K. Jones, Carlos Pedra 12:00 p m - Utilization of a New LV Assist 2:15 p m - Multiple Stent Thromboses Device for High-Risk Angioplasty 11:00 a m - Closure of a Very Large After BMS Implantation Markus Ferrari Coronary Fistula to RV Francis Almeda Howaida G. El-Said 12:15 p m - Left Main Stenting Followed by 2:30 p m - Multiple Stent Thromboses Retrograde Recanalization of a CTO 11:15 a m - Percutaneous Closure of After CTO Treatment Kikuchi Todashi PDA and VSD Costantino Costantini Bal Goyal 12:30 p m - Left Main and Multivessel Disease 2:45 p m - Simultaneous DES and BMS PCI During AMI 11:30 a m - Interventional Management of Thrombosis Bartlomiej Guzik Sinus of Valsalva Aneurysm Rupture Diego D. Grinfeld Ajit Mehta 12:45 p m - Left Main Stenting Complicated 3:00 p m - Adjourn by Iatrogenic Coronary AV Fistula 11:45 a m - PDA Stenting Through an Umbilical Artery Ali A. Youssef Moustafa Ashwin Mehta Tuesday, October 23 Structural Heart Disease Cases 10:00 a m -3:00 p m Moderators: Stephen J. D. Brecker, Coronary Cases Exhibit Hall, 2nd Level Moderators: Jose-Maria Hernandez, D. S. Gambhir, Charles E. Mullins Balbir Singh, Bernhard Witzenbichler Coronary Cases 1:00 p m - Kissing Stents for the Treatment of Pulmonary Stenosis 12:00 p m - CTO Recanalization Followed by Moderators: Daniel H. Berrocal, Karel T. Koch, Left Main PCI Using the Transradial Sim Kui-Hian Vaikom Mahadevan Approach 1:15 p m - ASD Corrected With Implantation 10:00 a m - Transradial Approach to PCI in the Chien-Jen Chen Setting of Cardiogenic Shock of Three Amplatzer Devices Paul Gordon 12:15 p m - Left Circumflex CTO Retrograde Chih-Yuan Fang Recanalization After Failed Anterograde 1:30 p m - Retrieval of Embolized VSD 10:15 a m - Primary Stenting Followed by Approach Percutaneous Aortic Valvuloplasty Occluder Device (First Case) Ashwin B. Mehta Aleem Khand Gianpaola Ussia 12:30 p m - CTO Recanalization of an 1:45 p m - Retrieval of Embolized VSD 10:30 a m - Intracoronary Injection of TNK Anomalous RCA After Two Prior Failed During Primary PTCA Occluder Device (Second Case) Attempts Costantino Costantini Rajeev Rathi Chung-Jen Wu

12:45 p m - Transradial Approach for the Treatment of Left Main Bifurcation PCI Kenichi Muramatsu

92 truth in evidence based medicine · challenge conventional wisdom · transform your thinking moderated complex case review sessions

Coronary Cases Coronary Cases Moderators: Steven L. Almany, Upendra Kaul, Moderators: Samuel K. Mathew, Robert J. Whitbourn Duane S. Pinto, Gennaro Sardella in t ro 2:00 p m - Retrieval of an Embolized Stent 12:00 p m - Complicated PCI After Mark E. Lanzieri Implantation of a Bifurcation Dedicated Stent 2:15 p m - Complex PCI in a Patient with Type C Interrupted Aortic Arch Jayesh Prajapati

Sim Ming 12:15 p m - Bifurcation Lesion Treated with a tURDAY agenda New Dedicated Stent sa 2:30 p m - Retrieval of a Stent Lodged at the LAD Ostium Pavel Cervinka Rahul Patil 12:30 p m - Septal Perforator Occlusion with Covered Stent and DES for HOCM 2:45 p m - Left Main Trifurcation Intervention sun DAY Complicated with Thrombus Roberto Baglini agenda Han-Mo Yang 12:45 p m - Interventional Safety Pin Removal from a Pulmonary Bronchus 3:00 p m - Adjourn Elchanan Bruckheimer agenda Endovascular Cases mon DAY Wednesday, October 24 Moderators: Nicola Corvaja, David H. Deaton, 10:00 a m -3:00 p m Roger M. Greenhalgh Exhibit Hall, 2nd Level 1:00 PM - Endovascular Treatment of a Delayed Diagnosis of Aorta Aneurysm agenda

Coronary Cases t ues DAY Moderators: Jose A. Condado, Rupture Alan W. Heldman, Arthur Teow Hin Tan Marcelo Cantarelli

10:00 a m - Retrograde Approach for 1:15 PM – Management of Superior Recanalization of a CTO Using the Mesenteric Artery Aneurysm “Lasso Loop” Michael Wholey agenda wed NESDAY Alexander Ossiyev 1:30 PM - Aortic Graft Disruption Corrected With PFO Occluder

10:15 a m - Bilateral Approach for CTO with the “Knuckle” Wire Technique Steven Goldberg

Masashi Kimura 1:45 PM - Multiple Interventional case reviews

10:30 a m - Sub-Intimal Tracking and Approaches to Treat Obstructive Lower Retrograde Re-Entry in a Complex CTO Case Extremity Disease Asif Qasim Taketsugu Tsuchiya

10:45 a m - PCI for CTO in a SVG Using

Coronary Cases agenda

Rotational Atherectomy t hurs DAY Moderators: Fausto Feres, Ben He, Jimmy Lim Expedito Ribeiro Structural Heart Disease Cases 2:00 p m - Management of DES Thrombosis Moderators: George S. Hanzel, with Implantation of a Different DES t raining Michael J. Mullen, Brian Whisenant Sandhir B. Prasad physician

11:00 a m - Management of Multiple Coronary 2:15 p m - Late Thrombosis Documented Fistula After Failed Surgical Attempt by Angioscopy Toru Kataoka Masamichi Yano t elli e a m 2:30 p m - Stent Displacement Due to Late even t s 11:15 - VSD Closure in a Patient with sa Previous Mitro and Aortic Valve Replacement Stent Fracture Stephane Noble Muhammad Rahman

11:30 a m - Thrombin Occlusion of Pulmonary 2:45 p m - Stent Fracture and Aneurysm Artery Perforation Formation After DES Implantation

Philipp Kahlert Chee Wo Wu ABS T RAC S

11:45 a m - Catheter Based Treatment of LV to 3:00 p m - Adjourn LA Fistula After Mitral Valve Replacement Reda Ibrahim general

www.tct2007.com 93 transcatheter cardiovascular therapeutics

thursday \ october 25, 2007

Breakfast Meetings TCT Closing Session: 10:10 a m - Case #2 Mathew Williams 7:00 a m -8:00 a m Case Reviews, Complications, Refer to page 105 for complete 10:20 a m - Case #3 program schedule. and Brain Teasers, Featuring Michael B. Collins “Interventional Jeopardy” 10:30 a m - Case #4 8:00 a m -12:00 p m Alaide Chieffo

high risk angioplasty and Room 207AB 10:40 a m - Case #5 cardiogenic shock: intra- James B. Hermiller, Jr Greatest Cases From Around the 10:50 a m - Case #6 aortic balloon pump case World: The Winners of the Most Edward M. Kreps presentations Challenging Case Competition 7:00 a m -8:00 a m Moderator: Alexandre Abizaid Interventional Jeopardy Room 209C Discussants: Fernando Alfonso, Single Jeopardy Moderator: Moderators: Neil K. Goyal, Steven L. Almany, Michael B. Collins, Alex Trabek Abizaid Srinivas Kesanakurthy, Tudor Vagaonescu David A. Cox, Issam D. Moussa, Double Jeopardy Moderator: Charles A. Simonton 7:00 a m - Case #1 Alexa Trabek Lansky Steve Tsai 8:00 a m - Retrograde CTO Recanalization Final Jeopardy Moderator: 7:07 a m - Q&A with Multiple Complications Alex Trabek Stone Chiung-Jen Wu Contestants: Fayaz Shawl, 7:12 a m - Case #2 James A. Higgins 8:10 a m - Retrograde CTO via Ulnar Access Charles A. Simonton, Paul S. Teirstein Anuj Bhasin Panel Discussants: George D. Dangas, 7:19 a m - Q&A William A. Gray, Roxana Mehran, 8:20 a m - DES Strut Fracture with Resulting 7:24 a m - Case #3 Gary S. Mintz Aneurism William Suh Alaide Chieffo 12:00 p m - Adjourn 7:31 a m - Q&A 8:30 a m - A New Technology for Cardiac 7:36 a m - Case #4 Arrest Joanna Wyrkzykowska Goran K. Olivecrona

7:43 a m - Q&A 8:40 a m - Stent Embolization with Two 7:48 a m - Case #5 Management Strategies Oleg Sakhorukov Afzalur Rahman

7:55 a m - Q&A 8:50 a m - An Access Site Nightmare Ajay J. Kirtane 8:00 a m - Adjourn

The Best TCT 2007 Late Breaking Board Review Course with Trials Revisited: A Critical Self Assessment for Reappraisal of Their Likely Impact Interventional Cardiology 9:00 a m : Moderator: Gregg W. Stone Discussants: Antonio Colombo, Fausto Feres, and Endovascular Medicine: William A. Gray, Martin B. Leon, THE FINAL EXAM Jeffrey W. Moses, Erick Schampaert, Sigmund Silber 8:00 a m -11:00 a m Room 146ABC The Experts Undressed: My Most 8:00 a m - The Final Exam Questions George D. Dangas Amazing, Horrendous, or

9:30 a m - The Final Exam Answers Surprising Coronary Case of George D. Dangas the Year Moderator: Jeffrey W. Moses 11:00 a m - Adjourn Discussants: Joseph P. Carrozza, Jr, Augusto D. Pichard, Jeffrey J. Popma, Martin T. Rothman, Paul S. Teirstein, Mark A. Turco

10:00 a m - Case #1 Antonio Colombo

94 truth in evidence based medicine · challenge conventional wisdom · transform your thinking Imagine . . . holding an accurate model of your patient’s heart in your hands.

Practice . . . a structural heart disease intervention using this heart.

See . . . a demonstration of the transformation of a routine cardiac CT into a heart in your hands.

Hands on Hearts in the Physician Training Center

This year, Hands on Hearts offers two unique experiences to put a heart in your hands.

• Hands on anatomical instruction showing a variety of pathologies • Accurate physical models of living patients’ hearts made using new 3-D technology

These sessions are individualized, involving one-on-one interaction to address specific questions and learn new technologies.

Please visit the Physician Training Center, located on the lower level. transcatheter cardiovascular therapeutics

physician training center

PHYSICIAN TRAINING CENTER their patients, and the nature of many TEACHIMAGE™ interventions by this opportunity to interact The Physician Training Center, located on one-on-one with experts using hearts from TeachImage™ consists of a suite of online the lower level at the entrance of the an amazing library of actual-case hearts. learning tools combined with a series of theaters, will be devoted to hands-on Second, accurate physical models of living integrated lectures led by physician experts. interactive technical training and will patients’ hearts can now be made using new TeachCTA™ features interactive CT highlight coronary, endovascular, and 3-D printing technology that transforms angiography cases that allow users to meet structural (valvular and congenital) heart medical images into a heart model you can society mentoring guidelines. Immediate disease interventions. hold, examine, and practice a structural feedback enables participants to compare heart disease intervention. From the 3-D Lab their interpretations with those of experts. of the Interventional Cardiology Group at the The Physician Training Center will consist TeachFFR™ provides interactive case University of Colorado comes multiple of three distinct areas, each offering a unique studies, “Guess the FFR” exercises, and a physical models from patients with a variety educational experience: library of narrated presentations on the of defects, such as ASD, VSD, valvular • Hands on Hearts subject of fractional flow reserve as it relates abnormalities and vascular abnormalities, • TeachImage™ to complex multivessel disease. Each case immediately subsequent to executed • Specialty Device Training study provides interactive Q&A sessions and transcatheter interventions. Participants see audio annotations by a leading physician. how these models are produced from cardiac TeachIVUS™ has more than 300 cases and a CT images of the patient and then can growing library of narrated presentations. The HANDS ON HEARTS practice interventions on the model. user will be able to identify a variety of IVUS Participants will then better understand the parameters in simulation mode and instantly interaction of catheter shape and anatomy, compare his/her analysis to an expert’s. closure devices and defects, and potential challenges and complications that can be predicted by practicing on the patient’s model rather than the real patient. Computer Specialty Device Training graphics experts and interventional cardiologists will introduce you to this novel Cordis Corporation: Biologics and new use of medical images. Delivery Systems Pathologies to be demonstrated include: • ASD (large with deficient rims, NOGA XP Cardiac Navigation System fenestrated) Plus Mapping and Injection Catheters Imagine . . . holding an accurate model of • VSD (post-surgical patch dehiscence, Sessions consist of a half-hour overview of your patient’s heart in your hands . . . muscular, post-MI, post-AVR) the next generation of products, a half-hour Practice . . . a structural heart disease • Prosthetic mitral perivalvular defect demonstration of the NOGA XP System by a intervention using this heart . . . • Aortic ulceration clinical specialist, and an open discussion See . . . a demonstration of the • Large abdominal aortic aneurysm and Q&A. Please visit the Biologics Delivery transformation of a routine cardiac CT • Aortic-LA fistula Systems Specialty Device Training pavilion into a heart in your hands . . . • Single ventricle to register. This year Hands on Hearts offers two unique • Normal heart Monday, October 22 experiences to put a heart in your hands. • Pre- and post-percutaneous AVR Sessions begin at 10:00 a m , 12:00 p m , The session is individualized, involving • Congenital PA stenosis and 2:00 p m one-on-one interaction to address specific Walk-up demonstration at 4:00 p m questions and learn new technologies. Monday, OCTOBER 22 Tuesday, October 23 First, a hands-on anatomical instruction will 10:00 a m -5:00 p m Sessions begin at 9:00 a m , 11:00 Am, be provided by experts in cardiac pathology 1:30 PM, and 3:30 PM using human cadaver hearts showing a Tuesday, OCTOBER 23 variety of pathologies. From the collection of 9:00 a m -5:00 p m the CVPath Institute, Inc, Gaithersburg, MD, wednesday, OCTOBER 24 comes unique heart specimens and experts 9:00 a m -5:00 p m to help increase your knowledge of normal and abnormal cardiac pathological findings. Participants can view and examine heart specimens with coronary, valvular, and congenital heart disease pathologies. Interventionalists can enhance their understanding of anatomy, the maladies of

96 truth in evidence based medicine · challenge conventional wisdom · transform your thinking physician training center

Cordis Endovascular, a division of Wednesday, October 24 (ONLY) Cordis Corporation, Sessions begin at 9:00 AM, 11:00 AM, 1:00 PM, and 3:00 PM a Johnson & Johnson company in t ro

Cordis OPTEASE® Retrievable Vena Cava Filter and Cordis TRAPEASE® FoxHollow Technologies, Inc Permanent Vena Cava Filter NightHawk™ Plaque Excision System Each 2-hour session consists of a physician tURDAY and New Novel Technologies agenda didactic and case review, and a hands-on sa Each 1-hour session consists of didactic in-service. Upon completion of the workshop, presentations, Q&A, hands-on test stations, attendees will be certified to use the and expert physician interaction. Please visit OPTEASE® Retrievable Vena Cava Filter and the FoxHollow Specialty Device Training ® sun DAY the TRAPEASE Permanent Vena Cava Filter. agenda pavilion to register. Sessions are designed for 20 attendees. To register, please visit the Cordis Endovascular Monday, October 22 Specialty Device Training pavilion or the 10:00 a m -5:00 p m Cordis booth in the Exhibit Hall, Level 2. Tuesday, October 23 agenda mon DAY Monday, October 22 (ONLY) 9:00 a m -5:00 p m

Sessions begin at 10:00 AM, 12:00 PM, Wednesday, October 24 and 2:00 PM 9:00 a m -5:00 p m

®

Cordis PRECISE Pro™ RX Nitinol Stent agenda t ues DAY ® and Cordis ANGIOGUARD RX Emboli St. Jude Medical Capture Guidewire System Proxis Embolic Protection System Each 2-hour session consists of a physician Each session includes a 45-minute didactic session with a physician expert and a didactic and case review, and a hands-on agenda

in-service. Upon completion of the workshop, 45-minute in-service on the Proxis Embolic wed NESDAY attendees will be certified to use the Protection System with a clinical specialist.

PRECISE® PRO™ RX. Sessions are designed Please visit the St. Jude Medical Specialty for 20 attendees. To register, please visit the Device Training pavilion to register. case

Cordis Endovascular Specialty Device reviews Tuesday, October 23 Training pavilion or the Cordis booth in the Sessions begin at 9:00 a m , 11:00 a m , Exhibit Hall, Level 2. 1:30 p m , and 3:30 p m

Tuesday, October 23 (ONLY) Wednesday, October 24

Sessions begin at 9:00 AM, 11:00 AM, Sessions begin at 9:00 a m , 11:00 a m , agenda t hurs DAY 1:00 PM, and 3:00 PM 1:30 p m , and 3:30 p m

FRONTRUNNER® XP CTO Catheter and OUTBACK® LTD™ Re-Entry Catheter t raining Sessions consist of a half-hour overview of physician the CTO Technology provided by a physician expert, a half-hour discussion of challenging cases followed by Q&A, and a half-hour t elli e

hands-on demonstration of the even t s sa FRONTRUNNER® XP CTO Catheter and OUTBACK® LTD™ Re-Entry Catheter. Upon completion of the workshop, attendees will be certified to use the FRONTRUNNER® XP CTO Catheter and OUTBACK® LTD™ Re-Entry Catheter. Sessions are designed for ABS T RAC S 20 attendees. To register, please visit the Cordis Endovascular Specialty Device Training pavilion or the Cordis booth in the

Exhibit Hall, Level 2. general

www.tct2007.com 97 transcatheter cardiovascular therapeutics

satellite symposia

Sunday, October 21 An Introduction to the Pathway PV™ Delivering Safety to Today’s Patients Atherectomy System Sponsored by Biosensors International, Sponsored by Pathway Medical Devax, Inc, and Xtent, Inc Breakfast Meetings Room 144A, Washington Convention Center Renaissance Washington, DC Hotel, SMT Advanced DES Systems: Grand Ballroom South Early Clinical Experience of Enhanced Innovations to Optimize Clinical Outcomes Moderators: Peter J. Fitzgerald, Gregg W. Stone IntraCoronary Drug Delivery Using Sponsored by Sahajanand Medical 7:00 p m - Reception and Registration ClearWay™ RX Catheter to Treat AMI Technologies Pvt Ltd 8:00 p m - Welcome and ACS Patients Room 144C, Washington Convention Center Gregg W. Stone Sponsored by Atrium Medical Corporation 8:05 p m - Current Perspective on Drug- Room 143C, Washington Convention Center Eluting Stent Safety Moderator: C. Michael Gibson Evening Satellite Symposia Peter J. Fitzgerald 7:00 a m - Benefits of IntraCoronary and OCI: 8:20 p m - XTENT Custom NX Drug-Eluting Local Drug Delivery for AMI Patients Impella: Redefining the Standards of Stent System C. Michael Gibson Circulatory Support for Acute Heart Failure Bernard De Bruyne 7:20 a m - Early US Clinical Experience Using Sponsored by ABIOMED, Inc 8:35 p m - Devax Axxess Bifurcation Stent ClearWay™ RX Catheter in AMI Patients Renaissance Washington, DC Hotel, Stefan Verheye Jeffrey J. Popma Renaissance Ballroom 8:50 p m - Biosensors BioMatrix Biolimus 7:30 a m - Early US Clinical Experience Using Moderators: Mark B. Anderson, A9-Eluting Coronary Stent: A Next ClearwayTM RX Catheter in AMI Patients Eberhard Grube, Jose P.S. Henriques, Generation Drug-Eluting Stent for Treatment Thomas Scott Magnus Ohman, William O’Neill, Fred Resnic of Coronary Artery Disease 7:40 a m - Early European Clinical Experience 7:30 a m - Reception and Registration Stephan Windecker Using ClearWay™ RX Catheter in AMI 8:00 p m - Welcome 9:05 p m - An Evidence-Based Approach to Patients William O’Neill Safety: What We Have Learned from Diana A. Gorog 8:05 p m - Future Perspectives of Circulatory Preclinical Studies of Drug-Eluting Stents 7:50 a m - Q&A Support in Acute Heart Failure: Rationale for Renu Virmani 8:00 a m - Adjourn a Continuum of Care 9:20 p m - Analysis of the Current Data: Magnus Ohman Biolimus A9 Trials and Registries Optimizing Medical Therapy for 8:20 p m - Bridging the Gap Between Eberhard Grube Treatment of Angina in the Era of Cardiology and Surgery: What Makes Sense 9:35 p m - Closing Remarks Intervention for Our Patients? Gregg W. Stone Sponsored by the Cardiovascular Research Eberhard Grube Foundation and educational partner 9:40 p m - Q&A 8:35 p m - Protecting the Heart Under Stress Thornton Medical Communications 10:00 p m - Adjourn Supported through an educational grant by During High-Risk Interventions: How Far Can CV Therapeutics, Inc We Push the Limit? Carotid Stenting: Focus on Technique Fred Resnic Room 143B, Washington Convention Center and Reducing Stroke Moderator: William E. Boden 8:50 p m - Recovering the Dysfunctional Sponsored by Cardiovascular Research Heart: Is it Time for a Paradigm Shift in 7:00 a m - Welcome Foundation and educational partner William E. Boden Management of ACS? WakeHeart Cerebrovascular and Peripheral Jose P.S. Henriques Research LLC 7:05 a m - Medical Therapy for Patients with Supported through an educational grant from Angina Pectoris and Coronary Artery Disease 9:05 p m - Recovering the Failing Heart: The Boston Scientific Corporation, Cordis® Who Do Not Get Revascularized: The Surgeons Can Still Pick it Up When Cardiac and Vascular InstituteSM, ev3, “Rational” Interventionalist’s Perspective Cardiologists Give Up WakeMed Health and Hospitals* Frederick Feit Mark B. Anderson *Commercial supporters as of 9/21/07 9:20 p m - Late Breaking Clinical Trials with 7:25 a m - Reducing Clinical Events and Grand Hyatt, Independence Ballroom Minimally Invasive Circulatory Support Ischemia in the Post-PCI Patient with Moderators: Ravish Sachar, Jay S. Yadav Persistent Symptoms Technology: IMPRESS, PROTECT, and 7:00 p m - Reception and Registration William E. Boden RECOVER, What Does it All Mean? William O’Neill 8:00 p m - Welcome 7:45 a m - Q&A Jay S. Yadav William E. Boden 9:35 p m - Panel Discussion 10:00 p m - Adjourn 8:05 p m - Timing, Location, and 8:00 a m - Adjourn Characterization of Strokes in CAS: A Review of Current Data William A. Gray

98 truth in evidence based medicine · challenge conventional wisdom · transform your thinking satellite symposia

8:15 p m - Approaching the High-Risk Patient: 9:35 p m - Q&A 8:00 a m - Adjourn Symptomatic Patients and Octogenarians Tim A. Fischell Christopher J. White Advanced Endovascular Techniques for 9:40 p m - Real World Challenges in

the Treatment of Infrainguinal Disease in t ro 8:25 p m - Accessing the Carotid for Interventional Cardiology: Case Review and Intervention: How Do We Reduce the Risk? Audience Response Sponsored by the Cardiovascular Jay S. Yadav Panel Research Foundation Supported through an educational grant 8:35 p m - Alternatives to the Aortic Arch: 10:00 p m - Adjourn by Edwards Lifesciences

Radial/Brachial Approaches tURDAY

Room 149AB, Washington agenda Tift Mann Making Your Case: Up-to-Date Answers sa Convention Center for Developing Trends in PCI 8:40 p m - Embolic Protection Devices: The Moderator: Krishna Rocha-Singh Pros and Cons Sponsored by INNOVIA Education 7:00 a m - Challenges to Techniques and Gary Ansel Institute, LLC Supported through an educational grant from Technologies for the Treatment of sun DAY 8:50 p m - Is it Possible to Match Stent agenda sanofi-aventis, US Infrainguinal Disease: An Overview to Anatomy? Grand Hyatt, Constitution Ballroom Krishna Rocha-Singh Rajesh M. Dave Moderator: C. Michael Gibson 7:05 a m - Evolving Strategies for the Use of 9:00 p m - Post-Dilating the Lesion: The Nitinol Stents and Nitinol Stent Grafts for 7:00 p m - Reception and Registration Moment of the Greatest Risk (and Femoropopliteal Occlusive Disease agenda 8:00 p m - Welcome and Symposium Overview mon DAY Opportunity) John R. Laird, Jr Ravish Sachar, Matthew Hook C. Michael Gibson 7:20 a m - Adjunct Therapies to PTA: Have 8:05 p m - New Guidelines, Studies, and 9:10 p m - Putting it All Together: Complex Extractional Atherectomy, Cryoplasty, and Interventions in PCI Case Presentations Laser Atherectomy Shown Their Values? Steven R. Steinhubl agenda Ravish Sachar, Matthew Hook Lawrence A. Garcia t ues DAY 8:20 p m - Recent Trends in PCI: Evidence 9:45 p m - What Is the Most Effective Focus of 7:40 a m - Bare Metal Stents, Drug-Eluting from National Registries Future Iteration? Designing New Trials and Stents, Bioabsorbable Stents: Evolving Eric D. Peterson Devices Therapies for Infrapopliteal Occlusive Kenneth Rosenfield 8:35 p m - Interactive Case Studies: Disease Interactive Discussion of Case Studies agenda 9:55 p m - Closing Remarks Thomas O. McNamara wed NESDAY Provided by Symposium Participants with a Ravish Sachar 7:55 a m - Q&A Focus on STEMI, NSTEMI, and Elective 10:00 p m - Adjourn Interventions (PCI/Peripheral) 8:00 a m - Adjourn

C. Michael Gibson case

Acute STEMI: Overcoming Peri- Management of Peripheral Arterial reviews Procedural Challenges in Patients 9:30 p m - PCI in 2007: Take Away Messages Disease: Challenges and Conquests Ehtisham Mahmud Undergoing PCI Sponsored by the Cardiovascular Research Sponsored by i3 CME 9:45 p m - Q&A Foundation Supported through an educational grant from C. Michael Gibson Supported through an educational grant agenda

PDL BioPharma, Inc 10:00 p m - Adjourn from Spectranetics t hurs DAY Marriott Metro, Ballroom Room 144B, Washington Convention Center Moderator: William E. Boden Moderator: Michael R. Jaff 7:00 p m - Reception and Registration Monday, October 22 7:00 a m - Challenges and Options in 8:00 p m - Welcome Managing Infrainguinal Arterial Disease t raining William E. Boden James Joye physician

8:05 p m - Challenges to Achieving Optimal Breakfast Meetings 7:15 a m - When to Intervene in Below-Knee Quality of Care and Outcomes in STEMI Peripheral Arterial Disease Strategies to Reduce Vascular Access William E. Boden Robert M. Bersin t elli e

Complications even t s

7:30 a m - Technical Strategies for sa 8:30 p m - Question and Answer Session Sponsored by Abbott Vascular Endovascular Intervention in Critical Limb William E. Boden Room 143B, Washington Convention Center Ischemia 8:35 p m - Contemporary Reperfusion Moderators: Steven R. Bailey, Gary Ansel Strategies for STEMI: Insights from Recent Benjamin W. Starnes, Zoltan G. Turi 7:45 a m - Strategies for Management of Clinical Trials 7:00 a m - Good Accesss = Good Hemostatsis In-Stent Restenosis ABS T RAC S Stephen G. Ellis Zoltan G. Turi Tony Das 9:05 p m - Q&A 7:20 a m - The Arterial Healing Impact of 8:00 a m - Adjourn Stephen G. Ellis Closure Devices 9:10 p m - Minimizing Peri-Procedural Steven R. Bailey general Complications: Practical Issues and 7:40 a m - Patient Selection and Access Site Recommendations Complications Tim A. Fischell Benjamin W. Starnes

www.tct2007.com 99 transcatheter cardiovascular therapeutics

satellite symposia

The Coherex FlatStent™: The Future of 7:25 a m - Case Presentation: Sizing Antiplatelet Therapy for ACS: Weighing PFO Closure Considerations Long-Term Outcome vs. Short-Term Risk Sponsored by Coherex Medical, Inc Peter Dejaegere Sponsored by Potomac Center for Medical

Room 144C, Washington Convention Center 7:45 a m � Q&A Education Moderators: David R. Holmes, Martin B. Leon, Supported through an educational grant from 8:00 a m - Adjourn Mark Reisman, Robert J. Sommer, Schering Plough Corp Jonathan M. Tobis, Brian Whisenant Room 143A, Washington Convention Center Optical Coherence Tomography: Current Moderator: C. Michael Gibson 7:00 a m - New Frontiers: Structural Heart Applications and Future Development Surgery in the Interventional Suite Sponsored by LightLab Imaging, Inc 7:00 a m - Welcome Martin B. Leon Room 144A, Washington Convention Center C. Michael Gibson 7:10 a m - The Coherex FlatStent™ PFO Moderator: Gary S. Mintz 7:05 a m - Antiplatelet Therapy: Anti-Ischemic Closure System: Device Design and Benefits Versus Bleeding Risk 7:00 a m - Openings Comments Preclinical Testing C. Michael Gibson Gary S. Mintz Brian Whisenant 7:20 a m - Rationale for Role of Antiplatelet 7:05 a m - Identification of vulnerable plaques 7:20 a m - Initial Experience with the Therapy by OCT Coherex FlatStent Paul A. Gurbel Takashi Akasaka Jonathan M. Tobis 7:35 a m - Advances in Antiplatelet/ 7:17 a m - Evolving Technologies for Coronary 7:30 a m - Establishing a Migraine PFO Antithrombotic Therapy in ACS and PCI Imaging Research Program: Real World Issues David J. Moliterno Peter J. Fitzgerald Robert J. Sommer 7:50 a m - Q&A and Concluding Remarks 7:29 a m - OCT for Stent Evaluation 7:40 a m - Optimizing Patient Selection and C. Michael Gibson Evelyn Regar Clinical Trial Design in Migraine 8:00 a m - Adjourn Mark Reisman 7:41 a m - OCT for BEYOND: Intracoronary Light-Based Imaging 7:50 a m - The Potential Global Impact of an Clinical Aspects of Transradial Access Sergio Waxman Approved Migraine Indication for PFO Sponsored by Terumo Interventional Systems 7:53 a m - Q&A Room 154AB, Washington Convention Center 8:00 a m - Adjourn 8:00 a m - Adjourn Moderator: Jeffrey J. Popma

DES Safety Summit: A Clinical Update 7:00 a m - Decreased Complications and Sponsored by Cordis® Cardiac and Contrast Media Use in High-Risk Increased Clinical Efficiency in Certain Types Vascular InstituteSM Patients: The Latest Data of Procedures and Patients Room 150A, Washington Convention Center Sponsored by NACCME Jeffrey J. Popma Moderator: David G. Rizik Supported through an educational grant 7:15 a m - The Need for Increased Training to Each session will be followed by five from Bracco Diagnostics Inc Establish Clinical Proficiency in Transradial minutes of Q&A Organized by HMP Communications Access Room 150B, Washington Convention Center John T. Coppola 7:00 a m - Assessing the Landscape of Stent Moderator: Jonathan S. Reiner Thrombosis 7:30 a m - How Simulator Training Can Speed David G. Rizik 7:00 a m - Contrast-Induced Nephropathy: the Adoption of a Steeper Learning Curve in Who Is a High-Risk Patient? Transradial Access 7:20 a m - The Role of Antiplatelet Therapy Cindy L. Grines Resistance in the Modern DES Era Yves R. Louvard Daniel I. Simon 7:15 a m - Safety of Angiographic Contrast 7:45 a m - Use of Transradial Access in the Media in High-Risk Patients: Data from the STEMI Patients 7:40 a m - Higher Risk Patients CARE Study Raj Makkar Jean Fajadet Jonathan S. Reiner 8:00 a m - Adjourn 8:00 a m - Adjourn 7:30 a m - Reducing Risk in Patients with Renal Impairment Undergoing Cardiac Performing Aortic Valve Replacement Angiography in the Cath Lab Evening Satellite Symposia Roxana Mehran Sponsored by CoreValve, Inc What Leads to Optimal Outcomes? What Room 143C, Washington Convention Center 7:45 a m - Q&A We Have Learned: CAPTURE 3500 Moderator: Maurice Buchbinder 8:00 a m - Adjourn Predictors 7:00 a m - The CoreValve ReValving � System: Sponsored by Cardiovascular Research Technology Update and Patient Selection Foundation Maurice Buchbinder Supported through an educational grant from 7:15 a m - Case Presentation: Learning Curve Abbott Vascular Considerations Renaissance Washington, DC Hotel, Raoul Bonan Renaissance Ballroom Moderator: William A. Gray

100 truth in evidence based medicine · challenge conventional wisdom · transform your thinking satellite symposia

7:00 p m - Reception and Registration New Evidence in DES Outcomes: The 9:25 p m - Q&A

8:00 p m - Optimizing Outcomes by Patient Road Traveled Since the World Congress 10:00 p m - Adjourn and Lesion Selection of Cardiology 2006 Klaus Mathias Sponsored by Cordis® Cardiac and Critical Challenges and Landmark in t ro Vascular InstituteSM Advances in Vascular Interventional 8:15 p m - Avoidance and Management of Organized by Cardiovascular Research Peri- and Post-Procedural Complications Management Foundation Peter Schneider Sponsored by University of the Grand Hyatt, Constitution Ballroom Massachusetts School of Medicine Office of p m tURDAY 8:30 - Evolution of CAS Outcomes in Moderator: Christian Spaulding agenda Continuing Education sa Contemporary Trials: Are We Really Getting 7:00 p m - Reception and Registration Supported through an educational grant from Better? The Medicines Company William A. Gray 8:00 p m - Year in Review: The Impact of the Organized by CMEducation Resources, LLC Headlines on Clinical Practice 8:50 p m - Improvement in Cognitive Function Marriot Metro, Ballroom Christian Spaulding sun DAY After CAS: Relevance to the Clinical Moderator: Deepak L. Bhatt agenda Indications for CAS 8:25 p m - Understanding the Drug-Eluting 8:00 p m - Where Metal Meets Thrombus and Jay A. Yadav Stent Evidence: The Latest Data Set on PCI Endothelium: A State of the “Union” to Date 9:05 p m - Late Breaking ACT-1 Lead in Keynote Address Stephan Windecker Patients Outcomes: Can These Data Help Deepak L. Bhatt agenda mon DAY Predict Pivotal Trial Outcomes 8:50 p m - My Experience with Drug-Eluting 8:30 p m - The Evolving Antithrombotic Jon Matsumura Stents: Applying the Evidence to Clinical Landscape for Patients with ST-Elevation Practice 9:20 p m - Regulatory and Reimbursement Myocardial Infarction: What’s on the Jeffrey W. Moses Landscape: Current and Anticipated HORIZON

9:05 p m - Where Does the Road Lead Next? agenda William A. Gray Gregg W. Stone t ues DAY The Future of Sirolimus-Eluting Stents 9:30 p m - Case Reviews in CAS 8:55 p m - Getting in the Stream of Lowell F. Satler 9:50 p m - Q&A Antithrombotic Therapy for ACS: What Do 9:20 p m - Q&A The Trials Tell Us? To Switch or Not to 10:00 p m - Adjourn 9:45 p m - Adjourn Switch: If, When, How, To What? These Are agenda

Managing It Today, Planning for the Questions wed NESDAY The New Era in Drug-Eluting Stents Ron Waksman Tomorrow: Optimizing Antiplatelet Sponsored by Medtronic, Inc Therapy in PCI 9:20 p m - Bleeding, Mortality, and Risk Renaissance Washington, DC Hotel, Profiling for Invasive Vascular Management

Sponsored by INNOVIA Education Institute Grand Ballroom case

of ACS reviews Supported through an educational grant from Moderator: Martin B. Leon Steven V. Manoukian AstraZeneca LP 7:00 p m - Reception and Registration Renaissance Washington, DC Hotel, 9:45 p m - Where Metal Meets Thrombus and Congressional Ballroom 8:00 p m - Critical insights from the Pivotal Vascular Endothelium: A Case Study Analysis Moderators: Peter B. Berger, David J. Moliterno ENDEAVOR IV Trial: Subset Analyses, IVUS of Upstream Interventions agenda

Findings, Case Examples, and Perspectives Deepak L. Bhatt, Steven V. Manoukian, t hurs DAY 7:00 p m - Reception and Registration Martin B. Leon Gregg W. Stone, Ron Waksman 8:00 p m - Welcome 8:10 p m - Thoughts on PCI Safety: Do Future David J. Moliterno 10:00 p m - Adjourn Generation Products Solve This Concern 8:05 p m - Antiplatelet Therapy Before PCI: Stephan Windecker t raining How Much and When? physician 8:25 p m - Reconciling Angiographic and David J. Moliterno Tuesday, October 23 Clinical Results After Stent Treatment: A 8:25 p m - Platelet Inhibition and Variable Critical Appraisal and Recommendations for Response: Implications for Patient Outcomes Clinical Assessments of Future Stents

Breakfast Meetings t elli e Peter B. Berger Jeffrey J. Popma even t s sa

8:45 p m - Panel Discussion 8:45 p m - Will Next Generation Anti-Platelet Metallic Stents vs. DES: Philosophies and Case Discussions 9:05 p m - Antiplatelet Therapy After PCI: How Agents Impact Clinical Outcomes After DES Much and How Long? Treatment Sponsored by Abbott Vascular Adnan Kastrati Peter B. Berger Room 150A, Washington Convention Center Moderators: Stephen G. Ellis, Gregory J. Mishkel ABS T RAC S 9:25 p m - New Antiplatelet Therapies: Arrival 9:05 p m - Updated Status Report on Clinical of the Next Generation Outcomes with Medtronic Stent Clinical 7:00 a m - Introduction and Market Overview Steven R. Steinhubl Program: Clinical Trial Experiences and Stephen G. Ellis, Gregory J. Mishkel “Real World” Outcomes 7:05 a m - Changes in Today’s Practice: Stent 9:45 p m - Q&A and Closing Remarks Alan C. Yeung

Thrombosis and Healing Mechanisms general 10:00 p m - Adjourn Stephen G. Ellis, Gregory J. Mishkel

www.tct2007.com 101 transcatheter cardiovascular therapeutics

satellite symposia

7:20 a m - Role of Bare Metal Stents vs. First 7:05 a m - What Every Clinician Should Know Solutions to Coronary Chronic Total Generation DES About Iodinated Contrast Media Occlusions Stephen G. Ellis, Gregory J. Mishkel Charles J. Davidson Sponsored by Medtronic, Inc

7:40 a m - Second Generation DES 7:20 a m - CTA or Invasive Coronary Room 150B, Washington Convention Center Stephen G. Ellis, Gregory J. Mishkel Angiography: What Would You Do in This Moderator: William Lombardi Case? 7:55 a m - Closing Remarks 7:00 a m - Opening Remarks and Stephen G. Ellis, Gregory J. Mishkel James K. Min Introductions 7:35 a m - Acute Kidney Injury After Contrast: William Lombardi 8:00 a m - Adjourn A Serious Problem by Any Name 7:05 a m - Practical Techniques and The AngioSculpt® Scoring Balloon Peter A. McCullough Approaches to CTOs Catheter: New Innovations for the 7:50 a m - Q&A and Closing Remarks William Lombardi

Treatment of Challenging Coronary and 8:00 a m - Adjourn 7:15 a m - Lesion SpecificA pproaches to CTOs Peripheral Lesions James Zidar Sponsored by AngioScore, Inc The Role Of Heparin Bonded Devices 7:25 a m - Approaching CTOs in an Emerging Room 143A, Washington Convention Center In The Treatment Of Lower Limb Arterial Market: Experience from India Moderator: Martin B. Leon Disease Ibrahim Alrashdan 7:00 a m - Welcome Sponsored by Gore and Associates 7:35 a m - Case Review: Panel Discussion Martin B. Leon Room 149AB, Washington Convention Center Ibrahim Alrashdan, William Lombardi, Moderator: Tom Keefe 7:03 a m - Overview of the AngioSculpt James Zidar Technology Platform for Coronary and 7:00 a m - Transcending Mechanical Solutions 7:55 a m - Q&A Peripheral Vascular Disease with the GORE PROPATEN Vascular Graft 8:00 a m - Adjourn Martin B. Leon Richard Neville 7:15 a m - Emerging Role of the AngioSculpt 7:20 a m - SFA Endoluminal Bypass with the AngioJet®: A Safe Therapy and Device for the Treatment of Coronary GORE VIABAHN® Endoprosthesis with Independent Predictor for Lowering Heparin Bioactive Surface Bifurcations and Other Complex Lesion Stent Thrombosis Tanvir Bajwa Subsets Sponsored by Possis Medical Patrick Whitlow 7:40 a m - Q&A Room 144A, Washington Convention Center

7:25 a m - Long-Term Results with the 8:00 a m - Adjourn Moderator: Cindy L. Grines AngioSculpt Scoring Balloon for the 7:00 a m - AngioJet in STEMI Treatment of Critical Limb Ischemia: COOL IT: Experience in Cooling Cardiac Cindy L. Grines The Belgian Experience Arrest STEMI Patients 7:20 a m - Angiojet in STEMI & SVGs Patrick J. Peeters Sponsored by Medivance, Inc George Sianos 7:35 a m - Importance of the AngioSculpt in Room 143C, Washington Convention Center the “Toolbox” of a Comprehensive Moderator: Michael R. Mooney 7:40 a m - AngioJet and Late Stent Thrombosis Endovascular Interventionalist 7:00 a m - The Application of Hypothermia in Fadi A. Matar Rajesh Dave the Newest Treatment for STEMI Post- 8:00 a m - Adjourn 7:45 a m - Next Generation Devices and a Cardiac Arrest: Why and How They Can Be Drug-Coated AngioSculpt Balloon Done Simultaneously for Best Outcomes? Gary Gershony Michael R. Mooney Nine Cases That Will Change Your Practice: FFR Case Review a m 7:15 a m - Role of Intensivists for the Critical 7:50 - Closing Remarks Sponsored by Radi Medical Systems Patient Management Immediately Following Martin B. Leon Room 152B, Washington Convention Center Cardiac Intervention 8:00 a m - Adjourn Moderator: Morton J. Kern William M. Parham, III 7:00 a m - Opening Comments Hemodynamics, Electrolytes, Acute 7:30 a m - Implementation of Simultaneous Morton J. Kern Kidney Injury: Novel Considerations in Treatments for STEMI and Therapeutic Contrast Selection Hypothermia: Treatment Protocols from 7:05 a m - Angiographic Conundrums: Ostial and Branch Lesions Sponsored by Center for Biomedical Rural to Tertiary as well as Those Presenting Morton J. Kern Communications, Inc (CBC) at Tertiary Center Supported through an educational grant from Barbara Unger 7:20 a m - MVD and Use in Complex Patients Nico Pijls GE Healthcare 7:45 a m - Q&A Organized by PAREXEL MMS 7:35 a m - Dilemmas in Practice: 8:00 a m - Adjourn Room 143B, Washington Convention Center SVG and CABG Moderator: Peter A. McCullough Augusto D. Pichard

7:00 a m - Introductory Remarks 7:50 a m - Q&A Peter A. McCullough Morton J. Kern and panel

8:00 a m - Adjourn

102 truth in evidence based medicine · challenge conventional wisdom · transform your thinking satellite symposia

Magnetic Navigation and Therapeutic Evening Satellite Symposia 9:30 p m - Q&A Tools for Complex Cases 10:00 p m - Adjourn Sponsored by Sterotaxis, Inc The Science Behind Stent Leadership Room 144C, Washington Convention Center Sponsored by Abbott Vascular PCI Today: Insights into Short and in t ro Moderator: Patrick W. Serruys Renaissance Washington, DC Hotel, Long-Term Risk Reduction With Renaissance Ballroom 7:00 a m - Welcome Antiplatelet Therapy Moderator: Patrick W. Serruys Patrick W. Serruys Sponsored by Voxmedia LLC 7:00 p m - Reception and Registration Supported through an educational grant from 7:05 a m - Stereotaxis Experience at OLVG: tURDAY agenda

Bristol-Myers Squibb Company and sa First 500 Patients 8:00 p m - Introduction to the Meeting Ferdinand Kiemeneij Patrick W. Serruys sanofi-aventis Grand Hyatt Hotel, Independence Ballroom A 8:05 p m - Role of BMS in a DES World 7:20 a m - Integration of MSCT Imaging in Moderator: Cindy L. Grines James B. Hermiller, Jr Coronary Magnetic Navigation: From Type A *A brief question and answer session will sun DAY Lesion to Total Occlusions 8:20 p m - SPIRIT II and III 1-Year Update follow each presentation. agenda Robert Jan Van Geuns Patrick W. Serruys 7:00 p m - Reception and Registration 7:35 a m - Emerging Peripheral Applications 8:40 p m - Intravascular Ultrasound Evaluation 8:00 p m - Introduction of the Stereotaxis System of XIENCET™: Results from SPIRIT III Cindy L. Grines John J. Young Peter J. Fitzgerald agenda 8:05 p m - Contemporary PCI Practice Patterns mon DAY 7:50 a m - Q&A and Closing Comments 8:55 p m - The Science Behind Bioabsorbable Christopher P. Cannon Patrick W. Serruys DES: BVS/ABSORB Update 8:30 p m - Our Evolving Understanding of 8:00 a m - Adjourn Dariusz Dudek Loading Oral Antiplatelet Therapy 9:10 p m - Cardiovascular Disease in Women: Shamir R. Mehta agenda From Access to Closure: Device Based Do Meaningful Differences Affect Prognosis t ues DAY Management of Complex Cases and Therapeutic Response Following PCI 8:55 p m - Antiplatelet Therapy Post PCI Sponsored by St. Jude Medical Alexandra Lansky Cindy L. Grines Room 152A, Washington Convention Center 9:25 p m - Q&A 9:20 p m - Understanding Definitions and Moderators: Art Lee, Frederic S. Resnic Guidelines: An Interventionalist’s Perspective

10:00 p m - Adjourn agenda Donald E. Cutlip 7:00 a m - Interventional Strategies for Wiring wed NESDAY Challenging Anatomy and Chronic Occlusions The Amazing Shrinking Infarct: Results 9:45 p m - Case Presentation Art Lee from AMIHOT II: SuperOxygenation Cindy L. Grines 7:30 a m - Relationship Between the Use of Therapy for the Treatment of Acute 10:00 p m - Adjourn VCP and Retroperitoneal Hemorrhage case Myocardial Infarction reviews Frederic S. Resnic Sponsored by TherOx, Inc Preclinical to Patients: 8:00 a m - Adjourn Renaissance Washington, DC Hotel The DES Pathway Congressional Ballroom Sponsored by Boston Scientific Corporation Why Cardiologists Should Consider Moderator: Jack L. Martin Renaissance Washington, DC Hotel agenda

Transradial Access for their Practice Grand Ballroom t hurs DAY 7:00 p m - Reception and Registration Sponsored by Terumo Interventional Systems Moderator: Keith D. Dawkins 8:00 p m - Introduction Room 144B, Washington Convention Center 7:00 p m - Reception and Registration Moderator: Jeffrey J. Popma Jack L. Martin 8:00 p m - Welcome and Introductions 7:00 a m - Starting a Transradial Practice: 8:05 p m - Super Oxygenated Therapy: Why Keith D. Dawkins t raining Considerations, Roadblocks, etc. Does it Work? physician 8:10 p m - Drug Development: What Do We Jeffrey J. Popma J. Richard Spears Know About the Actions of Current DES 7:15 a m - How Transradial Benefits My 8:10 p m - Previous Studies of Ancillary Molecules? Practice: A Personal Experience Therapies to PCI in AMI Aloke V. Finn t elli e Jeffrey J. Popma Simon R. Dixon even t s 8:25 p m - Drug-Eluting Stents State of the sa 7:30 a m - Benefits of Transradial to the 8:30 p m - Infarct Size: Is It a Valid Endpoint? State – Is There Calm After the Storm? Patient, Staff, and Hospital Todd D. Miller Keith D. Dawkins Shigeru Saito 8:45 p m - Remodeling in AMI: The Leiden 8:40 p m - BSC the Next Platform: What is the 7:45 a m - Procedures Other Than Cardiac Experience in AMIHOT I Clinical Performance of the Next Generation Hazem Warda ABS T RAC S Which are Suited for Trans-Radial Access DES Stent? Fina Mauri Ferre 9:00 p m - Results of AMIHOT II: Mark A. Turco An In-Depth Look 8:00 a m - Adjourn 8:55 p m - Dual Anti-Platelet Therapy: What Jack L. Martin Impact Does Dual Antiplatet Therapy Have

9:20 p m - How Do I Incorporate Super on DES Clinical Outcomes? general Oxygenated Therapy in the Cath Lab? Steven R. Steinhubl D. Christopher Metzger, Ezio Bramucci

www.tct2007.com 103 transcatheter cardiovascular therapeutics

satellite symposia

9:10 p m - Questions & Answers 7:20 a m - Balloon Angioplasty, Cryoplasty, 7:00 a m - Welcome Keith Dawkins, Aloke Finn, Mark Turco, and Stenting for CLI Michael Slack, David Hildick-Smith Steven Steinhubl Thomas M. Shimshak 7:10 a m - GORE HELEX Septal Occluder in 9:30 p m - Adjourn 7:35 a m - Excisional Atherectomy and Laser Multi-Fenestrated ASD: A Case Study Therapy for CLI Michael Slack Clinical Insight: SilverHawk Rajesh M. Dave 7:30 a m - GORE HELEX Septal Occluder: Performance in Diabetics and Treating 7:45 a m - Q&A A UK Perspective on Stroke and Migraine BTK Disease Treatment 8:00 a m - Adjourn Sponsored by FoxHollow Technologies David Hildick-Smith Marriot Metro, Ballroom Chronic Total Occlusions: Clinical 7:50 a m - Q&A Moderator: Roger Gammon Evidence, Devices, and Latest 8:00 a m - Adjourn 7:00 p m - Reception and Registration Techniques Sponsored by Cardiovascular Research 8:00 p m - Forging New Frontiers: Advances in Early Clinical Cerebral Protection the Treatment of Infrapopliteal Disease Foundation Results and Evaluation with the Roger Gammon Supported through an educational grant from FiberNet EPS Kensey Nash Corporation Sponsored by Lumen Biomedical, Inc 8:30 p m - Anti-Restenosis, Plaque Analysis Room 143A, Washington Convention Center and the Future Room 144B, Washington Convention Center Moderators: John S. Douglas, Jr, Daniel Lerner Moderator: Subbarao V. Mylavarapu Charles A. Simonton 7:00 a m - Introduction 9:30 p m - European Experiences with 7:00 a m - Clinical Evidence for CTO SilverHawk Subbarao V. Mylavarapu Intervention and Newest Devices Thomas Zeller 7:05 a m - Procedural Evaluation and Charles A. Simonton Highlights of the New Delivery Tactics 10:00 p m - Adjourn 7:15 a m - My Favorite Devices and Horst Sievert Techniques for Antegrade Approach 7:30 a m - US Carotid Pilot Study Results Richard Heuser Wednesday, October 24 Gary M. Ansel 7:30 a m - My Favorite Devices and 7:50 a m - A Case in Review with the FiberNet Techniques for Retrograde Approach EP System Etsuo Tsuchikane Breakfast Meetings Subbarao V. Mylavarapu 7:45 a m - Case Examples of CTO Intervention 8:00 a m - Adjourn Closing the Gap: Atrial Defect John S. Douglas, Jr

Interventions in Adults 8:00 a m - Adjourn Beyond Angiography: Near-Infrared Sponsored by AGA Medical Corporation Spectroscopy and Other Methods for Room 144C, Washington Convention Center Transcatheter Heart Valve Fundamentals Plaque Characterization Moderator: Ted E. Feldman from Science to Patient: Edwards Sponsored by InfraReDx, Inc

7:00 a m - Opening Comments SAPIEN THV Room 144A, Washington Convention Center Ted E. Feldman Sponsored by Edwards Lifesciences Moderators: James E. Muller, Gregg W. Stone, Room 152A, Washington Convention Center Sergio Waxman, James A. Goldstein 7:05 a m - How to Setup ACHD Practice Moderator: John G. Webb Ted E. Feldman 7:00 a m - Overview of Vulnerable Plaque 7:00 a m - Introduction James E. Muller 7:20 a m - Implant Tips and Tricks John G. Webb John M. Lasala 7:10 a m - Characterization of Non-Flow 7:10 a m - Valve Design, Materials, and Process Limiting Coronary Lesions: PROSPECT and 7:35 a m - Adult Patient: Case Study Review Larry Wood Beyond Howard Hermann 7:30 a m - Delivering the Valve for Procedural Gregg W. Stone 7:50 a m - Q&A and Long-Term Success 7:20 a m - SPECTACL Trial 8:00 a m - Adjourn John G. Webb Sergio Waxman 7:45 a m - Q&A and Conclusion CLI: Real World Treatment Strategies 7:30 a m - Clinical Imperatives for Plaque John G. Webb, Larry Wood Sponsored by Cardiovascular Research Characterization: Scenarios in which Lesion Foundation Interrogation May Be Important The GORE HELEX Septal Occluder: Supported through an educational grant from James A. Goldstein An Innovative Tool For Atrial Septal Abbott Vascular 7:40 a m - Q&A Room 150A, Washington Convention Center Defect Closure 8:00 a m - Adjourn Moderator: Thomas M. Shimshak Sponsored by Gore and Associates Room 154AB, Washington Convention Cente MediGuide Medical Positioning System: 7:00 a m - Welcome Moderators: Michael Slack, First Clinical Experience Thomas M. Shimshak David Hildick-Smith Sponsored by MediGuide, Inc 7:05 a m - Diagnosis of Critical Limb Ischemia Room 143C, Washington Convention Center and Optimal Medical Therapy Moderator: Martin B. Leon Michael R. Jaff

104 truth in evidence based medicine · challenge conventional wisdom · transform your thinking satellite symposia

7:00 a m - Medical Positioning System Thursday, October 25 7:15 a m - Advantages and Experiences with Overview Proximal Embolic Protection in SVGs Martin B. Leon Daniel Dadourian in t ro 7:10 a m - First Clinical Experience Breakfast Meetings 7:30 a m - Interventional Experiences with Andreas Jeron Proximal Embolic Protection in AMI Karel Koch 7:30 a m - Future MPS Applications Clinical Results from the Appraisal Trial: Moshe Y. Flugelman Novel Systematic Delivery of a c-myc 7:45 a m - Q&A

a m RNA Inhibitor for the Prevention of a m tURDAY

7:45 - Q&A 8:00 - Adjourn agenda Restenosis sa 8:00 a m - Adjourn Sponsored by Global Therapuetics Solutions to Peripheral Total Occlusions Room 201, Washington Convention Center Sponsored by Medtronic, Inc Moderator: S. Ward Casscells sun DAY Room 150B, Washington Convention Center 7:00 a m - Welcome agenda Moderators: John R. Laird, Jr, Dirk Schienert S. Ward Casscells

7:00 a m - Introduction 7:05 a m - Overview of NEUGENE® Antisense John R. Laird, Jr Drug, Its Method of Action, and What’s Next

7:05 a m - Treatment Option Overview Patrick L. Iversen agenda mon DAY John R. Laird, Jr 7:15 a m - Results of the APPRAISAL Trial

7:20 a m - Crossing CTOs in the SFA Stefan Sack

Dirk Schienert 7:25 a m - University of Essen IVUS 6-Month

7:40 a m - Crossing CTOs in the Iliac Follow-Up of the APPRAISAL Trial agenda John R. Laird, Jr Sebastian Philipp t ues DAY

7:55 a m - Q&A 7:35 a m - Outline of Upcoming Clinical Trial

John R. Laird, Jr, Dirk Schienert 7:45 a m - Q&A and Closing Remarks

8:00 a m - Adjourn S. Ward Casscells

8:00 a m - Adjourn agenda

Functional Mitral Regurgitation and the wed NESDAY Left Ventricle: A Reshaping Therapy Acute and Chronic Treatment of

Sponsored by Myocor®, Inc Myocardial Infarction Patient Room 143B, Washington Convention Center

Sponsored by Medtronic, Inc case Moderator: Peter Block Room 202A, Washington Convention Center reviews 7:00 a m - Welcome Moderator: Mark A. Turco Peter Block 7:00 a m - Welcome 7:10 a m - Importance of the Left Ventricle Mark A. Turco when Treating FMR

7:10 a m - Washington Hospital Center agenda Robert Bourge t hurs DAY Experience in Treating AMI Patients 7:30 a m - iCoapsys Pre-Clinical Experience Ron Waksman Wesley R. Pedersen 7:20 a m - Case Reviews Using Export 7:50 a m - Q&A Aspiration Catheter t raining 8:00 a m - Adjourn Charles Ilsley physician

Coronary Computed Tomographic 7:40 a m - Managing the AMI Patient Post Procedure Angiography (CTA) and IVUS/FFR: The Robert Dieter New PCI Paradigm t elli e 7:55 a m - Q&A even t s Sponsored by Volcano Corporation sa Room 149AB, Washington Convention Center Mark A. Turco

Moderator: Harvey S. Hecht 8:00 a m - Adjourn

7:00 a m - The New Paradigm of CTA Guided IVUS/FFR for Appropriate, Cost Effective PCI Proxis: Embolic Protection in SVGs and

Harvey S. Hecht AMI: Theory, Evidence and Practice ABS T RAC S Sponsored by St. Jude Medical 7:30 a m - Case Studies Room 202B, Washington Convention Center Harvey S. Hecht Moderator: Gregg W. Stone 7:50 a m - Q&A 7:00 a m - Embolic Protection in SVGs and general 8:00 a m - Adjourn AMI: From Theory to Evidence Gregg W. Stone

www.tct2007.com 105 transcatheter cardiovascular therapeutics

ABSTRACTs

Please see the TCT abstract TCT-9: Assessment of TCT18: Coronary Plaque Burden is TCT-27: Comparison of Simple supplement in the American Percutaneous Transluminal Related to Serum HDL-C Levels, vs. Complex Stenting Strategy for Journal of Cardiology for a Septal Myocardial Ablation in But Not to Other Lipid Parameters: Coronary Artery Bifurcation complete listing of all authors and Hypertrophic Obstructive Volumetric Intravascular Lesions in Daily Practice the text of each abstract. Cardiomyopathy: Evaluation by Ultrasound Analysis Zhan Gao et al Contrast Enhanced Magnetic Eduardo Missel et al TCT-1: Complete vs. Culprit Vessel TCT-28: Impact of Diabetes on Resonance Imaging Percutaneous Revascularization TCT-19: Detection of Lipid-Rich Repeat Revascularization After Kamaldeep Chawla et al in Patients with Non ST-Segment Coronary Plaques through Blood Unprotected Left Main Stenting Elevation Acute Coronary TCT-10: Pooled Analysis in Autopsy Specimens with a in the Drug-Eluting Stent Era. Syndromes of Three Carotid Artery Stenting Novel Catheter-Based Near- A Report from the French Left Anibal A. Damonte et al Trials: Major Adverse Events in Infrared Spectroscopy System Main Taxus Registry Patients with Anatomic vs. Craig Gardner et al Beatriz Vaquerizo et al TCT-2: Biochemical Assessment Physiological Risk Factors of the Atherosclerotic Plaque TCT-20: Detection of Lipid TCT-29: Long-Term Results Barry Katzen et al Necrotic Core Content In Patients Rich Lesions in Human Comparing Simple vs. Complex with Coronary Artery Disease TCT-11: The CAPTURE Registry: Atherosclerotic Plaques by Stenting Techniques in the Adam Rdzanek et al Timing, Distribution, Severity and IntraVascular MRI Catheter Treatment Of Bifurcational Type of Stroke Following Carotid Assaf Weiss et al Unprotected Left Main Disease TCT-3: ST-Segment Analysis Artery Stenting in Symptomatic Primiano Lombardi et al Using Wireless Technology in TCT-21: High Coronary and Asymptomatic Patients Acute Myocardial Infarction Compliance Differential TCT-30: Association of Severity William Gray et al (STAT-MI) Trial Between Stenotic and Distal of Aortic Valve Calcification to James Maher et al TCT-12: New Distal Embolic Arterial Segments is Associated Segmental Coronary Artery Protection Device using a Three with Coronary Artery Disease Disease as Depicted by Number TCT-4: Angiographic Findings Dimensional Filter. Fibernet: Instability of Significantly Diseased Vessels and Outcomes in Unresponsive 1st Carotid Human Study Anthony J. White et al Using 64 Slice Cardiac CT- Patients with ST-Elevation Michel Henry et al Angiography Myocardial Infarction TCT-22: A Prospective, Shah Azmoon et al Resuscitated from Cardiac Arrest TCT-13: Evaluation of Proficiency Multicenter Clinical Trial to Vinay R. Hosmane et al Using a Simulator: Results from Evaluate the BioSTAR TCT-31: Resonant Balloon the Assessment of Operator Bioabsorbable Septal Repair Expandable Stent Designed TCT-5: Cellular Interventional Performance by the Simbionix Implant for the Closure of Atrial for the Improved Visualization Therapy for Non-Revascularizable Carotid StEnting Simulator Study Level Shunts: The BEST-Study and Implantation in MRI Coronary Artery Disease - How (ASSESS) Michael Mullen et al Erwin Immel et al Many Patients are Eligible? Giora Weisz et al Thomas Kiernan et al TCT-23: Transcatheter Device TCT-32: Identification of Culprit TCT-14: Vascular Complications Occlusion of Atrial Septal Defects Vessel in Acute Coronary TCT-6: Infarct Size and Myocardial 1998-2007: Evidence with Pulmonary Hypertension - Syndrome by Cardiac Blood Flow After for Better Outcomes Initial Results from the MAGIC Magnetic Resonance CD 133+ Stem Cells Therapy Robert J. Applegate et al Registry Chiara Lanzillo in Large Myocardial Infarction: Scott Lim A Randomized Controlled Trial TCT-15: Relationship Between TCT-33: Performance Evaluation Alessandro Colombo et al the Use of Vascular Closure TCT-24: Transcatheter Closure of Flat-Panel and 64 Detector Row Devices and Development of of High-Risk Muscular Ventricular CT-for Characterization of TCT-7: Results from the Retroperitoneal Hemorrhage Septal Defects with the Vulnerable Plaque Multicenter, Prospective, Following Percutaneous CardioSEAL Occluder: L. Maximilian Buja et al Randomized, Single-Blind Trial on Coronary Intervention Mid-Term Follow-Up from TCT-34: Drug-Eluting Stents for Intracoronary or Combined Frederic S. Resnic et al the CardioSEAL VSD Registry the Treatment of Chronic Total Percutaneous Intramyocardial and Scott Lim et al Intracoronary Administration of TCT-16: Extravascular Closure Occlusion: A Comparison with Non-Selected Autologous Bone for Patients with High Risk TCT-25: Percutaneous PDA Sirolimus, Paclitaxel, Zotarolimus, Marrow Cells to Patients After Femoral Anatomy Closure Using The Chinese Tacrolimus-Eluting, and EPC Acute Myocardial Infarction Mitchell N. Rashid et al “Blockaid” Duct Occluder: Initial Capture Stent: Multicenter Experience Registry in Asia Mariann Gyongyosi et al TCT-17: Radial Access PCI Is Sunil Thanvi et al Sunao Nakamura et al • TCT-8: Repeated Autologous Associated with Reduced Bone Marrow Mononuclear Transfusion and One Year Mortality TCT-26: DES Use for Bifurcation • TCT-35: The Efficacy of Bilateral Cell Therapy in Patients with Large Rates. M.O.R.T.A.L. Study Lesions Treatment: Is There Any Approach for the Lesions with Myocardial Infarction (Mortality Benefit Of Reduced Difference in Clinical Outcomes Chronic Total Occlusion in Acute Yao Kang et al Transfusion After Angioplasty Between the One- vs. Two-Stent Results CART-Registry Using the Arm or Leg) Strategy? Masashi Kimura et al Alex J. Chase et al Daniela Trabattoni et al

• Top PEER-REVIEWED ABSTRACT

106 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-36: Retrograde Recanalisation • TCT-46: Analysis of Left Main TCT-55: Clopidogrel Pretreatment • TCT-63: The European of Chronically Occluded Coronary Coronary Artery Bifurcation vs. Clopidogrel Exposure Prior to Multicenter, Randomized, Arteries. Initial Multicenter Lesions Treated with Biolimus- PCI in the ACUITY Trial: Does Double-Blind Study of the

Experience Eluting DEVAX AXXESS Plus it Really Matter? Sirolimus-Eluting Stent in the in t ro Georgios Sianos et al Nitinol Self-Expanding Stent: Steve Steinhubl et al Treatment of Patients with De Intravascular Ultrasound Results Novo Coronary Artery Lesions: TCT-37: Recanalization of Chronic TCT-56: Impact of Anemia on of the AXXENT-Trial 5-Year Clinical Outcomes of the Total Coronary Occlusions Using 1-Year Ischemic Events and Takao Hasegawa et al E-SIRIUS TRIAL the CROSSER System as a First Mortality Among Patients with tURDAY

Henning Kelbaek et al agenda

Attempt:The CRAFT-Study TCT-47: JIM Results of Cappella Acute Coronary Syndromes sa Antonio Colombo et al Sideguard™ for Treatment of Undergoing Percutaneous • TCT-64: Three-Year Clinical Coronary Bifurcations Coronary Intervention TCT-38: Pioglitazone Induced Results from the TAXUS V De Eberhard Grube et al Steven V. Manoukian et al Regression and Shift in Novo Trial: Long-Term Safety and Efficacy of the Paclitaxel-Eluting

Plaque Composition In sun DAY TCT-48: The pH Paradox in • TCT-57: Time Course of agenda TAXUS Stent in Complex Lesions Coronary Atherosclerosis: Humans: Impact of Rapid Neointimal Coverage Following Stephen G. Ellis et al Insight from an Intravascular Restoration of Local Acid Loading Sirolimus-Eluting Stent Ultrasounds Analysis on Reperfusion Injury Implantation: Up to Two Years • TCT-65: Safety and Durable Fabrizio Clementi et al in Acute Myocardial Infarction Serial Angioscopic Study Efficacy of the Polymer-Based, agenda Naoto Kino et al Masaki Awata et al mon DAY TCT-39: Yellow Plaques Remain Paclitaxel-Eluting TAXUS Stent: Final 5-Year Outcomes from the After Sirolimus-Eluting Stent TCT-49: Infarct Thickening with • TCT-58: The Impact of Stent TAXUS IV Trial Implantation: Angioscopic Hydroxyapatite Gel Attenuates Left Thrombosis on the Long-Term Gregg W. Stone et al Comparison with Bare-Metal Ventricular Remodeling After MI Efficacy of Drug-Eluting Stents in Stents Liam P. Ryan et al Patients with Acute Myocardial • TCT-66: Stent Thrombosis, agenda Masaki Awata et al Infarction - Insights into the Myocardial Infarction, and t ues DAY TCT-50: Clinical Outcome RESEARCH and T-SEARCH Mortality Following Drug-Eluting TCT-40: First Results of a Following PCI Using Titanium- Registries and Bare Metal Stent Coronary New Method for Angiographic Nitride-Oxide Coated Stents in Joost Daemen et al Interventions in Patients with Calculation of Coronary Flow Complex Patients Diabetes Mellitus

Reserve Stephan Windecker et al TCT-59: Four-Year Follow-Up agenda

Michael Maeng et al wed NESDAY Harald Rittger et al Patients with ST-Segment TCT-51: Short- and Mid-Term Elevation Acute Myocardial • TCT-67: ABSORB Trial: Twelve TCT-41: A Flow-Guided Concept Intravascular Ultrasound Analysis Infarction Treated with Sirolimus- Months Results of Clinical to Treat Side Branches in of the New ENDEAVOR CR Eluting Stent and Paclitaxel- Evaluation of the Bioabsorbable

True Bifurcation Lesions: Zotarolimus-Eluting Stent: Insights case

Eluting Stent: Multicenter Registry Everolimus-Eluting Coronary Stent reviews A Randomized Clinical Study from the Sunao Nakamura et al System in the Treatment of (Thueringer Bifurcation Study, RESOLUTE Trial Patients with De Novo Native THUEBIS-Study) Katsuhisa Waseda et al • TCT-60: Triple Antiplatelet Coronary Artery Lesions Hubertus von Korn et al Therapy Improves Long-Term TCT-52: Near-to-Complete Short Patrick W. Serruys et al Outcomes After Percutaneous

TCT-42: The PATRIOT (Peripheral Term Re-Endothelialization in agenda Coronary Intervention in Patients • TCT-68: Percutaneous Treatment t hurs DAY Approach To Recanalization In Sirolimus-Eluting DES Using with Acute Coronary Syndromes of Unprotected Left Main Coronary Occluded Totals) Study Results Electro-Grafting Technology (eG™) Yaling Han et al James Joye et al Renu Virmani et al Stenoses with Paclitaxel-Eluting Stents. Mid-Term Results of a • TCT-61: Diabetes as a Predictor TCT-43: Renal Angioplasty and TCT-53: Twelve-Month Clinical French Prospective Multicenter for Stent Thrombosis, Myocardial t raining Stenting Under Protection. Outcomes Post Absorbable Metal Study (FRIEND Register) physician Infarction and Mortality After Limitations. First Human Study Stent Implantation in Human Didier Carrié et al Coronary Stent Implantation - with a 3-D Filter: The Fibernet Coronary Arteries: Results from the A Danish Population-Based • TCT-69: Impact of Sirolimus- Michel Henry et al PROGRESS Study Cohort Study Eluting Stent and Paclitaxel-

Ron Waksman et al t elli e TCT-44: Endovascular Repair of Michael Maeng et al Eluting Stent on the Outcome even t s sa Thoracic Aortic Aneurysms and TCT-54: Long-Term Outcomes of of Patients with Sirolimus-Eluting TCT-62: Predictors of Adverse Symptomatic Type B Dissections Patients with Acute Coronary Stent Failure: Multicenter Registry Events in Patients with in High-Risk Non-Surgical Syndromes and Chronic Renal Sunao Nakamura et al Unprotected Left Main Disease Patients: Results of a Insufficiency Undergoing Treated with Drug-Eluting Stents: • TCT-70: Long-Term Results Single-Center Study Percutaneous Coronary

Evidence from a Collaborative After Sirolimus-Eluting Stent ABS T RAC S Joaquin Solis et al Intervention and Being Treated Meta-Regression Implantation for In-Stent with Bivalirudin vs. Heparin Plus a TCT-45: Chronic Mesenteric Giuseppe Biondi Zoccai et al Restenosis: Evidence for a Glycoprotein IIb/IIIa Inhibitor: Ischemia: Experience With PTA/ Late Catch-Up Phenomenon? Results from the Randomized Stenting in Celiac and SMA Imad Sheiban et al

ACUITY Trial general Disease in 99 Patients Roxana Mehran et al David E. Allie et al

www.tct2007.com 107 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-71: Prevalence and Clinical • TCT-80: High Clopidogrel • TCT-89: Long-Term Durability TCT-97: Gene Transfer of Sarco/ Implication of Stent Fracture Maintaining Dosage Improves of Endoluminal Stenting for Endoplasmic Reticulum Calcium After Sirolimus-Eluting Stent Long-Term Clinical Outcomes in Obstructive Lesions of the ATPase Inhibits Neointima Implantation - The Impact Patients with Acute Coronary Subclavian Artery: Multicenter Formation in Human Mammary of Lesion Complexity Syndrome Undergoing Drug Registry Arteries While Augmenting Kazushige Kadota et al Eluting Stent Implantation Sunao Nakamura et al Endothelial Cell Proliferation Yaling Han et al Roger Hajjar et al TCT-72: Long-Term (Up to 5 Years) • TCT-90: The Long-Term Clinical Outcomes of Drug -Eluting TCT-81: Variability In P2Y12- Prognosis of Patients with Small TCT-98: Diagnostic and Prognostic Stents for Coronary In-Stent Mediated Platelet Reactivity Is Abdominal Aortic Aneurysms Values of Platelet Glycoprotein IIb/ Restenosis in the Real World - Not Associated with Peri- Following Surgery or Surveillance: IIIa Gene Polymorphism in the Insights from the DESIRE-ISR procedural Ischemic Events 12-Year Final Follow-Up of Pathogenesis of In-Stent Registry in Patients on Maintenance Patients Enrolled in the UK Restenosis Julio P. Maia et al Clopidogrel Therapy Treated Small Aneurysm Trial Helmy H. El-Ghawaby et al with Bivalirudin Monotherapy R. M. Greenhalgh et al • TCT-73: Late and Very-Late TCT-99: Regional STEMI Networks Matthew J. Price et al Stent Thrombosis Following TCT-91: Increased Incidence of in Southern California Reduce Elective Drug-Eluting Stent TCT-82: Clopidogrel Resistance Device-Related Complications Door-to-Balloon Times: Pooled Implantation in Unprotected and Stentthrombosis: A Causal with the Use of SilverHawk Data from 4 Counties Left Main Coronary Artery: Relation? Atherectomy for the Treatment Ivan C. Rokos et al A Multicentre Registry Stefan Hoffmann et al of Infrainguinal Peripheral Arterial • TCT-100: The FINESSE Alaide Chieffo et al Disease TCT-83: Impact of Cilostazol (Facilitated Intervention with Luis A. Guzman et al TCT-74: Dual Antiplatelet Therapy on Performance of Drug-Eluting Enhanced Reperfusion Speed to Following Percutaneous Coronary Stent According to Stent Type • TCT-92: Three-Year Follow-Up Stop Events) Trial: Results of the Intervention with Stent Subgroup Analysis of After Carotid Artery Stenting in Formal Low Molecular Weight Implantation in Patients on DECLARE Trial High Surgical Risk Patients: The Heparin Substudy Chronic Oral Anticoagulation Seung-Whan Lee et al BEACH and CABERNET-Trials Gilles Montalescot et al Renata Rogacka et al Christopher J. White et al • TCT-84: Long Term Results of TCT-101: Primary PCI Performed TCT-75: Percutaneous Coronary Stenting TASC C Lesions in the TCT-93: Report of the U.S. with Delay <120 Minutes from Interventions in Patients ≥90 Years SIROCCO II Study: Multi-Center, Experience in Post Marketing Diagnosis Seems Acceptable in of Age: Are We Pushing the Limits? Prospective, Double-Blinded, Trials in Carotid Stenting in Terms of Short-Term Clinical Abid Assali et al Randomized, Two-Arm Feasibility Asymptomatic High Surgical Risk Outcomes. Results from Clinical Investigation of the Cordis Patients: Achievement EUROTRANSFER Registry TCT-76: Transfer of ST-Elevation Sirolimus Coated SMART™ Nitinol and Characterization of Zbigniew Siudak et al Myocardial Infarction Patients Selfexpandable Stent for the Targeted Outcomes with Cardiogenic Shock for TCT-102: Safety and Efficacy of Treatment of Obstructive William A. Gray et al Primary Percutaneous Coronary Bivalirudin With and Without Superficial FemoralA rtery Disease Intervention TCT-94: Closed- or Open-Cell Glycoprotein IIb/IIIa Inhibitors in Dierk Scheinert et al Timothy D. Henry et al Stents in Carotid Artery Stenting? Patients with Acute Coronary • TCT-85: Severe Calcification and Short-Term Outcome of Patients Syndromes Undergoing TCT-77: Impact of Distal Length of Stented Segments Are Undergoing Carotid Stenting Embolization Occurring Percutaneous Coronary Inter- Independent Risk-Factors for Stent According to the During Direct-PCI on Infarct vention: 1-Year Results from the Fractures Stent Type Size and Infarct Transmurality: Randomized ACUITY Trial Jacqueline Sax et al Dimitrios N. Nikas et al Harvey D. White et al A Magnetic Resonance Imaging Study • TCT-86: Diagnostic Accuracy of TCT-95: Hyperperfusion Syndrome TCT-103: Nationwide Trends Massimo Napodano et al Renal Pressure Measurements to Following Carotid Artery Stenting: in the Utilization of Coronary Assess the Significance ofR enal The Largest Single-Operater Series Artery Bypass Surgery (CABG) TCT-78: Coronary Stent Artery Stenosis: Comparison with to Date Prescription with Computed in the US Intravascular Ultrasound, Hutton P. Brantley et al Mohammad Reza Movahed et al Tomographic Coronary Angiography Quantitative Angiography, Christopher A. Glover et al • TCT-96: Cytotoxic T-Lymphocyte • TCT-104: Temporal Trends in and Duplex Ultrasound Antigen 4 Gene Polymorphism Coronary Revascularization TCT-79: Carotid Angioplasty and Massoud A. Leesar et al Associated with ST-Segment Stenting Under Protection Is Procedures, Outcomes, and Costs: TCT-87: Interim Report on the Elevation Acute Myocardial Becoming the Gold Standard Results from the US Medicare Zilver(R) PTX(TM) Clinical Trial Infarction Treatment of a Carotid Stenosis in Program Gary M. Ansel et al Hon-Kan Yip et al Jason W. Ryan et al High- and Low-Risk Patients Michel Henry et al • TCT-88: Treating Below-Knee Critical Limb Ischemia with Drug Eluting Stents. Early and Late Clinical Outcomes • Top PEER-REVIEWED ABSTRACT Andrew Feiring et al

108 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-105: Comparison of Outcomes TCT-114: Efficacy of Triple • TCT-124: Percutaneous TCT-134: Treatment of Patients Between Patients Undergoing Antiplatelet Therapy for Diabetic Treatment of Functional with Single Lesion in the Proximal Percutaneous Coronary Stent Patients After Percutaneous Mitral Regurgitation: Interim Segment of Left Anterior

Implantation with Eptifibatide and Coronary Intervention Evolution Study Results with Descending Artery Suffering from in t ro Abciximab: An Analysis Using Yaling Han et al the Monarc System Chronic Stable Angina. Drug- Propensity Score Methods Karl-Heinz Kuck et al Eluting Stents vs. Surgical TCT-115: Effect of Jean-Pierre Dery et al Treatment with Left Internal Lipid Lowering Therapy on TCT-125: Percutaneous Trans- Mammary Artery Grafting • TCT-106: Outcomes and Progression of Intermediate Coronary-Venous Repair of Mitral tURDAY

Eleftherios Tsiamis et al agenda

Complications with Off- vs. Coronary Atherosclerotic Plaque Valve Using CARILLON™ Device. sa On-Label Use of Drug-Eluting Evaluated by Virtual Histology Initial Single-Center Experience TCT-135: Comparison of Vascular Stents: Results from the Intravascular Ultrasound Tomasz Siminiak et al Response to Zotarolimus-Eluting STENT-Registry Kenya Nasu et al Stent vs. Paclitaxel-Eluting Stent TCT-126: Long-Term Durability Bruce R. Brodie et al Implantation: IVUS Results from sun DAY

TCT-116: Impact of Transfusion and Safety of Percutaneous agenda the Zomaxx I Trial TCT-107: Defective Insulin on 1-Year Ischemic Events and Septal-Sinus Shortening Katsuhisa Waseda et al Signaling Induces a Relative Mortality Among Patients with Jason Rogers et al Resistance to Rapamycin via Loss Acute Coronary Syndromes • TCT-136: Efficacy and Safety at TCT-127: Percutaneous Reduction of mTOR Regulation of p27Kip1 Undergoing Percutaneous 3 and 5 Years in the Canadian of Periprosthetic Leaks: A agenda Protein Levels Coronary Intervention Multicenter, Randomized, mon DAY Promising Alternative T. Cooper Woods et al Steven V. Manoukian et al Double-Blind Trial of the to Repeat Surgery Sirolimus-Eluting Stent in TCT-108: Increased Tissue Factor TCT-117: Is N-acetylcysteine Jeannot Potvin et al the Treatment of Patients Expression after DES Implants in Effective for Prevention of TCT-128: Indications, Description, with De Novo Coronary Porcine Coronary Arteries May Contrast-Induced Nephropathy?

and Results on Percutaneous agenda Contribute to Cezar S. Staniloae et al Artery Lesions (C-SIRIUS) t ues DAY Transcatheter Repairs of Mitral Erick Schampaert et al Late Stent Thrombosis • TCT-118: Transarterial Paravalvular Regurgitations Go Haraguchi et al TCT-137: Safety and Efficacy Percutaneous Aortic Valve Marcelino Cortés et al of Switching from Either TCT-109: Influence of Metabolic [PAV] Insertion: Canadian TCT-129: Long-Term Follow-Up Unfractionated Heparin or

Syndrome on Coronary Single Centre Experience agenda of Percutaneous Closure of Atherosclerosis. Angiographic Sanjeevan Pasupati et al Enoxaparin plus a Glycoprotein wed NESDAY Left Atrial Appendage Evaluation of 500 Patients with IIb/IIIa Inhibitor to Bivalirudin • TCT-119: Six-Month to One-Year GianPaolo Ussia et al Monotherapy in Patients with Stable and Unstable Angina Clinical Outcomes Following Stefano Galli et al TCT-130: PROTECT-I: A Non-ST-Elevation Acute Coronary

Retrograde Percutaneous Aortic case Prospective Feasibility Trial Syndromes Managed with an TCT-110: Non-Invasive Imaging of Valve Replacement in High-Risk reviews Investigating the Use of the Invasive Strategy: Results from the the Human Coronary Sinus and Its Patients: A Report from the IMPELLA® RECOVER® LP Randomized ACUITY Trial Relationship to Mitral Annulus and REVIVAL-II Trial 2.5 System in High-Risk Harvey White et al Coronary Arteries in Normal and Susheel Kodali et al PCI Patients Mitral Regurgitation Patients TCT-138: Application of • TCT-120: Transapical Aortic William O’Neill et al Statistical Process Control to Plot agenda Olivier Dubreuil et al t hurs DAY Valve Implantation in High- TCT-131: First-in-Man Use the Door-to-Balloon Time for Data TCT-111: The Effect of Debulking Risk Surgical Patients: of the Reitan Catheter Pump Feedback and Analysis in Patients Pre-Drug Eluting Stent for Medium Term Results (RCP) for Circulatory Support Presenting with Acute Myocardial Bifurcated Coronary Lesions in Michael A. Borger et al in Patients Undergoing High- Infarction Unprotected Left Main: Sub Babu Kunadian et al t raining TCT-121: Six-Month Echo Risk Percutaneous Coronary physician Analyses of PERFECT-Registry Assessment of Prosthetic Intervention (PCI) Yuji Oikawa et al TCT-139: Safety and Clinical Aortic Valve Function Following Martin T. Rothman et al Utility of the TAXUS Express Stent TCT-112: First-in-Man Experience Transcatheter Aortic Valve • TCT-132: Safety and in Unstable and Stable Angina:

with Foxhollow™ Coronary Plaque Replacement: A Report A Pooled Analysis of TAXUS t elli e Feasibility of Percutaneous even t s Excision Device for Treatment of from the REVIVAL-II Trial sa Autologous Skeletal Myoblast Randomized Clinical Trials Complex Coronary Bifurcation Mathew Williams et al Transplantation for Ischemic Keith D. Dawkins et al Lesions TCT-122: Re-Dilation of Balloon Cardiomyopathy: 1-Year Results R. Stefan Kiesz et al TCT-140: Why Do the Patients Expandable Aortic Valves [BEAV]: of the CAUSMIC Trial with Myocardial Infarction Due to TCT-113: Orbital Atherectomy for What do we Know? Nabil Dib et al Left Circumflex Artery Occlusion Percutaneous Treatment of Below Sanjeevan Pasupati et al ABS T RAC S TCT-133: Heart Failure Not Receive Reperfusion Therapy? the Knee Vascular Stenosis: • TCT-123: Significant Reverse Improvement After Autologous Stanislav Simek et al Results of the OASIS Multicenter Remodeling of the Left Ventricle Bone Marrow Mononuclear Study One Year After Percutaneous Cells (abmmc) Transplantation

Khusrow Niazi et al general Mitral Repair with the MitraClip™ Jorge Tuma-Mubarack et al Device Michael Rinaldi et al

www.tct2007.com 109 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-141: Relationship Between TCT-149: Effect of Prolonged Dual TCT-159: Preliminary Results of TCT-168: The Impairment of Left Door-to-Balloon Delay and Antiplatelet Therapy Following the Novel TMI (TriReme Medical Ventricular Rotation Assessed by a Mortality in Patients with Stemi Drug-Eluting Stent Implantation Inc.) Antares Side Branch (SB) Two-Dimensional Speckle-Tracking Undergoing Primary Angioplasty on Risk of Bleeding Events Adaptive System (Antares SASTM Echocardiography Is an Important After Inter-Hospital Transfer. Nuccia Morici et al Stent) for the Treatment of De Predictor for Detection of Ischemia The Real Registry Novo Coronary Bifurcation Lesions Induced Left Ventricular TCT-150: Optimal Platelet Antonio Manari et al Ricardo A. Costa et al Dysfunction Inhibition After PCI: Data from the Takashi Yamano et al TCT-142: A Comparative Study on Optimal Platelet Inhibition with TCT-160: Treatment of Coronary the Feasibility and Safety TIrofiban and Variable Clopidogrel Bifurcation Lesions with a Novel TCT-169: Association of Mitral of Transulnar Artery vs. Transradial Dosing Post Percutaneous Dedicated Stent: Procedural and Valve Calcification to Coronary Artery Access for PCI in Patients Coronary Intervention Trial: Clinical Outcomes Artery Calcium Using 64-Slice with Coronary Heart Disease The OPTIC Trial Ricardo M. Falú et al Cardiac Computed Tomography Xianghua Fu et al H. M. Mardikar et al Ramin Ebrahimi et al TCT-161: Use of Drug-Eluting TCT-143: The Effect of Post- TCT-151: VASP Phosphorylation Stents for the Treatment of TCT-170: Association of Presence Dilation of the Culprit Lesion on Analysis Prior to Percutaneous Coronary Bifurcation Lesions. and Severity of Mitral Valve the Outcomes of Patients Coronary Intervention for Exclusion Results from a Large Real Calcification to Significant Undergoing Primary Percutaneous of Post-Procedural Major Adverse World Registry Coronary Artery Stenosis Using Coronary Intervention for Acute Cardiovascular Events Helen Routledge et al 64-Slice CT-Angiography Myocardial Infarction Laurent Bonello et al Norman E Lepor et al TCT-162: Impact of Left David Brosh et al TCT-152: Cilostazol Could Circumflex Ostium During TCT-171: Is Drug-Eluting Stent TCT-144: Efficacy of a 24-Hour Ameliorate Platelet “Crossover” Drug-Eluting Stent Necessary for Coronary Primary Percutaneous Coronary Responsiveness to Clopidogrel Implantation in Left Main Revascularization in Intervention Service on in Patients Undergoing Primary Coronary Artery: An Intravascular Immunosuppressed Post- Outcome in Patients with Percutaneous Coronary Ultrasound Study Transplant Patients? STEMI in Clinical Practice Intervention Katsumasa Sato et al James A. Burke et al Rainer Hoffmann et al Lee Kyounghoon et al TCT-163: Quantitative Analysis TCT-172: Antiplatelet Therapy • TCT-145: Influence of TCT-153: Do Obese Patients Allows to Predict Side Branch Does Not Increase the Omeprazole on the Antiplatelet Undergoing Percutaneous Coronary Compromise After Main Branch Complication Rate of Action of Clopidogrel Associated to Intervention Require a Higher Stenting of Bifurcation Lesions Endomyocardial Biopsy in Aspirin: The Randomized Clopidogrel Loading and Dobrin I. Vassilev et al Cardiac Transplant Recipients Double-Blind Ocla Study Maintenance Dose? George V. Moukarbel et al TCT-164: Continued Dynamic Martine Gilard et al Mohammed Abuzahra et al Improvement in Valve Function • TCT-173: Circulating • TCT-146: Low Dose Aspirin TCT-154: Platelet Function in from Procedure to Discharge Mesenchimal Stem Desensitization Protocol is Safe the Early Phase of Acute in the (COREVALVE) Self- Cells and Progression of and Efficient Before Coronary Myocardial Infarction Expanding Percutaneous Aortic Coronary Atherosclerosis Intervention in Allergic Patients Zenon Huczek et al Bioprosthesis: UK TEE Substudy vs. In-Stent Restenosis Stephane Mock et al Hasan A. Jilaihawi et al Francesco Pelliccia et al TCT-155: Platelet Behaviour TCT-147: Preoperative After Thienopyridine Treatment TCT-165: Non-Invasive Imaging of TCT-174: Oct-4+ Very Small Thienopyridine Use in Patients Discontinuation in Patients the Human Coronary Sinus and Its Embrionic-Like Stem Cells in with Non-ST-Elevation Acute with DES Relationship to Mitral Annulus and Adult Bone Marrow with Potential Coronary Syndromes Undergoing Daniela Trabattoni et al Coronary Arteries by Multidetector for Cardiac Differentiation - Novel Coronary Artery Bypass Surgery Computed Tomography Population of Cells for TCT-156: Comparison of Reduces Adverse Ischemic Events: Olivier Dubreuil et al Cardiac Repair Studies Atorvastain 10 mg vs. 40 mg 1-Year Results from the Wojciech Wojakowski et al in Clopidogrel Resistance after TCT-166: Assessment of Left ACUITY Trial Coronary Stenting in Patients with Atrial Appendage Ejection Fraction TCT-175: The “MarrowMiner”: A Ramin Ebrahimi et al Acute Coronary Syndrome in Three Dimensions with 64-Slice Minimally Invasive Device and TCT-148: Prolonged Dual Soon Jun Hong et al Computed Tomography Method for the Rapid Harvest of Antiplatelet Therapy Improves Hidehiko Hara et al Marrow Derived Stem Cells for Use TCT-157: Optimizing Provisional Clinical Outcomes After Sirolimus- in Regenerative Medicine: T-Stenting in a Bench Model TCT-167: The Role of Multislice Eluting Stents Implantation in Evaluation in Cadavers and Manfred Zehetgruber et al Computed Tomography in the High-Risk Patients Porcine Models Assessment of Transcatheter Aortic Dean Jia et al TCT-158: Complex Forms of Daniel Kraft et al Valve Replacement Asymmetry Within the Ostial David A. Wood et al Junction: Novel Insights from Ex Vivo Analysis of Human Coronary Bifurcations • Top PEER-REVIEWED ABSTRACT Mary E. Russell et al

110 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-176: Comparison of TCT-185: Endothial Cell- TCT-196: Self-Expanding TCT-206: Is Carotid Artery the Different Timing for Dependent Niche Contributes Stents Designed for the Stenting a Durable Technique? Intracoronary Administration to Self-Renewal and Expansion of Improved Visualization and Acute and Up to Four-Years

of Bone Marrow Mononuclear Cell Cd34+ Progenitor Cells Delivered Implantation in MRI Long-Term Clinical Results from a in t ro After Acute ST-Elevation by Coronary Arteries Irwin Immel et al Single-Center Consecutive Series Myocardial Infarction Shaoheng Zhang et al of Patients TCT-197: Combined Intraoperative Rongchong Huang Piero Montorsi et al TCT-186: Coronary Collateral Innominate and Common Carotid TCT-177: Catheter-Based Growth After Sirolimus-Eluting Intervention with Simultaneous TCT-207: Renal Dysfunction - tURDAY agenda

Endomyocardial Injection of Stent Implantation Compared with Carotid Endarterectomy: A “True” A Significant Predictor of sa Umbilical Cord Blood-Derived Bare Metal Stent Implantation Endovascular Hybrid Approach Long-Term Morbidity and Mortality Stem Cells Fails to Modify LV Hideaki Kaneda et al David E. Allie et al in Carotid Artery Stenting Function in a Porcine Chronic Fareed Shaikh et al TCT-188: The Interleukin Ib-511 TCT-198: Safety of New Device- Myocardial Infarction Model sun DAY Polymorphism is Associated with Based Approach for Treating TCT-208: Carotid Stenting: agenda Dongming Hou et al the Risk of Developing Restenosis Diastolic Heart Failure Six-Year Experience Based on a TCT-178: Serial In Vivo Tracking of After Coronary Stenting in Mexican Shay Dubi et al Large Series of 1218 Patients Intramyocardially Injected Patients Francesco Bedogni et al TCT-199: The Acute and Chronic Autologous Bone Marrow Emma Miranda Malpica et al Effect of Force on Myocardium TCT-209: Safety of Carotid agenda Origin Mesenchymal Stem mon DAY TCT-189: Feasibility of Molecular Local Geometry and Dynamics Artery Stenting in Persons Cells, Modified for Transgene Analysis of Percutaneously Lea Lak et al Aged 80 and Over Expression of Positron-Emission Collected Peripheral Atheroma George S. Chrysant et al Tomography Reporter Gene in TCT-200: Serial Quantitative Brian L. Stauffer et al Porcine Myocardial Infarction Coronary Analyses for the TCT-210: Trans-Radial / Trans-

TCT-190: Directed Evolution of Evaluation of 1-Year Change in Brachial Carotid Stenting Safety agenda

Mariann Gyongyosi et al t ues DAY Human Apolipoprotein A-I Milano Saphenous Vein Grafts and Feasibility Trial TCT-179: TransCatheter Protein and Expression Nobuaki Suzuki et al Chiung-Jen Wu et al Transplantation of Stem Cells for in Escherichia Coli Treatment of Acute Myocardial TCT-201: First US Experience with TCT-211: Association of Carotid Benjamin M. Althouse et al Infarction (TCTSTAMI 2): a Percutaneous Surgical VAD Disease Using Ultrasound to • TCT-191: Reduced Mark Anderson et al Coronary Artery Stenosis and agenda

6-Month and 12-Month wed NESDAY Postprocedural Stay with Coronary Calcium Using 64 Slice Follow-Up Outcomes TCT-202: Simultaneous Coronary Rongchong Huang et al Percutaneous AVR (pAVR): Cardiac CT-Angiography Revascularization Combining First UK Experience of pAVR Using Hooman Madyoon et al TCT-180: Spontaneous Endoscopic Bypass Grafting and

a Self-Expanding System case PCI: Intraoperative Experience in TCT-212: Age-Related Outcomes

Neovascularization After reviews Hasan A.Jilaihawi et al Myocardial Infarction Documented Elective and Emergency in Carotid Artery Stenting - Is It by Quantitative Myocardial • TCT-192: Targeted Renal Procedures Safe in the Elderly? Contrast Echocardiography: Its Therapy in High-Risk Cardiac Guy J. Friedrich et al Raaid Museitif et al Surgery: Early Safety and Correlates to Endothelial TCT-203: A Combined Surgical TCT-213: The CROSSER CTO

Progenitor Cells Feasibility with a Novel Catheter agenda and Percutaneous Approach Recanalization Catheter - t hurs DAY Treatment for Renal Function Motoo Date et al Through the Axillary Artery to Worldwide Coronary Results Preservation During High-Risk TCT-181: A Novel Subset of Introduce the Impella Recover LP Louis Cannon Coronary Artery Bypass Grafting T-Cells (Angiogenic T-Cells) 5.0 for Short-Term David E. Allie et al TCT-214: A Major Challenge in the Circulatory Support Facilitates EPC Differentiation and Interventional Era: Prognostic t raining TCT-193: The QuantumCor Kayan Y. Lam et al physician Has Clinical Relevance Impact of Drug-Eluting Stent for RF Device: A Less Invasive Han-Mo Yang et al • TCT-204: Defining the High Coronary Chronic Total Occlusion Alternative to Surgical MVR TCT-182: In Vivo Transfer of Endovascular Risk Patient with David Antoniucci et al Richard R. Heuser et al Carotid Stenosis: Insights from the Human Chemokine-Like Factor 1 TCT-215: Incidence and Treatment t elli e Gene Improves the Function TCT-194: Comparison of Cordis Carotid Stent Collaborative even t s Outcomes of Chronic Total sa Stent or Bypass Surgery Herbert D. Aronow et al of Myocardium and Enhances Occlusions: A Report from the for the Midterm Results Myocardial Proliferation in Acute TCT-205: Different Tissue 2000 to 2001 New York State of Left Main Disease Myocardial Infarction Rats Composition of Carotid and Angioplasty Registry Jin-Ho Choi et al Liu Qianzhu et al Coronary Atherosclerotic Plaques Christopher L. Gade et al

TCT-195: Resonant Nitinol in Symptomatic Patients (Virtual ABS T RAC S TCT-184: Validation of a New TCT-216: Are Second Attempts Prosthetic Heart Valve for Histology Study) Percutaneous Porcine Chronic Justified After a Failed MRI Guided Implantation Arkadiusz L. Pietrasik et al Myocardial Ischemia Model Intervention in Coronary Erwin Immel et al Utilizing a Reduction Stent Chronic Total Occlusions? Xiaoshun Liu et al Kotaro Obunai et al general

www.tct2007.com 111 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-217: Recanaliztion of the TCT-224: One-Year Outcomes for TCT-232: Long-Term Outcomes TCT-241: Lack of Clinical Stumpless Chronic Total Occlusion Recanalization of Long SFA CTO’s After Sirolimus-Eluting Stent Long-Term Benefit of Drug Under Intravascular Ultrasound with the Viabahn (WL Gore & Implantation for Right Coronary Eluting-Stent Compared Guidance Associates, Flagstaff, AZ) Stent Artery Ostial Lesions: 1-Year to Bare Metal Stent in Saphenous Juhwan Lee et al Graft in Claudicants Clinical Follow-Up Results Vein Grafts Ashish Pershad from j-Cypher Registry Giuseppe Gioia et al TCT-218: Immediate and Hiroshi Ueda et al Mid-Term Outcomes of 100 TCT-225: Clinical Outcomes TCT-242: Late Luminal Response Consecutive Chronic Total After Successful Percutaneous TCT-233: Comparison of Coronary After Stenting in Chronic Total Occlusions (CTO) Treated Revascularization of Chronic Artery Bypass Surgery and Occlusions: A Comparison with the Star Technique Total Occlusions in the Drug- Percutaneous Drug-Eluting Stent Between Bare Metal Stent and Cosmo Godino et al Eluting Stent Era Implantation for Treatment of Left Sirolimus-Eluting Stent Kotaro Obunai et al Main Coronary Artery Stenosis: Implantation TCT-219: Four-Year Durability Analysis by Propensity Score Hiroyuki Tanaka et al of Sirolimus-Eluting Stent in TCT-226: Clinical Results Adjustment and by Surgical Risk Patients with Chronic Total of Percutaneus Coronary TCT-243: Bio-Engineered R-Stent Anthony J. White et al Occlusions Compared with Intervention for Chronic Total with Endothelial Progenitor Cells Bare Metal Stent: Multicenter Occlusion: Predictive Factor for TCT-234: Gender Differences (EPCs): 6-Month Clinical Registry in Asia Procedural Failure in Recent in Hospital Mortality After Follow-Up in Real World PCI Sunao Nakamura et al Technical Development and Percutaneous Coronary Registry New Stiff Guide Wire Era Intervention Yoon-Sin Chong et al TCT-220: Comparison of Efficacy Masanori Shiba et al Talia Chilon et al and Durability of Sirolimus-Eluting TCT-245: Drug-Eluting Stents Stent and Paclitaxel-Eluting Stent TCT-227: Retrograde Percutaneous TCT-235: Gender Difference in for the Treatment of Left Main in Patients with Chronic Total Recanalization Of Coronary Clinical Outcomes Following Coronary Artery Disease with Occlusions: Multicenter Registry Chronic Total Occlusions: Sirolimus-Eluting Stent Sirolimus, Paclitaxel, Zotarolimus, Sunao Nakamura et al Outcomes and Technical Tips and Implantation: A Long-Term (Up Tacrolimus-Eluting Stent, and EPC Tricks From 17 Patients to 5 Years) Clinical Follow-Up Capture Stent: Multicenter TCT-221: Role of Low-Dose Giuseppe Biondi Zoccai et al Daniela Trabattoni et al Dobutamine and Contrast Registry in Asia Sunao Nakamura et al Enhanced Cardiac MRI to Predict • TCT-228: OLYMPIA Global TCT-236: Angiographic Variables Functional Recovery in Patients TAXUS Liberté Registry: 12-Month That Predict Troponin Release TCT-246: Four-Year Durability of with Chronic Coronary Total Results in High-Risk Subsets in Following Elective Percutaneous Sirolimus-Eluting Stent in Patients Occlusion and Benefits of the First 7,000 Patients Coronary Intervention with Unprotected Left Main Percutaneous Revascularization. Oscar A. Mendiz et al Stephen P. Hoole et al Coronary Arteries Compared with MRI, Coronary Angiography and Bare Metal Stents: Multicenter • TCT-229: Risk of Death and TCT-238: Real-World Safety Clinic Follow-Up at Six Months Registry in Asia Myocardial Infarction in Patients and Efficacy of the Endeavor After Successful PCI Intervention Sunao Nakamura et al With and Without Repeat Zotarolimus-Eluting Stent: 1-Year Fabio A. Sgura et al Revascularization Following Clinical Outcomes in the First TCT-247: Insulin Resistance, TCT-222: Effect of Stenting 2,000 Patients in ENDEAVOR FIVE Thrombotic Events and Impact of Re-canalization for Chronic Total J. Dawn Abbott et al Chaim Lotan et al Antiplatelet Therapy Following Occlusion with Drug-Eluting Stent PCI: Results of the CREDO- • TCT-230: Sirolimus-Eluting TCT-239: Comparison of on Viable Myocardium and Cardiac Insulin Resistance Substudy Stents Reduce the Incidence of Long-Term Outcomes of Drug- Performance in Patients With or Rohit Bhatheja et al Late Adverse Events in Patients Eluting Stent vs. Bare Metal Stent Without Diabetes Mellitus with Small Coronary Arteries. in Patients with Stable Angina in TCT-249: The Angiographic and Xianghua Fu et al The SES-SMART-Long-Term the Real World Setting: No Clinical Impact of Lesion Full TCT-223: Short-Term Outcomes Clinical Study Sustained Suppression of Efficacy Coverage Using Sirolimus-Eluting Following Revascularization of Alberto Menozzi et al After Drug-Eluting Stent Stenting: Full-Cover Stenting vs. Symptomatic Lower Extremity Nobuaki Kokubu et al Spot Stenting TCT-231: In-Hospital Mortality of Chronic Total Occlusions Using Tomoko Gochi et al Compassionate-Use Percutaneous TCT-240: The Presence of a Controlled Blunt Microdissection Coronary Intervention (PCI): A Chronic Total Occlusion in Patients TCT-250: Incidence, Predictors, Catheter - A Single Center Single Center Experience and with St-Elevation Myocardial and Clinical Implications of Stent Experience Implications for the Public Infarction is Responsible for the Thrombosis After Percutaneous Mallik Thatipelli et al Reporting of Physician-Specific Increased Mortality Related with Coronary Intervention for PCI Outcomes Multivessel Coronary Disease Bifurcation Lesions Using Sergio Waxman et al Sergio B. Baptista et al Drug-Eluting Stents Helen Routledge et al

• Top PEER-REVIEWED ABSTRACT

112 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-251: Assessing the Influence TCT-259: Steady Increase of TCT-270: Long-Term Clinical TCT-279: Long-Term Follow-Up of Lesion Length in Long-Term (up Percutaneous Intervention Outcome of Sirolimus-Eluting of Commom Clinical Situations to Five Years) Clinical Outcomes of Procedures and Drug-Eluting Stent Stent Implantation of Total Stent with Off-Label Drug-Eluting

Unselected Patients Treated with Use Over One Year in China Length over 40 mm: From Stent Use in t ro Drug-Eluting Stents: Lessons Improved Short- and Long-Term Two-Year Clinical Outcome Asif Qasim et al Learned from the DESIRE Prognosis in Patients with of the j-Cypher Registry TCT-280: Three-Year Outcome (Drug Eluting Stents In the Coronary Artery Disease Shinichi Shirai et al of Sirolimus-Eluting Stent REal world) Registry Shaoping Nie et al TCT-271: Percutaneous Coronary Implantation for Coronary tURDAY

Alberto Fonseca et al agenda

TCT-260: Comparative Impact of Intervention vs. Medical Therapy Artery Bifurcation Lesions sa TCT-252: The Long-Term Safety of Multiple Inflammatory Markers for in Stable Coronary Artery Disease: Curtiss T. Stinis et al Bare Metal, Sirolimus-, or the Prediction of Future Cardiac A Meta-Analysis TCT-281: The Comparison of Paclitaxel-Eluting Stents for Events in Patients with Unstable Umamahesh C. Rangasetty et al Coronary Artery Bypass Surgery On- vs. Off-Label Indications Angina Treated by Percutaneous sun DAY TCT-272: Comparison of Efficacy with Drug-Eluting Stent agenda Joost Daemen et al Coronary Intervention and Durability Between Sirolimus- Implantation for the Treatment Konstantina Bouki et al TCT-253: Immediate Procedural Eluting Stent and Paclitaxel- of Multivessel Coronary Artery and Long-Term Clinical Outcomes TCT-261: Long-Term (up to Five Eluting Stent in Unprotected Left Disease After Drug Eluting Stent Years) Results of Drug-Eluting Main Coronary Arteries: Jeong Hoon Yang et al agenda Implantation to Ostial Saphenous Stents for the Treatment of Multicenter Registry mon DAY TCT-282: Long-Term Clinical Vein Graft Lesions Saphenous Vein Grafts: Insights Sunao Nakamura et al Outcomes of Single Drug-Eluting Sahin Kaplan et al from the DESIRE-SVG (Drug- TCT-273: Comparison of 1-Year Stent in Non-Diabetic Patients Eluting Stents in REal World - TCT-254: Clinical Outcomes Clinical Outcomes of Endothelial with a Focal Lesion of Large Vessel Saphenous Vein Graft) Registry Following Multivessel vs. Progenitor Cell Capture Stent and in “Real World” agenda

José de Ribamar Costa et al t ues DAY Single-Vessel Percutaneous Sirolimus-Eluting Bioabsorbable Yue-Jin Yang et al Coronary Interventions in the TCT-262: Comparison of Outcome Polymer-Coated Stent in Patients TCT-283: Incidence and Contemporary Drug-Eluting Between Complete and Incomplete Undergoing Primary Percutaneous Predictors of Very Late Stent Stent Era Revascularization with Drug- Coronary Intervention for Acute Thrombosis After Drug-Eluting Dmitriy N. Feldman et al Eluting Stents in Patients with Myocardial Infarction

Stent Implantation agenda

Multivessel Disease Eric Chong et al wed NESDAY TCT-255: Off-Label Sirolimus- Jon Suh et al Keun-Ho Park et al Eluting Stent Implanation Does TCT-274: Drug-Eluting Stent TCT-284: Safety and Efficacy Not Lead to an Increase in Death TCT-264: High Balloon Inflation Implantation for Degenerative of Primary Percutaneous Coronary and Myocardial Infarction Pressures Are Safe and Associated Saphenous Vein Grafts

Intervention for Acute Myocardial case

John Cosgrave et al with Improvements in John Cosgrave et al reviews Infarction Complicated by Angiographic Parameters in TCT-256: Comparison of One Year TCT-275: Durable Clinical Benefit Cardiogenic Shock in an Drug-Eluting Stent Implantation Outcome of Sirolimus- and Following Paclitaxel-Eluting Stent Institution Without On-Site Asif Qasim et al Paclitaxel-Eluting Stents for Deployment in Patients with Very Cardiothoracic Support Patients with Ultra-Long Coronary TCT-265: Comparison of 6-Month Long Coronary Lesions: Yau Weissman et al agenda

Lesions In Real Word Clinical Outcomes of Four Second Multicenter Registry in Asia t hurs DAY TCT-285: Incidence and Clinical Yuejin Yang et al Generation Drug-Eluting Stents in Sunao Nakamura et al Significance of Neomembrane Complex Coronary Stenoses TCT-257: Long-Term Clinical TCT-276: In-Hospital, 6-Month at the New Carina After Kissing Eric Chong et al Comparison of Drug-Eluting Stent Angiogaphic And Clinical Results Stenting in Unprotected Left Main and Bare Metal Stent in the TCT-266: The Recovery of Torsion After Left Main Stenting in Coronary Artery Intervention t raining physician Treatment of Saphenous Vein Graft Reflects the Transmural Extent of Drug-Eluting Stent Era Seung-Woon Rha et al Disease. Results of the REAL Infarction in Patients with Acute Keun-Ho Park et al • TCT-286: The FINESSE (Registro Regionale Angioplastiche Myocardial Infarction TCT-277: Is Adjunctive Balloon (Facilitated Intervention with Emilia Romagna) Registry Takashi Yamano et al

Postdilatation Necessary with Enhanced Reperfusion Speed t elli e Luigi Vignali et al even t s TCT-268: Calcification in Target Drug-Eluting Stent? A Single to Stop Events) Trial: Results sa TCT-258: In-Hospital Outcomes Lesion and Stent Delivery Route as Center Experience of the Formal Low Molecular for Patients Undergoing Important Determinant for Zhan Gao et al Weight Heparin Substudy Percutaneous Coronary Coronary Restenosis after Gilles Montalescot et al TCT-278: Percutaneous Coronary Interventions in Emergency Sirolimus-Eluting Stent Intervention With and Without • TCT-287: A Non-Randomized,

Procedure Setting Implantation ABS T RAC S Drug-Eluting Stents in Patients Prospective Study of IVC Filter Olivier Lairez et al Shumpei Mori et al with End Stage Renal Disease on Retrieval Without Interim Filter TCT-269: The Long-Term Dialysis Replacement Therapy Manipulation Using the Gunther Outcomes and Incidence of Stent Luis Gruberg et al Tulip Vena Cava Filter

Thrombosis with Sirolimus-Eluting H. Bob Smouse general Stent in Hemodialysis Patients Yutaka Koyama et al

www.tct2007.com 113 transcatheter cardiovascular therapeutics

ABSTRACTs

• TCT-288: No Improvement of TCT-296: The Value of TCT-306: Apoptosis and Contrast TCT-315: Economic Burden of Clinical Outcome and No Increase Computerized Angioplasty in Nephrotoxicity Contrast-Induced Nephropathy in Stent Thrombosis 2 Years After Patients Undergoing Coronary Carlo Briguori et al (CIN): Implications for Guideline Primary PCI for Acute ST-Segment Stenting: a Prospective, Development TCT-307: A Comparison of Elevation Myocardial InfarctION Randomized Trial Teresa Zyczynski et al Contemporary Definitions of with Paclitaxel-Eluting Stents Teddy Weiss et al Contrast Nephropathy in Patients TCT-316: Can Dipyridamole Safely Compared to Uncoated Stents: TCT-297: Clinical, Undergoing Percutaneous Coronary Replace Clopidogrel/ ASA in DES Results of the PASSION Trial Angiographic, and IVUS Outcomes Intervention and a Proposal Patients Undergoing Non-Cardiac Maurits T. Dirksen et al with the TAXUS Liberté Stent: A for a Novel Nephropathy Surgery? TCT-289: A Prospective, Pooled Analysis of the TAXUS Grading System Ayman K. Magd et al Randomized, Multicenter ATLAS Program Kishore Harjai et al TCT-317: Long-Term (Three Years) Study Comparing the Double Mark A. Turco et al TCT-308: A Prospective Outcome in Patients with Kissing(DK) Crush with Classical TCT-298: The Influence of Statin Randomized Trial Comparing Unprotected Left Main Coronary Crush for the Treatment of Treatment Initiated in Hospital on Normal Saline and Sodium Artery Stenosis Treated with Coronary Bifurcation Lesions: the Coronary Heart Disease Patients Bicarbonate With or Without Drug-Eluting Stent Implantation DKCRUSH-1 Bifurcation Study Who Received Revascularization N-Acetylcysteine for Prevention of Alaide Chieffo et al with Drug-Eluting Stents and with Normal Cholesterol Level Contrast-Induced Nephropathy Shaoliang Chen TCT-318: Nonalcoholic Fatty Liver Jia Hui Wu et al Fareed Shaikh et al Predicts Outcomes of Patients TCT-291: Increased Late Mortality TCT-299: CARE I: First-in-Man TCT-309: Risk Factors and Clinical with Premature Coronary Heart After Sirolimus-Eluting vs. Bare Clinical Experience with a Outcomes for Contrast Induced Disease Undergoing Percutaneous Metal Stents in Diseased Guidewire-Based 0.014” Stent Nephropathy Post Percutaneous Coronary Intervention Saphenous Vein Grafts: Results Delivery Platform Using the Coronary Intervention in Patients Chen Zhong et al from the Randomized DELAYED CardioMind Coronary Stent with Normal Baseline Renal RRISC Trial TCT-319: Late Stent Thrombosis Delivery System Function Pierfrancesco Agostoni et al after Drug-Eluting and Bare Metal Robert J. Whitbourn et al Eric Chong et al Stenting Procedures: Modeling the TCT-292: Long-Term Clinical TCT-300: Instent Neointimal TCT-310: Intra-Renal Infusion Long-Term Economic Impact Outcomes (up to Five Years) of Hyperplasia After Percutaneous of Fenoldopam Reduces the Risk Mark A. Turco et al Unselected High-Risk Patients Intervention for ST-Elevation of Contrast Induced Nephropathy Treated with Drug-Eluting Stents TCT-320: The Fate of Coronary Myocardial Infarction and in High-Risk Patients: Results (DES) - Results from the Artery Aneurysm Developed After Treatment With Granulocyt-Colony from the BeRITe! Multicenter Prospective, Non-Randomized Drug-Eluting Stent Implantation Stimulating Factor: a Blinded Registry DESIRE (Drug-Eluting Stents In Chul-Mintz et al Quantitative Intracoronary Giora Weisz et al the Real World) Registry Ultrasound Analysis of STEMMI TCT-321: 2.5 mm Cypher Stent Ricardo A. Costa et al TCT-311: Contrast-Induced Trial Patients for ≤2.25 mm Coronary Arteries: Nephropathy: Is Cystatin C a More TCT-293: Impact of Statins on Federica Baldazzi et al Acute and Follow-Up Results of Sensitive Marker than Creatinine? Short-Term and Mid-Term Clinical Original Implantation Technique TCT-302: Early Clinical Results of Richard J. Solomon et al Outcomes in Patients with Acute Takehiro Yamashita et al a Tissue (Peritoneal) Lined Stent Myocardial Infarction in Asian TCT-312: Comparison of Iodixanol Grafts for Superficial Femoral TCT-322: Day Procedure Population vs. Ioversol for Prevention of Artery Occlusive Disease Intervention is Safe and Seung-Woon Rha et al Contrast Induced Nephropathy in Albrecht Kramer et al Complication Free in Higher Risk Diabetic Patients Undergoing TCT-294: TAXUS Liberté Patients Undergoing Transradial TCT-303: Intravascular Ultrasound Coronary Angiography or Attenuates the Risk of Restenosis Angioplasty and Stenting The Assessment of TAXUS Liberté Intervention in Diabetics: Results from the “DISCHARGE” Study Performance in Two TAXUS Felipe Hernandez et al TAXUS ATLAS Program Andrew D. Small ATLAS Trials John A. Ormiston et al TCT-313: Contrast Nephropathy in Neil J. Weissman et al TCT-323: The Incidence of Patients with Chronic Kidney TCT-295: Intravascular Ultrasound Thrombosis After Implantation TCT-304: Patient Characteristics Disease Undergoing Either (IVUS) Findings in Coronary of Drug-Eluting Stents in the in Trials vs.“Real World” Practice Diagnostic or Interventional Lesions Treated with the “Real World” in the Treatment of Coronary Procedures 17-Estradiol Drug-Eluting Stents - Jilin Chen et al Disease with Drug-Eluting Stents Abel E. Moreyra et al A Pooled Analysis of the Ethos I Ravi K. Ramana et al TCT-324: Does “Upstream” TCT-314: Soluble Tumor Necrosis and II Trials Administration of Platelet GP IIb/ TCT-305: Comparison Between Factor Alpha Receptor Type I and Julio Paiva et al IIIa Receptor Inhibition Affect Drug-Eluting Stents and Coronary Contrast Induced Nephropathy Infarct Artery Perfusion Among Artery Bypass Surgery for the After Coronary Intervention STEMI Patients Undergoing Treatment of Diabetic Patients George Syros et al Primary Percutaneous Coronary with Multivessel Disease Intervention? Yan Qiao et al • Top PEER-REVIEWED ABSTRACT Sushma Koneru et al

114 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-325: Twelve-Months Results TCT-333: Accuracy and Precision TCT-342: Negative Hounsfield TCT-351: A Comparison of of DES in Unprotected Left Main: of a Novel 3-D Angiographic Unit Value with Multi-Detector 64-MSCT, Conventional Cine- Comparison Between Surgery and Reconstruction and Quantification Computed Tomography as a Angiography and Intravascular

PCI in an Academic Hospital Software (CAAS QCA 3-D) in Predictor for Slow-Flow/ No-Reflow Ultrasonography to Detect Stent in t ro Fabrizio Clementi et al Measuring Intracoronary Length During Percutaneous Coronary Fractures Using Marker Wire in Angioplasty Intervention Nirat Beohar et al • TCT-326: Coronary Sinus Patients Kyohei Yamaji et al Assessment by Cardiac Computed TCT-352: How Often Does Jacek A. Legutko et al Tomographic Angiography in TCT-343: Predictive Value Restenosis Occur in Patients tURDAY agenda

Patients with Dominant Left TCT-334: Intracoronary Raman of Dobutamine Stress Without Obvious Mechanical sa Circumflex Artery Diagnostics in a Human-to-Porcine Echocardiography for Coronary Problems for Restenosis After Ambarish Gopal et al Xenograft Model Artery Disease in Liver Drug-Eluting Stent Implantation? Jason T. Motz et al Transplant Candidates • TCT-327: Effect of Statin An Intravascular Ultrasound Study Matthew E. Harinstein et al Byoung-Keuk Kim et al

Therapy on Coronary Fibrous- sun DAY TCT-335: Patient Radiation Dose agenda Cap Thickness in Patients with According to the Puncture Site in TCT-344: Coronary Plaque TCT-353: Improved Coronary Acute Myocardial Infarction: Invasive Cardiology Morphology of Non-Culprit Lesions Artery Imaging with 64-Slice An Optical Coherence Jerome Clerc et al in Patients with Recent Acute Computed Tomography Angiogram: Tomography Study Coronary Syndrome A Meta-Analysis TCT-336: The V-Tachogram. agenda Takashi Kubo et al Adam Rdzanek et al Tejas Brahmbhatt et al mon DAY Improving the Diagnostic Quality • TCT-328: Intravascular of the Left Ventricular Angiogram TCT-345: Miniaturized Catheter for TCT-354: In Vivo Virtual-Histology Ultrasound Findings in Elderly Peter Vandermyden et al Evaluating Plaque Composition via Intravascular Ultrasound Patients with Coronary Artery Raman Spectroscopy Characteristics in Patients with TCT-337: Relation Between Late Disease: Diffuse Atherosclerosis, Alexandra H. Chau et al Acute ST-Elevation Myocardial

Instent Neointimal Proliferation agenda Negative Remodeling and Infarction and Stable Coronary t ues DAY and Amount of Residual Plaque TCT-346: Lesion Characteristics Calcified Plaque Artery Disease Outside the Drug-Eluting Stents: of Thin-Cap Fibroatheroma at Young Joon Hong et al Gabriel Vorobiof et al An Intravascular Ultrasound Study Non-Infarct-Related Segment: TCT-329: Histopathologic on Cypher and Taxus Stents An Optical Coherence Tomography TCT-355: Feasibility and

Validation of Virtual Histology Chi-Hang Lee et al Study In Vivo Diagnostic Accuracy of 64-Slice agenda

Intravascular Ultrasound Analysis Kenichi Fujii et al Multidetector Computed wed NESDAY TCT-338: The Difference of of Peri-Calcific Necrotic Core Area Tomography Coronary Angiography Vascular Response Following TCT-347: Incidence, Predictors, Sang-Wook Kim et al In Patients with Dilated Coronary Intervention Between and Outcome of Plaque Prolapse Cardiomyopathy: Preliminary

TCT-330: Comparative Virtual Ruptured Plaque and Erosive After Stent Implantation in case

Results reviews Histology (VH) and Integrated Plaque Assessed by Optical Patients with Acute Myocardial Daniela Trabattoni et al Backscatter (IB) Intravascular Coherence Tomography Infarction: An Intravascular Ultrasound Analysis of Takashi Kubo et al Ultrasound Analysis TCT-356: Validation of a Novel Calcified Plaque Young Joon Hong et al Automated Optical Coherence TCT-339: Impact of Preprocedure Sang-Wook Kim et al Tomography Analysis System for

Multislice Computed Tomographic TCT-348: Culprit Lesions in agenda Evaluation of Vascular Healing t hurs DAY TCT-331: Correlation of Fibrous Coronary Angiography to Predict Patients with Acute Coronary After DES Implantation Cap Thickness with Local Procedural Outcome of Syndrome Have Increased Plaque Yoshie Suzuki et al Inflammatory Activation in Percutaneous Revascularization for Volume Without a Change in Atheromatic Plaques Prone to Chronic Total Occlusion Relative Plaque Composition: An TCT-357: Coronary Artery Lesions Rupture. Study with Optical Mariko Ehara Intravascular Ultrasound Virtual of Diabetic Patients have Greater t raining physician Coherence Tomography and Histology Analysis Necrotic Core and Calcium TCT-340: Feasibility and Intravascular Thermography Andrew D. Frutkin et al Content: A Lesion Analysis by Diagnostic Accuracy of 64-Slice in Patients with Acute Intravascular Ultrasound Virtual Multidetector Computed TCT-349: Relationship Between Coronary Syndrome Histology (IVUS-VH)

Tomography Coronary Angiography Cardiovascular Risk as Predicted t elli e Sophia Vaina et al Andrew D. Frutkin et al even t s in the Evaluation of In-Stent by Established Risk Scores and sa TCT-332: Patients with Greater Restenosis: Preliminary Results Coronary Artery Plaque TCT-358: Repeat Angiographic Framingham Estimates of Cardiac Daniela Trabattoni et al Composition as Detected by Virtual Outcomes of Recurrent Risk Have Increased Coronary Histology Intravascular Ultrasound Vasospastic Angina Following TCT-341: The Incidence and Artery Plaque Burden Without a Analysis. The PREDICT-Pilot Study Conventional Antianginal Predictors of Postprocedural

Change in Relative Plaque Mohamed Abdel-Wahab et al Medication ABS T RAC S Incomplete Stent Apposition After Composition: An Analysis by Seung-Woon Rha et al Angiographically Determined TCT-350: Laser Speckle Intravascular Ultrasound Virtual Successful Drug-Eluting Stent Imaging Using Optical Fiber TCT-359: Influence of Local Vessel Histology Implantation Bundles: Implications for the Wall Calcium on Neointimal Andrew D. Frutkin et al

Yong-Seok Kim et al Intravascular Characterization of Hyperplasia After Sirolimus- general Atherosclerotic Plaque Eluting Stent Implantation Seemantini K. Nadkarni et al Maoto Habara et al

www.tct2007.com 115 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-360: Noninvasive Imaging of TCT-369: Late Stent Recoil of the TCT-378: IVUS Assessment of TCT-386: Neointimal Hyperplasia Vulnerable Atherosclerotic Plaques Bioabsorbable Everolimus Eluting Small Vessels Treated with the and Peri-Stent Remodeling After by Multislice Computed Tomography Coronary Stent and its Relationship CardioMind Coronary Stent Sirolimus-Eluting or Paclitaxel- Hironori Kitabata et al with Stent Strut Distribution and Delivery System: First-in-Man Eluting Stent Implantation in Plaque Morphology Clinical Experience with a Diabetic Patients - A Randomised TCT-361: Comparison of Plaque Shuzou Tanimoto et al Guidewire-Based 0.014” Stent Vulnerability Between Diabetic vs. Intravascular Ultrasound Study Delivery Platform (Care I Trial) Kisette Okkels Jensen et al Non-Diabetic Patients: Analysis of TCT-370: Long-Term Impact Alexandre Abizaid et al Virtual Histology Intravascular of Two-Stent Technique for TCT-387: South Asians with Ultrasound and Optical Coherence Unprotected Left Main Bifurcation TCT-379: Treatment of Bifurcation Diabetes have Worse Outcomes Tomography Stenosis as Compared with Lesions Using Dedicated Following Primary PCI than Duk-Woo Park et al Single-Stent Technique Bifurcation Stents vs. Classic Bare Diabetic Non-Asians Seung-Jung Park et al Metal Stents. Randomized Control Rodney De Palma et al TCT-362: Compositional Analysis Trial with 6-Month Angiographic of Angioscopic Yellow Plaques in TCT-372: Two-Year Follow-Up of a TCT-388: Fingertip Thermal Follow-Up Coronary Arteries with In Vivo First-in-Man Registry with a Reactivity Measured Endothelial Pavel Cervinka et al Intravascular Ultrasound Bioabsorbable Polymer Based Function Is Impaired in Radiofrequency Data Analysis Sirolimus Eluting Stent (Medistra TCT-380: Comparison of Patients with Insulin Shin-Ichiro Yokoyama et al Excel Drug-ElutIng Stent Trial - Long-Term Cardiac Adverse Events Resistance, Metabolic MEDISTRA Study) Between Sirolimus- Eluting Stent Syndrome and Diabetes TCT-363: Comparison of Teguh Santoso et al (SES) and Paclitaxel-Eluting Stent Naser Ahmadi et al Multidetector 64-Slice Computed (PES) in Patients with Diabetes. Tomographic Angiography to TCT-373: Evidence for the Return TCT-389: High Post-Treatment KOrean Multicenter Angioplasty Coronary Angiography to Assess of Coronary Vaso- Reactivity Platelet Reactivity Is Associated TEam (KOMATE) Registry the Patency of Coronary Artery Following Absorption of a with Adverse Long-Term Outcome Jung-Sun Kim et al Bypass Grafts Bioabsorbable Magnesium Alloy in Patients with Type 2 Diabetes Refat Jabara et al Coronary Stent TCT-381: Influence of Insulin Mellitus and Acute Coronary Gopal Ghimire et al Requirement on Event Rates in Syndrome TCT-364: Target Lesion Vessel Diabetics Receiving Drug- Eluting Carlos Cuellas et al Size Predicts Sirolimus-Eluting TCT-374: A Trend Towards Lower Stents: Results from the Stent Expansion: An Intravascular Mortality After Drug-Eluting Stent TCT-390: Metabolic Control in Cardioquest Interventional Ultrasound Study Implantation in the “Real World” Type 2 Diabetic Patients with Database Ryotaro Yamada et al Albert Alahmar et al Acute Coronary Syndrome Is Fadi Matar et al Related to a Better Outcome After TCT-365: Comparison Between TCT-375: Clinical and Safety TCT-382: Angioplasty Now Interventional Procedures Three-Dimensional Angiographic Outcomes Among Patients Matches Surgery in the Treatment Roberto Baglini et al Reconstruction and Intravascular Receiving the Endeavor of Multivessel Diabetes. Results of Ultrasound Imaging for the Zotarolimus-Eluting Stent: A TCT-391: Gender Differences in 5-Year Follow-Up from the Measurement of Intracoronary Pooled Analysis of Endeavor I to IV Long-Term Outcomes Following BART-Study Cross-Sectional Luminal Anthony Gershlick et al Percutaneous Coronary Akhil Kapur et al Dimensions Intervention of Patients with TCT-376: Single Centre Registry of Tim A. Fischell et al TCT-383: Impact of Abnormal Non-ST-Elevation Acute Coronary a Biodegradable Polymer Based Glucose Tolerance on Syndrome: Results from the TCT-366: Optical Coherence Biolimus A9-Eluting Stent in Real Angiographically Silent Coronary ACUITY Trial Tomography Compared to World Cases: 6-Month Clinical and Atherosclerosis - An Intravascular Alexandra J. Lansky et al Intravascular Ultrasound for Angiographic Follow-Up Ultrasound Study Detecting Small Degrees of Teguh Santoso et al TCT-392: A Comparison of Naohiko Nemoto et al Neointimal Hyperplasia Anti-Thrombin Therapies During TCT-377: Baseline and Immediate Fumiaki Ikeno et al TCT-384: Hyperacute Reduction Elective Percutaneous Coronary Postprocedure Clinical and and Absence of Subsequent Intervention in the Modern Era: TCT-367: Thin Cap Fibroatheroma Angiographic Factors Predictive of Elevation in Circulating Bivalirudin vs. Heparin Alone and CalcifiedP laque Are High-Risk Target Lesion Revascularization Endothelial Progenitor Cells During Christopher L. Gade et al for Micro Embolus During Coronary Among Patients Receiving the Percutaneous Coronary Stenting: A Virtual Histology Endeavor Zotarolimus-Eluting TCT-393: Predictors of Major Intervention in Diabetics Intravascular Ultrasound Study Stent: A Pooled Analysis of Vascular Access Site Li Ching Lee Takahiro Kawamoto et al Endeavor I to IV Complications in Patients with Jeffrey Popma et al TCT-385: An Association Between Acute Coronary Syndromes TCT-368: Patient Radiation Dose the Glycemic Control and the in Invasive Cardiology According to Undergoing Percutaneous Coronary Extent of Coronary Artery Operator Experience Intervention: Insights from the Jerome Clerc et al Calcification Assessed by ACUITY Trial Calcification Score Analysis Steven V. Manoukian et al Yu Kataoka et al

• Top PEER-REVIEWED ABSTRACT

116 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-394: Major Bleeding is TCT-403: Comparative Analysis of TCT-413: Experience with the TCT-422: One-Year Outcomes of a Associated with Increased the Overlap Segment of Sirolimus- BioMatrix® Biolimus A9®-Eluting Randomized Study of the JanusTM One-Year Mortality and Ischemic Eluting vs. Zotarolimus-Eluting Stent in a Real-World Population: Tacrolimus-Eluting Stent for

Events in Patients with Acute Stents: A Tridimensional Clinical Results for the BEACON Treatment of Severe Coronary in t ro Coronary Syndromes Undergoing Intravascular Ultrasound Study Registry Artery Diseases Percutaneous Coronary Leandro Ignacio Lasave et al Tian Hai Koh et al Yaling Han et al Intervention: The ACUITY Trial TCT-404: Novel Macromolecular TCT-414: Novel Surface TCT-423: Initial Experience with Steven Manoukian et al Prodrug Technology for Drug Modification for Reducing Polymer Endeavor Stent in a Real-World tURDAY agenda

TCT-395: Drug-Eluting Stent for Eluting Stents Burden on Drug-Eluting Stents is Clinical Practice: An Angiographic sa the Treatment of Small Coronary Shrirang V. Ranade et al Highly Compatible with Pig and Intravascular Ultrasound Artery with Sirolimus, Paclitaxel, Coronary Arteries Analysis TCT-405: Safety and Performance Zotarolimus, Tacrolimus-Eluting Toshiro Shinke et al Pedro B. Andrade et al Evaluation of the Biosensors Stent and EPC Capture Stent: sun DAY International’s Biolimus A9 TCT-415: The Safety and Efficacy TCT-424: The Effect of Drug- agenda Multicenter Registry in Asia Drug-Eluting Stent (BioMatrix)- of the Endeavor Zotarolimus- Eluting Stents on Clinical and Sunao Nakamura et al The Stealth I Study Long-Term Eluting Stent System in Japanese Angiographic Outcomes in TCT-396: Six-Month IVUS Analysis Safety Follow-Up Patients with Symptomatic Diabetic Patients: Multicenter of Complex Coronary Artery Eberhard Grube et al Coronary Artery Disease: Registry agenda Lesions Treated with Biolimus-A9 ENDEAVOR Japan at Nine Months Sunao Nakamura et al mon DAY TCT-406: In Vivo Performance Eluting XTENT-Stent: Results of Shigeru Sato of New Biodegradable Stent TCT-425: Impact of Diabetic the CUSTOM II Trial Coating Materials in a Porcine TCT-416: Long-Term Results from Status and Insulin Treatment on Takao Shimohama et al Coronary Model the First-in-Man Application of 2-Year Clinical Outcomes After TCT-397: Clinical Outcomes at Robert W. Hergenrother et al Bevacizumab-Eluting Stent: A Sirolimus-Eluting Stent agenda 1-Year for the Next-Generation Novel Approach for the Inhibition Implantation in the MATRIX t ues DAY TCT-407: One-Year Clinical Endeavor Resolute Stent: of Plaque Neovascularization Registry Outcomes Associated with the Use The RESOLUTE Konstantinos Toutouzas et al Jiro Aoki of a Zotarolimus-Eluting Stent: A First-in-Human Study Single-Center Canadian Experience TCT-417: A Comparison of Clinical TCT-426: The Impact of Diabetes Ian Meredith et al

Luke Drzymala and Angiographic Outcomes After on 1-Year Major Adverse agenda

TCT-398: Preclinical Studies of Bioabsorbable Polymer vs. Durable Cardiovascular Events in Patients wed NESDAY TCT-408: Off-Label DES vs. BMS the Endeavor Resolute Stent with Polymer Sirolimus-Eluting Stent Undergoing Multi-Vessel Treatment: Outcomes at Two Years Extended Release of Zotarolimus for the Treatment of Coronary Robert J. Applegate et al Percutaneous Coronary Using the BioLinx Polymer Artery Disease in a “Real World” Revascularization TCT-409: Tetramethylpyrazine- case

Josiah N. Wilcox et al Setting: 1-Year Follow-Up Results Daniel Tsyvine et al reviews Eluting Stents on Vascular Smooth Hai-Bo Liu et al TCT-399: In-Vitro Evaluation TCT-427: Impact of Cilostazol on Muscle Cell Apoptosis and of a Novel Dual-Drug Eluting Stent TCT-418: Importance of Polymer Restenosis and Clinical Outcomes In-Stent Restenosis to Target Inflammation and Hydrophilicity/Hydrophobicity on MA Gen Shan et al After Drug-Eluting Stent Proliferation Following Stent Biocompatibility of DES Coatings Implantation from the DECLARE- agenda

Implantation TCT-410: Short- and Mid-Term Kishore Udipi et al LONG &-DIABETES t hurs DAY Dorna Hakimimehr et al Outcomes of a Biodegradable Seong-Wook Park et al TCT-419: Polysulfone Polymer Polymer-Based Sirolimus-Eluting TCT-400: Long-Term Outcomes of Coating for Drug-Eluting Stents: TCT-428: Paclitaxel-Eluting Stent for Treatment of “Real- Paclitaxel-Eluting Stents in Advantages of Polymer Based Drug Coronary Stents in Patients World” Patients: Multi-Center Treating Unprotected Left Main Delivery Without Increased with Diabetes Mellitus: Pooled t raining

Registry of Excel BiodegrAdable physician Coronary Artery Stenosis Incidence of Stent Thrombosis Analysis from Five Randomized Drug EluTing StEnt (CREATE) Yaling Han et al Harald Mayr et al Yaling Han et al Trials Ajay J. Kirtane et al TCT-401: Drug-Eluting Stents for TCT-420: A Novel Biodegradable TCT-411: First Clinical

the Treatment of Very Long Polymer Modified with Peptide for TCT-429: Impact of Diabetes t elli e

Comparison of Nobori Drug- even t s Coronary Artery Stenosis: A Drug-Eluting Stent Mellitus in the Late Clinical sa Eluting Stent with Cypher Stent: Comparison with Sirolimus, Yanchao Zhao et al Outcomes (up to Five Years) of NOBORI CORE Clinical Trial Paclitaxel, Zotarolimus, Tacrolimus- Patients with Coronary Lesions Miodrag Ostojic et al TCT-421: One-Year Outcome of A Eluting Stent and EPC Capture Treated with Drug-Eluting Stents - Novel Polymer Biodegradable Stent: Multicenter Registry in Asia TCT-412: Safety of Genous™ A Sub Analysis of the DESIRE Sirolimus-Eluting Stent: Data from

Sunao Nakamura et al Stent Implantation in Patients Registry ABS T RAC S a Single Center Pilot Registry with High Risk of Bleeding. A Adriana C. Moreira et al TCT-402: Two-Year Outcome After Yaling Han et al Single-Center Prospective Registry Implantation of a Novel Drug- Victoria Martin-Yuste et al Eluting Stent Using Bioabsorbable-

Polymer Technology in Myocardial general Infarction Eduardo Tin Hay et al

www.tct2007.com 117 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-430: Comparison Between TCT-438: Effect of the PPAR TCT-448: Incidence of Persistent • TCT-458: Clinical Presentation Diabetic and Non-Diabetic Agonist Rosiglitazone on and Late Acquired-incomplete of In-Stent Restenosis - Experience Patients Treated with the Endeavor Endothelial Function and Stent Apposition After First- vs. from Western Sweden Stent. An Angiographic and Inflammatory Biomarkers in Second-Generation Drug-Eluting Elmir Omerovic et al Intravascular Ultrasound Analysis Non-Diabetics Undergoing Stents TCT-459: A Collaborative Pedro Beraldo Andrade Percutaneous Intervention Dimytri Siqueira et al Meta-Analysis on 1,274 Patients Justin P. Levisay et al TCT-431: Predictors of Target TCT-449: Variable Histological Undergoing Percutaneous Vessel Reintervention in the TCT-439: Different Response of and Ultrasonic Characteristics of Drug-Eluting Stenting for TAXUS-CYPHER “What’s Your Interleukin-18 After Percutaneous Restenosis After Drug-Eluting Unprotected Left Main Coronary Real-World Experience” Registry: Coronary Intervention, Compared Stents Artery Disease Focus on Highest-Risk Diabetic to Other Inflammatory Markers, Nobuaki Suzuki et al Giuseppe Biondi Zoccai et al Patients in Patients with Unstable Angina TCT-450: Optical Coherence TCT-460: Population William O’Neill et al Konstantina Bouki et al Tomography in Assessing Percent Characteristics, Treatment, TCT-432: Outcomes of Primary TCT-441: Wall Inflammation of Area Stenosis in Porcine Coronary Assignment, and Survival of Percutaneous Coronary Stents: Fast Taxol Eluting vs. Stent Studies: Validation Against Elderly Patients with Aortic Intervention with Drug-Eluting Polyzene-F Coated Stents Histology and IVUS Stenosis Referred for Percutaneous Stents in Diabetics with Acute Ulrike Stampfl et al Carlos L. Alviar et al Valve Replacement Myocardial Infarction: Results Amber M. Otten et al TCT-442: Sirolimus is a Potent TCT-451: Differential Recovery of from the STENT-Registry Inhibitor of Atherosclerotic Plaque Coronary Endothelial Dysfunction TCT-461: Same-Day Discharge Thomas D. Stuckey et al and Aneurysm Formation in an Associated with Zotarolimus- vs. Post Percutaneous Coronary TCT-433: Comparison of Two-Year Apolipoprotein E Deficient Mouse Sirolimus-Eluting Stents Intervention in the DES Era - Clinical Outcome of Sirolimus- Model Jin Won Kim et al The Practical Experience Eluting Stent vs. Off-Pump Lei Zhao et al Darach Oh-Ici et al TCT-452: Three In Vivo Preclinical Coronary Artery Bypass Surgery in TCT-443: Systemic Inflammatory Models to Assess Re- TCT-462: Safety And Feasibility of Diabetic Patients with Multivessel Activation and Endothelial Repair Endothelialization Following Percutaneous Coronary Disease After Stenting: A Comparison of Coronary Stent Implantation Intervention for Unprotected Kenichiro Yamagata et al Drug-Eluting Stents with Bare Laura E. Perkins et al Left Main Disease at a Center TCT-434: Eptifibatide-Eluting Metal Stents Without On-Site Cardiac Surgery TCT-453: Suppressed Response of Stents: In Vivo Effect on Kreton Mavromatis et al Faustino Miranda et al Serum Matrix Gla Protein Levels to Thrombosis and Neo- Intimal TCT-444: Early Treatment with Percutaneous Coronary TCT-463: Platelet Inhibition and Hyperplasia Simvastatin in Myocardial Intervention in Patients with Myocardial Necrosis in Elective Kamal Chitkara et al Infarction to Reduce Levels of Diffuse Coronary Artery Disease Coronary Artery Stenting TCT-435: Intracoronary Multiple Inflammatory Markers Konstantina Bouki et al Andrew Wiper et al Application of Abciximab in FLAME Randomized Clinical Trial TCT-454: Endothelialization of TCT-464: Relationship Between Patients with ST-Elevation Wojciech Wojakowski et al Coronary Stents: What Happens Improvement in Serum ApoB/ Myocardial Infarction TCT-445: Experimental Research when the Strut is Located Over the ApoA1 Ratio and Progression/ Jochen Wöhrle et al on Establishing Chronic Heart Ostium of a Sidebranch? Regression of Coronary Artery TCT-436: Implantation of Failure Model of Miniswine with Armando Perez de Prado et al Plaque with HMG-CoA Reductase Paclitaxel-Eluting Stents Reduce Intracoronary Perfusion of Plastic Inhibitors (Statins): A 3-D TCT-455: Platelet Activation and Circulating Endothelial Progenitor Microspheres by an 4F Intravascular Ultrasound Adhesion After Exposure to Cells and Inflammatory Cytokines Angiographic Catheter (3-D-IVUS) Study Nanofilm andM icroporous in Patients with Stable CAD Xanghua Fu et al Hiroaki Takashima et al Hydroxyapatite Stent Coating: An Undergoing Elective PCI TCT-446: Immunoadsorption in Ex-Vivo Study of Hydroxyapatite- TCT-466: Low Molecular Weight Wojciech Wojakowski et al Dilated Cardiomyopathy Coated Stents Deployed in a Heparin as an Adjunct in Acute TCT-437: Impact of Diabetes Alexander Staudt et al Continuous Flow-Chamber Model ST-Elevation Myocardial Infarction: Mellitus and Statin Administration Carlos L. Alviar et al A Meta-Analysis TCT-447: Usefulness of Falling on Local Inflammatory Activation Sarabjeet Singh et al Body Temperature for Prediction TCT-456: Time Pattern of Stent of Non-Culprit Lesions: Correlation of Adverse Outcomes in Congestive Endothelialization in a Swine • TCT-467: Nitric Oxide Inhalation with Systemic Inflammation Heart Failure Coronary Model: Characterization Improves Microvascular Flow and Maria Drakopoulou et al Amany Ahmed et al and Quantification Decreases Infarction Size After Armando Perez de Prado et al Myocardial Ischemia and Reperfusion TCT-457: Carbostent™ Is Not Xiaoshun Liu et al Superior to Stainless-Steel Stents in Preventing In-Stent Re-Stenosis of High-Risk Lesions • Top PEER-REVIEWED ABSTRACT Helmy H. El-Ghawaby

118 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-468: Prognostic Significance TCT-477: Novel Helical Stent TCT-486: Bleeding and Vascular TCT-495: Low Stent Deployment of Baseline Platelet Reactivity in Design Elicits Spiral Blood Flow Complication Associated Mortality Pressure Is Risk Factor for Acute Myocardial Infarction Pattern and Inhibits Neointima Following Percutaneous Coronary Sub-Acute Stent Thrombosis

Treated with Primary Angioplasty Formation in Porcine Carotid Intervention Can Be Reduced with Afzalur Rahman et al in t ro Zenon Huczek et al Arteries Multiple Practice Changes TCT-496: “Real-World” Rates of Toshiro Shinke et al John Robb et al TCT-469: Incidence, Outcome, Stent Thrombosis from a Large and Treatment of No-Reflow TCT-478: Percutaneous TCT-487: Is Small Peri-Procedural Australian Multi-Centre Registry: Phenomenon in Patients with Transluminal Angioplasty and Creatine Kinase-MB Release Still Drug-Eluting Stents Are No Worse tURDAY agenda

ST-Segment Elevation Myocardial Stenting of Extracranial Vertebral Important in Contemporary Than Bare Metal Stents sa Infarction Artery Stenoses Percutaneous Coronary Bryan P. Yan et al Ihab B. Abdalrahman et al Michel Henry et al Intervention Era? TCT-497: Is There Any Survival Mohammed Andron et al TCT-470: Admission B-Type TCT-479: Long-Term Comparison Benefit with Drug-Eluting Stent

Natriuretic Peptide Levels Predicts sun DAY of Carotid Stenting for TCT-488: Emergency Coronary Compared to Bare Metal Stent? agenda Microvascular Obstructions in Symptomatic vs. Asymptomatic Artery Bypass Surgery Following Analysis of Unselected All PCI Acute Myocardial Infarction Patients Percutaneous Coronary Cases in Single Center Registry Min-Kyung Kim et al Andres Sanchez et al Intervention: Predictors and Jin-Ho Choi et al Prognosis in a Contemporary TCT-471: The Effect of Preventive TCT-480: Residual Stenosis TCT-498: Comparison of Clinical agenda Database mon DAY Intracoronary Administration of Following Carotid Artery Stent Benefit and Safety Between Luis Gruberg et al Anisodamineon Microcirculation Placement Is Associated with Drug-Eluting Stents and Bare Perfusion in Miniswines with AMI Higher Incidence of In-Stent TCT-489: Stent Fracture After Metal Stents in Subjects Over Xianghua Fu et al Restenosis Implantation of Sirolimus-Eluting 75 Years of Age Jocelyn Spoon et al Stents: Incidence, Predictors, and Horma Ouldzein et al TCT-472: The Effect of agenda Clinical Outcome t ues DAY Intracoronary Administration of TCT-481: Beneficial Impact of TCT-499: Stent Thrombosis. Tomoko Gochi et al Anisodamine on Heart Function Cilostazol on Restenosis and A Single Center Experience and Ventricular Systolic Synchrony Target Vessel Revascularization TCT-490: Incidence and Predictors Taku Honda et al in AMI Patients with No-Reflow After Percutaneous Coronary of Bleeding Among Patients TCT-500: Clinical Presentation of

Phenomenon Post PCI Identified Intervention: Evidence from a Undergoing Rescue Percutaneous agenda Patients with In-Stent Restenosis by Myocardial Blush Grade Meta-Analysis of Randomized Coronary Intervention After Failed wed NESDAY in the Drug-Eluting Stent Era Xianghua Fu et al Clinical Trials Fibrinolysis for ST-Elevation Michael S. Lee et al Giuseppe Biondi Zoccai et al Myocardial Infarction TCT-473: Statin Pre-Treatment Sukesh C. Burjonroppa et al TCT-501: Point-of-Care Assays

Preserves Microvascular Integrity 482: Cilostazol Nearly Abolishes case Demonstrate Resistance to in Patients with Re-Established Angiographic Restenosis After TCT-491: Late Stent reviews Clopidogrel, but Not Aspirin, Coronary Perfusion in ST-Elevation Sirolimus-Eluting Stent Malapposition After Drug-Eluting in Patients with Previous Stent Myocardial Infarction Implantation for Complex Coronary Stent Implantation Is Related to Thrombosis Peter W. Radke et al Artery Disease: Subgroup Analysis High Incidence of Very Late Stent Alex R. Hobson et al of Declare Trial Thrombosis

TCT-474: Effects of Atorvastatin agenda Hyun-Sook Kim et al Juying Qian et al TCT-502: Gender, Body Mass, and t hurs DAY 10 mg vs. 40 mg in 8-Month the Risk of Periprocedural Follow-Up Coronary Flow Reserve TCT-483: Stent-Based Delivery of TCT-492: Renal Failure is an Bleeding Following Percutaneous and Clinical Events in Patients Antisense Oligodeoxynucleotides Independent Predictor of Stent Coronary Intervention; Insights with Acute Myocardial Infarction Targeted to the PDGF A-Chain Thrombosis After PCI of from the APPROACH Registry Soon Jun Hong et al Decreases In-Stent Restenosis of Unprotected Left Main. Insights t raining Jonathan Byrne et al physician the Coronary Artery from the French Left Main TAXUS TCT-475: Effect, Safety, and Shin-Ichiro Yokoyama et al Registry TCT-503: The SYNTAX Score Feasibility of Intracoronary Beatriz Vaquerizo Predicts Periprocedural Myocardial Combining Administration of TCT-484: Effects of G-CSF on Necrosis During Percutaneous

Anisodamine and Tirofiban on “No Arterial Hyperplasia and Cardiac TCT-493: Risk of Stent t elli e

Coronary Intervention even t s Reflow” Phenomenon Following Remodeling in Rats Acute Thrombosis, Myocardial Infarction sa William J. van Gaal et al PCI in Patients With AMI Myocardial Infarction Model and Death After Drug-Eluting Xianghua Fu et al Shin-Ichiro Yokoyama et al Stent Percutaneous Coronary TCT-504: Incidence and Predictors Interventions - A Population Based of Coronary Artery Bypass Surgery TCT-476: Long-Term (Two Years’) • TCT-485: Non-Cardiac Adverse Cohort Study Following Bare-Metal and TAXUS Follow-Up of Consecutive Patients Events After PCI as Predictors

Morten Bottcher et al Drug-Eluting Coronary Stent ABS T RAC S Treated with Percutaneous Carotid of Mortality: Shifting the Focus Implantation Intervention from MACE to MANE (Major TCT-494: Results of Emergency Jack L. Martin et al Andres Sanchez et al Adverse Non-Cardiac Events) PCI with DES in Patients with Kishore Harjai et al Catheter-Induced Left Main TCT-505: Clinical Predictors of Stent Thrombosis in the “Real Coronary Artery Dissection: Acute general and Long-Term Results World” Drug-Eluting Stent Era Mohamed Chettibi et al Eduardo Tin Hay et al

www.tct2007.com 119 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-506: Does TCT-516: Clinical Efficacy and TCT-526: Matched-Pair Analysis of • TCT-535: Expanded Use of the Polytetrafluoroethylene-Covered Angiographical Patency-Rate After Endovascular vs. Open Surgical TAXUS Express2 Paclitaxel- Stent Implantation for Coronary Balloon-Angioplasty of Diffuse Abdominal Aortic Aneurysm Repair Eluting Stent: Insights on Safety Artery Perforation During Infrapopliteal Obstructions in in Young Low-Risk Patients and Long-Term Outcomes from the Percutaneous Coronary Patients with Critical Limb Nicolas Diehm et al 7000-Patient ARRIVE Registry Intervention Reduce the Incidence Ischemia Program TCT-527: Predictors of Mortality of Emergency Cardiac Surgery? Andrej Schmidt et al John M. Lasala et al After Peripheral Endovascular Kevin Copeland et al TCT-517: Prevalence and Revascularization for Symptomatic • TCT-536: Predictors for Stent TCT-507: A Years Experience of Predictors of Renal Artery Stenosis Peripheral Arterial Disease Thrombosis in Real-World Use of In-Stent Emergencies - Restenosis in Patients with Coronary Artery David M. Safley et al the TAXUS Express2 Paclitaxel- Is Not a Benign Problem Disease: A Systematic Evaluation Eluting Stent: Insights from the TCT-528: Clinical Feasibility Malcolm C. Finlay et al in a Serial of 651 Consecutive 7000-Patient ARRIVE Program and Angiographic Follow-Up of Patients Referred to a Coronary John M. Lasala et al TCT-509: Gender-Related Endovascular Stent-Graft for Angiography Differences and Emergency Type B Dissection (Stantford). TCT-537: Risk of Stent Under- Romain Ollivier et al Coronary Artery Bypass Graft Experience of a Single Center Deployment due to Over- Surgery Following Percutaneous TCT-518: Percutaneous Treatment in Brazil Estimation of Labeled vs. “In Vivo” Coronary Intervention of Chronic Total Occlusions in Augusto Daige da Silva et al Compliance of The Cypher™ Stent Luis Gruberg et al Patients with Severe Limb Delivery Balloon TCT-529: Patency of Endovascular Ischemia: Is There a Role for Mihas M. Kodenchery et al • TCT-510: Impact of Cilostazol Treated Central Vein Stenosis and New Devices? on Target Lesion Revascularization Occlusion in Patients with TCT-538: Temporal Improvements Luis A. Guzman et al and Restenosis After Endovascular Hemodialysis Access in Door-to-Balloon Times for Therapy for the Femoro-Popliteal TCT-519: Four-Year Follow-Up Chiung-jen Wu et al Primary Percutaneous Coronary Lesions After Implantation of Intervention: Results from the TCT-530: Improvement of Left Osamu Iida et al Selfexpanding Nitinol Stents in CRUSADE and ACTION Registries Ventricular Diastolic Function the Superficial Femoral Artery Christopher P. Cannon et al TCT-511: Long Term Outcome of After Treatment of Renal Artery Matthias Ulrich et al Pelvic Intervention According to Stenosis with Stenting TCT-539: A Clinical Risk Score for the New TASC Classification: A TCT-520: Drug-Eluting Stents for Giuseppe Gioia et al Prediction of Stent Thrombosis Single Centre Experience Below the Knee Lesions: Using Prospective Data from TCT-531: In Vitro Release Kinetics Sebastian Sixt et al Long-Term Results Real-World Use of the TAXUS Test for the Development of Oscar R. Rosales et al Express2 Paclitaxel-Eluting Stent TCT-512: VIABAHN Stent-Graft for Peripheral Arterial Paclitaxel Kenneth Baran et al Symptomatic Recurrent In-Stent TCT-521: Renal Angioplasty Eluting Self Expandable Stent Restenosis of Superficial Femoral and Stenting. A Series of 857 Byung Doo Kwon et al TCT-540: Comparison of Artery: Immediate Success and Procedures. Is It Safe? How Implantation of Drug-Eluting TCT-532: Secondary Interventions Long-Term Patency to Avoid and Manage Stents vs. Minimally Invasive and Mortality Following Mohamed Djelmami-Hani et al Complications? Coronary Artery Bypass Surgery in Endovascular Aortic Aneurysm Michel Henry et al Patients with Ostial Lesion of Left TCT-513: Alternative Modalities of Repair: Device-Specific Results Anterior Descending Coronary Transpedal Retrograde Access for TCT-522: Long Term Major from the UK EVAR Trials Artery the Treatment of Complex Adverse Cardiac and Vascular Roger M. Greenhalgh et al In Hyun Jung et al Tibioperoneal Lesions Events Following Renal Artery • TCT-533: Final 5-Year Clinical Miguel Montero-Baker et al Stenting TCT-541: Primary Percutaneous Follow-Up of TAXUS II: Long-Term Rohit Bhatheja et al Coronary Intervention in ST- TCT-514: Renal Angioplasty and Anti-Restenotic Efficacy and Elevation Myocardial Infarction Stenting Under Embolic Protection TCT-523: Endovascular Treatment Safety for Slow- and Moderate- Patients Following Cardiac Arrest Devices. A Must? of Subclavian Stenosis: Release Polymer-Based, Paclitaxel- Timothy D. Henry et al Michel Henry et al A Preferred Option Eluting TAXUS Stents Arshad Ali et al Antonio Colombo et al Nicorandil Prevents TCT-515: Endovascular Therapy of TCT-542: Microvascular Dysfunction and Subclavian and Innominate Artery TCT-524: Contrast/Controlled • TCT-534: Long-Term Safety and Myocardial Damage Resulting from Stenosis: Long-Term Results and Microfoam Sclerotherapy as an Clinical Efficacy Outcomes of the Percutaneous Coronary Intervention Factors Influencing Outcome Alternative to Surgery of Recurrent Paclitaxel-Eluting Stent from a Atsushi Hirohata et al Tadeusz Przewlocki et al Saphenous Vein Reflux Patient-Level Meta-Analysis Johann C. Ragg of the TAXUS Clinical Trials TCT-543: Randomized Trial of Stephen G. Ellis et al Sirolimus-Eluting Stent vs. Bare TCT-525: Percutaneous Peripheral Metal Stent in Acute Myocardial Interventions in Diabetic Patients Infarction (SESAMI 2-Year Results) with Critical Limb Ischemia Maurizio Menichelli et al Francesco Liistro et al

• Top PEER-REVIEWED ABSTRACT

120 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING ABSTRACTs

TCT-544: The Impact of TCT-554: Direct Stenting After TCT-562: One-Year Follow-Up of TCT-572: Occlusive Restenosis Sirolimus-Eluting Stent on Small Thrombus Removal Before Primary MIST-I: A Prospective, Multicenter, Following Drug-Eluting Stent Vessel in Patients with Diabetes - Angioplasty in Acute Myocardial Randomized, Double Blind, Implantation: Outcomes of a

The Result from the HIJC-DESR Infarction: A Sub-Anaysis of the Placebo-Controlled Trial to Percutaneous Therapeutic Strategy in t ro Junichi Yamaguchi et al DEAR-MI Study Evaluate the Efficacy of Patent Tiziana Claudia Aranzulla et al Pedro L. Silva Orrego et al Foramen Ovale Closure with the TCT-545: Percutaneous Coronary TCT-573: Drug-Eluting Stents for STARFlex® Septal Repair Implant Intervention of Unprotected Left TCT-555: Predictive Value of the Treatment of In-Stent to Prevent Refractory Migraine Main Coronary Artery in the Urgent Pre-Procedural N-Terminal Restenosis In High-Risk Diabetic tURDAY

Headaches (the MIST-III Trial): agenda

Clinical Setting. Clinical and Pro-B-Type Natriuretic Peptide Patients: Results After a sa Full Data from MIST-I Angiographic Outcomes Level for Development of Long-Term Follow-Up Michael Mullen et al Alberto Hendler No-Reflow Phenomenon and Imad Sheiban et al Recovery of Left Ventricular TCT-563: Visualization of the Left TCT-546: Off-Label Use of TCT-574: Treatment of DES Ejection Fraction in Acute Atrial Appendage in 3-D: Complex sun DAY Drug-Eluting Stents: No Advantage Restenosis with Balloon agenda ST-Segment Elevation Myocardial Anatomy and Structure in in Saphenous Vein Grafts Angioplasty Compared with DES Infarction Patients Who Underwent Multidetector CTA as an Aid to Polly A. Moore et al Implantation: 18 Months Clinical Primary Percutaneous Coronary Percutaneous Obliteration Outcome TCT-547: Implantation of Intervention Strategies Gennaro Sardella et al Sirolimus-Eluting Stents in Youngkeun Ahn et al Hidehiko Hara et al agenda Saphenous Vein Grafts. Clincal TCT-575: Long-Term Results of mon DAY TCT-556: Comparison of TCT-564: Choosing the Size of Follow-Up Results from the Stenting of In-Stent Restenosis Effectiveness of Bare Metal Stents Percutaneous Aortic Valves: German Cypher Stent Registry with Drug-Eluting Stents: vs. Drug-Eluting Stents in Patients Assessing the Impact of Aortic Rainer Hoffmann et al Cypher vs. Taxus with Acute Myocardial Infarction Valve Annulus Size and Mariann Gyongyosi et al

TCT-548: The Effect of Debulking agenda

Who Underwent Single-Vessel Calcification t ues DAY Pre-Drug Eluting Stent for Percutaneous Coronary Vasilis Babaliaros et al TCT-576: One-Year Outcomes of Bifurcated Coronary Lesions on Intervention in Large Coronary Paclitaxel-Eluting Stent TCT-565: Predictors of Systemic Avoiding the Plaque Shifting and Arteries Implantation as an Initial Embolism After Successful Resenosis. Sub Analysis of PrE Doo Sun Sim et al Treatment Strategy for Sirolimus- Balloon Mitral Valvuloplasty

Rapamycin-Eluting Stent Eluting Stent Failure agenda

TCT-557: Primary Angioplasty: Massimo Napodano et al wed NESDAY FlExi-CuT-(PERFECT) Registry Justin P. Levisay et al A Randomized Study Comparing Yuji Oikawa et al TCT-566: Impact of Calcium Radial vs. Femoral Approach TCT-577: Long-Term Analysis Location on Aortic Stenosis TCT-549: Improved Transrenal Roberto V. Botelho et al of a Consecutive Series of Severity: A 3-D Analysis by

Anchorage of a Balloon Deployable Drug-Eluting Stent Restenosis case

TCT-558: Transfer for Primary Multislice Computed Tomography reviews Knitted Polyester Stent-Graft: Treated with Another Drug-Eluting Angioplasty in Elderly Patients in Autopsy and Living Hearts Experiments in Dogs Stent Implantation: Lessons from with Acute Myocardial Infarction Hidehiko Hara et al Robert Guidoin et al the Real-World Experience Francesco Liistro et al TCT-567: Percutaneous Closure of José de Ribamar Costa et al TCT-550: Drug-Eluting Stents Not TCT-559: Percutaneous Mitral Post Myocardial Infarction

Associated with Improved Clinical TCT-578: A New Score for agenda Repair with the MitraClip™ Device Ventricular Septal Defects t hurs DAY Outcome in Dialysis Patients Significant Renal Atherosclerosis for Functional Mitral Peter N. Ruygrok et al Undergoing Percutaneous Coronary in Patients with Coronary or Regurgitation: Acute Success and Intervention TCT-568: One Year Results Using Supraaortic Artery Atherosclerosis 12-Month Durability Omer R. Zuberi et al a Novel Magnetic Navigation Tadeusz Przewlocki et al James Hermiller et al System to Perform Alcohol Septal t raining TCT-551: Long-Term Clinical TCT-579: Non-Invasive 64- physician TCT-560: Efficacy and Safety of Ablation Outcomes and Stent Thrombosis Channel Multidetector Computed Direct Coronary Stenting: Acute John Buergler et al After Drug-Eluting Stent and vs. Tomography Angiography in Outcome of Direct Stenting in Bare Metal Stent for Acute TCT-570: Long-Term Clinical Peripheral Arterial Disease: A Type A, B, and C Lesions

Myocardial Infarction Outcome of Alternative Treatment Validation Study in the Treatment t elli e Mansour M. Sallam et al even t s Seung-Whan Lee et al Strategies for Drug-Eluting Stents of Femoral, Popliteal, and sa TCT-561: Long-Term Follow-Up of Restenosis Infrapopliteal Disease TCT-552: Impact of Mitral Valvuloplasty with Single Francesco Liistro et al David E. Allie et al Thienopyridine Administration Balloon. Independent Predictors of Prior to Primary Stenting in Acute TCT-571: Midterm Results of PCI TCT-580: EPics I Study: Survival and Event Free Survival Myocardial Infarction for Restenosis with Stent Fracture Evaluation of Possible Abdominal

Edison C. Peixoto et al ABS T RAC S LeRoy E. Rabbani et al After Sirolimus-Eluting Stent Aortic Aneurysms in Patients Who Implanataion Have Undergone Previous CABG TCT-553: Long-Term Outcome of Kazushige Kadota et al Carlo A. Dall’Olmo et al Infrainguinal Angioplasty and Stenting for Critical Limb Ischemia Todd M. Bayer et al general

www.tct2007.com 121 transcatheter cardiovascular therapeutics

ABSTRACTs

TCT-581: Identification of Vascular TCT-589: Prevention of • TCT-599: Detection of Lipid TCT-607: Single Centre Responses to Coronary Stenting by Intravascular Access Induced Rich Plaque by Near-Infrared Experience of Balloon Mitral Optical Coherence Tomography: A Vascoconstriction of Porcine Spectroscopy (NIRS) in Patients Valvuloplasty (BMV) In Sub-Analysis from the Japanese Femoral Arteries by Nitric Oxide Undergoing Coronary Intervention: Pregnant Females Multi-Center Safety Trial Elution from a Coated Introducer Results in an Unblinded Cohort of Jayesh Prajapati et al Mitsuyasu Terashima et al Sheath the SPECTrospic Assessment of TCT-608: The Impact of the Mariann Gyongyosi et al Coronary Lipid (SPECTACL) Study TCT-582: Real-Time MRI of Sirolimus-Eluting Stent on Sergio Waxman et al Peripheral Chronic Total Occlusion TCT-590: Vascular Access Site Long-Term Prognosis for the Interventions: Visualization of Management in Peripheral TCT-600: Feasibility and Safety of High-Risk Population of Elderly Devices Ex Vivo in Animals and Vascular Patients with Limited IntraVascular MRI (IVMRI) for Women with Coronary Artery Lesions In Vivo Pre/post Vascular Access: Results Using the Measurement of Lipid Fraction Disease Intervention in Patients Boomerang Wire in Brachial, Index of Coronary Plaque Yu Kataoka et al Yoriyasu Suzuki et al Axillary, and Popliteal Artery Giora Weisz et al TCT-609: Gender Differences “Sticks” TCT-583: Usual Dose of TCT-601: First In Vivo Experience in Patients with Acute Myocardial David E. Allie et al Simvastatin Does Not Inhibit with a Novel Low-Pressure Infarction Treated with Primary Disease Progression and Lumen TCT-591: Extravascular Closure Self-Expanding Intraarterial PCI: A Single Center One-Year Loss in the Peri-Stent Reference with the Mynx Sealant Following Shield: A 1-Month Study Experience Segments in Normocholesterolemic Endovascular Procedures Comparing Two Balloon Alessandra Repetto et al Patients: A Serial Intravascular Dierk Scheinert et al Expandable Stents in Porcine TCT-610: BMV - A Bridge to Ultrasound Assessment Coronary Arteries TCT-592: Safety and Efficacy of Uncomplicated and Safe Delivery Young Joon Hong et al Greg L. Kaluza et al Starclose with 6-Month Follow-Up: in Pregnant Patients with Mitral TCT-584: Diagnostic Accuracy A Single Center Registry TCT-602: High-Risk Lipid Profile Stenosis of 64 Multislice Computed Edward J. Toggart et al Is Related to the Ratio of Necrotic Bhupesh R. Shah Tomography (MSCT) as Compared Core to Calcification in Human TCT-593: Femoral Artery Puncture with Digital Subtraction Coronary Arteries: Results from the Above the Proximal Third of the Angiography (DSA) in Patients Prospective, Multi-Center, Global Femoral Head Better Predicts with Peripheral Vascular Disease VH-IVUS Registry Retroperitoneal Hemorrhage in (PVD) Eduardo Missel et al Percutaneous Coronary Shahrzad Shareghi et al Intervention than Arteriotomies TCT-603: Pro-Inflammatory TCT-585: Screening for Deep Above the Most Inferior Border or Chemokines are Expressed in the Vein Thrombosis in Asyptomatic Origin of the Inferior Epigastric Pig Model of Complex Coronary High-Risk Patients. A Comparison Artery Lesions Induced by Intramural Between Digital Yen-Dong Ho et al Injection of Lipids Photoplethysmography and Armando Tellez et al TCT-594: A Quantitative Venous Ultrasonography Angiographic Evaluation of the TCT-604: The Differences Between Babak Sharif-Kashani et al Target Zone for Vascular Access Plaque Compositions in Ruptured TCT-586: The Role of 64-Channel Zoltan G. Turi et al and Non-Ruptured Atherosclerotic CTA in the Diagnosis and Overall Plaques. Study with Intravascular TCT-596: A New Method of Access Management of Chronic Ultrasound and Virtual Histology Site Management After Mesenteric Artery Disease Tomas Kovarnik et al Percutaneous Aortic Valvuloplasty David E. Allie et al Using Conventional Suture TCT-605: Necrotic Core and TCT-587: In Vivo 3-D Deformations Mediated Closure Devices its Ratio to Dense Calcium of the Human Iliac Artery Due to Philipp Kahlert et al are Predictors of High-Risk Hip Flexion Non-ST-Elevation Acute Coronary TCT-597: The Multi-Center, Eric Cao et al Syndromes: Results from the Randomized Clinical Trial of the Prospective Multi-Center TCT-588: Are Radial Artery FISH Device: A Novel Procedure Global VH-IVUS Registry Anomalies a Major Cause of Sheath and Closure Device Eduardo Missel et al Transradial Procedure Failure? Anthony A. Bavry et al Ted S. Loet al TCT-606: Comparison of Gender TCT-598: The Feasibility of and Age for Plaque Components in Percutaneous Transradial Cronary Patients with Angina Pectoris- Intervention for Saphenous Vein An IVUS Radiofrequency Data Graft Lesions and Comparison with (VH-IVUS) Analysis Transfemoral Route Atsushi Hirohata et al Sudhir Rathore et al

• Top PEER-REVIEWED ABSTRACT

122 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING Save the dates for these NEW important meetings.

ABSTRACTs in t ro tURDAY agenda sa sun DAY agenda

INVESTIGATE agenda mon DAY EVALUATE EDUCATE Advances in Invasive agenda and Noninvasive t ues DAY

agenda

Imaging wed NESDAY

May 2-4, 2008 July 28-30, 2008 Loews Miami Beach Hotel Seattle, Washington case Miami Beach, Fl reviews COURSE DIRECTORS Martin B. Leon, MD COURSE DIRECTORS Mark Reisman, MD Linda D. Gillam, MD agenda Gregg W. Stone, MD William A. Gray, MD t hurs DAY John G. Webb, MD Gary S. Mintz, MD Michael Poon, MD Gregg W. Stone, MD t raining physician Steve D. Wolff, MD t elli e even t s sa

sponsored by ABS T RAC S THE CARDIOVASCULAR RESEARCH FOUNDATION general Please visit www.crf.org for more information.

www.tct2007.com 123 transcatheter cardiovascular therapeutics

abstract Graders

The TCT Course Directors and the Abstract Larry S. Dean, MD, FSCAI Ik-Kyung Jang, MD, PhD Selection Committee, which included faculty David H. Deaton, MD Mariell Jessup, MD from both the Cardiovascular Research Pim J. de Feyter, MD Neeraj Jolly, MD, FSCAI Foundation and the Society for Carlo Di Mario, MD David E. Kandzari, MD Cardiovascular Angiography and Simon R. Dixon, MB, ChB Adnan Kastrati, MD Interventions, chaired by Ted Feldman, MD, Serge Doucet, MD Upendra Kaul, MD wish to express their sincere appreciation to Helmut Drexler, MD Henning Kelbaek, MD all of the physicians who selflessly donated Stephen G. Ellis, MD Gad Keren, MD their time and expertise as TCT 2007 Raimund Erbel, MD Morton J. Kern, MD Abstract Graders. Steven M. Ettinger, MD, FSCAI Carey Kimmeslstiel, MD Peter Faries, MD Takeshi Kimura, MD Alexandre Abizaid, MD, PhD David Faxon, MD Nicholas Kipshidze, MD, PhD David E. Allie, MD William F. Fearon, MD Neal S. Kleiman, MD Yaron Almagor, MD Andrew Feiring, MD, FSCAI Lloyd W. Klein, MD, FSCAI Franz Wolfgang Amann, MD Frederick Feit, MD David F. Kong, MD John A. Ambrose, MD Ted Feldman, MD Vincent On-Hing Kwok, MD Brian H. Annex, MD James J. Ferguson III, MD Jean-Marc LaBlanche, MD David Antoniucci, MD Francisco Fernandez-Aviles, MD, PhD John R. Laird, Jr, MD Joseph D. Babb, MD Michael Fishbein, MD Michael Landzberg, MD Steven R. Bailey, MD Tim Fishcell, MD, FSCAI Alexandra Lansky, MD Donald Baim, MD Peter J. Fitzgerald, MD, PhD John M. Lasala, MD, PhD Christie Ballantyne, MD Dina Fleischer Warren K. Laskey, MD Stephen Balter, PhD Mark S. Freed, MD Michel R. Le May, MD Gerald Barbeau, MD William J. French, MD Robert J. Lederman, MD Theodore A. Bass, MD Shmuel Fuchs, MD Thierry Lefevre, MD Eric R. Bates, MD D. S. Gambhir, MD Martin B. Leon, MD Jorge Belardi, MD Roger Gammon, MD Norman E. Lepor, MD Keith Benzuly, MD Jorge Gaspar, MD Amir Lerman, MD Alex Berenstein, MD Junbo Ge, MD Marian Limacher, MD Peter B. Berger, MD Anthony H. Gershlick, MD Hugo Londero, MD Rafael Beyar, MD, DSc Ian Gilchrist, MD Michael J. Mack, MD Deepak L. Bhatt, MD Robert Giugliano, MD Tift Mann, MD Luc Bilodeau, MD Sheldon Goldberg, MD Michael L. Marin, MD William E. Boden, MD Corey Goldman Stevwn Marso, MD Gregory Braden, MD James Goldstein, MD Alice Mascette, MD Jeffrey Brinker, MD Cindy L. Grines, MD Detlef G. Mathey, MD Bruce R. Brodie, MD Liliana Grinfeld, MD Peter A. McCullough, MD Elchanan Bruckheimer, MBBS Giulio Guagliumi, MD Shamir R. Mehta, MD Christopher P. Cannon, MD Yaling Han, MD Gary S. Mintz, MD Stephane G. Carlier, MD, PhD Michael Haude, MD Kazuaki Mitsudo, MD John Carroll, MD Marian C. Hawkey, RN David J. Moliterno, MD Joseph P. Carrozza, Jr, MD Michel Henry, MD Pedro R. Moreno, MD Charles E. Chambers, MD, FSCAI James B. Hermiller, Jr, MD Douglass A. Morrison, MD, PhD James H. Chesebro, MD Howard C. Herrmann, MD Issam D. Moussa, MD Bernard Chevalier, MD Richard R. Heuser, MD Timothy Murphy, MD Kenneth Chin, MBBS Stuart T. Higano, MD Sherif F. Nagueh, MD Michael W. Cleman, MD, FSCAI Vincent B. Ho, MD Franz-Josef Neumann, MD David J. Cohen, MD Rainer Hoffmann, MD Thach N. Nguyen, MD, FSCAI Marc Cohen, MD David R. Holmes, Jr, MD Elizabeth Ofili, MD, MPH Antonio Colombo, MD Mun K. Hong, MD Jeffrey W. Olin, DO Monica Colvin-Adams Angela Hoye, MB, ChB John Ormiston, MD, MB, ChB Anthony Comerota, MD Judy Hsia, MD Charles D. O’Shaughnessy, MD Mark W. Connolly, MD Eileen Hsich, MD Manish A. Parikh, MD Michael J. Cowley, MD Sharon Hunt, MD Seung-Jung Park, MD, PhD Deborah Crabbe, MD Ioannis Iakovou, MD Michael Parmacek, MD Charles J. Davidson, MD Frank Ing, MD, FSCAI Juan C. Parodi, MD Bernard De Bruyne, MD, PhD Thomas Ischinger, MD Emerson Perin, MD, PhD Giuseppe De Luca, MD Alice K. Jacobs, MD Harry R. Phillips, MD Teresa De Marco, MD Michael R. Jaff, DO Nico H. J. Pijls, MD, PhD Ivan De Scheerder, MD, PhD

124 truth in evidence based medicine · challenge conventional wisdom · tRANSFORM your THINKING abstract Graders

Stuart J. Pocock, PhD Sergio Waxman, MD Matthew J. Price, MD Nanette Wenger, MD LeRoy E. Rabbani, MD Judah Weinberger MD

Stephen R. Ramee, MD Bonnie H. Weiner, MD in t ro Rita Redberg, MD, MSc William S. Weintraub, MD Mark Reisman, MD Neil J. Weissman, MD Flavio Ribichini, MD Giora Weisz, MD Donald R. Ricci, MD Robert Whitbourn, MD, MBBS tURDAY

Charanjit S. Rihal, MD Christopher White, MD, FSCAI agenda sa Barbara Roberts, MD, FACC Harvey White, MD Alfredo Rodriguez, MD, PhD James Whiting, PhD Campbell Rogers, MD William Wijns, MD Kenneth Rosenfield, MD, FSCAI Robert L. Wilensky, MD sun DAY Todd K. Rosengart, MD Stephan Windecker, MD agenda Allan M. Ross, MD Steven D. Wolff, MD, PhD John H. Rundback, MD S. Chiu Wong, MD Manel Sabate, MD, PhD Jay S. Yadav, MD David J. Sahn, MD John J. Young, MD agenda Michael H. Salinger, MD, FSCAI Bram Zuckerman, MD mon DAY Erick Schampaert, MD Dierk Scheinert, MD Ann Marie Schmidt, MD David Schneider, MD agenda Joachim Schofer, MD t ues DAY Helmut Schuhlen, MD Gerhard Schuler, MD Allan Schwartz, MD Robert S. Schwartz, MD

Matthew Selman, MD agenda wed NESDAY Samin Sharma, MD, FSCAI Horst Sievert, MD, PhD Ulrich Sigwart, MD

Robert Simari, MD case

Daniel I. Simon, MD reviews Michael Simons, MD Robert Sommer, MD Amanda G. M. R. Sousa, MD, PhD Eduardo M. R. Sousa, MD agenda

William Spencer, MD t hurs DAY Steven Steinhubl, MD Joseph Stella, MD Pieter R. Stella, MD Peter H. Stone, MD t raining Thomas D. Stuckey, MD physician Gabor I. Sutsch, MD Doris A. Taylor, PhD James E. Tcheng, MD

Martyn Thomas, MD t elli e even t s Patricia Thorpe, MD sa Jonathan M. Tobis, MD Carl L. Tommaso, MD, FSCAI Etsuo Tsuchikane, MD, PhD Zoltan G. Turi, MD

E. Murat Tuzcu, MD ABS T RAC S Philip Urban, MD Barry F. Urtesky, MD, FSCAI Arnoud W. J. van’t Hof, MD, PhD Francesco Versaci, MD general Jiri J. Vitek, MD, PhD Karol Watson, MD

www.tct2007.com 125 transcatheter cardiovascular therapeutics

acknowledgements

The TCT program development and Kiersten Feil ADMINISTRATIVE SUPPORT STAFF organization is a year-round effort. Many Medical Writer / Editor Nancy Collins people play important roles that ensure the Publications Gabriella Gallo-Cisak success of TCT by contributing their Michelle Gong Darcy Cavanaugh experience and expertise. The Cardiovascular CME Coordinator Diane Salerno-Madrid Research Foundation wishes to give special Meetings and Conventions thanks to all those who have worked tirelessly and with great dedication to our Katie Herrion mission. Coordinator CORE LABORATORIES Exhibitor Services, Meetings and Conventions Rasha Aaskar Guadalupe Hogarty Richard Abendroth Management Team Sr. Meeting Planner Harpreet Bharaj Meetings and Conventions Sinan Biro Johnnie White, CMP Laura Cassidy Director Sarah McDaniel Celia Castellanos Meetings and Conventions Meeting Planner Maria P. Corral Meetings and Conventions Jeffrey Benner Ecaterina Cristea Director Cody Pietras Lokesh Dani Publications Content Coordinator Maria de las M. Vazquez Publications Meg Breeden Champika Djurkovic TCT Event Manager Scott Allan Wallick Hiroshi Doi Copy Editor Ovidiu Dressler Lisa Hathaway Publications Michael Duval Manager Ivana C. Jankovic Lesia Zimmer Exhibitor Services Guillaume Joelson Senior Coordinator Jason Kahn Takashi Kubo Meetings and Conventions Manager Akiko Maehara Editorial Services Fatima Masumova Publications Shannon Myers SENIOR MANAGEMENT GROUP Fun Lee, CMP Dana Lazar Manager Marvin L. Woodall Jian Liu Meeting Planning Chief Executive Officer Rena Luger Mitchel B. Lustre Meetings and Conventions Matthew P. Pazaryna Katharine Lymberis Chief Operating Office and Todd Wagner Sofia Papamitrou Chief Financial Officer Production Manager Shady Prestol Publications Donald L. Abrams Snehal Rathod Colleen Whelan Chief Administrative Officer Bahram Ahmad Sahid Sr. Manager and General Counsel Raquel Sanchez CME Program Development Roni Amiel Anthony Tam Director Kenichi Tsujita Information Technology Shawnalee Vassell Junqing Yang PLANNING GROUP Jeffrey Benner Sarah Beecroft Director Program Coordinator Publications Meetings and Conventions Irene Bihl Steve Cannarelli Director Sr. Graphic Designer Operations Publications Tina Finnegan Jeff Chamlee Director Multimedia Producer Human Resources Publications George Lombardi Elizabeth DeVita Financial Controller and Sr. Meeting Planning Coordinator Administrative Director Meetings and Conventions Johnnie White, CMP Simone DeVone Director Executive Assistant Meetings and Conventions Meetings and Conventions

126 truth in evidence based medicine · challenge conventional wisdom · transform your thinking acknowledgements

DATA COORDINATING AND Factoid Team INFORMATioN TECHNOLOGY ANALYSIS CENTER Andrea Abizaid Louis Cruz Manzoor Alam Tayo Addo Richard Han in t ro Mustafa Al-Hindi Jiro Aoki Bryan Kay Zaenab Al-Rehani Sam Brar Vineet Persad Oscar Amarilla Adriano Caixeta Christina J. Annest Jose Ribamar Costa Ricardo Costa Neteria Augcomfar MARKETING AND PUBLIC RELATIONS tURDAY agenda

Ecaterina Cristea sa Floni Bajraktari Irma Damhuis Damiana Fiscella Delia Banu Claire Laporte Sonia Burgher Neil Goyal Erin Conroy Eric Heller Shoshanna Daniels John Iakovou sun DAY OFFICE OF LEGAL AFFAIRS agenda Florencia De Los Santos Srinivas Iyengar Ossen Delbrun Vijaya Kensakurthy Ruth Mansueto LaTosha Dennis Ravi Kilaru Terry Zisowitz Marina Dizik Young-Hak Kim Monica Embacher Jian Liu agenda mon DAY Rahul Gada Julio Maia THE JACK H. SKIRBALL CENTER FOR Matthew Gower Ben Matthew CARDIOVASCULAR RESEARCH Carl Hart Eduardo Missel Juan Carbonell Rita V. Hoard Ray Miu Eugenia Nikolsky Francy Castro

Sarah L. Jhung agenda Yanping Cheng t ues DAY Sapna Kapoor Paulo Marcio Nunes Gerard B. Conditt Vijaya Kesanakurthy Tereza Pucelikova Duane Dennis Christina Lam Viveka Sareen Alyssa M. Flynn Kiran Medasani Dimytri Siqueira Emilia Solinas Patricia Glennon Lenuta Micsa agenda Danielle Grieve Gopinathan Mohan George Syros wed NESDAY Anguo Gu Joyce Montanez Tudor Vagaonescu Jennifer McGrego Carol Moore Akira Murata Kathleen Morgan

Beiping Qiang case

Dierdre Murphy FINANCE reviews Kathy Troyan Jocelyne Papcharalombous Yuliya Bogomolny Jie Wang Helen Parise Adam Gold Kai Xu Vijay S. Poonai Shana Heath Genghua Yi Ramona Pop Angelle Kashanian

Anne-Marie Ramirez agenda Karina Kopaniecka t hurs DAY Yan Rosentsveyg Gayle Lambert Brendon P. Ryan Eileen Morales Eugene Salgado Kathy Troyan Patrick S. Tioseco Cheryl Turnbull t raining Villa Tourkova Qudsia Van Rose physician Dawn Walburg Timothy Wright Lifang Xie HUMAN RESOURCES AND t elli e OFFICE SERVICES even t s sa Amanda Bishop Toni Canzoneri Aryel Flores De Valgaz KenDell Jackson

Kelli Lynch ABS T RAC S Kara McDermott Laura L. Stilwell Emilia K. Valtcheva general

www.tct2007.com 127 transcatheter cardiovascular therapeutics

acknowledgements

QUALITY ASSURANCE Maria Fe Serrantes, RN Stephanie Quach, RN Jessica Forman, RPA-C Michael Querijero, RPA-C Ruby Jain Terri Franklin-Bond Sheehan Raab, AS Harte Fuentes, RN Siobhan Reilly, RN Richard Gemming, MPH Agnes Ruiz TCTMD Nenita Generales, RN Teisha Ruiz Josh Hartman Isidro Gonzales Jennifer Sanders, RN Yemilet Gonzalez Ana Leah Saniel, RN Lu-Kan Gorman, RN Amy Sebak BOARD OF DIRECTORS OF the Jessica Graff, RPA-C Kotatii Sei-Jedah, RN CARDIOVASCULAR RESEARCH Sophia Graham, AS Tamara Seney B. Denise Groff, RN Harry Sherman FOUNDATION Yonina Grossberg Kristin A. Snow Michael R. Henson Geraldo Gual Jeanie Sohn Martin B. Leon, MD Michael Guiry, RPA-C Alina Sokolinskaya Dana G. Mead, Jr Stacy Hall Samantha Sookdeo Jeffrey W. Moses, MD Marian Hawkey, RN Krisna Sricharoon Arthur J. Pergament Mike Herscher Barbara Stock, RN Allan Schwartz, MD Laura Higginbotham Deborah Sugirtharaj Gregg W. Stone, MD Derrrick Horn, RN Pedro Susana Marvin L. Woodall Elena Hoskin George Syros, MD Seing Houy, RPA-C Vivian Tamara, RN Srinivas Iyengar, MD Maria Lourdes Tan-Uy, RN Columbia University Medical Center Suzanne Jakubiak Annicia Thomas Sean Ahearn, RPA-C Bevi James Cheri Tomasino, RPA-C Dan C. Almodovar, RPA-C Tina Jones Sudhi Tyagi Caesar Alvero, AS Maricar Jordana, RN June Valent, RN Regina Amelko Rona Kahn Marcos Valerio, RN Osama Amine, AS Jennifer Kaminski, RN Tamara Van Gelder, AS Lisa Badri, RPA-C Paul Kelly, RN Albina Varibrus, RPA-C Zoraya Boissand Cathy Kennedy Hongge Wei, AS Paul Boland Viola King Annelle Williams David Borsh, RN Sunny Koshy, AS Tiffany Wong, RPA-C Russell Brandwein, RPA-C Hyun-Sook Kwack, RN Karen Wu, RPA-C Somjot Brar, MD Vanessa Laroche Vasquez Xiomara Kelle Brocker, RN Felicia Leon Jennifer Yandow, RPA-C Galina Bukh, RPA-C Louis Lopez Farida Yeasmeen Marilyn Castaldi Miriam Lucca-Susana Maria Younessian, RN Celia Castellanos Erika Marrero Nadzeya Zhylinskaya, RPA-C Kia Clarkson, RPA-C Salim Benjamin Mathew, MD Teraza Conway Lourdes Matias, RN Beatriz Custodio Valerie Medina Neil Dasqupta Donna Miles, RPA-C Frances David, RN Christine Millare, RPA-C Vicente De Braganca Kin Man Raymond Miu, MD Michael Deleon, RN Enid Montalvo Hilda Devlin, RN Andy Morales Eunice Dilone Dora Mussenden Pilar Dolcimascolo, RPA-C Erwin Navarro Michele Dondero, RN Hilary Nirenberg, ANP, MPH Ed Donovan, RN Jhan Nunez Reynald Dorsainvil, AS Lisa Ocasio Bryan Dotson Kevin O’Connor, RPA-C Eulalia D’Souza, RN Mariamne Orta Matthew Dudley, AS Lataisha Ousley Devon Dyett Kate Ozemebhoya, RPA-C Claudia Echeverry, AS Elene Papakostas Mary Egan, RN Irene Pilosova, RPA-C Yuan Fang, AS Jackie Price

128 truth in evidence based medicine · challenge conventional wisdom · transform your thinking acknowledgements

Commercial Support Acknowledgment

TCT 2007 is sponsored by the Cardiovascular Research Foundation and partially funded through educational grants from commercial supporters. in t ro The Cardiovascular Research Foundation strives to ensure that its programs are as educational as possible and free from commercial bias. To support this endeavor, TCT directors and co-directors create organizational and scientific committees to assist in educational content development and

oversight for live cases, concurrent sessions, case reviews, practical workshops, and scientific tURDAY agenda

symposia. These sessions are developed without influence from commercial supporters. sa

The Cardiovascular Research Foundation gratefully acknowledges the major benefactors of TCT 2007: sun DAY Abbott Vascular agenda Boston Scientific Corporation Cordis Cardiac & Vascular InstituteSM Cook Incorporated Medtronic, Inc agenda The Medicines Company mon DAY

The Cardiovascular Research Foundation gratefully acknowledges the major benefactors of the Percutaneous Intervention for the Surgeon course: agenda Medtronic, Inc t ues DAY St. Jude Medical Edwards Lifesciences

The Cardiovascular Research Foundation appreciates agenda

the educational grant support provided by wed NESDAY

Abiomed, Inc Evalve, Inc AccessClosure, Inc FlowCardia, Inc AGA Medical Corporation FlowMedica, Inc case reviews AngioScore, Inc FoxHollow Technologies, Inc Asahi Intecc USA, Inc GE Healthcare Atrium Medical Corporation Kensey Nash Corporation Bracco Diagnostics, Inc Medicure Pharma, Inc

Bioheart, Inc OrbusNeich agenda t hurs DAY Biotronik GmbH & Co KG Orqis Medical Corporation Capella, Inc PDL BioPharma, Inc CardioMind, Inc Radi Medical Systems Cardiovascular Systems, Inc Radiant Medical, Inc

Cierra, Inc TherOx, Inc t raining physician CoreValve Viacor, Inc Daiichi-Sankyo, Inc and Eli Lilly and Company Tryton Medical, Inc Datascope Corp Volcano Corporation Edwards Lifesciences, LLC Xtent, Inc t elli e even t s sa

It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational programs. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity. Discussion of off-label product usage, and/or off-label product use during live cases, is made at the sole discretion ABS T RAC S of the faculty and is not endorsed by the Cardiovascular Research Foundation or the program directors for this activity. Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the program audience any

real or apparent conflict of interest related to the content of their presentation(s). Faculty not general complying with this policy are not permitted to participate in this activity.

www.tct2007.com 129 See The Complete Solution for Thrombus™ INTRODUCING at TCT Booth 7075

O ll A ze Never

When it comes to removing thrombus, one thrombectomy device does not fi t all patients. Making a positive impact on patient outcomes Possis Medical, the pioneer of the AngioJet® technology used in over 300,000 cases, provides a full For the first time a multi-component compliance program spectrum of thrombectomy devices and indications that address thrombus throughout the body. has been designed to help your drug-eluting stent patients The AngioJet® Rheolytic™ Thrombectomy System offers seven specialized catheters providing choice stay on the anti-platelet therapy you prescribe. in length, platform, clot removal power and profi le to match physician preference and the needs of each unique case. Add combination therapy provided by AngioJet Power Pulse™ Delivery for large, Talk to us about how this integrated program can benefit diffi cult to remove thrombus and add the ease of use and deliverability of the Fetch® Aspiration your patients. Catheter for small, fresh clot and you have all the tools you need.

With a range of therapies and indications unmatched in the industry, Possis provides a perfect fi t for everyone in a single source solution.

VISIT US AT BOOTH 3021

The StentplusTM Program is brought to you by Boston Scientific Corporation. © 2007 The AngioJet System includes several models that are marketing for thrombectomy of coronary arteries and Phone: EU +30 693 241 1248 US +1 800 810 7677 USCV5478.101.0 7/07 bypass grafts, A.V. access conduits, and peripheral arteries and peripheral veins. See product Information Fax: EU +30 210 271 1559 US +1 763 780 2227 For Use for specifi c and complete prescribing information. AngioJet, Rheolytic, Power Pulse, Fetch and The Complete Solution for Thrombus are trademarks of Possis Medical, Inc. 2007 1799-001 7/2007 www.possis.com See The Complete Solution for Thrombus™ at TCT Booth 7075

O ll A ze Never

When it comes to removing thrombus, one thrombectomy device does not fi t all patients.

Possis Medical, the pioneer of the AngioJet® technology used in over 300,000 cases, provides a full spectrum of thrombectomy devices and indications that address thrombus throughout the body.

The AngioJet® Rheolytic™ Thrombectomy System offers seven specialized catheters providing choice in length, platform, clot removal power and profi le to match physician preference and the needs of each unique case. Add combination therapy provided by AngioJet Power Pulse™ Delivery for large, diffi cult to remove thrombus and add the ease of use and deliverability of the Fetch® Aspiration Catheter for small, fresh clot and you have all the tools you need.

With a range of therapies and indications unmatched in the industry, Possis provides a perfect fi t for everyone in a single source solution.

The AngioJet System includes several models that are marketing for thrombectomy of coronary arteries and Phone: EU +30 693 241 1248 US +1 800 810 7677 bypass grafts, A.V. access conduits, and peripheral arteries and peripheral veins. See product Information Fax: EU +30 210 271 1559 US +1 763 780 2227 For Use for specifi c and complete prescribing information. AngioJet, Rheolytic, Power Pulse, Fetch and The Complete Solution for Thrombus are trademarks of Possis Medical, Inc. 2007 1799-001 7/2007 www.possis.com Proven Terumo coronary guidewire technology NOW AVAILABLE in the U.S.

Coronary Guidewire

Precision you can feel.

� Exceptional tip shape retention Allows lesion crossing and multi-vessel procedures

� Unique DuoCore™ Technology Provides 1:1 torque transfer, excellent steerability and pushability

� Advanced coatings Enhance smooth trackability and superior device delivery

Precision is TERUMO Territory.

Visit us at TCT Booth # 6079

For more information, call 800.862.4143 to speak to an Inside Sales Customer Care Representative, or visit www.terumomedical.com/interventional

Terumo Interventional Systems • 2101 Cottontail Lane • Somerset, NJ 08873 • Fax: 800.411.5870 © 2007 Terumo Medical Corporation. All rights reserved. All brand names are trademarks or registered trademarks of Terumo.

TERUMO INTERVENTIONAL SYSTEMS Where ingenuityandintegrityconverge. www.cookmedical.com orbooth#5065. For more information regarding ourproducts, visit can deliverwithconfi physicians. Together, better patient care isapromise we closecollaborationhave developedfrom with ahistoryof exceed their performanceexpectations. Ourqualitystandards to cliniciansandpatients that ourdevicesandtechnologies Competing againstdisease, westrivetoprovide assurance minimally invasiveprocedures. community byproviding products andservicestosupport For 44years, Cook Medicalhas servedtheworld’s clinical dence.

© COOK 2007

Cardiology

Cordis ®

Experience You Can Trust.

Long-term Performance In Large Vessels* up to 3.5 mm 25 p < 0.0001 The CYPHER® Stent n = 283 Bare-Metal Stent n = 292 20.2 20 Mean RVD = 3.22 mm mean RVD = 3.24 mm

15 NS = Not significant p = NS 12 10 8.5 p = NS % of Patients 5 4.6 1.7 0.7 77% 0 ARC1 Death or MI Target Lesion Definite/Probable Revascularization Stent Thrombosis (TLR)

Safely Reducing TLR in Large Vessels out to 4 Years

* Large vessels are defined as 3.17 mm to 3.5 mm. Based on pooled analysis from the RAVEL, SIRIUS, E-SIRIUS and C-SIRIUS Trials. These trials were not individually or collectively powered to assess differences in the rates for rare events, such as death, myocardial infarction (MI) or stent thrombosis.

1Academic Resource Consortium Definite - Acute coronary syndrome AND - Angiographic confirmation of ST or occlusion OR - Pathologic confirmation of acute stent thrombosis Probable - Unexplained death within 30 days - Target vessel MI without angiographic confirmation or ST or other identified culprit lesion The CYPHER® Stent is indicated for de novo lesions in coronary arteries ™ with sizes between 2.5 mm and 3.5 mm. Make your first intervention last

Sirolimus-eluting Stent made by Cordis Corporation pursuant to a license from Wyeth Pharmaceuticals © Cordis Corporation 2007 August 2007 155-5957-1 Cordis CYPHER® Sirolimus-eluting Coronary Stent Essential Prescribing Information

Device Component Description: Precautions - Pre- and Post-Procedure Antiplatelet Regimen: Stent in pediatric patients below the age of 18 years have Precautions - Magnetic Resonance Imaging (MRI): the proximal stent in the placement of the distal stent and The CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent) is a In the pivotal clinical trial of the CYPHER® Stent, clopidogrel or ticlopidine not been established. Through non-clinical testing, single and two overlapping CYPHER® may reduce the chances of dislodging the proximal stent, or device/drug combination product comprised of two regulated compo- was administered pre-procedure and for a period of three months post- • Geriatric use: Clinical studies of the CYPHER® Stent did Stents have been shown to be MRI safe at field strengths of 3 Tesla or disrupting stent coating. nents: a device (a Bx VELOCITY® Coronary Stent System) and a drug procedure. Aspirin was administered concomitantly with clopidogrel or not find that patients age 65 years and over differed with less, and a maximum whole body averaged specific absorption rate • Balloon pressures should be monitored during inflation. product (a formulation of sirolimus in a polymer coating). The device ticlopidine and then continued indefinitely to reduce risk of thrombosis. regard to safety and efficacy compared to younger patients. (SAR) of 4.0 W/kg for 15 minutes of MRI. Single and two overlapping Do not exceed rated burst pressure as indicated on component consists of the Bx VELOCITY® Stent premounted onto a • Non-Coronary use: The safety and effectiveness of this CYPHER® Stents should not migrate in this MRI environment. Non- the product label. Use of pressures higher than those stent delivery system (SDS), either the RAPTOR™ PTCA Dilatation It is very important that the patient is compliant with the post-proce- product has not been established in the cerebral, carotid, or clinical testing has not been performed to rule out the possibility of specified on the product label may result in a ruptured Catheter (Over-the Wire (OTW)) or the RAPTORRAIL® PTCA Dilatation dural antiplatelet recommendations. Early discontinuation of prescribed peripheral vasculature. stent migration at field strengths higher than 3 Tesla. balloon with possible intimal damage and dissection. Catheter (Rapid Exchange (RX)). The range of stent diameters is made antiplatelet medication could result in a higher risk of thrombosis, my- • Do not attempt to pull an unexpanded stent back through possible by varying the number of circumferential “cells” on the stent. ocardial infarction or death. Prior to Percutaneous Coronary Interven- Precautions – Lesion/Vessel Characteristics: In this testing, single CYPHER® Stents up to 33 mm in length produced the guiding catheter, as dislodgment of the stent from the The 2.5, 2.75 and 3.0 mm diameter 316L stainless steel stents have six tion (PCI), if a surgical or dental procedure is anticipated that requires The safety and effectiveness of the CYPHER® Stent have not been es- a temperature rise of less than 1 degree Celsius (1ºC), and two over- balloon may occur. circumferential cells, whereas, the 3.5 mm diameter 316L stainless steel early discontinuation of antiplatelet therapy, the interventionalist and tablished in the following patient populations: lapped 33 mm length CYPHER® Stents produced a temperature rise of • Stent retrieval methods (use of additional wires, snares stents have seven circumferential cells. The stent is crimped on various patient should carefully consider whether a drug-eluting stent and its • Patients with unresolved vessel thrombus at the lesion site. less than 2 degrees Celsius (2ºC) at a maximum whole body averaged and/or forceps) may result in additional trauma to the size delivery catheter balloons, which are sized from 2.5 to 3.5 mm. associated recommended antiplatelet therapy is the appropriate PCI • Patients with coronary artery reference vessel diameter specific absorption rate (SAR) of 4.0 W/kg for 15 minutes of MRI. The coronary vasculature and/or the vascular access site. treatment choice. Following PCI, should a surgical or dental procedure < 2.5 mm or > 3.5 mm. effect of heating in the MRI environment for stents with fractured struts Complications may include bleeding, hematoma, or Drug Component Description: be recommended, the risks and benefits of the procedure should be • Patients with lesions located in the saphenous vein graft, in is not known. The effect of heating in the MRI environment on the pseudoaneurysm. The active pharmaceutical ingredient in the CYPHER® Stent is sirolimus weighed against the possible risk associated with early discontinuation the unprotected left main coronary artery, ostial lesions, or drug or polymer coating is not known. • Ensure full coverage of the entire lesion/dissection site so (also known as Rapamycin). Sirolimus is a macrocyclic lactone produced of antiplatelet therapy. lesions located at a bifurcation. that there are no gaps between stents. by Streptomyces hygroscopicus. The chemical name of sirolimus is • Patients with diffuse disease or poor overflow distal to the MR imaging quality may be compromised if the area of interest is in the (3S,6R,7E,9R,10R,12R,14S,15E, 17E,19E,21S,23S,26R,27R,34aS)- Patients who require early discontinuation of antiplatelet therapy (e.g., identified lesions. exact same area or relatively close to the position of the stent. Precautions - Stent/System Removal: 9,10,12,13,14,21,22,23, 24,25,26,27,32,33,34,34a-hexadecahydro- secondary to active bleeding) should be monitored carefully for cardiac • Patients with tortuous vessels in the region of the obstruc- Should unusual resistance be felt at any time during either lesion 9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- events. At the discretion of the patient’s treating physicians, the an- tion or proximal to the lesion. Precaution – Preparation: access or removal of the stent delivery system before stent implantation, 1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27- tiplatelet therapy should be restarted as soon as possible. • Patients with a recent acute myocardial infarction where • AVOID manipulation of the stent during flushing of the the entire system should be removed as asingle unit. epoxy-3H-pyrido[2,1-c ][1,4] oxaazacyclohentriacontine-1,5,11,28,29 there is evidence of thrombus or poor flow. guidewire lumen, as this may disrupt the placement of the (4H,6H,31H)-pentone. Its molecular formula is C51H79NO13 and its Precautions - Use of Multiple Stents: • Patients with more than two overlapping stents. stent on the balloon. When removing the delivery system as a single unit: molecular weight is 914.2. The extent of the patient’s exposure to drug and polymer is directly re- • Patients for longer than 24 months follow-up. • Do NOT apply negative or positive pressure to the balloon • Do not retract the delivery system into the guiding catheter. lated to the number of stents implanted. Use of more than two during the delivery system preparation. • Advance the guidewire into the coronary anatomy as far The inactive ingredients in the CYPHER® Stent contain parylene C and CYPHER® Stents has not received adequate clinical evaluation. Use of Precautions - Drug Interactions: distally as safely possible. the following two non-erodible polymers: polyethylene-co-vinyl acetate more than two CYPHER® Stents will result in the patient receiving Several drugs are known to affect the metabolism of sirolimus, and Precautions - Stent Handling: • Tighten the rotating hemostatic valve to secure the stent (PEVA) and poly n-butyl methacrylate (PBMA). A combination of the larger amounts of drug and polymer than the experience reflected in the other drug interactions may be inferred from known metabolic effects. • For single use only. Do not resterilize or reuse this delivery system to the guiding catheter; then remove the two polymers mixed with sirolimus (67%/33%) makes up the basecoat clinical studies. Sirolimus is known to be a substrate for both cytochrome P450 IIIA4 product. Note the “Use By” date on the product label. guiding catheter and stent delivery system as a single unit. formulation which is applied to a parylene C treated stent.A drug-free (CYP3A4) and P-glycoprotein. • Do not remove the stent from the delivery balloon topcoat solution of PBMA polymer is applied to the stent surface. The To avoid the possibility of dissimilar metal corrosion, do not implant – removal may damage the stent and coating Failure to follow these steps or applying excessive force to the stent drug/polymer coating is adhered to the entire surface (i.e., luminal and stents of different materials in tandem where overlap or contact is pos- Consideration should be given to the potential for drug interaction and/or lead to stent embolization. The stent system is delivery system can potentially result in loss or damage to the stent or abluminal) of the stent. sible. Potential interactions of the CYPHER® Stent with other drug- when deciding to place a CYPHER® Stent in a patient who is taking a intended to perform as a system. stent delivery system. eluting or coated stents have not been evaluated and should be avoided drug that could interact with sirolimus, or when deciding to initiate • Do not induce a vacuum on the delivery system Indications: whenever possible. therapy with such a drug in a patient who had recently received a prior to reaching the target lesion. If it is necessary to retain the guidewire in position for subsequent ar- The CYPHER® Stent is indicated for improving coronary luminal diam- CYPHER® Stent.The effect of drug interactions on the safety or efficacy • Special care must be taken not to handle or in any way tery/lesion access, leave the guidewire in place and remove all other eter in patients with symptomatic ischemic disease due to discrete de It is noteworthy that there have been no prospective randomized trials of the CYPHER® Stent has not been determined. disrupt the stent on the balloon. This is most important while system components. novo lesions of length < 30 mm in native coronary arteries with a ref- specifically designed to assess multiple or overlapping CYPHER® Stents removing the catheter from the packaging, placing it over erence vessel diameter of > 2.5 to < 3.5 mm. for long lesions in a single vessel. A retrospective analysis of subjects Precautions - Coronary Artery Surgery – Effect on Anasto- the guidewire, and advancing it through the large-bore Precautions – Post-Procedure in randomized and non-randomized trials and clinical registries did not moses: rotating hemostatic valve and guiding catheter hub. • Great care must be exercised when crossing a newly Contraindications: suggest an increased rate of myocardial infarctions associated with the There have been rare reports of bronchial anastomotic dehiscence of • Stent manipulation (e.g., rolling the mounted stent with deployed stent with an intravascular ultrasound (IVUS) Use of the CYPHER® Stent is contraindicated in the following patient use of multiple or overlapping CYPHER® Stents in a single vessel, com- transplant anastomoses in lung transplant patients who were receiving your fingers) may cause coating damage, contamination or catheter, a coronary guidewire or balloon catheter to avoid types: pared to that of bare-metal stents. oral sirolimus therapy. In a vessel that has recently been implanted with dislodgement of the stent from the delivery system balloon. disrupting the stent placement, apposition, geometry, and/or • Patients with a hypersensitivity to sirolimus or its structurally a CYPHER® Stent, the sirolimus concentrations are expected to be sev- • Use only the appropriate balloon inflation media. Do not use coating. related compounds. Precautions - Brachytherapy: eral fold higher than systemic sirolimus concentrations.Therefore, con- air or any gaseous medium to inflate the balloon as this may • Through non-clinical testing, single and two overlapping • Patients with a known hypersensitivity to polymethacrylates The safety and effectiveness of the CYPHER® Stent in patients with sideration should be given to the possibility that the presence of a cause uneven expansion and difficulty in deployment of CYPHER® Stents have been shown to be MRI safe at field or polyolefin copolymers. prior brachytherapy of the target lesion have not been established.The CYPHER® Stent may compromise the healing of coronary artery vas- the stent. strengths of 3 Tesla or less. MR imaging quality may be safety and effectiveness of use of brachytherapy to treat in-stent cular anastomoses. No such event was observed in the very limited ex- compromised if the area of interest is in the exact same area Coronary artery stenting is contraindicated for use in: restenosis in a CYPHER® Stent have not been established. Both vas- perience from clinical trials. Precautions - Stent Placement: or relatively close to the position of the stent. • Patients in whom antiplatelet and/or anticoagulation therapy cular brachytherapy and the CYPHER® Stent alter arterial remodeling. • The vessel should be pre-dilated with an appropriate sized • In the pivotal clinical trial of the CYPHER® Stent, clopidogrel is contraindicated. The synergy between these two treatments has not been determined. Precautions - Immune Suppression Potential: balloon. or ticlopidine was administered pre-procedure and for a • Patients judged to have a lesion that prevents complete Sirolimus, the active ingredient of the CYPHER® Stent, is an immuno- • Do not prepare or pre-inflate the balloon prior to stent period of three months post-procedure. Aspirin was admin- inflation of an angioplasty balloon or proper placement of Precautions - Use in Conjunction with Other Procedures: suppressive agent that is also available in oral formulations. The mean deployment other than as directed. istered concomitantly with clopidogrel or ticlopidine and the stent or delivery catheter. The safety and effectiveness of using mechanical atherectomy devices peak systemic blood concentration of sirolimus following placement of • Guiding catheters used must have lumen sizes that are then continued indefinitely to reduce the risk of thrombosis. (directional atherectomy catheters, rotational atherectomy catheters) up to two CYPHER® Stents (1.05 ng/ml) is substantially lower than suitable to accommodate the stent delivery system. • Patients who require early discontinuation of antiplatelet Warnings: or laser angioplasty catheters in conjunction with CYPHER® Stent im- the therapeutic concentrations usually obtained when sirolimus oral • Do not induce a negative pressure on the delivery catheter therapy (e.g. secondary to active bleeding) should be • Please ensure that the inner package has not been opened plantation have not been established. formulations are used as prophylaxis for renal transplant rejection. In prior to placement of the stent across the lesion. This may monitored carefully for cardiac events. At the discretion or damaged as this may indicate the sterile barrier has been clinical studies of CYPHER® Stents when used according to its intended cause premature dislodgment of the stent from the balloon. of the patient’s treating physician, the antiplatelet therapy breached. Precautions - Use in Special Populations: use, there were no reports of immune suppression. However, for pa- • Although the stent delivery balloon catheter is strong enough should be restarted as soon as possible. • The use of the product carries the risks associated with • Pregnancy: Pregnancy Category C. There are no adequate tients who receive several CYPHER® Stents simultaneously, it may be to expand the stent without rupture, a circumferential tear coronary artery stenting, including subacute thrombosis, and well-controlled studies in pregnant women or men possible for systemic concentrations of sirolimus to approach immuno- of the carrier balloon distal to the stent and prior to Drug Information vascular complications, and/or bleeding events. intending to father children. Effective contraception should suppressive levels temporarily, especially in patients who also have he- complete expansion of the stent could cause the balloon to • Patients with a known hypersensitivity to 316L stainless be initiated before implanting a CYPHER® Stent and for 12 patic insufficiently or who are taking drugs that inhibit CYP3A4 or become tethered to the stent, requiring surgical removal. In Mechanism of Action: steel may suffer an allergic reaction to this implant. weeks after implantation. The CYPHER® Stent should be P-glycoprotein. This possibility should be considered for such patients, case of rupture of the balloon, it should be withdrawn and, The mechanism (or mechanisms) by which a CYPHER® Stent affects used during pregnancy only if the potential benefit out- particularly if they are also taking oral sirolimus (or rapamycin), other if necessary, a new balloon catheter exchanged over the neointima production as seen in clinical studies has not been estab- Precautions - General Precautions: weighs the potential risk to the embryo or fetus. immunosuppressive agents, or are otherwise at risk for immune sup- guidewire to complete the expansion of the stent. lished. Sirolimus inhibits T-lymphocyte activation and smooth muscle • Only physicians who have received adequate training should • Use during lactation: A decision should be made whether pression. • Implanting a stent may lead to a dissection of the vessel and endothelial cell proliferation in response to cytokine and growth perform implantation of the stent. to discontinue nursing or to implant the stent, taking into distal and/or proximal to the stented portion and may cause factor stimulation. In cells, sirolimus binds to the immunophilin, FK Bind- • Stent placement should only be performed at hospitals account the importance of the stent to the mother. Precautions - Lipid Elevation Potential: acute closure of the vessel requiring additional intervention ing Protein-12 (FKBP-12).The sirolimus-FKBP-12 complex binds to and where emergency coronary artery bypass graft surgery can • Gender: Clinical studies of the CYPHER® Stent did not find The use of oral sirolimus in renal transplant patients was associated (CABG, further dilatation, placement of additional stents, or inhibits the activation of the mammalian Target of Rapamycin (mTOR), be readily performed. any significant differences in safety and effectiveness for with increased serum cholesterol and triglycerides that in some cases other intervention). leading to inhibition of cell cycle progression from the G1 to the S • Subsequent stent blockage may require repeat dilatation of male and female patients. required treatment. The effect was seen with both low and high dose • Do not expand the stent if it is not properly positioned in the phase. the arterial segment containing the stent. The long-term • Ethnicity: Clinical studies of the CYPHER® Stent did not prolonged oral therapy in a dose related manner.When used according vessel. outcome following repeat dilatation of endothelialized include sufficient numbers of patients to assess for differ- to the indications for use, the systemic sirolimus concentrations from the • Placement of the stent has the potential to compromise side Pharmacokinetics of the CYPHER® Stent: stents is not well characterized. ences in safety and effectiveness due to ethnicity, either by CYPHER® Stent are expected to be lower than the concentrations usu- branch patency. The pharmacokinetics of sirolimus as delivered by the CYPHER® Stent • Do not use Ethiodol or Lipiodol contrast media. individual category or when grouped by Caucasian and ally obtained in transplant patients, but the magnitude and duration of • When treating multiple lesions, the distal lesion should be has been determined in patients with coronary artery disease after im- • Do not expose the delivery system to organic solvents, such non-Caucasian. any effect of those concentrations on lipids is not known. initially stented, followed by stenting of the more proximal plantation of one (n=10) or two (n=9) CYPHER® Stents. as alcohol, or detergents. • Pediatric use: The safety and efficacy of the CYPHER® lesion(s). Stenting in this order minimizes the need to cross Cordis CYPHER® Sirolimus-eluting Coronary Stent Essential Prescribing Information

Device Component Description: Precautions - Pre- and Post-Procedure Antiplatelet Regimen: Stent in pediatric patients below the age of 18 years have Precautions - Magnetic Resonance Imaging (MRI): the proximal stent in the placement of the distal stent and The CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent) is a In the pivotal clinical trial of the CYPHER® Stent, clopidogrel or ticlopidine not been established. Through non-clinical testing, single and two overlapping CYPHER® may reduce the chances of dislodging the proximal stent, or device/drug combination product comprised of two regulated compo- was administered pre-procedure and for a period of three months post- • Geriatric use: Clinical studies of the CYPHER® Stent did Stents have been shown to be MRI safe at field strengths of 3 Tesla or disrupting stent coating. nents: a device (a Bx VELOCITY® Coronary Stent System) and a drug procedure. Aspirin was administered concomitantly with clopidogrel or not find that patients age 65 years and over differed with less, and a maximum whole body averaged specific absorption rate • Balloon pressures should be monitored during inflation. product (a formulation of sirolimus in a polymer coating). The device ticlopidine and then continued indefinitely to reduce risk of thrombosis. regard to safety and efficacy compared to younger patients. (SAR) of 4.0 W/kg for 15 minutes of MRI. Single and two overlapping Do not exceed rated burst pressure as indicated on component consists of the Bx VELOCITY® Stent premounted onto a • Non-Coronary use: The safety and effectiveness of this CYPHER® Stents should not migrate in this MRI environment. Non- the product label. Use of pressures higher than those stent delivery system (SDS), either the RAPTOR™ PTCA Dilatation It is very important that the patient is compliant with the post-proce- product has not been established in the cerebral, carotid, or clinical testing has not been performed to rule out the possibility of specified on the product label may result in a ruptured Catheter (Over-the Wire (OTW)) or the RAPTORRAIL® PTCA Dilatation dural antiplatelet recommendations. Early discontinuation of prescribed peripheral vasculature. stent migration at field strengths higher than 3 Tesla. balloon with possible intimal damage and dissection. Catheter (Rapid Exchange (RX)). The range of stent diameters is made antiplatelet medication could result in a higher risk of thrombosis, my- • Do not attempt to pull an unexpanded stent back through possible by varying the number of circumferential “cells” on the stent. ocardial infarction or death. Prior to Percutaneous Coronary Interven- Precautions – Lesion/Vessel Characteristics: In this testing, single CYPHER® Stents up to 33 mm in length produced the guiding catheter, as dislodgment of the stent from the The 2.5, 2.75 and 3.0 mm diameter 316L stainless steel stents have six tion (PCI), if a surgical or dental procedure is anticipated that requires The safety and effectiveness of the CYPHER® Stent have not been es- a temperature rise of less than 1 degree Celsius (1ºC), and two over- balloon may occur. circumferential cells, whereas, the 3.5 mm diameter 316L stainless steel early discontinuation of antiplatelet therapy, the interventionalist and tablished in the following patient populations: lapped 33 mm length CYPHER® Stents produced a temperature rise of • Stent retrieval methods (use of additional wires, snares stents have seven circumferential cells. The stent is crimped on various patient should carefully consider whether a drug-eluting stent and its • Patients with unresolved vessel thrombus at the lesion site. less than 2 degrees Celsius (2ºC) at a maximum whole body averaged and/or forceps) may result in additional trauma to the size delivery catheter balloons, which are sized from 2.5 to 3.5 mm. associated recommended antiplatelet therapy is the appropriate PCI • Patients with coronary artery reference vessel diameter specific absorption rate (SAR) of 4.0 W/kg for 15 minutes of MRI. The coronary vasculature and/or the vascular access site. treatment choice. Following PCI, should a surgical or dental procedure < 2.5 mm or > 3.5 mm. effect of heating in the MRI environment for stents with fractured struts Complications may include bleeding, hematoma, or Drug Component Description: be recommended, the risks and benefits of the procedure should be • Patients with lesions located in the saphenous vein graft, in is not known. The effect of heating in the MRI environment on the pseudoaneurysm. The active pharmaceutical ingredient in the CYPHER® Stent is sirolimus weighed against the possible risk associated with early discontinuation the unprotected left main coronary artery, ostial lesions, or drug or polymer coating is not known. • Ensure full coverage of the entire lesion/dissection site so (also known as Rapamycin). Sirolimus is a macrocyclic lactone produced of antiplatelet therapy. lesions located at a bifurcation. that there are no gaps between stents. by Streptomyces hygroscopicus. The chemical name of sirolimus is • Patients with diffuse disease or poor overflow distal to the MR imaging quality may be compromised if the area of interest is in the (3S,6R,7E,9R,10R,12R,14S,15E, 17E,19E,21S,23S,26R,27R,34aS)- Patients who require early discontinuation of antiplatelet therapy (e.g., identified lesions. exact same area or relatively close to the position of the stent. Precautions - Stent/System Removal: 9,10,12,13,14,21,22,23, 24,25,26,27,32,33,34,34a-hexadecahydro- secondary to active bleeding) should be monitored carefully for cardiac • Patients with tortuous vessels in the region of the obstruc- Should unusual resistance be felt at any time during either lesion 9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- events. At the discretion of the patient’s treating physicians, the an- tion or proximal to the lesion. Precaution – Preparation: access or removal of the stent delivery system before stent implantation, 1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27- tiplatelet therapy should be restarted as soon as possible. • Patients with a recent acute myocardial infarction where • AVOID manipulation of the stent during flushing of the the entire system should be removed as asingle unit. epoxy-3H-pyrido[2,1-c ][1,4] oxaazacyclohentriacontine-1,5,11,28,29 there is evidence of thrombus or poor flow. guidewire lumen, as this may disrupt the placement of the (4H,6H,31H)-pentone. Its molecular formula is C51H79NO13 and its Precautions - Use of Multiple Stents: • Patients with more than two overlapping stents. stent on the balloon. When removing the delivery system as a single unit: molecular weight is 914.2. The extent of the patient’s exposure to drug and polymer is directly re- • Patients for longer than 24 months follow-up. • Do NOT apply negative or positive pressure to the balloon • Do not retract the delivery system into the guiding catheter. lated to the number of stents implanted. Use of more than two during the delivery system preparation. • Advance the guidewire into the coronary anatomy as far The inactive ingredients in the CYPHER® Stent contain parylene C and CYPHER® Stents has not received adequate clinical evaluation. Use of Precautions - Drug Interactions: distally as safely possible. the following two non-erodible polymers: polyethylene-co-vinyl acetate more than two CYPHER® Stents will result in the patient receiving Several drugs are known to affect the metabolism of sirolimus, and Precautions - Stent Handling: • Tighten the rotating hemostatic valve to secure the stent (PEVA) and poly n-butyl methacrylate (PBMA). A combination of the larger amounts of drug and polymer than the experience reflected in the other drug interactions may be inferred from known metabolic effects. • For single use only. Do not resterilize or reuse this delivery system to the guiding catheter; then remove the two polymers mixed with sirolimus (67%/33%) makes up the basecoat clinical studies. Sirolimus is known to be a substrate for both cytochrome P450 IIIA4 product. Note the “Use By” date on the product label. guiding catheter and stent delivery system as a single unit. formulation which is applied to a parylene C treated stent.A drug-free (CYP3A4) and P-glycoprotein. • Do not remove the stent from the delivery balloon topcoat solution of PBMA polymer is applied to the stent surface. The To avoid the possibility of dissimilar metal corrosion, do not implant – removal may damage the stent and coating Failure to follow these steps or applying excessive force to the stent drug/polymer coating is adhered to the entire surface (i.e., luminal and stents of different materials in tandem where overlap or contact is pos- Consideration should be given to the potential for drug interaction and/or lead to stent embolization. The stent system is delivery system can potentially result in loss or damage to the stent or abluminal) of the stent. sible. Potential interactions of the CYPHER® Stent with other drug- when deciding to place a CYPHER® Stent in a patient who is taking a intended to perform as a system. stent delivery system. eluting or coated stents have not been evaluated and should be avoided drug that could interact with sirolimus, or when deciding to initiate • Do not induce a vacuum on the delivery system Indications: whenever possible. therapy with such a drug in a patient who had recently received a prior to reaching the target lesion. If it is necessary to retain the guidewire in position for subsequent ar- The CYPHER® Stent is indicated for improving coronary luminal diam- CYPHER® Stent.The effect of drug interactions on the safety or efficacy • Special care must be taken not to handle or in any way tery/lesion access, leave the guidewire in place and remove all other eter in patients with symptomatic ischemic disease due to discrete de It is noteworthy that there have been no prospective randomized trials of the CYPHER® Stent has not been determined. disrupt the stent on the balloon. This is most important while system components. novo lesions of length < 30 mm in native coronary arteries with a ref- specifically designed to assess multiple or overlapping CYPHER® Stents removing the catheter from the packaging, placing it over erence vessel diameter of > 2.5 to < 3.5 mm. for long lesions in a single vessel. A retrospective analysis of subjects Precautions - Coronary Artery Surgery – Effect on Anasto- the guidewire, and advancing it through the large-bore Precautions – Post-Procedure in randomized and non-randomized trials and clinical registries did not moses: rotating hemostatic valve and guiding catheter hub. • Great care must be exercised when crossing a newly Contraindications: suggest an increased rate of myocardial infarctions associated with the There have been rare reports of bronchial anastomotic dehiscence of • Stent manipulation (e.g., rolling the mounted stent with deployed stent with an intravascular ultrasound (IVUS) Use of the CYPHER® Stent is contraindicated in the following patient use of multiple or overlapping CYPHER® Stents in a single vessel, com- transplant anastomoses in lung transplant patients who were receiving your fingers) may cause coating damage, contamination or catheter, a coronary guidewire or balloon catheter to avoid types: pared to that of bare-metal stents. oral sirolimus therapy. In a vessel that has recently been implanted with dislodgement of the stent from the delivery system balloon. disrupting the stent placement, apposition, geometry, and/or • Patients with a hypersensitivity to sirolimus or its structurally a CYPHER® Stent, the sirolimus concentrations are expected to be sev- • Use only the appropriate balloon inflation media. Do not use coating. related compounds. Precautions - Brachytherapy: eral fold higher than systemic sirolimus concentrations.Therefore, con- air or any gaseous medium to inflate the balloon as this may • Through non-clinical testing, single and two overlapping • Patients with a known hypersensitivity to polymethacrylates The safety and effectiveness of the CYPHER® Stent in patients with sideration should be given to the possibility that the presence of a cause uneven expansion and difficulty in deployment of CYPHER® Stents have been shown to be MRI safe at field or polyolefin copolymers. prior brachytherapy of the target lesion have not been established.The CYPHER® Stent may compromise the healing of coronary artery vas- the stent. strengths of 3 Tesla or less. MR imaging quality may be safety and effectiveness of use of brachytherapy to treat in-stent cular anastomoses. No such event was observed in the very limited ex- compromised if the area of interest is in the exact same area Coronary artery stenting is contraindicated for use in: restenosis in a CYPHER® Stent have not been established. Both vas- perience from clinical trials. Precautions - Stent Placement: or relatively close to the position of the stent. • Patients in whom antiplatelet and/or anticoagulation therapy cular brachytherapy and the CYPHER® Stent alter arterial remodeling. • The vessel should be pre-dilated with an appropriate sized • In the pivotal clinical trial of the CYPHER® Stent, clopidogrel is contraindicated. The synergy between these two treatments has not been determined. Precautions - Immune Suppression Potential: balloon. or ticlopidine was administered pre-procedure and for a • Patients judged to have a lesion that prevents complete Sirolimus, the active ingredient of the CYPHER® Stent, is an immuno- • Do not prepare or pre-inflate the balloon prior to stent period of three months post-procedure. Aspirin was admin- inflation of an angioplasty balloon or proper placement of Precautions - Use in Conjunction with Other Procedures: suppressive agent that is also available in oral formulations. The mean deployment other than as directed. istered concomitantly with clopidogrel or ticlopidine and the stent or delivery catheter. The safety and effectiveness of using mechanical atherectomy devices peak systemic blood concentration of sirolimus following placement of • Guiding catheters used must have lumen sizes that are then continued indefinitely to reduce the risk of thrombosis. (directional atherectomy catheters, rotational atherectomy catheters) up to two CYPHER® Stents (1.05 ng/ml) is substantially lower than suitable to accommodate the stent delivery system. • Patients who require early discontinuation of antiplatelet Warnings: or laser angioplasty catheters in conjunction with CYPHER® Stent im- the therapeutic concentrations usually obtained when sirolimus oral • Do not induce a negative pressure on the delivery catheter therapy (e.g. secondary to active bleeding) should be • Please ensure that the inner package has not been opened plantation have not been established. formulations are used as prophylaxis for renal transplant rejection. In prior to placement of the stent across the lesion. This may monitored carefully for cardiac events. At the discretion or damaged as this may indicate the sterile barrier has been clinical studies of CYPHER® Stents when used according to its intended cause premature dislodgment of the stent from the balloon. of the patient’s treating physician, the antiplatelet therapy breached. Precautions - Use in Special Populations: use, there were no reports of immune suppression. However, for pa- • Although the stent delivery balloon catheter is strong enough should be restarted as soon as possible. • The use of the product carries the risks associated with • Pregnancy: Pregnancy Category C. There are no adequate tients who receive several CYPHER® Stents simultaneously, it may be to expand the stent without rupture, a circumferential tear coronary artery stenting, including subacute thrombosis, and well-controlled studies in pregnant women or men possible for systemic concentrations of sirolimus to approach immuno- of the carrier balloon distal to the stent and prior to Drug Information vascular complications, and/or bleeding events. intending to father children. Effective contraception should suppressive levels temporarily, especially in patients who also have he- complete expansion of the stent could cause the balloon to • Patients with a known hypersensitivity to 316L stainless be initiated before implanting a CYPHER® Stent and for 12 patic insufficiently or who are taking drugs that inhibit CYP3A4 or become tethered to the stent, requiring surgical removal. In Mechanism of Action: steel may suffer an allergic reaction to this implant. weeks after implantation. The CYPHER® Stent should be P-glycoprotein. This possibility should be considered for such patients, case of rupture of the balloon, it should be withdrawn and, The mechanism (or mechanisms) by which a CYPHER® Stent affects used during pregnancy only if the potential benefit out- particularly if they are also taking oral sirolimus (or rapamycin), other if necessary, a new balloon catheter exchanged over the neointima production as seen in clinical studies has not been estab- Precautions - General Precautions: weighs the potential risk to the embryo or fetus. immunosuppressive agents, or are otherwise at risk for immune sup- guidewire to complete the expansion of the stent. lished. Sirolimus inhibits T-lymphocyte activation and smooth muscle • Only physicians who have received adequate training should • Use during lactation: A decision should be made whether pression. • Implanting a stent may lead to a dissection of the vessel and endothelial cell proliferation in response to cytokine and growth perform implantation of the stent. to discontinue nursing or to implant the stent, taking into distal and/or proximal to the stented portion and may cause factor stimulation. In cells, sirolimus binds to the immunophilin, FK Bind- • Stent placement should only be performed at hospitals account the importance of the stent to the mother. Precautions - Lipid Elevation Potential: acute closure of the vessel requiring additional intervention ing Protein-12 (FKBP-12).The sirolimus-FKBP-12 complex binds to and where emergency coronary artery bypass graft surgery can • Gender: Clinical studies of the CYPHER® Stent did not find The use of oral sirolimus in renal transplant patients was associated (CABG, further dilatation, placement of additional stents, or inhibits the activation of the mammalian Target of Rapamycin (mTOR), be readily performed. any significant differences in safety and effectiveness for with increased serum cholesterol and triglycerides that in some cases other intervention). leading to inhibition of cell cycle progression from the G1 to the S • Subsequent stent blockage may require repeat dilatation of male and female patients. required treatment. The effect was seen with both low and high dose • Do not expand the stent if it is not properly positioned in the phase. the arterial segment containing the stent. The long-term • Ethnicity: Clinical studies of the CYPHER® Stent did not prolonged oral therapy in a dose related manner.When used according vessel. outcome following repeat dilatation of endothelialized include sufficient numbers of patients to assess for differ- to the indications for use, the systemic sirolimus concentrations from the • Placement of the stent has the potential to compromise side Pharmacokinetics of the CYPHER® Stent: stents is not well characterized. ences in safety and effectiveness due to ethnicity, either by CYPHER® Stent are expected to be lower than the concentrations usu- branch patency. The pharmacokinetics of sirolimus as delivered by the CYPHER® Stent • Do not use Ethiodol or Lipiodol contrast media. individual category or when grouped by Caucasian and ally obtained in transplant patients, but the magnitude and duration of • When treating multiple lesions, the distal lesion should be has been determined in patients with coronary artery disease after im- • Do not expose the delivery system to organic solvents, such non-Caucasian. any effect of those concentrations on lipids is not known. initially stented, followed by stenting of the more proximal plantation of one (n=10) or two (n=9) CYPHER® Stents. as alcohol, or detergents. • Pediatric use: The safety and efficacy of the CYPHER® lesion(s). Stenting in this order minimizes the need to cross Everolimus Eluting Coronary Stent System

The XIENCE™ V SPIRIT Family of Trials Visionary Science

XIENCE™ V SPIRIT WOMEN SPIRIT IV • International • U.S. clinical trial clinical trial • Currently enrolling SPIRIT V • Currently enrolling patients and selecting patients and selecting investigators • International clinical trial investigators • Currently enrolling patients

Learn more about our clinical activities at booth #3047, Halls D & E

CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.

AP2926175A ™

ThromCatThrombectomy Catheter System

Mechanical Thrombectomy Made Simple • Quick and Easy Set-up • Excellent Deliverability • One Button Control • Completely Disposable

To find out more about Kensey Nash products, visit us at TCT 2007 Booth #6091

United States Product Sales: 888-453-6739 (4KENSEY) International Product Sales: +49-6196-9994110

US Indication: The ThromCat™ System is indicated for mechanical removal of thrombus in synthetic hemodialysis access grafts and native vessel dialysis fistulae. www.kenseynash.com EU Indication: The ThromCat™ System is indicated for use for percutaneous ThromCat is a trademark of Kensey Nash Corporation. transluminal thrombus removal in native coronary arteries and infrainguinal arteries. © Copyright 2007 Kensey Nash Corporation Everolimus Eluting Coronary Stent System

The XIENCE™ V SPIRIT Family of Trials Visionary Science

MULTI-LINK VISION® Stent

MULTI-LINK VISION® Stent Delivery System

Everolimus

Fluoropolymer

SPIRIT IV (U.S.), SPIRIT V (International), XIENCE™ V SPIRIT WOMEN (International) are currently enrolling patients. SPIRIT IV and XIENCE™ V SPIRIT WOMEN are also selecting investigators. For more information, please visit booth #3047, Halls D & E

CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.

AP2926174A